data_1e4r_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1e4r _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 28.4 t . . . . . 0 N--CA 1.493 1.679 0 CA-C-O 121.266 0.555 . . . . 0.0 110.482 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.9 tt -57.47 -32.37 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.163 -0.961 . . . . 0.0 110.646 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 59.4 ttt180 -56.08 -31.83 63.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 110.485 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -66.03 -30.38 70.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.263 -0.898 . . . . 0.0 110.239 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.04 5.85 21.26 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -82.59 -178.49 52.39 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.402 HG21 HD11 ' A' ' 12' ' ' ILE . 23.8 mm -112.1 166.64 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.146 -1.208 . . . . 0.0 110.273 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.501 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.4 m -120.22 153.79 35.79 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.183 -0.948 . . . . 0.0 109.998 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.499 ' O ' ' N ' ' A' ' 32' ' ' LYS . 20.0 tp60 -153.7 154.93 35.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.434 -0.791 . . . . 0.0 109.714 179.689 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.541 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 72.5 t80 -59.88 -36.39 76.84 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.164 -0.96 . . . . 0.0 110.252 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.541 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 38.8 mmt180 -148.42 152.44 36.97 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.344 -0.848 . . . . 0.0 109.958 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 69.5 m -123.03 152.25 41.13 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.128 -0.982 . . . . 0.0 110.289 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.7 pt -103.82 165.92 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.326 -0.858 . . . . 0.0 109.899 179.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.78 -42.75 37.72 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.477 ' C ' ' CD1' ' A' ' 20' ' ' LEU . 3.3 tm? -51.01 -35.15 32.49 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.177 -1.19 . . . . 0.0 110.404 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.8 mtp180 -89.87 150.16 22.34 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.186 -0.946 . . . . 0.0 110.485 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 92.4 m-70 -108.3 141.21 40.43 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.313 -0.867 . . . . 0.0 109.818 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.429 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 76.4 tttt -121.83 121.93 38.3 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.179 -0.95 . . . . 0.0 110.74 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 28.8 pt -101.43 -6.3 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.388 -0.82 . . . . 0.0 109.793 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.44 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -178.17 -174.22 44.27 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.515 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 89.1 m -111.27 111.04 21.82 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.177 -1.19 . . . . 0.0 110.31 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.402 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 38.9 t -53.71 -48.18 69.81 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.225 -0.922 . . . . 0.0 109.958 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.515 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -149.84 -163.29 11.01 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.582 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 9.7 m -89.81 -42.94 0.42 Allowed Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 120.998 -1.295 . . . . 0.0 110.221 179.799 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.584 ' O ' ' CD1' ' A' ' 31' ' ' PHE . 50.4 Cg_endo -82.27 7.21 5.24 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.499 1.263 . . . . 0.0 109.555 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.584 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 57.7 m-85 -151.87 169.21 22.84 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.324 -0.86 . . . . 0.0 110.284 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.501 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 93.2 mttt -131.21 157.3 43.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.342 -0.849 . . . . 0.0 109.656 179.285 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.44 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 42.3 t -84.77 119.01 24.81 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.095 -1.003 . . . . 0.0 110.255 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 97.8 m -145.44 157.24 44.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.293 -0.879 . . . . 0.0 110.315 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.209 179.877 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 7.3 t . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.074 0.464 . . . . 0.0 110.525 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.5 pt -60.03 -14.66 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.18 -0.95 . . . . 0.0 110.264 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 78.0 mmt-85 -64.38 -34.91 79.25 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.294 -0.879 . . . . 0.0 110.117 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -65.58 -26.18 67.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.337 -0.852 . . . . 0.0 110.027 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.89 -1.07 13.51 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.79 -176.73 50.97 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.4 pt -128.63 163.77 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.348 -1.089 . . . . 0.0 110.002 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.486 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.2 m -103.38 154.41 19.44 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.092 -1.005 . . . . 0.0 109.951 -179.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.533 ' O ' ' N ' ' A' ' 32' ' ' LYS . 4.9 tp60 -149.42 151.26 33.72 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.306 -0.871 . . . . 0.0 109.989 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.435 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 67.6 t80 -55.21 -44.66 75.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 110.131 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.435 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 48.3 mmm-85 -150.23 143.0 24.69 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.363 -0.836 . . . . 0.0 110.233 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 90.4 m -109.49 153.25 24.33 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.25 -0.907 . . . . 0.0 110.127 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.541 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 38.3 pt -103.76 176.45 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.274 -0.891 . . . . 0.0 110.233 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.72 -33.04 81.01 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.541 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 3.9 mm? -61.2 -34.93 75.88 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -1.162 . . . . 0.0 110.056 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -99.45 149.04 23.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.259 -0.901 . . . . 0.0 110.063 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 72.8 m80 -107.74 134.79 50.2 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.188 -0.945 . . . . 0.0 110.213 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.465 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 35.6 tttm -97.22 107.26 19.75 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.325 -0.859 . . . . 0.0 110.239 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -69.74 -32.44 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 110.179 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.453 ' O ' ' HE2' ' A' ' 23' ' ' LYS . . . -166.41 -173.17 34.54 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.436 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 61.8 m -104.25 100.04 9.77 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.244 -1.15 . . . . 0.0 110.309 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.415 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 35.9 t -52.22 -43.88 64.49 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.202 -0.936 . . . . 0.0 109.734 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.436 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -154.59 -163.37 11.92 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 179.737 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.584 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 15.8 m -90.46 -41.86 0.4 Allowed Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.035 -1.274 . . . . 0.0 110.34 179.695 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.588 ' HG2' ' CD2' ' A' ' 31' ' ' PHE . 45.8 Cg_endo -81.92 7.0 5.32 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.466 1.245 . . . . 0.0 109.785 179.084 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.588 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 88.9 m-85 -153.65 170.96 19.58 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.263 -0.898 . . . . 0.0 110.351 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 14' ' ' GLN . 61.5 mttm -133.19 156.55 47.29 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.472 -0.768 . . . . 0.0 109.635 179.512 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.465 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 10.8 t -84.74 113.06 21.04 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.243 -0.911 . . . . 0.0 110.282 -179.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.7 m -138.84 143.22 38.72 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.345 -0.847 . . . . 0.0 110.064 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.257 -179.858 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 34.4 t . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 121.243 0.544 . . . . 0.0 110.184 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.0 tp -52.18 -28.48 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.404 -0.81 . . . . 0.0 110.385 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 48.6 ttp180 -57.16 -31.55 65.51 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.169 -0.957 . . . . 0.0 110.469 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -67.14 -30.6 70.64 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.286 -0.884 . . . . 0.0 110.25 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 116.06 8.28 13.62 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -85.83 -177.19 50.19 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 34.8 pt -116.62 162.35 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.185 -1.185 . . . . 0.0 110.064 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.491 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.1 m -113.19 155.1 25.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.121 -0.987 . . . . 0.0 110.141 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.477 ' O ' ' N ' ' A' ' 32' ' ' LYS . 65.2 tt0 -154.29 155.46 35.21 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.404 -0.81 . . . . 0.0 109.835 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.571 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 60.1 t80 -57.79 -44.69 86.44 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.177 -0.952 . . . . 0.0 110.257 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.571 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 41.0 mmt180 -145.95 150.2 35.62 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.35 -0.844 . . . . 0.0 110.267 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.1 m -120.62 126.06 49.31 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.211 -0.931 . . . . 0.0 110.052 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.5 pt -134.03 165.32 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.227 -0.921 . . . . 0.0 110.205 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.91 -169.73 40.78 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 94.8 mt -51.78 -29.99 21.14 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.34 -1.094 . . . . 0.0 110.273 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 81.0 mtm180 -53.08 148.98 7.23 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.246 -0.909 . . . . 0.0 110.278 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 45.8 p-80 -135.18 164.46 27.62 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.27 -0.894 . . . . 0.0 109.968 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.489 ' CE ' ' HA ' ' A' ' 26' ' ' THR . 68.5 tttt -112.69 99.06 7.64 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.12 -0.987 . . . . 0.0 110.519 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.404 HD13 ' HD2' ' A' ' 35' ' ' LYS . 90.1 mt -60.52 -43.43 94.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.288 -0.883 . . . . 0.0 110.069 179.68 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.433 ' O ' ' HE2' ' A' ' 23' ' ' LYS . . . -144.06 -173.77 15.77 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.489 ' HA ' ' CE ' ' A' ' 23' ' ' LYS . 90.2 m -108.9 105.5 15.08 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.265 -1.138 . . . . 0.0 110.366 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.432 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 48.6 t -55.67 -44.25 77.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -0.929 . . . . 0.0 109.767 179.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.484 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -152.41 -167.11 14.91 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.805 -1.718 . . . . 0.0 108.805 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.606 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 2.0 m -87.36 -43.18 0.52 Allowed Pre-proline 0 C--N 1.299 -1.602 0 O-C-N 121.227 -1.16 . . . . 0.0 110.003 179.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.606 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.3 Cg_endo -83.3 7.63 5.09 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 O-C-N 123.628 1.33 . . . . 0.0 109.564 179.153 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.572 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 88.6 m-85 -152.07 170.63 19.45 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -0.893 . . . . 0.0 110.207 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.491 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 92.2 mttt -134.03 156.4 48.28 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.529 -0.732 . . . . 0.0 109.634 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.448 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 42.6 t -84.62 121.51 27.73 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.138 -0.976 . . . . 0.0 110.23 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 65.9 m -142.18 139.5 32.08 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.251 -0.905 . . . . 0.0 110.258 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . 0.404 ' HD2' HD13 ' A' ' 24' ' ' ILE . 94.8 mttt . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.078 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 47.7 t . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 121.077 0.465 . . . . 0.0 110.434 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 1.6 mp -63.36 -32.27 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.17 -0.957 . . . . 0.0 109.885 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 17.1 tpt180 -55.97 -36.95 68.42 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.376 -0.828 . . . . 0.0 110.332 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -77.46 -9.78 59.09 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.332 -0.855 . . . . 0.0 110.3 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.92 6.33 65.39 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -74.21 -172.26 26.91 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 51.7 mt -122.45 169.35 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -1.161 . . . . 0.0 110.187 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.481 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.6 m -134.81 155.22 51.01 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.314 -0.866 . . . . 0.0 110.096 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.419 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 28.1 mt-30 -153.04 156.43 38.75 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.509 -0.744 . . . . 0.0 109.95 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.502 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 81.8 m-85 -52.62 -34.89 53.16 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.142 -0.974 . . . . 0.0 110.032 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.457 ' NH1' ' HE3' ' A' ' 32' ' ' LYS . 26.9 tpt180 -151.95 165.76 33.62 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.395 -0.815 . . . . 0.0 110.097 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 23.4 m -138.28 128.11 25.3 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.22 -0.925 . . . . 0.0 110.129 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 pt -142.44 167.34 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.292 -0.88 . . . . 0.0 110.171 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.44 -150.54 23.59 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.541 ' O ' ' CD2' ' A' ' 22' ' ' HIS . 4.2 mm? -67.69 -19.66 65.2 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.352 -1.087 . . . . 0.0 109.999 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.0 mtt180 -54.81 142.8 27.75 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.354 -0.841 . . . . 0.0 110.323 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.541 ' CD2' ' O ' ' A' ' 20' ' ' LEU . 96.4 m-70 -128.25 161.06 30.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.401 -0.812 . . . . 0.0 110.015 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.46 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 25.2 ttmt -122.54 126.61 48.14 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.198 -0.939 . . . . 0.0 110.31 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 35.0 pt -99.19 -9.6 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.263 -0.898 . . . . 0.0 110.06 179.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.439 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -173.33 -171.74 38.2 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.53 ' O ' ' CG2' ' A' ' 26' ' ' THR . 15.0 t -109.82 106.93 16.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.253 -1.145 . . . . 0.0 110.218 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 20.7 t -59.31 -37.8 78.66 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.211 -0.931 . . . . 0.0 110.106 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -170.3 -164.9 26.8 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.602 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 61.7 m -88.7 -41.62 0.46 Allowed Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 120.903 -1.351 . . . . 0.0 110.148 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.602 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.1 Cg_endo -82.88 8.62 4.49 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 123.504 1.265 . . . . 0.0 109.425 178.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 69.5 m-85 -155.8 172.42 18.37 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.382 -0.823 . . . . 0.0 110.469 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.481 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 65.0 mttm -135.83 158.17 45.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.557 -0.715 . . . . 0.0 109.172 178.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.46 ' O ' ' HG3' ' A' ' 23' ' ' LYS . 38.3 t -77.4 121.07 23.29 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.978 -1.076 . . . . 0.0 109.956 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 56.0 m -147.64 150.95 35.35 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.107 -0.995 . . . . 0.0 110.355 -179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.187 179.99 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 43.0 t . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.263 0.554 . . . . 0.0 110.279 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.482 HG13 ' N ' ' A' ' 8' ' ' ARG . 40.8 pt -56.53 -29.05 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -0.883 . . . . 0.0 110.266 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.482 ' N ' HG13 ' A' ' 7' ' ' ILE . 58.8 ttt-85 -63.43 -41.88 98.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.247 -0.908 . . . . 0.0 110.233 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 -66.0 -26.72 67.67 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.291 -0.881 . . . . 0.0 110.176 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.4 16.34 14.89 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.87 -176.46 36.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 18.9 pt -119.67 151.04 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.262 -1.14 . . . . 0.0 110.011 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.1 m -101.52 153.13 20.0 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.147 -0.971 . . . . 0.0 109.992 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.496 ' O ' ' N ' ' A' ' 32' ' ' LYS . 43.6 tp60 -154.38 154.29 33.03 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.342 -0.849 . . . . 0.0 109.839 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.487 ' N ' ' HG3' ' A' ' 14' ' ' GLN . 64.2 t80 -54.89 -34.59 63.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.273 -0.892 . . . . 0.0 110.764 -179.649 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.413 ' HA ' ' HD3' ' A' ' 16' ' ' ARG . 22.1 tpp180 -156.64 164.33 38.29 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.165 -0.959 . . . . 0.0 110.218 -179.816 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 93.5 m -133.43 127.8 34.15 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.299 -0.876 . . . . 0.0 110.156 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.537 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 42.7 pt -59.28 161.43 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.237 -0.914 . . . . 0.0 110.324 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.82 -35.42 52.95 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.537 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 4.4 mm? -58.46 -28.72 65.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.285 -1.126 . . . . 0.0 110.436 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.454 ' HG2' ' HB3' ' A' ' 34' ' ' CYS . 20.5 tpp180 -106.5 130.08 54.34 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.137 -0.977 . . . . 0.0 110.479 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 12.8 p80 -105.82 153.82 21.39 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.401 -0.812 . . . . 0.0 109.636 179.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.516 ' CB ' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -118.79 124.85 48.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.085 -1.01 . . . . 0.0 110.572 -179.761 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 61.0 mt -68.08 -34.85 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.931 . . . . 0.0 109.824 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.473 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -151.78 -169.25 17.1 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.527 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 27.5 m -111.31 101.34 9.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -1.172 . . . . 0.0 110.39 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.412 ' C ' ' O ' ' A' ' 26' ' ' THR . 40.5 t -44.54 -51.33 9.01 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.303 -0.873 . . . . 0.0 109.806 179.595 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.527 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -145.57 -164.95 11.05 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 108.587 -1.805 . . . . 0.0 108.587 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.581 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.9 m -88.27 -44.38 0.47 Allowed Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 120.821 -1.399 . . . . 0.0 110.08 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.581 ' CD ' ' N ' ' A' ' 29' ' ' SER . 45.2 Cg_endo -80.43 7.8 4.55 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 O-C-N 123.554 1.291 . . . . 0.0 110.083 179.203 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.581 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 89.6 m-85 -149.17 170.52 18.25 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.227 -0.921 . . . . 0.0 110.269 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.496 ' N ' ' O ' ' A' ' 14' ' ' GLN . 98.1 mttt -131.37 159.07 39.04 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.463 -0.773 . . . . 0.0 109.505 179.18 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.516 ' O ' ' CB ' ' A' ' 23' ' ' LYS . 47.8 t -84.61 115.79 22.82 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.048 -1.032 . . . . 0.0 110.406 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.461 ' SG ' ' HB3' ' A' ' 23' ' ' LYS . 71.7 m -142.54 130.86 22.2 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.136 -0.977 . . . . 0.0 110.092 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 96.2 mttt . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.26 -179.782 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.404 ' O ' ' HB ' ' A' ' 7' ' ' ILE . 45.9 t . . . . . 0 N--CA 1.492 1.655 0 CA-C-O 121.284 0.564 . . . . 0.0 110.315 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.472 HG21 ' N ' ' A' ' 8' ' ' ARG . 7.0 tt -175.06 -28.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.236 -0.915 . . . . 0.0 110.706 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.472 ' N ' HG21 ' A' ' 7' ' ' ILE . 15.6 mtm180 -57.29 -30.62 64.86 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.943 -1.098 . . . . 0.0 109.492 179.415 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -65.99 -29.42 69.8 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.618 -0.676 . . . . 0.0 110.368 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 107.48 9.74 28.52 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.93 171.05 48.36 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.8 pt -111.68 161.8 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -1.124 . . . . 0.0 110.176 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.474 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.2 m -104.36 154.33 19.96 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.162 -0.962 . . . . 0.0 109.921 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.533 ' O ' ' N ' ' A' ' 32' ' ' LYS . 63.2 tt0 -155.13 153.42 30.79 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.41 -0.806 . . . . 0.0 109.565 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.473 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 63.2 t80 -59.14 -39.48 82.52 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.043 -1.036 . . . . 0.0 110.36 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.473 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 17.1 mmm180 -144.59 146.76 32.49 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.268 -0.895 . . . . 0.0 110.348 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.2 t -109.14 156.26 20.05 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.254 -0.903 . . . . 0.0 110.441 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.502 HG22 HD11 ' A' ' 18' ' ' ILE . 31.1 pt -110.46 162.79 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.252 -0.905 . . . . 0.0 110.191 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.06 -36.74 52.58 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.468 ' N ' ' CD2' ' A' ' 20' ' ' LEU . 4.2 mm? -56.33 -35.31 67.46 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.194 -1.18 . . . . 0.0 110.169 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 -100.77 129.17 46.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.218 -0.926 . . . . 0.0 110.128 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 77.9 t60 -88.07 124.98 34.31 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.352 -0.842 . . . . 0.0 110.295 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.465 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 27.3 ttpp -97.33 117.18 30.97 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.294 -0.879 . . . . 0.0 110.132 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 35.9 pt -97.62 0.32 10.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.177 -0.952 . . . . 0.0 110.315 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.92 -172.35 43.82 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.487 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 88.4 m -119.46 111.5 18.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -1.118 . . . . 0.0 110.226 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.432 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 45.8 t -54.04 -53.32 54.61 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.247 -0.908 . . . . 0.0 109.795 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.487 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -142.12 -165.36 10.47 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 108.651 -1.779 . . . . 0.0 108.651 179.475 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.608 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 23.5 m -87.27 -41.69 0.52 Allowed Pre-proline 0 C--N 1.304 -1.412 0 O-C-N 121.027 -1.278 . . . . 0.0 110.052 179.618 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.608 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.3 Cg_endo -81.75 7.46 5.02 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 O-C-N 123.506 1.266 . . . . 0.0 109.681 178.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.587 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 86.7 m-85 -151.92 171.09 18.34 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.296 -0.877 . . . . 0.0 110.448 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 14' ' ' GLN . 62.0 mttm -128.6 157.76 40.37 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.429 -0.794 . . . . 0.0 109.264 179.347 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.465 ' O ' ' HG3' ' A' ' 23' ' ' LYS . 48.9 t -91.76 117.56 29.87 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.985 -1.072 . . . . 0.0 110.301 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 96.9 m -135.43 131.42 36.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.211 -0.93 . . . . 0.0 110.595 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.2 ptmm? . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.241 179.925 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.458 ' HB2' ' SG ' ' A' ' 27' ' ' CYS . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.637 0 CA-C-O 121.346 0.593 . . . . 0.0 110.035 . . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.413 ' CG2' ' N ' ' A' ' 8' ' ' ARG . 4.8 tp -65.16 -33.43 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.286 -0.884 . . . . 0.0 110.105 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.413 ' N ' ' CG2' ' A' ' 7' ' ' ILE . 81.0 mtt180 -52.15 -37.94 56.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.3 -0.875 . . . . 0.0 110.336 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -71.08 -6.83 42.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.39 -0.819 . . . . 0.0 110.251 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 81.49 13.96 79.27 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.423 ' C ' HG13 ' A' ' 12' ' ' ILE . . . -96.71 -170.7 34.25 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.423 HG13 ' C ' ' A' ' 11' ' ' GLY . 27.2 mt -132.53 172.53 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.297 -1.119 . . . . 0.0 109.622 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 6.1 m -137.39 159.59 41.5 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.916 -1.115 . . . . 0.0 111.346 -179.586 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 53.9 tp60 -157.67 153.63 27.02 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.475 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 44.1 t80 -44.74 -46.4 10.42 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.979 -1.076 . . . . 0.0 110.392 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.475 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 30.3 mmt180 -137.71 146.58 43.9 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.327 -0.858 . . . . 0.0 110.012 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 77.3 m -111.65 131.02 55.57 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.118 -0.988 . . . . 0.0 110.503 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.489 HG22 HD11 ' A' ' 18' ' ' ILE . 19.4 pt -133.47 164.59 34.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.195 -0.941 . . . . 0.0 110.217 179.714 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.78 -161.35 23.71 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.489 ' O ' ' CE1' ' A' ' 22' ' ' HIS . 53.2 mt -70.56 -24.52 62.8 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.283 -1.128 . . . . 0.0 110.126 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 100.0 mtt180 -57.36 142.86 42.14 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.326 -0.859 . . . . 0.0 110.313 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.489 ' CE1' ' O ' ' A' ' 20' ' ' LEU . 77.6 m-70 -119.6 160.9 21.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.214 -0.929 . . . . 0.0 110.089 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.523 ' CE ' ' OG1' ' A' ' 26' ' ' THR . 76.9 tttt -99.7 97.94 8.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.166 -0.959 . . . . 0.0 110.381 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 89.9 mt -67.37 -26.96 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.188 -0.945 . . . . 0.0 110.181 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -164.33 -169.05 27.36 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.534 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 92.3 m -122.98 111.01 16.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.245 -1.15 . . . . 0.0 110.429 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.458 ' SG ' ' HB2' ' A' ' 6' ' ' CYS . 33.4 m -59.43 -43.47 93.07 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.239 -0.913 . . . . 0.0 109.523 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.534 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -154.28 -160.96 10.14 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.612 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 5.2 m -86.84 -41.65 0.54 Allowed Pre-proline 0 C--N 1.301 -1.515 0 O-C-N 120.941 -1.329 . . . . 0.0 109.977 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.612 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.8 Cg_endo -81.58 7.79 4.8 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 123.539 1.284 . . . . 0.0 109.987 179.19 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.589 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 52.6 m-85 -149.73 179.36 8.07 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.218 -0.926 . . . . 0.0 110.812 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.537 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 68.7 mttt -148.26 161.85 40.68 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.515 -0.74 . . . . 0.0 109.396 179.625 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.425 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 46.9 t -88.88 110.11 20.79 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.611 -1.306 . . . . 0.0 109.78 179.533 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 89.2 m -137.09 150.51 48.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.184 -0.948 . . . . 0.0 110.334 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 99.9 mttt . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.141 179.814 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.326 0.584 . . . . 0.0 110.133 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.458 HG13 ' N ' ' A' ' 8' ' ' ARG . 32.3 pt -67.86 -26.15 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.356 -0.84 . . . . 0.0 110.098 179.763 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.458 ' N ' HG13 ' A' ' 7' ' ' ILE . 76.7 mtt85 -49.56 -33.07 13.94 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.202 -0.936 . . . . 0.0 110.336 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 55.5 t-20 -68.92 -23.65 64.19 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.357 -0.839 . . . . 0.0 110.723 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 111.36 -2.93 28.04 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.44 -168.94 41.61 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 51.3 mt -131.6 170.77 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.355 -1.085 . . . . 0.0 109.949 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.524 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.5 m -135.88 159.39 41.81 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.019 -1.051 . . . . 0.0 110.485 179.682 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.479 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 11.6 pt20 -155.64 169.86 23.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.466 -0.771 . . . . 0.0 109.78 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.487 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 96.3 m-85 -58.04 -36.94 73.47 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.302 -0.874 . . . . 0.0 110.842 -179.653 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.469 ' O ' ' HG3' ' A' ' 14' ' ' GLN . 38.3 mmt180 -146.46 153.63 40.66 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.144 -0.972 . . . . 0.0 110.517 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.4 m -122.31 161.94 22.42 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.249 -0.907 . . . . 0.0 109.839 179.519 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.523 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 34.6 pt -113.98 172.83 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.057 -1.027 . . . . 0.0 110.315 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.99 -33.92 64.79 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.523 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 22.9 mt -59.6 -33.64 71.73 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -1.132 . . . . 0.0 110.264 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -101.8 133.79 45.98 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.344 -0.847 . . . . 0.0 110.056 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 66.6 t-80 -88.28 124.85 34.29 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.261 -0.899 . . . . 0.0 110.216 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.498 ' CE ' HG23 ' A' ' 26' ' ' THR . 74.0 tttt -88.02 90.45 8.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.213 -0.929 . . . . 0.0 110.106 179.827 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.9 tt -64.95 -30.98 51.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.189 -0.944 . . . . 0.0 110.358 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' A' ' 33' ' ' CYS . . . -170.02 -171.21 35.29 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.498 HG23 ' CE ' ' A' ' 23' ' ' LYS . 58.2 p -116.31 103.04 10.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.343 -1.092 . . . . 0.0 110.485 -179.732 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 62.6 m -47.95 -48.6 32.06 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.742 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.16 -160.09 8.53 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.594 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 8.4 m -89.99 -41.61 0.42 Allowed Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.082 -1.246 . . . . 0.0 110.67 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.594 ' CD ' ' N ' ' A' ' 29' ' ' SER . 46.4 Cg_endo -81.16 7.83 4.72 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 123.472 1.248 . . . . 0.0 109.997 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.578 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 83.9 m-85 -150.36 171.79 16.43 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.255 -0.903 . . . . 0.0 110.438 179.575 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.524 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 93.8 mttt -135.58 158.99 43.01 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.408 -0.808 . . . . 0.0 108.995 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.487 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 4.8 t -89.29 118.78 29.21 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.767 -1.208 . . . . 0.0 109.907 179.506 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 95.4 m -144.31 147.43 33.48 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.133 -0.979 . . . . 0.0 110.299 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 91.5 mttt . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.17 179.721 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.452 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 53.1 t . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.232 0.539 . . . . 0.0 110.107 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.507 HG13 ' N ' ' A' ' 8' ' ' ARG . 46.7 pt -57.25 -33.49 43.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.241 -0.912 . . . . 0.0 110.279 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.507 ' N ' HG13 ' A' ' 7' ' ' ILE . 65.9 ttt-85 -59.79 -35.51 74.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.207 -0.933 . . . . 0.0 110.17 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.407 ' OD1' ' O ' ' A' ' 9' ' ' ASN . 45.9 t-20 -75.65 -23.23 56.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 109.983 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 112.32 2.07 26.3 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.96 -178.88 48.94 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 57.2 mt -114.63 171.72 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.23 -1.159 . . . . 0.0 110.27 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.3 m -124.6 150.57 45.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 110.053 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.444 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 56.6 tt0 -152.71 154.18 34.75 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.613 -0.679 . . . . 0.0 109.712 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.53 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 89.2 m-85 -57.89 -40.05 79.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.056 -1.027 . . . . 0.0 110.307 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.427 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 24.9 mmm180 -145.0 156.29 43.86 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.309 -0.869 . . . . 0.0 110.496 -179.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.1 m -128.24 160.83 30.89 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.241 -0.912 . . . . 0.0 110.055 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.538 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 48.4 pt -110.71 172.35 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.13 -0.981 . . . . 0.0 110.295 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.45 -33.88 62.79 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.538 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 9.5 mp -62.01 -34.2 75.75 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.157 -1.202 . . . . 0.0 110.224 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 70.7 mtp85 -102.85 113.82 27.58 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.249 -0.907 . . . . 0.0 109.938 179.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 65.7 m170 -68.37 152.26 45.68 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.178 -0.952 . . . . 0.0 110.52 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.467 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 71.4 tttt -120.69 96.69 5.22 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.316 -0.865 . . . . 0.0 109.979 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.496 HD11 HG22 ' A' ' 24' ' ' ILE . 49.5 mm -65.53 -26.46 39.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.274 -0.892 . . . . 0.0 110.601 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.404 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -175.99 -167.84 35.42 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.449 ' HA ' ' HA ' ' A' ' 32' ' ' LYS . 49.5 p -106.57 105.87 16.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -1.077 . . . . 0.0 110.52 -179.808 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.463 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 42.4 t -50.67 -35.76 32.46 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -0.914 . . . . 0.0 109.53 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -161.68 -160.77 11.16 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.448 -1.861 . . . . 0.0 108.448 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.589 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 60.6 m -89.64 -41.89 0.43 Allowed Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 120.942 -1.328 . . . . 0.0 109.956 179.495 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.589 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.0 Cg_endo -83.29 8.87 4.36 Favored 'Trans proline' 0 C--N 1.31 -1.496 0 O-C-N 123.422 1.222 . . . . 0.0 109.557 178.853 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.572 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 95.6 m-85 -153.02 172.45 16.82 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.357 -0.839 . . . . 0.0 110.802 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 93.4 mttt -134.41 160.01 39.29 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 179.092 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 45.7 t -83.8 117.08 23.04 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.983 -1.073 . . . . 0.0 109.911 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 58.9 m -144.12 156.78 44.48 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.233 -0.917 . . . . 0.0 110.506 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 94.8 mttt . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.092 179.829 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 48.1 t . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 121.225 0.536 . . . . 0.0 110.21 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 37.1 pt -109.93 -11.51 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.293 -0.88 . . . . 0.0 110.235 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 30.0 mmt180 -57.95 -32.4 67.79 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.152 -0.968 . . . . 0.0 110.327 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -67.16 -26.22 66.55 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.385 -0.822 . . . . 0.0 110.436 -179.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.4 13.24 33.53 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.78 -169.92 42.92 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 47.2 mt -129.09 171.12 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.439 -1.036 . . . . 0.0 109.795 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.551 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 5.8 m -136.47 160.18 39.53 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.936 -1.103 . . . . 0.0 111.214 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.4 ' O ' ' C ' ' A' ' 15' ' ' TYR . 44.2 tt0 -160.06 154.39 23.62 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.725 -0.609 . . . . 0.0 109.501 179.507 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.443 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 40.2 t80 -43.21 -45.81 5.81 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.005 -1.059 . . . . 0.0 110.656 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.443 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 0.6 OUTLIER -139.42 147.04 40.86 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.255 -0.903 . . . . 0.0 110.292 179.819 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 66.5 m -112.72 126.12 55.06 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.304 -0.872 . . . . 0.0 110.324 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 26.9 pt -129.99 163.91 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.936 . . . . 0.0 110.176 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.94 -167.08 26.46 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.556 ' CD1' ' N ' ' A' ' 20' ' ' LEU . 10.1 mp -68.6 -21.63 64.49 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.264 -1.139 . . . . 0.0 110.347 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 94.7 mtt-85 -54.68 138.69 41.08 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.371 -0.831 . . . . 0.0 110.178 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -109.62 170.41 8.08 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.238 -0.914 . . . . 0.0 109.971 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.493 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 79.9 tttt -115.33 113.25 23.57 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.014 -1.054 . . . . 0.0 110.607 -179.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 45.5 mm -70.45 -31.06 45.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.406 -0.809 . . . . 0.0 109.963 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.448 ' O ' ' N ' ' A' ' 33' ' ' CYS . . . -174.59 -166.49 32.62 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.737 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.487 HG21 ' O ' ' A' ' 28' ' ' GLY . 51.8 m -113.45 109.33 18.49 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.208 -1.172 . . . . 0.0 110.711 -179.669 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.461 ' SG ' ' HA ' ' A' ' 33' ' ' CYS . 60.0 m -58.17 -51.46 69.62 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.173 -0.955 . . . . 0.0 109.897 179.577 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.487 ' O ' HG21 ' A' ' 26' ' ' THR . . . -141.49 -164.22 9.9 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.933 -1.667 . . . . 0.0 108.933 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.622 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 14.9 m -85.96 -41.41 0.6 Allowed Pre-proline 0 C--N 1.301 -1.521 0 O-C-N 120.939 -1.33 . . . . 0.0 109.954 179.358 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.622 ' CD ' ' N ' ' A' ' 29' ' ' SER . 45.4 Cg_endo -81.34 8.16 4.55 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 O-C-N 123.501 1.264 . . . . 0.0 109.84 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.6 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 67.3 m-85 -153.25 169.15 23.76 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.08 -1.012 . . . . 0.0 110.975 -179.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.551 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 92.8 mttt -133.8 160.1 38.63 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.1 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.493 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 2.9 t -90.26 120.01 31.05 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.744 -1.222 . . . . 0.0 110.337 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 73.4 m -142.67 142.18 31.99 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.86 . . . . 0.0 110.226 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 86.2 tttt . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.124 179.9 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 81.8 m . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 121.213 0.53 . . . . 0.0 109.955 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.51 HG22 ' N ' ' A' ' 8' ' ' ARG . 12.5 tt -59.46 -39.48 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.322 -0.861 . . . . 0.0 109.957 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.51 ' N ' HG22 ' A' ' 7' ' ' ILE . 17.4 ttm105 -56.77 -38.52 72.59 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.308 -0.87 . . . . 0.0 109.932 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 88.1 m-20 -69.32 -27.72 65.62 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.365 -0.835 . . . . 0.0 109.919 179.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.94 8.66 8.68 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -88.98 -177.93 46.21 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.508 ' CG1' ' O ' ' A' ' 34' ' ' CYS . 46.8 pt -132.23 161.24 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.321 -1.105 . . . . 0.0 109.806 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.475 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.2 m -113.56 154.21 27.52 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.951 -1.093 . . . . 0.0 110.559 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.465 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 11.5 tp60 -151.17 155.82 39.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.563 -0.71 . . . . 0.0 109.74 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.685 ' CE1' ' CE1' ' A' ' 31' ' ' PHE . 56.4 m-85 -54.94 -42.56 72.45 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.111 -0.993 . . . . 0.0 110.599 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.444 ' HD3' ' O ' ' A' ' 15' ' ' TYR . 89.1 mmt-85 -144.54 154.96 43.43 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.254 -0.903 . . . . 0.0 110.399 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 94.2 m -123.1 138.36 54.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.325 -0.859 . . . . 0.0 109.995 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.455 HD13 ' CB ' ' A' ' 20' ' ' LEU . 36.0 pt -102.0 170.23 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -0.909 . . . . 0.0 110.326 -179.859 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -48.21 -43.5 25.95 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.455 ' CB ' HD13 ' A' ' 18' ' ' ILE . 14.2 tp -47.26 -46.7 24.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.207 -1.172 . . . . 0.0 110.311 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -101.39 128.0 47.78 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 110.261 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -88.71 135.32 33.57 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.874 . . . . 0.0 110.198 179.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.526 ' CD ' ' HB3' ' A' ' 32' ' ' LYS . 37.9 ttpt -95.95 117.07 29.92 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.282 -0.887 . . . . 0.0 110.064 179.815 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.43 HG22 HD11 ' A' ' 24' ' ' ILE . 43.0 mm -75.4 -27.27 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.339 -0.851 . . . . 0.0 110.136 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.483 ' O ' ' HB2' ' A' ' 33' ' ' CYS . . . -169.9 -156.51 11.09 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 72.9 p -115.74 113.2 23.14 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.354 -1.086 . . . . 0.0 110.14 179.624 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.52 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 42.2 t -68.73 -29.83 68.33 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.396 -0.815 . . . . 0.0 110.019 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -176.81 -163.61 29.34 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.944 -1.663 . . . . 0.0 108.944 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.604 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.5 m -87.39 -42.9 0.52 Allowed Pre-proline 0 C--N 1.303 -1.413 0 O-C-N 121.076 -1.25 . . . . 0.0 110.055 179.647 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.604 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.9 Cg_endo -81.7 6.94 5.33 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 O-C-N 123.666 1.35 . . . . 0.0 109.663 179.13 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.685 ' CE1' ' CE1' ' A' ' 15' ' ' TYR . 73.3 m-85 -156.6 176.19 13.05 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.283 -0.886 . . . . 0.0 110.619 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.526 ' HB3' ' CD ' ' A' ' 23' ' ' LYS . 95.9 mttt -141.22 156.89 45.85 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.451 -0.781 . . . . 0.0 109.391 179.214 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.52 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 66.5 m -76.99 107.58 9.44 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.023 -1.048 . . . . 0.0 109.869 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.508 ' O ' ' CG1' ' A' ' 12' ' ' ILE . 63.5 m -142.52 136.28 29.18 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.168 -0.957 . . . . 0.0 110.318 -179.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 61.9 mttp . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.128 179.968 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 74.5 m . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 121.197 0.522 . . . . 0.0 110.292 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.5 tt -58.63 -31.17 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.936 179.74 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -61.13 -37.65 83.58 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.277 -0.89 . . . . 0.0 110.123 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -67.89 -29.22 68.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.383 -0.823 . . . . 0.0 110.326 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 122.78 -2.38 10.06 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.99 -173.36 45.54 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.415 HG23 ' N ' ' A' ' 13' ' ' CYS . 22.4 mm -130.97 170.38 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.284 -1.127 . . . . 0.0 110.159 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.46 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 2.4 m -119.63 151.49 38.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.185 -0.947 . . . . 0.0 109.862 179.761 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.471 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 51.6 tt0 -152.36 152.52 32.17 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.541 -0.724 . . . . 0.0 109.639 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.482 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 72.6 t80 -57.67 -38.53 75.29 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.183 -0.948 . . . . 0.0 110.473 -179.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.482 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 7.0 mmm180 -149.91 142.69 24.68 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.288 -0.883 . . . . 0.0 110.274 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.5 m -111.69 151.8 28.46 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.153 -0.967 . . . . 0.0 110.208 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.458 HG22 HD11 ' A' ' 18' ' ' ILE . 3.0 mt -97.95 -168.9 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.184 -0.948 . . . . 0.0 109.897 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -67.38 -43.71 86.84 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 63.9 mt -55.38 -36.78 66.74 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.338 -1.095 . . . . 0.0 109.962 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.7 mmt-85 -100.67 123.24 44.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.354 -0.841 . . . . 0.0 110.244 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -94.39 144.18 25.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 110.107 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.513 ' CE ' ' O ' ' A' ' 25' ' ' GLY . 72.2 tttt -103.53 102.1 11.98 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.216 -0.927 . . . . 0.0 110.371 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 86.1 mt -70.04 -21.37 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.218 -0.926 . . . . 0.0 110.11 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.513 ' O ' ' CE ' ' A' ' 23' ' ' LYS . . . -169.05 -161.5 19.48 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.535 ' O ' ' CG2' ' A' ' 26' ' ' THR . 14.0 t -119.3 112.03 18.93 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.306 -1.114 . . . . 0.0 110.283 179.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.517 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 11.6 t -58.87 -37.42 76.5 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.19 -0.944 . . . . 0.0 109.532 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -164.94 -154.79 8.13 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.432 -1.867 . . . . 0.0 108.432 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.579 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 2.3 m -90.27 -43.99 0.41 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 120.975 -1.309 . . . . 0.0 110.156 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.579 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.5 Cg_endo -82.76 11.72 3.14 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 O-C-N 123.564 1.297 . . . . 0.0 109.859 179.2 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.527 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 83.1 m-85 -155.38 174.16 15.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.209 -0.932 . . . . 0.0 110.57 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.434 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 67.5 mttm -137.11 159.31 42.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.638 -0.664 . . . . 0.0 109.36 179.183 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.517 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 76.7 m -78.07 105.72 9.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.031 -1.043 . . . . 0.0 110.203 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 4.9 m -136.0 138.46 42.26 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.143 -0.973 . . . . 0.0 110.275 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . 0.401 ' HA ' ' HD2' ' A' ' 35' ' ' LYS . 30.8 mmmt . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.176 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 85.3 m . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.178 0.513 . . . . 0.0 110.423 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.402 HG13 ' N ' ' A' ' 8' ' ' ARG . 47.1 pt -75.53 -28.51 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.251 -0.906 . . . . 0.0 110.191 179.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.402 ' N ' HG13 ' A' ' 7' ' ' ILE . 25.7 tpt180 -62.3 -32.75 73.53 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.26 -0.9 . . . . 0.0 110.02 179.685 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -78.54 -8.14 58.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 110.16 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 98.72 -2.73 58.74 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.36 172.61 49.14 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.324 -1.511 . . . . 0.0 109.324 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 56.6 mt -130.53 170.9 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.287 -1.125 . . . . 0.0 110.275 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.435 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.2 m -103.7 153.75 20.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.162 -0.962 . . . . 0.0 110.087 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.471 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 8.5 tp60 -151.67 152.99 33.53 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.514 -0.741 . . . . 0.0 109.748 179.636 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.588 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 57.5 t80 -60.14 -41.96 93.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.175 -0.953 . . . . 0.0 109.955 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.588 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 33.4 mmt180 -147.79 149.35 32.18 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.443 -0.786 . . . . 0.0 110.097 179.779 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 98.5 m -120.86 176.38 5.57 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.211 -0.93 . . . . 0.0 110.1 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.432 HG22 HD11 ' A' ' 18' ' ' ILE . 48.6 pt -122.37 175.45 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.258 -0.901 . . . . 0.0 110.436 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -59.06 -31.46 68.84 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.485 ' CD1' ' C ' ' A' ' 20' ' ' LEU . 3.1 tm? -59.48 -37.96 79.61 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.282 -1.128 . . . . 0.0 110.272 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.413 ' HG3' HD11 ' A' ' 20' ' ' LEU . 99.6 mtt180 -104.81 128.35 52.94 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.274 -0.891 . . . . 0.0 110.289 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -88.07 141.95 28.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.247 -0.908 . . . . 0.0 110.011 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.508 ' NZ ' ' O ' ' A' ' 25' ' ' GLY . 46.4 tttm -94.25 107.12 19.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.859 . . . . 0.0 110.352 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 38.5 mm -68.72 -31.68 51.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.282 -0.887 . . . . 0.0 110.485 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.508 ' O ' ' NZ ' ' A' ' 23' ' ' LYS . . . -165.91 -156.04 9.12 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 -179.544 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.521 ' O ' ' CG2' ' A' ' 26' ' ' THR . 14.8 t -122.28 106.92 11.54 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.682 -0.893 . . . . 0.0 109.872 179.639 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.516 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 37.9 t -62.75 -35.86 81.16 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.199 -0.938 . . . . 0.0 110.3 -179.452 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -169.08 -163.4 23.05 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.588 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.3 m -88.29 -43.3 0.47 Allowed Pre-proline 0 C--N 1.303 -1.422 0 O-C-N 121.062 -1.258 . . . . 0.0 110.32 179.856 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.588 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.8 Cg_endo -81.18 5.64 6.12 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.525 1.276 . . . . 0.0 109.572 179.307 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 63.7 m-85 -153.0 169.47 22.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.275 -0.891 . . . . 0.0 110.486 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.503 ' HB3' ' CE ' ' A' ' 23' ' ' LYS . 96.0 mttt -136.75 158.45 44.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.437 -0.789 . . . . 0.0 109.69 179.497 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.516 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 59.5 m -80.68 120.14 24.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.126 -0.983 . . . . 0.0 109.471 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.9 m -143.4 134.5 25.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.227 -0.921 . . . . 0.0 110.457 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.914 -1.041 . . . . 0.0 109.952 179.709 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.407 ' O ' ' SG ' ' A' ' 6' ' ' CYS . 45.3 t . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.279 0.561 . . . . 0.0 110.099 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.3 pt -113.73 -9.56 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.267 -0.896 . . . . 0.0 110.218 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 95.0 mtt-85 -65.8 -35.91 82.04 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.09 -1.006 . . . . 0.0 110.106 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.0 m120 -96.41 5.94 49.81 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.252 -0.905 . . . . 0.0 110.2 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 74.15 18.21 79.7 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.91 175.59 51.97 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 56.4 mt -120.56 170.27 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -1.137 . . . . 0.0 110.307 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.455 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 3.0 m -117.72 154.03 32.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.22 -0.925 . . . . 0.0 110.178 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.523 ' O ' ' N ' ' A' ' 32' ' ' LYS . 8.0 tt0 -160.38 151.2 18.75 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.646 -0.658 . . . . 0.0 109.567 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.448 ' HA ' ' HA ' ' A' ' 31' ' ' PHE . 83.8 t80 -55.53 -37.75 68.34 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.028 -1.045 . . . . 0.0 110.606 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.404 ' HG3' ' N ' ' A' ' 17' ' ' CYS . 14.2 tpt180 -146.05 163.1 36.32 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.255 -0.903 . . . . 0.0 110.233 -179.782 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.404 ' N ' ' HG3' ' A' ' 16' ' ' ARG . 20.1 m -139.37 125.63 20.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.468 -0.77 . . . . 0.0 109.789 179.545 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.0 pt -138.13 165.23 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.261 -0.9 . . . . 0.0 110.313 -179.697 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.11 -155.42 26.33 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.488 ' CD2' ' N ' ' A' ' 20' ' ' LEU . 4.5 mm? -61.78 -28.1 69.21 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.351 -1.087 . . . . 0.0 110.202 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 94.1 mtt180 -53.03 135.52 36.92 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.266 -0.896 . . . . 0.0 110.296 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -113.1 156.11 23.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.332 -0.855 . . . . 0.0 110.073 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 81.6 tttt -101.81 107.62 18.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.188 -0.945 . . . . 0.0 110.177 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 67.7 mt -76.98 -33.71 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.899 . . . . 0.0 110.215 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.468 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -169.71 -169.56 33.1 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 75.2 p -105.95 99.17 8.78 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.394 -1.063 . . . . 0.0 110.474 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.455 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 38.6 t -54.28 -40.05 67.48 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.169 -0.957 . . . . 0.0 109.722 179.655 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -155.99 -165.68 14.85 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 108.598 -1.801 . . . . 0.0 108.598 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.6 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 9.0 m -87.18 -42.97 0.53 Allowed Pre-proline 0 C--N 1.299 -1.625 0 O-C-N 121.128 -1.219 . . . . 0.0 109.825 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.6 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.0 Cg_endo -82.23 7.66 4.97 Favored 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.49 1.258 . . . . 0.0 109.691 178.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.582 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 90.5 m-85 -152.36 169.86 21.51 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.299 -0.876 . . . . 0.0 110.64 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 14' ' ' GLN . 96.3 mttt -130.9 159.36 37.65 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.012 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.468 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 47.2 t -85.51 121.18 27.85 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.962 -1.087 . . . . 0.0 109.801 179.759 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 97.3 m -138.21 141.87 39.98 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 110.342 -179.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . 0.425 ' OXT' ' HG2' ' A' ' 35' ' ' LYS . 88.0 tttt . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.164 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.497 ' O ' ' N ' ' A' ' 10' ' ' GLY . 10.1 t . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 121.176 0.512 . . . . 0.0 110.468 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.459 HG13 ' N ' ' A' ' 8' ' ' ARG . 50.0 pt -71.17 -30.52 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.188 -0.945 . . . . 0.0 110.015 -179.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.459 ' N ' HG13 ' A' ' 7' ' ' ILE . 51.0 ttt85 -66.21 -54.8 20.84 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.433 -0.792 . . . . 0.0 110.083 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -142.67 9.42 1.78 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.407 -0.808 . . . . 0.0 110.459 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 6' ' ' CYS . . . -83.65 -30.15 30.48 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.764 -1.335 . . . . 0.0 109.764 -179.763 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 129.61 -155.92 21.11 Favored Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.599 -1.286 . . . . 0.0 109.89 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 41.2 mt -96.34 171.0 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 O-C-N 121.692 -0.887 . . . . 0.0 109.668 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.502 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.1 m -139.7 153.39 47.22 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.069 -1.019 . . . . 0.0 110.414 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -161.09 157.21 25.69 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.726 -0.609 . . . . 0.0 109.908 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.473 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 87.5 m-85 -44.91 -37.31 3.84 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.16 -0.962 . . . . 0.0 110.206 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.442 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 25.7 mmm180 -147.31 147.11 30.03 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.321 -0.862 . . . . 0.0 110.128 179.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.1 m -111.56 130.25 55.8 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.24 -0.912 . . . . 0.0 110.065 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 43.3 pt -127.9 172.42 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.159 -0.963 . . . . 0.0 110.321 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.14 -156.04 23.31 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.516 ' CD1' ' N ' ' A' ' 20' ' ' LEU . 10.4 mp -87.26 -5.12 59.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.181 -1.188 . . . . 0.0 110.214 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 74.4 mtm180 -61.07 148.35 40.66 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.298 -0.876 . . . . 0.0 110.358 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.516 ' CE1' ' O ' ' A' ' 20' ' ' LEU . 63.4 m80 -119.01 143.65 46.95 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.362 -0.836 . . . . 0.0 110.17 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 36.4 ttpt -93.79 117.79 30.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.174 -0.954 . . . . 0.0 110.318 -179.757 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 22.4 pt -96.93 -8.79 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.16 -0.962 . . . . 0.0 110.176 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.27 -170.57 37.69 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 32' ' ' LYS . 81.7 p -129.82 108.28 10.03 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.278 -1.131 . . . . 0.0 110.347 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.457 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 46.6 m -51.99 -36.03 48.48 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.24 -0.913 . . . . 0.0 109.706 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -159.22 -159.37 9.67 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.589 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 16.9 m -90.12 -41.88 0.41 Allowed Pre-proline 0 C--N 1.302 -1.476 0 O-C-N 121.09 -1.241 . . . . 0.0 110.553 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.589 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.4 Cg_endo -80.24 6.64 5.21 Favored 'Trans proline' 0 C--N 1.311 -1.442 0 O-C-N 123.416 1.219 . . . . 0.0 109.845 179.445 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.527 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 45.4 m-85 -146.06 179.8 7.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.349 -0.845 . . . . 0.0 110.262 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.502 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 91.3 mttt -143.28 170.31 16.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.525 -0.734 . . . . 0.0 109.065 179.228 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 38.4 t -96.55 115.87 28.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.783 -1.198 . . . . 0.0 109.969 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 84.6 m -141.89 138.04 31.78 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.095 -1.003 . . . . 0.0 110.143 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.178 179.756 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 10.5 t . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.201 0.524 . . . . 0.0 110.157 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.6 tt -60.38 -32.53 51.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.157 -0.964 . . . . 0.0 110.405 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 84.3 mtt180 -60.55 -33.54 72.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.212 -0.93 . . . . 0.0 110.254 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 91.0 m-20 -62.02 -25.34 67.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 110.175 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.62 13.09 23.2 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.28 -172.74 44.66 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.0 pt -129.77 151.51 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.264 -1.139 . . . . 0.0 110.177 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 1.8 m -91.11 151.96 20.79 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.028 -1.045 . . . . 0.0 109.993 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.549 ' O ' ' N ' ' A' ' 32' ' ' LYS . 55.2 tt0 -146.23 150.68 36.27 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.401 -0.812 . . . . 0.0 109.881 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.554 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 62.0 t80 -59.1 -46.01 89.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.065 -1.022 . . . . 0.0 110.58 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.554 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 19.4 mmt180 -148.92 140.81 23.72 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.289 -0.882 . . . . 0.0 110.325 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 40.5 m -116.63 142.66 46.6 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.435 -0.791 . . . . 0.0 109.847 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.523 HD11 ' N ' ' A' ' 18' ' ' ILE . 3.4 mm -90.85 -168.96 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.155 -0.965 . . . . 0.0 110.149 -179.732 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.99 -30.9 69.7 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.925 -1.67 . . . . 0.0 108.925 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.428 ' CD1' ' N ' ' A' ' 20' ' ' LEU . 9.4 mp -63.77 -29.57 70.77 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.427 -1.043 . . . . 0.0 110.19 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 82.5 mtt-85 -105.34 128.27 53.4 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.189 -0.944 . . . . 0.0 110.562 -179.611 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 61.6 m170 -94.53 143.0 26.78 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.269 -0.894 . . . . 0.0 110.44 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.465 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 34.2 ttpt -109.26 117.38 33.94 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.257 -0.902 . . . . 0.0 110.61 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 80.4 mt -73.55 -35.38 44.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.187 -0.946 . . . . 0.0 109.826 179.578 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.469 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -160.72 -170.87 25.91 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.448 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 51.6 m -107.94 103.61 12.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.176 -1.191 . . . . 0.0 110.305 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.419 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 42.0 t -53.11 -48.28 67.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.299 -0.875 . . . . 0.0 109.967 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.448 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -149.59 -165.29 12.3 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 108.906 -1.677 . . . . 0.0 108.906 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.599 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.3 m -89.32 -42.3 0.43 Allowed Pre-proline 0 C--N 1.303 -1.444 0 O-C-N 121.095 -1.238 . . . . 0.0 110.417 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.599 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.2 Cg_endo -81.82 6.68 5.51 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.474 1.249 . . . . 0.0 109.715 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.502 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 97.9 m-85 -152.48 173.71 14.8 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.308 -0.87 . . . . 0.0 110.197 179.632 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.549 ' N ' ' O ' ' A' ' 14' ' ' GLN . 62.0 mttm -136.41 155.96 49.29 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.458 -0.776 . . . . 0.0 109.147 179.452 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.469 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 50.4 t -87.72 115.06 24.9 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.177 -0.952 . . . . 0.0 110.73 -179.67 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 56.3 m -132.39 145.64 51.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.262 -0.899 . . . . 0.0 109.956 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 56.7 tttp . . . . . 0 N--CA 1.492 1.64 0 O-C-N 121.089 -1.007 . . . . 0.0 110.348 -179.815 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.539 ' SG ' ' CG2' ' A' ' 24' ' ' ILE . 13.1 t . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 121.301 0.572 . . . . 0.0 110.431 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.449 HG13 ' N ' ' A' ' 8' ' ' ARG . 42.5 pt -57.46 -25.49 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.344 -0.847 . . . . 0.0 110.295 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.449 ' N ' HG13 ' A' ' 7' ' ' ILE . 67.8 ttt180 -58.72 -36.17 73.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.221 -0.924 . . . . 0.0 110.473 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 23.8 m120 -67.66 -28.34 67.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.223 -0.923 . . . . 0.0 110.364 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.83 8.0 16.5 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.64 179.62 52.97 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.6 pt -124.05 159.13 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.238 -1.154 . . . . 0.0 110.322 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.481 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 1.7 m -99.49 154.63 18.09 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.274 -0.891 . . . . 0.0 109.835 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.497 ' O ' ' N ' ' A' ' 32' ' ' LYS . 37.6 tp60 -156.74 154.77 30.53 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.223 -0.923 . . . . 0.0 109.887 179.722 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.581 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 50.2 t80 -58.86 -49.28 78.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.124 -0.985 . . . . 0.0 110.231 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.581 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 13.9 mmt85 -145.07 151.34 38.36 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.437 -0.789 . . . . 0.0 110.458 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.508 ' HB2' ' NE ' ' A' ' 21' ' ' ARG . 87.6 m -118.83 178.58 4.43 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.331 -0.856 . . . . 0.0 109.844 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.429 ' O ' ' O ' ' A' ' 19' ' ' GLY . 47.1 pt -101.78 175.3 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.091 -1.006 . . . . 0.0 110.485 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' A' ' 18' ' ' ILE . . . -50.03 178.78 0.03 OUTLIER Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.604 ' N ' ' CD2' ' A' ' 20' ' ' LEU . 2.7 mm? 46.47 42.3 10.67 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.319 -1.106 . . . . 0.0 109.37 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.508 ' NE ' ' HB2' ' A' ' 17' ' ' CYS . 25.5 ttm180 -79.52 134.85 36.51 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 110.631 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 70.0 m-70 -99.77 37.01 1.68 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 179.328 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.486 ' HE3' ' HA ' ' A' ' 26' ' ' THR . 60.8 tttt -73.36 108.92 6.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.413 -0.804 . . . . 0.0 110.534 -179.514 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.539 ' CG2' ' SG ' ' A' ' 6' ' ' CYS . 7.6 tp -78.68 -18.04 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.244 -0.91 . . . . 0.0 109.63 179.599 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.474 ' N ' HG21 ' A' ' 24' ' ' ILE . . . -165.46 -173.42 33.99 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.486 ' HA ' ' HE3' ' A' ' 23' ' ' LYS . 92.5 m -109.62 107.06 16.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.136 -1.214 . . . . 0.0 110.261 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.43 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 48.8 t -46.12 -63.72 0.92 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.399 -0.813 . . . . 0.0 109.687 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.477 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -129.63 -170.47 12.75 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 179.425 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.596 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.9 m -85.88 -42.19 0.61 Allowed Pre-proline 0 C--N 1.303 -1.445 0 O-C-N 121.01 -1.288 . . . . 0.0 109.898 179.484 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.608 ' HG2' ' CD2' ' A' ' 31' ' ' PHE . 52.0 Cg_endo -81.39 6.0 5.9 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 O-C-N 123.557 1.293 . . . . 0.0 109.428 179.189 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.608 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 86.8 m-85 -148.18 170.15 18.48 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.116 -0.99 . . . . 0.0 110.538 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.497 ' N ' ' O ' ' A' ' 14' ' ' GLN . 89.9 mttt -133.37 156.12 48.23 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.6 -0.688 . . . . 0.0 109.285 179.028 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 50.7 t -89.62 123.59 33.81 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.165 -0.96 . . . . 0.0 109.907 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.414 ' SG ' ' HD3' ' A' ' 21' ' ' ARG . 33.3 m -138.02 130.75 29.68 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 110.085 -179.796 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 86.2 tttt . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 118.041 -0.98 . . . . 0.0 110.171 -179.971 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 86.2 m . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 121.235 0.541 . . . . 0.0 110.334 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.405 HG22 ' N ' ' A' ' 8' ' ' ARG . 16.2 tt -61.43 -36.75 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.232 -0.918 . . . . 0.0 110.389 -179.658 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.405 ' N ' HG22 ' A' ' 7' ' ' ILE . 76.8 ttt-85 -53.12 -39.2 63.27 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.135 -0.978 . . . . 0.0 110.294 -179.849 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -65.59 -23.73 66.9 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.41 -0.806 . . . . 0.0 110.328 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 111.4 5.76 26.05 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.18 175.67 43.12 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 72.9 mt -127.83 171.96 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.273 -1.133 . . . . 0.0 110.021 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.424 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 1.5 m -102.49 147.84 26.26 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.177 -0.952 . . . . 0.0 109.752 179.565 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.482 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 27.2 tp60 -148.86 152.72 36.96 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.517 -0.739 . . . . 0.0 109.643 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.468 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 97.8 m-85 -60.34 -42.25 95.3 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.229 -0.919 . . . . 0.0 110.698 -179.537 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.44 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 29.2 mmm180 -149.3 142.22 24.76 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.233 -0.917 . . . . 0.0 110.605 -179.68 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.419 ' C ' HG21 ' A' ' 18' ' ' ILE . 67.5 m -119.94 126.52 51.08 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.304 -0.873 . . . . 0.0 109.955 179.598 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.419 HG21 ' C ' ' A' ' 17' ' ' CYS . 48.0 pt -143.35 168.04 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.124 -0.985 . . . . 0.0 110.456 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 66.39 -135.56 33.9 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 35.9 mt -59.38 -34.74 72.78 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.395 -1.062 . . . . 0.0 110.273 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -71.49 132.32 44.57 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.346 -0.846 . . . . 0.0 110.651 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 74.7 t60 -133.86 153.55 51.66 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.334 -0.854 . . . . 0.0 109.879 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.472 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 0.0 OUTLIER -110.61 124.45 51.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.111 -0.993 . . . . 0.0 110.731 -179.746 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 23.7 pt -103.66 -5.87 9.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.317 -0.864 . . . . 0.0 109.853 179.579 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.433 ' C ' ' HB2' ' A' ' 33' ' ' CYS . . . -159.41 -169.89 23.3 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.757 -1.737 . . . . 0.0 108.757 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.538 ' O ' ' CG2' ' A' ' 26' ' ' THR . 14.8 t -128.47 105.36 8.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.073 -1.251 . . . . 0.0 110.636 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.528 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 53.6 t -60.29 -29.6 68.93 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.283 -0.886 . . . . 0.0 109.43 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -168.7 -163.05 22.04 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.603 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 63.5 m -88.02 -41.58 0.49 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 120.891 -1.358 . . . . 0.0 109.999 179.488 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.603 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.4 Cg_endo -82.76 8.2 4.72 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.43 1.226 . . . . 0.0 109.519 179.003 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.577 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 97.7 m-85 -147.72 173.79 12.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.339 -0.851 . . . . 0.0 110.771 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -136.86 159.62 41.33 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.605 -0.684 . . . . 0.0 109.317 179.362 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.528 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 91.0 m -80.09 105.04 11.07 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.003 -1.061 . . . . 0.0 109.984 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 64.2 m -130.45 147.93 52.2 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.187 -0.946 . . . . 0.0 110.375 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . 0.428 ' OXT' ' HG3' ' A' ' 35' ' ' LYS . 64.4 pttt . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.19 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 32.8 t . . . . . 0 N--CA 1.491 1.603 0 CA-C-O 121.403 0.62 . . . . 0.0 110.099 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.546 ' CD1' ' O ' ' A' ' 11' ' ' GLY . 1.0 OUTLIER -69.31 -37.07 75.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.337 -0.852 . . . . 0.0 109.878 179.876 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 23.3 ttp180 -56.98 -32.7 66.35 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.243 -0.911 . . . . 0.0 110.535 -179.611 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -59.77 -30.16 68.69 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.197 -0.939 . . . . 0.0 109.746 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 124.04 14.09 3.85 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 179.433 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.546 ' O ' ' CD1' ' A' ' 7' ' ' ILE . . . -101.77 175.41 25.34 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.714 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.7 mt -119.03 169.54 9.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.27 -1.135 . . . . 0.0 110.026 179.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.497 ' SG ' ' CG1' ' A' ' 7' ' ' ILE . 1.9 m -112.17 153.18 27.43 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.153 -0.967 . . . . 0.0 110.071 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.518 ' O ' ' N ' ' A' ' 32' ' ' LYS . 11.9 tp60 -152.03 154.37 35.85 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.31 -0.869 . . . . 0.0 109.863 179.768 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.555 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 58.6 t80 -56.35 -37.5 70.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.107 -0.996 . . . . 0.0 110.258 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.555 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 35.2 mmt180 -146.14 157.49 43.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.256 -0.902 . . . . 0.0 110.228 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -122.53 154.63 37.63 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.244 -0.91 . . . . 0.0 110.333 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.472 HG13 ' HB2' ' A' ' 20' ' ' LEU . 14.6 pt -106.89 161.64 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.213 -0.929 . . . . 0.0 110.219 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.86 -29.42 54.95 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.534 ' CD1' ' N ' ' A' ' 20' ' ' LEU . 10.0 mp -65.04 -34.67 78.98 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.173 -1.192 . . . . 0.0 110.422 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.1 mtt180 -93.68 137.22 33.16 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.204 -0.935 . . . . 0.0 110.307 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -83.73 134.79 34.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.189 -0.944 . . . . 0.0 110.235 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -98.85 98.57 9.64 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.23 -0.919 . . . . 0.0 110.21 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 89.1 mt -66.78 -33.47 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.286 -0.884 . . . . 0.0 110.314 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.427 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -175.83 -167.14 34.34 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 64.6 p -104.88 104.15 13.87 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.426 -1.044 . . . . 0.0 110.462 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.425 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 49.9 t -56.09 -43.03 77.65 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.266 -0.896 . . . . 0.0 109.83 179.62 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -154.09 -166.57 15.06 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 179.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.596 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.1 m -88.6 -42.32 0.46 Allowed Pre-proline 0 C--N 1.301 -1.525 0 O-C-N 121.077 -1.249 . . . . 0.0 110.232 179.679 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.605 ' HG2' ' CD2' ' A' ' 31' ' ' PHE . 47.8 Cg_endo -81.83 6.59 5.57 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 O-C-N 123.504 1.265 . . . . 0.0 109.949 179.26 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.605 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 83.2 m-85 -151.57 170.78 18.83 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.153 -0.967 . . . . 0.0 110.409 179.728 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.518 ' N ' ' O ' ' A' ' 14' ' ' GLN . 94.4 mttt -132.7 156.89 46.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.336 -0.853 . . . . 0.0 109.653 179.524 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.427 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 9.8 t -84.48 121.6 27.81 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.225 -0.922 . . . . 0.0 110.143 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 71.6 m -133.59 132.75 41.21 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.315 -0.866 . . . . 0.0 110.25 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 84.6 tttt . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.119 179.929 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.45 ' O ' ' OD1' ' A' ' 9' ' ' ASN . 80.8 m . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 121.296 0.57 . . . . 0.0 110.385 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.457 HG21 ' N ' ' A' ' 8' ' ' ARG . 5.7 tt -58.19 -17.28 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.182 -0.949 . . . . 0.0 110.189 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.457 ' N ' HG21 ' A' ' 7' ' ' ILE . 9.1 tpm_? -66.63 -33.76 76.37 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.223 -0.923 . . . . 0.0 110.247 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.457 ' OD1' ' N ' ' A' ' 11' ' ' GLY . 47.4 p30 -84.98 4.98 31.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.149 -0.969 . . . . 0.0 110.182 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.76 -5.04 53.71 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.457 ' N ' ' OD1' ' A' ' 9' ' ' ASN . . . -72.63 175.78 43.44 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 70.1 mt -130.82 174.41 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -1.114 . . . . 0.0 110.198 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.47 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.6 m -127.16 150.68 49.4 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.213 -0.929 . . . . 0.0 110.174 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 4.4 tp-100 -156.04 151.74 27.22 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.677 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.515 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 73.6 t80 -56.98 -31.64 65.26 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.113 -0.992 . . . . 0.0 110.396 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.515 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 38.0 mmt180 -151.63 150.94 30.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.358 -0.839 . . . . 0.0 110.23 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 96.3 m -121.55 125.91 47.9 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.286 -0.884 . . . . 0.0 110.304 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.43 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 36.8 pt -62.27 166.41 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.239 -0.913 . . . . 0.0 110.126 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.85 -42.4 59.73 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.727 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.43 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 32.8 mt -51.86 -28.58 16.46 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.325 -1.103 . . . . 0.0 110.31 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 61.5 mtt-85 -117.66 118.95 33.49 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.235 -0.915 . . . . 0.0 110.487 -179.742 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -97.99 144.77 27.17 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.883 . . . . 0.0 109.814 179.741 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.473 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -99.78 107.0 18.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.133 -0.979 . . . . 0.0 110.643 -179.718 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 51.3 mm -64.08 -35.63 74.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.253 -0.904 . . . . 0.0 110.19 179.741 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.48 ' C ' ' HB2' ' A' ' 33' ' ' CYS . . . -141.56 -162.77 9.3 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.631 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.513 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 90.0 m -122.44 108.61 13.39 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.476 -1.014 . . . . 0.0 110.286 179.692 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.517 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 10.9 t -58.64 -32.59 69.2 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.224 -0.922 . . . . 0.0 109.587 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.513 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -172.02 -158.35 15.93 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.709 -1.757 . . . . 0.0 108.709 179.621 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.591 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.7 m -88.97 -43.09 0.44 Allowed Pre-proline 0 C--N 1.302 -1.485 0 O-C-N 120.839 -1.389 . . . . 0.0 110.215 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.591 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.2 Cg_endo -83.52 10.22 3.77 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.557 1.293 . . . . 0.0 109.533 179.009 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.548 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 79.0 m-85 -154.21 171.11 19.72 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.342 -0.849 . . . . 0.0 110.737 -179.861 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.47 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 95.5 mttt -134.32 161.28 35.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.588 -0.695 . . . . 0.0 109.196 179.168 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.517 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 58.0 m -80.37 100.06 8.25 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.063 -1.023 . . . . 0.0 110.185 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.455 ' SG ' ' HB3' ' A' ' 23' ' ' LYS . 19.8 m -129.38 158.35 39.38 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.143 -0.973 . . . . 0.0 110.339 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 117.936 -1.03 . . . . 0.0 109.999 179.732 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 84.3 m-20 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.243 0.544 . . . . 0.0 110.203 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.581 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 33.4 mp0 -59.8 -41.7 87.09 Favored Pre-proline 0 N--CA 1.492 1.665 0 O-C-N 121.282 -0.886 . . . . 0.0 111.374 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.581 ' CD ' ' N ' ' A' ' 2' ' ' GLU . 48.9 Cg_endo -77.22 -6.63 16.65 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 O-C-N 123.369 1.194 . . . . 0.0 110.605 -179.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.446 ' HB ' ' O ' ' A' ' 3' ' ' PRO . 60.0 t 56.0 173.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.118 -0.989 . . . . 0.0 110.255 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.519 ' OG ' ' CG2' ' A' ' 7' ' ' ILE . 74.9 p -67.7 177.15 2.15 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.235 -0.916 . . . . 0.0 110.35 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 28.4 t -61.64 -19.93 62.83 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.329 -0.857 . . . . 0.0 110.482 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.519 ' CG2' ' OG ' ' A' ' 5' ' ' SER . 9.9 tt -57.47 -32.37 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.163 -0.961 . . . . 0.0 110.646 -179.735 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.438 ' HD2' ' HB ' ' A' ' 4' ' ' VAL . 59.4 ttt180 -56.08 -31.83 63.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 110.485 -179.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -66.03 -30.38 70.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.263 -0.898 . . . . 0.0 110.239 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.04 5.85 21.26 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -82.59 -178.49 52.39 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.402 HG21 HD11 ' A' ' 12' ' ' ILE . 23.8 mm -112.1 166.64 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.146 -1.208 . . . . 0.0 110.273 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.501 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.4 m -120.22 153.79 35.79 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.183 -0.948 . . . . 0.0 109.998 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.499 ' O ' ' N ' ' A' ' 32' ' ' LYS . 20.0 tp60 -153.7 154.93 35.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.434 -0.791 . . . . 0.0 109.714 179.689 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.541 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 72.5 t80 -59.88 -36.39 76.84 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.164 -0.96 . . . . 0.0 110.252 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.541 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 38.8 mmt180 -148.42 152.44 36.97 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.344 -0.848 . . . . 0.0 109.958 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 69.5 m -123.03 152.25 41.13 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.128 -0.982 . . . . 0.0 110.289 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.7 pt -103.82 165.92 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.326 -0.858 . . . . 0.0 109.899 179.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.78 -42.75 37.72 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.477 ' CD1' ' C ' ' A' ' 20' ' ' LEU . 3.3 tm? -51.01 -35.15 32.49 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.177 -1.19 . . . . 0.0 110.404 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.8 mtp180 -89.87 150.16 22.34 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.186 -0.946 . . . . 0.0 110.485 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 92.4 m-70 -108.3 141.21 40.43 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.313 -0.867 . . . . 0.0 109.818 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.429 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 76.4 tttt -121.83 121.93 38.3 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.179 -0.95 . . . . 0.0 110.74 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 28.8 pt -101.43 -6.3 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.388 -0.82 . . . . 0.0 109.793 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.44 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -178.17 -174.22 44.27 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.515 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 89.1 m -111.27 111.04 21.82 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.177 -1.19 . . . . 0.0 110.31 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.402 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 38.9 t -53.71 -48.18 69.81 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.225 -0.922 . . . . 0.0 109.958 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.515 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -149.84 -163.29 11.01 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.582 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 9.7 m -89.81 -42.94 0.42 Allowed Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 120.998 -1.295 . . . . 0.0 110.221 179.799 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.584 ' O ' ' CD1' ' A' ' 31' ' ' PHE . 50.4 Cg_endo -82.27 7.21 5.24 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.499 1.263 . . . . 0.0 109.555 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.584 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 57.7 m-85 -151.87 169.21 22.84 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.324 -0.86 . . . . 0.0 110.284 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.501 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 93.2 mttt -131.21 157.3 43.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.342 -0.849 . . . . 0.0 109.656 179.285 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.44 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 42.3 t -84.77 119.01 24.81 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.095 -1.003 . . . . 0.0 110.255 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 97.8 m -145.44 157.24 44.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.293 -0.879 . . . . 0.0 110.315 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.209 179.877 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 24.3 m120 . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 121.329 0.585 . . . . 0.0 110.165 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.58 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 63.6 mm-40 -59.6 -42.99 94.76 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.276 -0.89 . . . . 0.0 110.989 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.58 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.4 Cg_endo -74.98 -11.11 21.5 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.333 1.175 . . . . 0.0 110.467 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.479 HG13 ' N ' ' A' ' 5' ' ' SER . 59.0 t 51.69 173.49 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.278 -0.889 . . . . 0.0 110.374 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.479 ' N ' HG13 ' A' ' 4' ' ' VAL . 68.0 m -105.42 129.39 53.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.3 -0.875 . . . . 0.0 109.987 179.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 7.3 t -62.33 -31.61 72.26 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.289 -0.882 . . . . 0.0 110.525 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.464 HG12 ' HB3' ' A' ' 5' ' ' SER . 36.5 pt -60.03 -14.66 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.18 -0.95 . . . . 0.0 110.264 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 78.0 mmt-85 -64.38 -34.91 79.25 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.294 -0.879 . . . . 0.0 110.117 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -65.58 -26.18 67.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.337 -0.852 . . . . 0.0 110.027 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.89 -1.07 13.51 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.79 -176.73 50.97 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.4 pt -128.63 163.77 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.348 -1.089 . . . . 0.0 110.002 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.486 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.2 m -103.38 154.41 19.44 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.092 -1.005 . . . . 0.0 109.951 -179.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.533 ' O ' ' N ' ' A' ' 32' ' ' LYS . 4.9 tp60 -149.42 151.26 33.72 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.306 -0.871 . . . . 0.0 109.989 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.435 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 67.6 t80 -55.21 -44.66 75.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 110.131 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.435 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 48.3 mmm-85 -150.23 143.0 24.69 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.363 -0.836 . . . . 0.0 110.233 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 90.4 m -109.49 153.25 24.33 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.25 -0.907 . . . . 0.0 110.127 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.541 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 38.3 pt -103.76 176.45 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.274 -0.891 . . . . 0.0 110.233 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.72 -33.04 81.01 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.541 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 3.9 mm? -61.2 -34.93 75.88 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -1.162 . . . . 0.0 110.056 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -99.45 149.04 23.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.259 -0.901 . . . . 0.0 110.063 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 72.8 m80 -107.74 134.79 50.2 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.188 -0.945 . . . . 0.0 110.213 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.465 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 35.6 tttm -97.22 107.26 19.75 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.325 -0.859 . . . . 0.0 110.239 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -69.74 -32.44 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 110.179 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.453 ' O ' ' HE2' ' A' ' 23' ' ' LYS . . . -166.41 -173.17 34.54 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.436 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 61.8 m -104.25 100.04 9.77 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.244 -1.15 . . . . 0.0 110.309 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.415 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 35.9 t -52.22 -43.88 64.49 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.202 -0.936 . . . . 0.0 109.734 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.436 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -154.59 -163.37 11.92 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 179.737 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.584 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 15.8 m -90.46 -41.86 0.4 Allowed Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.035 -1.274 . . . . 0.0 110.34 179.695 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.588 ' HG2' ' CD2' ' A' ' 31' ' ' PHE . 45.8 Cg_endo -81.92 7.0 5.32 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.466 1.245 . . . . 0.0 109.785 179.084 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.588 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 88.9 m-85 -153.65 170.96 19.58 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.263 -0.898 . . . . 0.0 110.351 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 14' ' ' GLN . 61.5 mttm -133.19 156.55 47.29 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.472 -0.768 . . . . 0.0 109.635 179.512 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.465 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 10.8 t -84.74 113.06 21.04 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.243 -0.911 . . . . 0.0 110.282 -179.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.7 m -138.84 143.22 38.72 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.345 -0.847 . . . . 0.0 110.064 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.257 -179.858 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.418 ' O ' ' O ' ' A' ' 4' ' ' VAL . 83.5 m-20 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.437 0.637 . . . . 0.0 110.072 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.598 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 34.7 tt0 -74.75 -39.46 3.57 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.872 . . . . 0.0 111.411 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 2' ' ' GLU . 46.5 Cg_endo -76.23 -14.41 18.57 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.187 1.098 . . . . 0.0 110.789 -179.296 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.418 ' O ' ' O ' ' A' ' 1' ' ' ASN . 15.5 m -135.87 146.8 28.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.154 -0.966 . . . . 0.0 110.351 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 62.8 m -114.99 144.2 43.97 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.223 -0.923 . . . . 0.0 110.159 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 34.4 t -63.22 -28.59 70.14 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.146 -0.972 . . . . 0.0 110.184 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.0 tp -52.18 -28.48 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.404 -0.81 . . . . 0.0 110.385 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 48.6 ttp180 -57.16 -31.55 65.51 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.169 -0.957 . . . . 0.0 110.469 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -67.14 -30.6 70.64 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.286 -0.884 . . . . 0.0 110.25 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 116.06 8.28 13.62 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -85.83 -177.19 50.19 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 34.8 pt -116.62 162.35 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.185 -1.185 . . . . 0.0 110.064 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.491 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.1 m -113.19 155.1 25.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.121 -0.987 . . . . 0.0 110.141 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.477 ' O ' ' N ' ' A' ' 32' ' ' LYS . 65.2 tt0 -154.29 155.46 35.21 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.404 -0.81 . . . . 0.0 109.835 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.571 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 60.1 t80 -57.79 -44.69 86.44 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.177 -0.952 . . . . 0.0 110.257 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.571 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 41.0 mmt180 -145.95 150.2 35.62 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.35 -0.844 . . . . 0.0 110.267 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.1 m -120.62 126.06 49.31 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.211 -0.931 . . . . 0.0 110.052 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.5 pt -134.03 165.32 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.227 -0.921 . . . . 0.0 110.205 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.91 -169.73 40.78 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 94.8 mt -51.78 -29.99 21.14 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.34 -1.094 . . . . 0.0 110.273 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 81.0 mtm180 -53.08 148.98 7.23 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.246 -0.909 . . . . 0.0 110.278 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 45.8 p-80 -135.18 164.46 27.62 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.27 -0.894 . . . . 0.0 109.968 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.489 ' CE ' ' HA ' ' A' ' 26' ' ' THR . 68.5 tttt -112.69 99.06 7.64 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.12 -0.987 . . . . 0.0 110.519 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.404 HD13 ' HD2' ' A' ' 35' ' ' LYS . 90.1 mt -60.52 -43.43 94.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.288 -0.883 . . . . 0.0 110.069 179.68 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.433 ' O ' ' HE2' ' A' ' 23' ' ' LYS . . . -144.06 -173.77 15.77 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.489 ' HA ' ' CE ' ' A' ' 23' ' ' LYS . 90.2 m -108.9 105.5 15.08 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.265 -1.138 . . . . 0.0 110.366 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.432 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 48.6 t -55.67 -44.25 77.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -0.929 . . . . 0.0 109.767 179.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.484 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -152.41 -167.11 14.91 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.805 -1.718 . . . . 0.0 108.805 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.606 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 2.0 m -87.36 -43.18 0.52 Allowed Pre-proline 0 C--N 1.299 -1.602 0 O-C-N 121.227 -1.16 . . . . 0.0 110.003 179.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.606 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.3 Cg_endo -83.3 7.63 5.09 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 O-C-N 123.628 1.33 . . . . 0.0 109.564 179.153 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.572 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 88.6 m-85 -152.07 170.63 19.45 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -0.893 . . . . 0.0 110.207 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.491 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 92.2 mttt -134.03 156.4 48.28 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.529 -0.732 . . . . 0.0 109.634 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.448 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 42.6 t -84.62 121.51 27.73 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.138 -0.976 . . . . 0.0 110.23 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 65.9 m -142.18 139.5 32.08 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.251 -0.905 . . . . 0.0 110.258 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . 0.404 ' HD2' HD13 ' A' ' 24' ' ' ILE . 94.8 mttt . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.078 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.455 ' HB2' ' HB ' ' A' ' 4' ' ' VAL . 97.2 m-20 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.37 0.605 . . . . 0.0 110.068 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.584 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 84.0 tt0 -60.81 -41.22 81.1 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.235 -0.916 . . . . 0.0 111.419 -179.751 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.584 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 47.4 Cg_endo -75.45 -1.86 11.84 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.364 1.191 . . . . 0.0 110.762 -179.404 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.455 ' HB ' ' HB2' ' A' ' 1' ' ' ASN . 61.0 t -137.49 172.51 14.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.158 -0.964 . . . . 0.0 110.106 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.443 ' OG ' HD11 ' A' ' 7' ' ' ILE . 21.4 t -79.15 137.11 37.33 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.247 -0.908 . . . . 0.0 110.022 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 47.7 t -61.47 -40.23 93.75 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.231 -0.918 . . . . 0.0 110.434 -179.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.443 HD11 ' OG ' ' A' ' 5' ' ' SER . 1.6 mp -63.36 -32.27 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.17 -0.957 . . . . 0.0 109.885 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 17.1 tpt180 -55.97 -36.95 68.42 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.376 -0.828 . . . . 0.0 110.332 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -77.46 -9.78 59.09 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.332 -0.855 . . . . 0.0 110.3 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.92 6.33 65.39 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -74.21 -172.26 26.91 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 51.7 mt -122.45 169.35 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -1.161 . . . . 0.0 110.187 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.481 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.6 m -134.81 155.22 51.01 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.314 -0.866 . . . . 0.0 110.096 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.419 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 28.1 mt-30 -153.04 156.43 38.75 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.509 -0.744 . . . . 0.0 109.95 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.502 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 81.8 m-85 -52.62 -34.89 53.16 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.142 -0.974 . . . . 0.0 110.032 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.457 ' NH1' ' HE3' ' A' ' 32' ' ' LYS . 26.9 tpt180 -151.95 165.76 33.62 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.395 -0.815 . . . . 0.0 110.097 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 23.4 m -138.28 128.11 25.3 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.22 -0.925 . . . . 0.0 110.129 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 pt -142.44 167.34 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.292 -0.88 . . . . 0.0 110.171 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.44 -150.54 23.59 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.541 ' O ' ' CD2' ' A' ' 22' ' ' HIS . 4.2 mm? -67.69 -19.66 65.2 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.352 -1.087 . . . . 0.0 109.999 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.0 mtt180 -54.81 142.8 27.75 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.354 -0.841 . . . . 0.0 110.323 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.541 ' CD2' ' O ' ' A' ' 20' ' ' LEU . 96.4 m-70 -128.25 161.06 30.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.401 -0.812 . . . . 0.0 110.015 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.46 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 25.2 ttmt -122.54 126.61 48.14 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.198 -0.939 . . . . 0.0 110.31 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 35.0 pt -99.19 -9.6 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.263 -0.898 . . . . 0.0 110.06 179.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.439 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -173.33 -171.74 38.2 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.53 ' O ' ' CG2' ' A' ' 26' ' ' THR . 15.0 t -109.82 106.93 16.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.253 -1.145 . . . . 0.0 110.218 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 20.7 t -59.31 -37.8 78.66 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.211 -0.931 . . . . 0.0 110.106 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -170.3 -164.9 26.8 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.602 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 61.7 m -88.7 -41.62 0.46 Allowed Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 120.903 -1.351 . . . . 0.0 110.148 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.602 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.1 Cg_endo -82.88 8.62 4.49 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 123.504 1.265 . . . . 0.0 109.425 178.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 69.5 m-85 -155.8 172.42 18.37 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.382 -0.823 . . . . 0.0 110.469 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.481 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 65.0 mttm -135.83 158.17 45.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.557 -0.715 . . . . 0.0 109.172 178.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.46 ' O ' ' HG3' ' A' ' 23' ' ' LYS . 38.3 t -77.4 121.07 23.29 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.978 -1.076 . . . . 0.0 109.956 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 56.0 m -147.64 150.95 35.35 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.107 -0.995 . . . . 0.0 110.355 -179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.187 179.99 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 23.8 m120 . . . . . 0 N--CA 1.494 1.747 0 CA-C-O 121.248 0.547 . . . . 0.0 110.108 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.605 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 87.5 tt0 -70.29 -40.45 11.92 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.32 -0.863 . . . . 0.0 111.19 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.605 ' CD ' ' N ' ' A' ' 2' ' ' GLU . 47.2 Cg_endo -76.84 -3.74 14.13 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 O-C-N 123.341 1.18 . . . . 0.0 110.835 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.56 ' CG2' ' N ' ' A' ' 5' ' ' SER . 0.9 OUTLIER -136.13 171.57 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.182 -0.949 . . . . 0.0 110.1 179.504 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.56 ' N ' ' CG2' ' A' ' 4' ' ' VAL . 47.0 m 55.31 54.38 8.74 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.415 -0.803 . . . . 0.0 110.138 -179.823 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 43.0 t -63.7 -39.59 94.69 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.224 -0.922 . . . . 0.0 110.279 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.482 HG13 ' N ' ' A' ' 8' ' ' ARG . 40.8 pt -56.53 -29.05 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -0.883 . . . . 0.0 110.266 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.482 ' N ' HG13 ' A' ' 7' ' ' ILE . 58.8 ttt-85 -63.43 -41.88 98.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.247 -0.908 . . . . 0.0 110.233 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 -66.0 -26.72 67.67 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.291 -0.881 . . . . 0.0 110.176 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.4 16.34 14.89 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.87 -176.46 36.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 18.9 pt -119.67 151.04 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.262 -1.14 . . . . 0.0 110.011 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.1 m -101.52 153.13 20.0 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.147 -0.971 . . . . 0.0 109.992 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.496 ' O ' ' N ' ' A' ' 32' ' ' LYS . 43.6 tp60 -154.38 154.29 33.03 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.342 -0.849 . . . . 0.0 109.839 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.487 ' N ' ' HG3' ' A' ' 14' ' ' GLN . 64.2 t80 -54.89 -34.59 63.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.273 -0.892 . . . . 0.0 110.764 -179.649 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.413 ' HA ' ' HD3' ' A' ' 16' ' ' ARG . 22.1 tpp180 -156.64 164.33 38.29 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.165 -0.959 . . . . 0.0 110.218 -179.816 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 93.5 m -133.43 127.8 34.15 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.299 -0.876 . . . . 0.0 110.156 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.537 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 42.7 pt -59.28 161.43 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.237 -0.914 . . . . 0.0 110.324 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.82 -35.42 52.95 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.537 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 4.4 mm? -58.46 -28.72 65.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.285 -1.126 . . . . 0.0 110.436 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.454 ' HG2' ' HB3' ' A' ' 34' ' ' CYS . 20.5 tpp180 -106.5 130.08 54.34 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.137 -0.977 . . . . 0.0 110.479 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 12.8 p80 -105.82 153.82 21.39 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.401 -0.812 . . . . 0.0 109.636 179.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.516 ' CB ' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -118.79 124.85 48.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.085 -1.01 . . . . 0.0 110.572 -179.761 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.418 HG23 ' HG2' ' A' ' 2' ' ' GLU . 61.0 mt -68.08 -34.85 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.931 . . . . 0.0 109.824 179.686 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.473 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -151.78 -169.25 17.1 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.527 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 27.5 m -111.31 101.34 9.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -1.172 . . . . 0.0 110.39 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.412 ' C ' ' O ' ' A' ' 26' ' ' THR . 40.5 t -44.54 -51.33 9.01 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.303 -0.873 . . . . 0.0 109.806 179.595 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.527 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -145.57 -164.95 11.05 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 108.587 -1.805 . . . . 0.0 108.587 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.581 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.9 m -88.27 -44.38 0.47 Allowed Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 120.821 -1.399 . . . . 0.0 110.08 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.581 ' CD ' ' N ' ' A' ' 29' ' ' SER . 45.2 Cg_endo -80.43 7.8 4.55 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 O-C-N 123.554 1.291 . . . . 0.0 110.083 179.203 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.581 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 89.6 m-85 -149.17 170.52 18.25 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.227 -0.921 . . . . 0.0 110.269 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.496 ' N ' ' O ' ' A' ' 14' ' ' GLN . 98.1 mttt -131.37 159.07 39.04 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.463 -0.773 . . . . 0.0 109.505 179.18 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.516 ' O ' ' CB ' ' A' ' 23' ' ' LYS . 47.8 t -84.61 115.79 22.82 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.048 -1.032 . . . . 0.0 110.406 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.461 ' SG ' ' HB3' ' A' ' 23' ' ' LYS . 71.7 m -142.54 130.86 22.2 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.136 -0.977 . . . . 0.0 110.092 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 96.2 mttt . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.26 -179.782 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 66.4 t30 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 121.207 0.527 . . . . 0.0 110.009 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.579 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 93.0 mt-10 -61.37 -42.89 87.42 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.152 -0.968 . . . . 0.0 111.054 -179.821 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.579 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 48.2 Cg_endo -76.12 -5.2 16.03 Favored 'Trans proline' 0 C--N 1.31 -1.466 0 O-C-N 123.403 1.212 . . . . 0.0 110.643 -179.604 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.546 ' CG2' ' O ' ' A' ' 3' ' ' PRO . 13.2 m 38.5 -161.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.579 -0.701 . . . . 0.0 110.685 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.483 ' HB3' ' O ' ' A' ' 4' ' ' VAL . 22.9 t 61.01 48.07 6.83 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.547 -0.721 . . . . 0.0 110.375 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.404 ' O ' ' HB ' ' A' ' 7' ' ' ILE . 45.9 t -76.08 119.99 20.77 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.359 -0.838 . . . . 0.0 110.315 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.472 HG21 ' N ' ' A' ' 8' ' ' ARG . 7.0 tt -175.06 -28.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.236 -0.915 . . . . 0.0 110.706 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.472 ' N ' HG21 ' A' ' 7' ' ' ILE . 15.6 mtm180 -57.29 -30.62 64.86 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.943 -1.098 . . . . 0.0 109.492 179.415 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -65.99 -29.42 69.8 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.618 -0.676 . . . . 0.0 110.368 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 107.48 9.74 28.52 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.93 171.05 48.36 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.8 pt -111.68 161.8 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -1.124 . . . . 0.0 110.176 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.474 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.2 m -104.36 154.33 19.96 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.162 -0.962 . . . . 0.0 109.921 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.533 ' O ' ' N ' ' A' ' 32' ' ' LYS . 63.2 tt0 -155.13 153.42 30.79 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.41 -0.806 . . . . 0.0 109.565 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.473 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 63.2 t80 -59.14 -39.48 82.52 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.043 -1.036 . . . . 0.0 110.36 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.473 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 17.1 mmm180 -144.59 146.76 32.49 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.268 -0.895 . . . . 0.0 110.348 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.2 t -109.14 156.26 20.05 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.254 -0.903 . . . . 0.0 110.441 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.502 HG22 HD11 ' A' ' 18' ' ' ILE . 31.1 pt -110.46 162.79 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.252 -0.905 . . . . 0.0 110.191 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.06 -36.74 52.58 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.468 ' N ' ' CD2' ' A' ' 20' ' ' LEU . 4.2 mm? -56.33 -35.31 67.46 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.194 -1.18 . . . . 0.0 110.169 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 -100.77 129.17 46.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.218 -0.926 . . . . 0.0 110.128 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 77.9 t60 -88.07 124.98 34.31 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.352 -0.842 . . . . 0.0 110.295 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.465 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 27.3 ttpp -97.33 117.18 30.97 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.294 -0.879 . . . . 0.0 110.132 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 35.9 pt -97.62 0.32 10.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.177 -0.952 . . . . 0.0 110.315 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.92 -172.35 43.82 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.487 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 88.4 m -119.46 111.5 18.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -1.118 . . . . 0.0 110.226 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.432 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 45.8 t -54.04 -53.32 54.61 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.247 -0.908 . . . . 0.0 109.795 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.487 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -142.12 -165.36 10.47 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 108.651 -1.779 . . . . 0.0 108.651 179.475 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.608 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 23.5 m -87.27 -41.69 0.52 Allowed Pre-proline 0 C--N 1.304 -1.412 0 O-C-N 121.027 -1.278 . . . . 0.0 110.052 179.618 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.608 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.3 Cg_endo -81.75 7.46 5.02 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 O-C-N 123.506 1.266 . . . . 0.0 109.681 178.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.587 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 86.7 m-85 -151.92 171.09 18.34 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.296 -0.877 . . . . 0.0 110.448 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 14' ' ' GLN . 62.0 mttm -128.6 157.76 40.37 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.429 -0.794 . . . . 0.0 109.264 179.347 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.465 ' O ' ' HG3' ' A' ' 23' ' ' LYS . 48.9 t -91.76 117.56 29.87 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.985 -1.072 . . . . 0.0 110.301 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 96.9 m -135.43 131.42 36.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.211 -0.93 . . . . 0.0 110.595 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.2 ptmm? . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.241 179.925 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 73.8 m-80 . . . . . 0 N--CA 1.496 1.836 0 CA-C-O 121.237 0.541 . . . . 0.0 110.2 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.586 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 79.8 tt0 -61.59 -42.72 85.48 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.142 -0.973 . . . . 0.0 110.726 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 52.2 Cg_endo -76.24 -155.26 0.05 OUTLIER 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.473 1.249 . . . . 0.0 110.34 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 4.0 t -131.38 167.83 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.115 -0.99 . . . . 0.0 110.178 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 92.7 p -78.35 153.45 31.64 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.201 -0.937 . . . . 0.0 110.289 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.458 ' HB2' ' SG ' ' A' ' 27' ' ' CYS . 0.3 OUTLIER -88.05 9.92 20.85 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.341 -0.849 . . . . 0.0 110.035 179.91 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.413 ' CG2' ' N ' ' A' ' 8' ' ' ARG . 4.8 tp -65.16 -33.43 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.286 -0.884 . . . . 0.0 110.105 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.413 ' N ' ' CG2' ' A' ' 7' ' ' ILE . 81.0 mtt180 -52.15 -37.94 56.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.3 -0.875 . . . . 0.0 110.336 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -71.08 -6.83 42.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.39 -0.819 . . . . 0.0 110.251 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 81.49 13.96 79.27 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.423 ' C ' HG13 ' A' ' 12' ' ' ILE . . . -96.71 -170.7 34.25 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.423 HG13 ' C ' ' A' ' 11' ' ' GLY . 27.2 mt -132.53 172.53 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.297 -1.119 . . . . 0.0 109.622 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 6.1 m -137.39 159.59 41.5 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.916 -1.115 . . . . 0.0 111.346 -179.586 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 53.9 tp60 -157.67 153.63 27.02 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.475 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 44.1 t80 -44.74 -46.4 10.42 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.979 -1.076 . . . . 0.0 110.392 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.475 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 30.3 mmt180 -137.71 146.58 43.9 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.327 -0.858 . . . . 0.0 110.012 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 77.3 m -111.65 131.02 55.57 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.118 -0.988 . . . . 0.0 110.503 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.489 HG22 HD11 ' A' ' 18' ' ' ILE . 19.4 pt -133.47 164.59 34.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.195 -0.941 . . . . 0.0 110.217 179.714 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.78 -161.35 23.71 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.489 ' O ' ' CE1' ' A' ' 22' ' ' HIS . 53.2 mt -70.56 -24.52 62.8 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.283 -1.128 . . . . 0.0 110.126 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 100.0 mtt180 -57.36 142.86 42.14 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.326 -0.859 . . . . 0.0 110.313 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.489 ' CE1' ' O ' ' A' ' 20' ' ' LEU . 77.6 m-70 -119.6 160.9 21.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.214 -0.929 . . . . 0.0 110.089 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.523 ' CE ' ' OG1' ' A' ' 26' ' ' THR . 76.9 tttt -99.7 97.94 8.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.166 -0.959 . . . . 0.0 110.381 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 89.9 mt -67.37 -26.96 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.188 -0.945 . . . . 0.0 110.181 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -164.33 -169.05 27.36 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.534 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 92.3 m -122.98 111.01 16.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.245 -1.15 . . . . 0.0 110.429 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.458 ' SG ' ' HB2' ' A' ' 6' ' ' CYS . 33.4 m -59.43 -43.47 93.07 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.239 -0.913 . . . . 0.0 109.523 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.534 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -154.28 -160.96 10.14 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.612 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 5.2 m -86.84 -41.65 0.54 Allowed Pre-proline 0 C--N 1.301 -1.515 0 O-C-N 120.941 -1.329 . . . . 0.0 109.977 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.612 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.8 Cg_endo -81.58 7.79 4.8 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 123.539 1.284 . . . . 0.0 109.987 179.19 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.589 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 52.6 m-85 -149.73 179.36 8.07 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.218 -0.926 . . . . 0.0 110.812 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.537 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 68.7 mttt -148.26 161.85 40.68 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.515 -0.74 . . . . 0.0 109.396 179.625 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.425 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 46.9 t -88.88 110.11 20.79 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.611 -1.306 . . . . 0.0 109.78 179.533 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 89.2 m -137.09 150.51 48.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.184 -0.948 . . . . 0.0 110.334 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 99.9 mttt . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.141 179.814 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.488 ' HB3' ' HB ' ' A' ' 4' ' ' VAL . 91.5 m-20 . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.379 0.609 . . . . 0.0 110.271 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.591 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 98.5 mt-10 -62.33 -43.51 85.38 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.385 -0.822 . . . . 0.0 111.277 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 45.3 Cg_endo -73.47 -6.46 18.81 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.344 1.181 . . . . 0.0 110.739 -179.415 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.488 ' HB ' ' HB3' ' A' ' 1' ' ' ASN . 65.5 t -130.15 172.69 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.247 -0.908 . . . . 0.0 109.915 179.635 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.457 ' OG ' HG12 ' A' ' 7' ' ' ILE . 94.6 p -146.82 156.51 43.18 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.287 -0.883 . . . . 0.0 110.052 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 1.3 p -95.82 13.7 25.77 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.899 . . . . 0.0 110.133 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.458 HG13 ' N ' ' A' ' 8' ' ' ARG . 32.3 pt -67.86 -26.15 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.356 -0.84 . . . . 0.0 110.098 179.763 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.458 ' N ' HG13 ' A' ' 7' ' ' ILE . 76.7 mtt85 -49.56 -33.07 13.94 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.202 -0.936 . . . . 0.0 110.336 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 55.5 t-20 -68.92 -23.65 64.19 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.357 -0.839 . . . . 0.0 110.723 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 111.36 -2.93 28.04 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.44 -168.94 41.61 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 51.3 mt -131.6 170.77 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.355 -1.085 . . . . 0.0 109.949 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.524 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.5 m -135.88 159.39 41.81 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.019 -1.051 . . . . 0.0 110.485 179.682 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.479 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 11.6 pt20 -155.64 169.86 23.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.466 -0.771 . . . . 0.0 109.78 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.487 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 96.3 m-85 -58.04 -36.94 73.47 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.302 -0.874 . . . . 0.0 110.842 -179.653 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.469 ' O ' ' HG3' ' A' ' 14' ' ' GLN . 38.3 mmt180 -146.46 153.63 40.66 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.144 -0.972 . . . . 0.0 110.517 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.4 m -122.31 161.94 22.42 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.249 -0.907 . . . . 0.0 109.839 179.519 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.523 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 34.6 pt -113.98 172.83 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.057 -1.027 . . . . 0.0 110.315 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.99 -33.92 64.79 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.523 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 22.9 mt -59.6 -33.64 71.73 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -1.132 . . . . 0.0 110.264 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -101.8 133.79 45.98 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.344 -0.847 . . . . 0.0 110.056 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 66.6 t-80 -88.28 124.85 34.29 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.261 -0.899 . . . . 0.0 110.216 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.498 ' CE ' HG23 ' A' ' 26' ' ' THR . 74.0 tttt -88.02 90.45 8.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.213 -0.929 . . . . 0.0 110.106 179.827 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.9 tt -64.95 -30.98 51.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.189 -0.944 . . . . 0.0 110.358 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' A' ' 33' ' ' CYS . . . -170.02 -171.21 35.29 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.498 HG23 ' CE ' ' A' ' 23' ' ' LYS . 58.2 p -116.31 103.04 10.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.343 -1.092 . . . . 0.0 110.485 -179.732 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.445 ' O ' ' HB2' ' A' ' 1' ' ' ASN . 62.6 m -47.95 -48.6 32.06 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.742 179.52 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.16 -160.09 8.53 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.594 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 8.4 m -89.99 -41.61 0.42 Allowed Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.082 -1.246 . . . . 0.0 110.67 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.594 ' CD ' ' N ' ' A' ' 29' ' ' SER . 46.4 Cg_endo -81.16 7.83 4.72 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 123.472 1.248 . . . . 0.0 109.997 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.578 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 83.9 m-85 -150.36 171.79 16.43 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.255 -0.903 . . . . 0.0 110.438 179.575 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.524 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 93.8 mttt -135.58 158.99 43.01 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.408 -0.808 . . . . 0.0 108.995 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.487 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 4.8 t -89.29 118.78 29.21 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.767 -1.208 . . . . 0.0 109.907 179.506 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 95.4 m -144.31 147.43 33.48 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.133 -0.979 . . . . 0.0 110.299 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 91.5 mttt . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.17 179.721 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.531 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . 82.0 m-20 . . . . . 0 N--CA 1.494 1.768 0 CA-C-O 121.385 0.612 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.592 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 76.3 tt0 -66.99 -41.52 36.4 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.344 -0.847 . . . . 0.0 111.47 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.592 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.0 Cg_endo -74.6 -8.23 20.29 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.241 1.127 . . . . 0.0 110.922 -179.118 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' A' ' 1' ' ' ASN . 28.8 m -131.74 150.94 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.016 -1.052 . . . . 0.0 110.2 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.449 ' OG ' HG12 ' A' ' 7' ' ' ILE . 6.1 t -111.99 135.63 52.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.255 -0.903 . . . . 0.0 110.359 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.452 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 53.1 t -63.42 -40.23 96.62 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.222 -0.923 . . . . 0.0 110.107 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.507 HG13 ' N ' ' A' ' 8' ' ' ARG . 46.7 pt -57.25 -33.49 43.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.241 -0.912 . . . . 0.0 110.279 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.507 ' N ' HG13 ' A' ' 7' ' ' ILE . 65.9 ttt-85 -59.79 -35.51 74.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.207 -0.933 . . . . 0.0 110.17 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.407 ' OD1' ' O ' ' A' ' 9' ' ' ASN . 45.9 t-20 -75.65 -23.23 56.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 109.983 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 112.32 2.07 26.3 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.96 -178.88 48.94 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 57.2 mt -114.63 171.72 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.23 -1.159 . . . . 0.0 110.27 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.3 m -124.6 150.57 45.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 110.053 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.444 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 56.6 tt0 -152.71 154.18 34.75 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.613 -0.679 . . . . 0.0 109.712 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.53 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 89.2 m-85 -57.89 -40.05 79.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.056 -1.027 . . . . 0.0 110.307 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.427 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 24.9 mmm180 -145.0 156.29 43.86 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.309 -0.869 . . . . 0.0 110.496 -179.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.1 m -128.24 160.83 30.89 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.241 -0.912 . . . . 0.0 110.055 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.538 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 48.4 pt -110.71 172.35 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.13 -0.981 . . . . 0.0 110.295 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.45 -33.88 62.79 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.538 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 9.5 mp -62.01 -34.2 75.75 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.157 -1.202 . . . . 0.0 110.224 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 70.7 mtp85 -102.85 113.82 27.58 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.249 -0.907 . . . . 0.0 109.938 179.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 65.7 m170 -68.37 152.26 45.68 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.178 -0.952 . . . . 0.0 110.52 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.467 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 71.4 tttt -120.69 96.69 5.22 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.316 -0.865 . . . . 0.0 109.979 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.496 HD11 HG22 ' A' ' 24' ' ' ILE . 49.5 mm -65.53 -26.46 39.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.274 -0.892 . . . . 0.0 110.601 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.404 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -175.99 -167.84 35.42 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.449 ' HA ' ' HA ' ' A' ' 32' ' ' LYS . 49.5 p -106.57 105.87 16.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -1.077 . . . . 0.0 110.52 -179.808 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.463 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 42.4 t -50.67 -35.76 32.46 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -0.914 . . . . 0.0 109.53 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -161.68 -160.77 11.16 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.448 -1.861 . . . . 0.0 108.448 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.589 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 60.6 m -89.64 -41.89 0.43 Allowed Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 120.942 -1.328 . . . . 0.0 109.956 179.495 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.589 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.0 Cg_endo -83.29 8.87 4.36 Favored 'Trans proline' 0 C--N 1.31 -1.496 0 O-C-N 123.422 1.222 . . . . 0.0 109.557 178.853 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.572 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 95.6 m-85 -153.02 172.45 16.82 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.357 -0.839 . . . . 0.0 110.802 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 93.4 mttt -134.41 160.01 39.29 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 179.092 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 45.7 t -83.8 117.08 23.04 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.983 -1.073 . . . . 0.0 109.911 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 58.9 m -144.12 156.78 44.48 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.233 -0.917 . . . . 0.0 110.506 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 94.8 mttt . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.092 179.829 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.523 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . 25.2 m120 . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.278 0.561 . . . . 0.0 110.238 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.606 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 86.6 tt0 -63.99 -42.64 71.11 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.304 -0.872 . . . . 0.0 111.165 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.606 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 49.2 Cg_endo -73.55 -155.18 0.04 OUTLIER 'Trans proline' 0 C--N 1.314 -1.262 0 O-C-N 123.335 1.176 . . . . 0.0 110.269 -179.402 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.459 ' O ' HG21 ' A' ' 4' ' ' VAL . 26.4 m -109.89 139.29 33.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.064 -1.023 . . . . 0.0 110.519 -179.555 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.4 ' O ' ' HB3' ' A' ' 6' ' ' CYS . 19.8 t -61.45 -26.03 67.62 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.261 -0.9 . . . . 0.0 110.089 179.802 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.4 ' HB3' ' O ' ' A' ' 5' ' ' SER . 48.1 t 55.06 41.33 31.85 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.263 -0.898 . . . . 0.0 110.21 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 37.1 pt -109.93 -11.51 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.293 -0.88 . . . . 0.0 110.235 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 30.0 mmt180 -57.95 -32.4 67.79 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.152 -0.968 . . . . 0.0 110.327 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -67.16 -26.22 66.55 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.385 -0.822 . . . . 0.0 110.436 -179.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.4 13.24 33.53 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.78 -169.92 42.92 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 47.2 mt -129.09 171.12 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.439 -1.036 . . . . 0.0 109.795 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.551 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 5.8 m -136.47 160.18 39.53 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.936 -1.103 . . . . 0.0 111.214 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.4 ' O ' ' C ' ' A' ' 15' ' ' TYR . 44.2 tt0 -160.06 154.39 23.62 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.725 -0.609 . . . . 0.0 109.501 179.507 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.443 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 40.2 t80 -43.21 -45.81 5.81 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.005 -1.059 . . . . 0.0 110.656 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.443 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 0.6 OUTLIER -139.42 147.04 40.86 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.255 -0.903 . . . . 0.0 110.292 179.819 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 66.5 m -112.72 126.12 55.06 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.304 -0.872 . . . . 0.0 110.324 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 26.9 pt -129.99 163.91 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.936 . . . . 0.0 110.176 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.94 -167.08 26.46 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.556 ' CD1' ' N ' ' A' ' 20' ' ' LEU . 10.1 mp -68.6 -21.63 64.49 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.264 -1.139 . . . . 0.0 110.347 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 94.7 mtt-85 -54.68 138.69 41.08 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.371 -0.831 . . . . 0.0 110.178 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -109.62 170.41 8.08 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.238 -0.914 . . . . 0.0 109.971 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.493 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 79.9 tttt -115.33 113.25 23.57 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.014 -1.054 . . . . 0.0 110.607 -179.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 45.5 mm -70.45 -31.06 45.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.406 -0.809 . . . . 0.0 109.963 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.448 ' O ' ' N ' ' A' ' 33' ' ' CYS . . . -174.59 -166.49 32.62 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.737 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.487 HG21 ' O ' ' A' ' 28' ' ' GLY . 51.8 m -113.45 109.33 18.49 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.208 -1.172 . . . . 0.0 110.711 -179.669 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.461 ' SG ' ' HA ' ' A' ' 33' ' ' CYS . 60.0 m -58.17 -51.46 69.62 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.173 -0.955 . . . . 0.0 109.897 179.577 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.487 ' O ' HG21 ' A' ' 26' ' ' THR . . . -141.49 -164.22 9.9 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.933 -1.667 . . . . 0.0 108.933 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.622 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 14.9 m -85.96 -41.41 0.6 Allowed Pre-proline 0 C--N 1.301 -1.521 0 O-C-N 120.939 -1.33 . . . . 0.0 109.954 179.358 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.622 ' CD ' ' N ' ' A' ' 29' ' ' SER . 45.4 Cg_endo -81.34 8.16 4.55 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 O-C-N 123.501 1.264 . . . . 0.0 109.84 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.6 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 67.3 m-85 -153.25 169.15 23.76 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.08 -1.012 . . . . 0.0 110.975 -179.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.551 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 92.8 mttt -133.8 160.1 38.63 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.1 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.493 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 2.9 t -90.26 120.01 31.05 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.744 -1.222 . . . . 0.0 110.337 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 73.4 m -142.67 142.18 31.99 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.86 . . . . 0.0 110.226 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 86.2 tttt . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.124 179.9 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.521 ' HB2' ' CG2' ' A' ' 4' ' ' VAL . 79.0 m-20 . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.228 0.537 . . . . 0.0 110.092 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.613 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 90.5 mt-10 -61.99 -44.34 89.51 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.268 -0.895 . . . . 0.0 111.653 -179.618 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.613 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 43.8 Cg_endo -70.54 -8.23 23.12 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 O-C-N 123.353 1.186 . . . . 0.0 111.12 -178.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.521 ' CG2' ' HB2' ' A' ' 1' ' ' ASN . 5.8 m -130.35 128.54 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.055 -1.028 . . . . 0.0 110.029 179.561 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 67.0 m -112.97 150.64 31.59 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.199 -0.938 . . . . 0.0 110.252 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 81.8 m -65.61 -23.9 66.93 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.225 -0.922 . . . . 0.0 109.955 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.51 HG22 ' N ' ' A' ' 8' ' ' ARG . 12.5 tt -59.46 -39.48 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.322 -0.861 . . . . 0.0 109.957 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.51 ' N ' HG22 ' A' ' 7' ' ' ILE . 17.4 ttm105 -56.77 -38.52 72.59 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.308 -0.87 . . . . 0.0 109.932 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 88.1 m-20 -69.32 -27.72 65.62 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.365 -0.835 . . . . 0.0 109.919 179.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.94 8.66 8.68 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -88.98 -177.93 46.21 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.508 ' CG1' ' O ' ' A' ' 34' ' ' CYS . 46.8 pt -132.23 161.24 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.321 -1.105 . . . . 0.0 109.806 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.475 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.2 m -113.56 154.21 27.52 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.951 -1.093 . . . . 0.0 110.559 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.465 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 11.5 tp60 -151.17 155.82 39.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.563 -0.71 . . . . 0.0 109.74 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.685 ' CE1' ' CE1' ' A' ' 31' ' ' PHE . 56.4 m-85 -54.94 -42.56 72.45 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.111 -0.993 . . . . 0.0 110.599 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.444 ' HD3' ' O ' ' A' ' 15' ' ' TYR . 89.1 mmt-85 -144.54 154.96 43.43 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.254 -0.903 . . . . 0.0 110.399 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 94.2 m -123.1 138.36 54.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.325 -0.859 . . . . 0.0 109.995 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.455 HD13 ' CB ' ' A' ' 20' ' ' LEU . 36.0 pt -102.0 170.23 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -0.909 . . . . 0.0 110.326 -179.859 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -48.21 -43.5 25.95 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.455 ' CB ' HD13 ' A' ' 18' ' ' ILE . 14.2 tp -47.26 -46.7 24.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.207 -1.172 . . . . 0.0 110.311 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -101.39 128.0 47.78 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 110.261 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -88.71 135.32 33.57 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.874 . . . . 0.0 110.198 179.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.526 ' CD ' ' HB3' ' A' ' 32' ' ' LYS . 37.9 ttpt -95.95 117.07 29.92 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.282 -0.887 . . . . 0.0 110.064 179.815 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.43 HG22 HD11 ' A' ' 24' ' ' ILE . 43.0 mm -75.4 -27.27 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.339 -0.851 . . . . 0.0 110.136 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.483 ' O ' ' HB2' ' A' ' 33' ' ' CYS . . . -169.9 -156.51 11.09 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 72.9 p -115.74 113.2 23.14 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.354 -1.086 . . . . 0.0 110.14 179.624 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.52 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 42.2 t -68.73 -29.83 68.33 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.396 -0.815 . . . . 0.0 110.019 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -176.81 -163.61 29.34 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.944 -1.663 . . . . 0.0 108.944 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.604 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.5 m -87.39 -42.9 0.52 Allowed Pre-proline 0 C--N 1.303 -1.413 0 O-C-N 121.076 -1.25 . . . . 0.0 110.055 179.647 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.604 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.9 Cg_endo -81.7 6.94 5.33 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 O-C-N 123.666 1.35 . . . . 0.0 109.663 179.13 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.685 ' CE1' ' CE1' ' A' ' 15' ' ' TYR . 73.3 m-85 -156.6 176.19 13.05 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.283 -0.886 . . . . 0.0 110.619 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.526 ' HB3' ' CD ' ' A' ' 23' ' ' LYS . 95.9 mttt -141.22 156.89 45.85 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.451 -0.781 . . . . 0.0 109.391 179.214 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.52 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 66.5 m -76.99 107.58 9.44 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.023 -1.048 . . . . 0.0 109.869 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.508 ' O ' ' CG1' ' A' ' 12' ' ' ILE . 63.5 m -142.52 136.28 29.18 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.168 -0.957 . . . . 0.0 110.318 -179.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 61.9 mttp . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.128 179.968 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.443 ' HB2' ' HB ' ' A' ' 4' ' ' VAL . 95.7 m-20 . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 121.358 0.599 . . . . 0.0 110.128 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.593 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 84.9 tt0 -63.79 -41.24 63.03 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.333 -0.854 . . . . 0.0 111.349 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.593 ' CD ' ' N ' ' A' ' 2' ' ' GLU . 48.1 Cg_endo -75.73 -8.36 19.16 Favored 'Trans proline' 0 C--N 1.312 -1.374 0 O-C-N 123.378 1.199 . . . . 0.0 110.624 -179.285 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.443 ' HB ' ' HB2' ' A' ' 1' ' ' ASN . 35.5 t -129.3 171.63 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.205 -0.934 . . . . 0.0 110.236 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.445 ' OG ' HG21 ' A' ' 7' ' ' ILE . 43.2 t -137.85 130.39 29.54 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.245 -0.91 . . . . 0.0 110.116 179.873 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 74.5 m -59.85 -26.71 66.05 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.197 -0.939 . . . . 0.0 110.292 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.445 HG21 ' OG ' ' A' ' 5' ' ' SER . 8.5 tt -58.63 -31.17 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.936 179.74 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -61.13 -37.65 83.58 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.277 -0.89 . . . . 0.0 110.123 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -67.89 -29.22 68.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.383 -0.823 . . . . 0.0 110.326 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 122.78 -2.38 10.06 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.99 -173.36 45.54 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.415 HG23 ' N ' ' A' ' 13' ' ' CYS . 22.4 mm -130.97 170.38 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.284 -1.127 . . . . 0.0 110.159 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.46 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 2.4 m -119.63 151.49 38.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.185 -0.947 . . . . 0.0 109.862 179.761 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.471 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 51.6 tt0 -152.36 152.52 32.17 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.541 -0.724 . . . . 0.0 109.639 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.482 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 72.6 t80 -57.67 -38.53 75.29 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.183 -0.948 . . . . 0.0 110.473 -179.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.482 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 7.0 mmm180 -149.91 142.69 24.68 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.288 -0.883 . . . . 0.0 110.274 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.5 m -111.69 151.8 28.46 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.153 -0.967 . . . . 0.0 110.208 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.458 HG22 HD11 ' A' ' 18' ' ' ILE . 3.0 mt -97.95 -168.9 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.184 -0.948 . . . . 0.0 109.897 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -67.38 -43.71 86.84 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 63.9 mt -55.38 -36.78 66.74 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.338 -1.095 . . . . 0.0 109.962 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.7 mmt-85 -100.67 123.24 44.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.354 -0.841 . . . . 0.0 110.244 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -94.39 144.18 25.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 110.107 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.513 ' CE ' ' O ' ' A' ' 25' ' ' GLY . 72.2 tttt -103.53 102.1 11.98 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.216 -0.927 . . . . 0.0 110.371 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 86.1 mt -70.04 -21.37 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.218 -0.926 . . . . 0.0 110.11 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.513 ' O ' ' CE ' ' A' ' 23' ' ' LYS . . . -169.05 -161.5 19.48 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.535 ' O ' ' CG2' ' A' ' 26' ' ' THR . 14.0 t -119.3 112.03 18.93 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.306 -1.114 . . . . 0.0 110.283 179.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.517 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 11.6 t -58.87 -37.42 76.5 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.19 -0.944 . . . . 0.0 109.532 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -164.94 -154.79 8.13 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.432 -1.867 . . . . 0.0 108.432 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.579 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 2.3 m -90.27 -43.99 0.41 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 120.975 -1.309 . . . . 0.0 110.156 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.579 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.5 Cg_endo -82.76 11.72 3.14 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 O-C-N 123.564 1.297 . . . . 0.0 109.859 179.2 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.527 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 83.1 m-85 -155.38 174.16 15.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.209 -0.932 . . . . 0.0 110.57 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.434 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 67.5 mttm -137.11 159.31 42.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.638 -0.664 . . . . 0.0 109.36 179.183 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.517 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 76.7 m -78.07 105.72 9.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.031 -1.043 . . . . 0.0 110.203 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 4.9 m -136.0 138.46 42.26 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.143 -0.973 . . . . 0.0 110.275 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . 0.401 ' HA ' ' HD2' ' A' ' 35' ' ' LYS . 30.8 mmmt . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.176 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.422 ' C ' ' HD2' ' A' ' 3' ' ' PRO . 82.3 m-20 . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.307 0.575 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.594 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 87.0 tt0 -64.15 -38.4 34.49 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.358 -0.839 . . . . 0.0 111.764 179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.594 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 45.6 Cg_endo -73.53 -4.04 14.75 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.05 1.026 . . . . 0.0 110.792 -179.386 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 57.9 t -118.9 173.08 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.153 -0.967 . . . . 0.0 109.811 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.43 ' HB3' HG12 ' A' ' 7' ' ' ILE . 66.6 m -129.8 143.65 50.91 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.164 -0.96 . . . . 0.0 110.473 -179.765 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 85.3 m -90.62 0.05 57.51 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.327 -0.858 . . . . 0.0 110.423 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.43 HG12 ' HB3' ' A' ' 5' ' ' SER . 47.1 pt -75.53 -28.51 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.251 -0.906 . . . . 0.0 110.191 179.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.402 ' N ' HG13 ' A' ' 7' ' ' ILE . 25.7 tpt180 -62.3 -32.75 73.53 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.26 -0.9 . . . . 0.0 110.02 179.685 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -78.54 -8.14 58.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 110.16 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 98.72 -2.73 58.74 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.36 172.61 49.14 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.324 -1.511 . . . . 0.0 109.324 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 56.6 mt -130.53 170.9 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.287 -1.125 . . . . 0.0 110.275 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.435 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.2 m -103.7 153.75 20.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.162 -0.962 . . . . 0.0 110.087 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.471 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 8.5 tp60 -151.67 152.99 33.53 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.514 -0.741 . . . . 0.0 109.748 179.636 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.588 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 57.5 t80 -60.14 -41.96 93.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.175 -0.953 . . . . 0.0 109.955 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.588 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 33.4 mmt180 -147.79 149.35 32.18 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.443 -0.786 . . . . 0.0 110.097 179.779 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 98.5 m -120.86 176.38 5.57 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.211 -0.93 . . . . 0.0 110.1 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.432 HG22 HD11 ' A' ' 18' ' ' ILE . 48.6 pt -122.37 175.45 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.258 -0.901 . . . . 0.0 110.436 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -59.06 -31.46 68.84 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.485 ' CD1' ' C ' ' A' ' 20' ' ' LEU . 3.1 tm? -59.48 -37.96 79.61 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.282 -1.128 . . . . 0.0 110.272 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.413 ' HG3' HD11 ' A' ' 20' ' ' LEU . 99.6 mtt180 -104.81 128.35 52.94 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.274 -0.891 . . . . 0.0 110.289 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -88.07 141.95 28.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.247 -0.908 . . . . 0.0 110.011 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.508 ' NZ ' ' O ' ' A' ' 25' ' ' GLY . 46.4 tttm -94.25 107.12 19.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.859 . . . . 0.0 110.352 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 38.5 mm -68.72 -31.68 51.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.282 -0.887 . . . . 0.0 110.485 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.508 ' O ' ' NZ ' ' A' ' 23' ' ' LYS . . . -165.91 -156.04 9.12 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 -179.544 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.521 ' O ' ' CG2' ' A' ' 26' ' ' THR . 14.8 t -122.28 106.92 11.54 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.682 -0.893 . . . . 0.0 109.872 179.639 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.516 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 37.9 t -62.75 -35.86 81.16 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.199 -0.938 . . . . 0.0 110.3 -179.452 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -169.08 -163.4 23.05 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.588 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.3 m -88.29 -43.3 0.47 Allowed Pre-proline 0 C--N 1.303 -1.422 0 O-C-N 121.062 -1.258 . . . . 0.0 110.32 179.856 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.588 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.8 Cg_endo -81.18 5.64 6.12 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.525 1.276 . . . . 0.0 109.572 179.307 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 63.7 m-85 -153.0 169.47 22.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.275 -0.891 . . . . 0.0 110.486 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.503 ' HB3' ' CE ' ' A' ' 23' ' ' LYS . 96.0 mttt -136.75 158.45 44.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.437 -0.789 . . . . 0.0 109.69 179.497 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.516 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 59.5 m -80.68 120.14 24.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.126 -0.983 . . . . 0.0 109.471 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.9 m -143.4 134.5 25.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.227 -0.921 . . . . 0.0 110.457 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.914 -1.041 . . . . 0.0 109.952 179.709 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.407 ' HB3' ' OG ' ' A' ' 5' ' ' SER . 84.8 m-20 . . . . . 0 N--CA 1.491 1.6 0 CA-C-O 121.17 0.51 . . . . 0.0 110.327 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.603 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 51.0 tp10 -66.75 -41.12 36.11 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.239 -0.913 . . . . 0.0 110.752 179.631 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.603 ' CD ' ' N ' ' A' ' 2' ' ' GLU . 54.7 Cg_endo -78.64 -154.71 0.05 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.378 1.199 . . . . 0.0 109.83 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.538 ' CG2' ' CD1' ' A' ' 7' ' ' ILE . 17.3 m -82.6 136.65 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 120.871 -1.143 . . . . 0.0 110.214 179.832 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.467 ' O ' HG22 ' A' ' 7' ' ' ILE . 58.8 m -129.91 161.02 31.8 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.199 -0.938 . . . . 0.0 110.51 -179.536 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.42 ' HB3' ' O ' ' A' ' 5' ' ' SER . 45.3 t 55.64 31.61 17.64 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.23 -0.919 . . . . 0.0 110.099 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.538 ' CD1' ' CG2' ' A' ' 4' ' ' VAL . 7.3 pt -113.73 -9.56 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.267 -0.896 . . . . 0.0 110.218 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 95.0 mtt-85 -65.8 -35.91 82.04 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.09 -1.006 . . . . 0.0 110.106 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.0 m120 -96.41 5.94 49.81 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.252 -0.905 . . . . 0.0 110.2 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 74.15 18.21 79.7 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.91 175.59 51.97 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 56.4 mt -120.56 170.27 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -1.137 . . . . 0.0 110.307 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.455 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 3.0 m -117.72 154.03 32.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.22 -0.925 . . . . 0.0 110.178 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.523 ' O ' ' N ' ' A' ' 32' ' ' LYS . 8.0 tt0 -160.38 151.2 18.75 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.646 -0.658 . . . . 0.0 109.567 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.448 ' HA ' ' HA ' ' A' ' 31' ' ' PHE . 83.8 t80 -55.53 -37.75 68.34 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.028 -1.045 . . . . 0.0 110.606 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.404 ' HG3' ' N ' ' A' ' 17' ' ' CYS . 14.2 tpt180 -146.05 163.1 36.32 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.255 -0.903 . . . . 0.0 110.233 -179.782 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.404 ' N ' ' HG3' ' A' ' 16' ' ' ARG . 20.1 m -139.37 125.63 20.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.468 -0.77 . . . . 0.0 109.789 179.545 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.0 pt -138.13 165.23 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.261 -0.9 . . . . 0.0 110.313 -179.697 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.11 -155.42 26.33 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.488 ' N ' ' CD2' ' A' ' 20' ' ' LEU . 4.5 mm? -61.78 -28.1 69.21 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.351 -1.087 . . . . 0.0 110.202 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 94.1 mtt180 -53.03 135.52 36.92 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.266 -0.896 . . . . 0.0 110.296 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -113.1 156.11 23.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.332 -0.855 . . . . 0.0 110.073 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 81.6 tttt -101.81 107.62 18.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.188 -0.945 . . . . 0.0 110.177 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 67.7 mt -76.98 -33.71 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.899 . . . . 0.0 110.215 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.468 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -169.71 -169.56 33.1 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 75.2 p -105.95 99.17 8.78 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.394 -1.063 . . . . 0.0 110.474 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.457 ' O ' ' HB2' ' A' ' 5' ' ' SER . 38.6 t -54.28 -40.05 67.48 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.169 -0.957 . . . . 0.0 109.722 179.655 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -155.99 -165.68 14.85 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 108.598 -1.801 . . . . 0.0 108.598 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.6 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 9.0 m -87.18 -42.97 0.53 Allowed Pre-proline 0 C--N 1.299 -1.625 0 O-C-N 121.128 -1.219 . . . . 0.0 109.825 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.6 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.0 Cg_endo -82.23 7.66 4.97 Favored 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.49 1.258 . . . . 0.0 109.691 178.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.582 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 90.5 m-85 -152.36 169.86 21.51 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.299 -0.876 . . . . 0.0 110.64 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 14' ' ' GLN . 96.3 mttt -130.9 159.36 37.65 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.012 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.468 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 47.2 t -85.51 121.18 27.85 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.962 -1.087 . . . . 0.0 109.801 179.759 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 97.3 m -138.21 141.87 39.98 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 110.342 -179.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . 0.425 ' HG2' ' OXT' ' A' ' 35' ' ' LYS . 88.0 tttt . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.164 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.532 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . 88.3 m-20 . . . . . 0 N--CA 1.493 1.675 0 CA-C-O 121.326 0.584 . . . . 0.0 110.201 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.596 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 39.7 tt0 -64.12 -41.12 59.48 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 111.767 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.596 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 47.9 Cg_endo -74.88 0.54 8.71 Favored 'Trans proline' 0 C--N 1.312 -1.381 0 O-C-N 123.318 1.168 . . . . 0.0 110.947 -179.111 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 27.7 m -145.82 128.75 9.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.114 -0.992 . . . . 0.0 110.348 179.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 39.0 m -97.88 134.89 40.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.353 -0.842 . . . . 0.0 109.767 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.497 ' O ' ' N ' ' A' ' 10' ' ' GLY . 10.1 t -72.26 -26.39 61.98 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.183 -0.948 . . . . 0.0 110.468 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.459 HG13 ' N ' ' A' ' 8' ' ' ARG . 50.0 pt -71.17 -30.52 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.188 -0.945 . . . . 0.0 110.015 -179.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.459 ' N ' HG13 ' A' ' 7' ' ' ILE . 51.0 ttt85 -66.21 -54.8 20.84 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.433 -0.792 . . . . 0.0 110.083 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -142.67 9.42 1.78 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.407 -0.808 . . . . 0.0 110.459 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 6' ' ' CYS . . . -83.65 -30.15 30.48 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.764 -1.335 . . . . 0.0 109.764 -179.763 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 129.61 -155.92 21.11 Favored Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.599 -1.286 . . . . 0.0 109.89 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 41.2 mt -96.34 171.0 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 O-C-N 121.692 -0.887 . . . . 0.0 109.668 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.502 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.1 m -139.7 153.39 47.22 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.069 -1.019 . . . . 0.0 110.414 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -161.09 157.21 25.69 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.726 -0.609 . . . . 0.0 109.908 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.473 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 87.5 m-85 -44.91 -37.31 3.84 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.16 -0.962 . . . . 0.0 110.206 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.442 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 25.7 mmm180 -147.31 147.11 30.03 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.321 -0.862 . . . . 0.0 110.128 179.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.1 m -111.56 130.25 55.8 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.24 -0.912 . . . . 0.0 110.065 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 43.3 pt -127.9 172.42 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.159 -0.963 . . . . 0.0 110.321 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.14 -156.04 23.31 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.516 ' CD1' ' N ' ' A' ' 20' ' ' LEU . 10.4 mp -87.26 -5.12 59.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.181 -1.188 . . . . 0.0 110.214 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 74.4 mtm180 -61.07 148.35 40.66 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.298 -0.876 . . . . 0.0 110.358 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.516 ' CE1' ' O ' ' A' ' 20' ' ' LEU . 63.4 m80 -119.01 143.65 46.95 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.362 -0.836 . . . . 0.0 110.17 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 36.4 ttpt -93.79 117.79 30.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.174 -0.954 . . . . 0.0 110.318 -179.757 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 22.4 pt -96.93 -8.79 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.16 -0.962 . . . . 0.0 110.176 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.27 -170.57 37.69 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 32' ' ' LYS . 81.7 p -129.82 108.28 10.03 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.278 -1.131 . . . . 0.0 110.347 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.457 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 46.6 m -51.99 -36.03 48.48 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.24 -0.913 . . . . 0.0 109.706 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -159.22 -159.37 9.67 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.589 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 16.9 m -90.12 -41.88 0.41 Allowed Pre-proline 0 C--N 1.302 -1.476 0 O-C-N 121.09 -1.241 . . . . 0.0 110.553 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.589 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.4 Cg_endo -80.24 6.64 5.21 Favored 'Trans proline' 0 C--N 1.311 -1.442 0 O-C-N 123.416 1.219 . . . . 0.0 109.845 179.445 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.527 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 45.4 m-85 -146.06 179.8 7.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.349 -0.845 . . . . 0.0 110.262 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.502 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 91.3 mttt -143.28 170.31 16.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.525 -0.734 . . . . 0.0 109.065 179.228 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 38.4 t -96.55 115.87 28.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.783 -1.198 . . . . 0.0 109.969 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 84.6 m -141.89 138.04 31.78 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.095 -1.003 . . . . 0.0 110.143 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.178 179.756 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.486 ' N ' ' CG2' ' A' ' 4' ' ' VAL . 58.6 t30 . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 121.357 0.598 . . . . 0.0 110.381 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.594 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 16.0 tp10 -64.05 -42.69 70.93 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.304 -0.872 . . . . 0.0 111.656 -179.575 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.594 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.1 Cg_endo -73.22 -6.28 18.62 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 O-C-N 123.235 1.124 . . . . 0.0 111.04 -179.228 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.486 ' CG2' ' N ' ' A' ' 1' ' ' ASN . 34.4 m -132.84 125.1 51.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.103 -0.998 . . . . 0.0 109.902 179.708 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 68.3 m -108.02 150.25 27.38 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.286 -0.884 . . . . 0.0 110.397 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 10.5 t -61.71 -23.29 66.03 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.184 -0.948 . . . . 0.0 110.157 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.6 tt -60.38 -32.53 51.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.157 -0.964 . . . . 0.0 110.405 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 84.3 mtt180 -60.55 -33.54 72.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.212 -0.93 . . . . 0.0 110.254 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 91.0 m-20 -62.02 -25.34 67.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 110.175 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.62 13.09 23.2 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.28 -172.74 44.66 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.0 pt -129.77 151.51 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.264 -1.139 . . . . 0.0 110.177 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 1.8 m -91.11 151.96 20.79 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.028 -1.045 . . . . 0.0 109.993 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.549 ' O ' ' N ' ' A' ' 32' ' ' LYS . 55.2 tt0 -146.23 150.68 36.27 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.401 -0.812 . . . . 0.0 109.881 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.554 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 62.0 t80 -59.1 -46.01 89.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.065 -1.022 . . . . 0.0 110.58 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.554 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 19.4 mmt180 -148.92 140.81 23.72 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.289 -0.882 . . . . 0.0 110.325 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 40.5 m -116.63 142.66 46.6 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.435 -0.791 . . . . 0.0 109.847 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.523 HD11 ' N ' ' A' ' 18' ' ' ILE . 3.4 mm -90.85 -168.96 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.155 -0.965 . . . . 0.0 110.149 -179.732 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.99 -30.9 69.7 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.925 -1.67 . . . . 0.0 108.925 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.428 ' CD1' ' N ' ' A' ' 20' ' ' LEU . 9.4 mp -63.77 -29.57 70.77 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.427 -1.043 . . . . 0.0 110.19 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 82.5 mtt-85 -105.34 128.27 53.4 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.189 -0.944 . . . . 0.0 110.562 -179.611 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 61.6 m170 -94.53 143.0 26.78 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.269 -0.894 . . . . 0.0 110.44 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.465 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 34.2 ttpt -109.26 117.38 33.94 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.257 -0.902 . . . . 0.0 110.61 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 80.4 mt -73.55 -35.38 44.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.187 -0.946 . . . . 0.0 109.826 179.578 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.469 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -160.72 -170.87 25.91 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.448 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 51.6 m -107.94 103.61 12.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.176 -1.191 . . . . 0.0 110.305 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.419 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 42.0 t -53.11 -48.28 67.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.299 -0.875 . . . . 0.0 109.967 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.448 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -149.59 -165.29 12.3 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 108.906 -1.677 . . . . 0.0 108.906 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.599 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.3 m -89.32 -42.3 0.43 Allowed Pre-proline 0 C--N 1.303 -1.444 0 O-C-N 121.095 -1.238 . . . . 0.0 110.417 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.599 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.2 Cg_endo -81.82 6.68 5.51 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.474 1.249 . . . . 0.0 109.715 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.502 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 97.9 m-85 -152.48 173.71 14.8 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.308 -0.87 . . . . 0.0 110.197 179.632 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.549 ' N ' ' O ' ' A' ' 14' ' ' GLN . 62.0 mttm -136.41 155.96 49.29 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.458 -0.776 . . . . 0.0 109.147 179.452 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.469 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 50.4 t -87.72 115.06 24.9 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.177 -0.952 . . . . 0.0 110.73 -179.67 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 56.3 m -132.39 145.64 51.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.262 -0.899 . . . . 0.0 109.956 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 56.7 tttp . . . . . 0 N--CA 1.492 1.64 0 O-C-N 121.089 -1.007 . . . . 0.0 110.348 -179.815 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.46 ' OD1' ' O ' ' A' ' 1' ' ' ASN . 45.2 p-10 . . . . . 0 N--CA 1.493 1.679 0 CA-C-O 121.429 0.633 . . . . 0.0 110.268 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.59 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 26.3 tt0 -58.11 -42.15 93.52 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.234 -0.916 . . . . 0.0 111.293 -179.816 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.59 ' CD ' ' N ' ' A' ' 2' ' ' GLU . 55.4 Cg_endo -78.16 -156.41 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.392 0 O-C-N 123.426 1.224 . . . . 0.0 110.403 -179.522 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.518 ' CG1' ' O ' ' A' ' 3' ' ' PRO . 20.9 m -157.45 146.93 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.186 -0.946 . . . . 0.0 110.036 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 88.2 p -127.4 144.19 51.09 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.227 -0.921 . . . . 0.0 110.081 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.539 ' SG ' ' CG2' ' A' ' 24' ' ' ILE . 13.1 t -59.66 -32.48 70.5 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.295 -0.878 . . . . 0.0 110.431 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.449 HG13 ' N ' ' A' ' 8' ' ' ARG . 42.5 pt -57.46 -25.49 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.344 -0.847 . . . . 0.0 110.295 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.449 ' N ' HG13 ' A' ' 7' ' ' ILE . 67.8 ttt180 -58.72 -36.17 73.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.221 -0.924 . . . . 0.0 110.473 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 23.8 m120 -67.66 -28.34 67.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.223 -0.923 . . . . 0.0 110.364 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.83 8.0 16.5 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.64 179.62 52.97 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.6 pt -124.05 159.13 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.238 -1.154 . . . . 0.0 110.322 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.481 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 1.7 m -99.49 154.63 18.09 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.274 -0.891 . . . . 0.0 109.835 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.497 ' O ' ' N ' ' A' ' 32' ' ' LYS . 37.6 tp60 -156.74 154.77 30.53 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.223 -0.923 . . . . 0.0 109.887 179.722 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.581 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 50.2 t80 -58.86 -49.28 78.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.124 -0.985 . . . . 0.0 110.231 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.581 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 13.9 mmt85 -145.07 151.34 38.36 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.437 -0.789 . . . . 0.0 110.458 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.508 ' HB2' ' NE ' ' A' ' 21' ' ' ARG . 87.6 m -118.83 178.58 4.43 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.331 -0.856 . . . . 0.0 109.844 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.429 ' O ' ' O ' ' A' ' 19' ' ' GLY . 47.1 pt -101.78 175.3 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.091 -1.006 . . . . 0.0 110.485 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' A' ' 18' ' ' ILE . . . -50.03 178.78 0.03 OUTLIER Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.604 ' N ' ' CD2' ' A' ' 20' ' ' LEU . 2.7 mm? 46.47 42.3 10.67 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.319 -1.106 . . . . 0.0 109.37 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.508 ' NE ' ' HB2' ' A' ' 17' ' ' CYS . 25.5 ttm180 -79.52 134.85 36.51 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 110.631 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 70.0 m-70 -99.77 37.01 1.68 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 179.328 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.486 ' HE3' ' HA ' ' A' ' 26' ' ' THR . 60.8 tttt -73.36 108.92 6.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.413 -0.804 . . . . 0.0 110.534 -179.514 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.539 ' CG2' ' SG ' ' A' ' 6' ' ' CYS . 7.6 tp -78.68 -18.04 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.244 -0.91 . . . . 0.0 109.63 179.599 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.474 ' N ' HG21 ' A' ' 24' ' ' ILE . . . -165.46 -173.42 33.99 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.486 ' HA ' ' HE3' ' A' ' 23' ' ' LYS . 92.5 m -109.62 107.06 16.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.136 -1.214 . . . . 0.0 110.261 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.43 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 48.8 t -46.12 -63.72 0.92 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.399 -0.813 . . . . 0.0 109.687 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.477 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -129.63 -170.47 12.75 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 179.425 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.596 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.9 m -85.88 -42.19 0.61 Allowed Pre-proline 0 C--N 1.303 -1.445 0 O-C-N 121.01 -1.288 . . . . 0.0 109.898 179.484 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.608 ' HG2' ' CD2' ' A' ' 31' ' ' PHE . 52.0 Cg_endo -81.39 6.0 5.9 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 O-C-N 123.557 1.293 . . . . 0.0 109.428 179.189 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.608 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 86.8 m-85 -148.18 170.15 18.48 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.116 -0.99 . . . . 0.0 110.538 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.497 ' N ' ' O ' ' A' ' 14' ' ' GLN . 89.9 mttt -133.37 156.12 48.23 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.6 -0.688 . . . . 0.0 109.285 179.028 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 50.7 t -89.62 123.59 33.81 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.165 -0.96 . . . . 0.0 109.907 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.414 ' SG ' ' HD3' ' A' ' 21' ' ' ARG . 33.3 m -138.02 130.75 29.68 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 110.085 -179.796 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 86.2 tttt . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 118.041 -0.98 . . . . 0.0 110.171 -179.971 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.468 ' HB3' ' O ' ' A' ' 4' ' ' VAL . 85.3 m-20 . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.447 0.641 . . . . 0.0 109.937 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.589 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 67.1 mm-40 -64.8 -40.62 49.62 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.492 -0.755 . . . . 0.0 111.723 -179.656 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.589 ' CD ' ' N ' ' A' ' 2' ' ' GLU . 46.1 Cg_endo -75.08 -16.59 19.94 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.256 1.135 . . . . 0.0 110.924 -179.04 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.469 HG11 ' O ' ' A' ' 3' ' ' PRO . 13.5 m -146.07 135.1 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.099 -1.001 . . . . 0.0 110.231 179.842 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.458 ' OG ' HG21 ' A' ' 7' ' ' ILE . 83.5 p -62.87 148.52 46.96 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.214 -0.928 . . . . 0.0 110.238 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 86.2 m -69.26 -26.59 64.84 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.313 -0.867 . . . . 0.0 110.334 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.458 HG21 ' OG ' ' A' ' 5' ' ' SER . 16.2 tt -61.43 -36.75 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.232 -0.918 . . . . 0.0 110.389 -179.658 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.405 ' N ' HG22 ' A' ' 7' ' ' ILE . 76.8 ttt-85 -53.12 -39.2 63.27 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.135 -0.978 . . . . 0.0 110.294 -179.849 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -65.59 -23.73 66.9 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.41 -0.806 . . . . 0.0 110.328 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 111.4 5.76 26.05 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.18 175.67 43.12 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 72.9 mt -127.83 171.96 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.273 -1.133 . . . . 0.0 110.021 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.424 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 1.5 m -102.49 147.84 26.26 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.177 -0.952 . . . . 0.0 109.752 179.565 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.482 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 27.2 tp60 -148.86 152.72 36.96 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.517 -0.739 . . . . 0.0 109.643 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.468 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 97.8 m-85 -60.34 -42.25 95.3 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.229 -0.919 . . . . 0.0 110.698 -179.537 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.44 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 29.2 mmm180 -149.3 142.22 24.76 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.233 -0.917 . . . . 0.0 110.605 -179.68 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.419 ' C ' HG21 ' A' ' 18' ' ' ILE . 67.5 m -119.94 126.52 51.08 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.304 -0.873 . . . . 0.0 109.955 179.598 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.419 HG21 ' C ' ' A' ' 17' ' ' CYS . 48.0 pt -143.35 168.04 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.124 -0.985 . . . . 0.0 110.456 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 66.39 -135.56 33.9 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 35.9 mt -59.38 -34.74 72.78 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.395 -1.062 . . . . 0.0 110.273 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -71.49 132.32 44.57 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.346 -0.846 . . . . 0.0 110.651 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 74.7 t60 -133.86 153.55 51.66 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.334 -0.854 . . . . 0.0 109.879 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.472 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 0.0 OUTLIER -110.61 124.45 51.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.111 -0.993 . . . . 0.0 110.731 -179.746 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 23.7 pt -103.66 -5.87 9.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.317 -0.864 . . . . 0.0 109.853 179.579 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.433 ' C ' ' HB2' ' A' ' 33' ' ' CYS . . . -159.41 -169.89 23.3 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.757 -1.737 . . . . 0.0 108.757 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.538 ' O ' ' CG2' ' A' ' 26' ' ' THR . 14.8 t -128.47 105.36 8.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.073 -1.251 . . . . 0.0 110.636 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.528 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 53.6 t -60.29 -29.6 68.93 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.283 -0.886 . . . . 0.0 109.43 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -168.7 -163.05 22.04 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.603 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 63.5 m -88.02 -41.58 0.49 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 120.891 -1.358 . . . . 0.0 109.999 179.488 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.603 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.4 Cg_endo -82.76 8.2 4.72 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.43 1.226 . . . . 0.0 109.519 179.003 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.577 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 97.7 m-85 -147.72 173.79 12.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.339 -0.851 . . . . 0.0 110.771 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -136.86 159.62 41.33 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.605 -0.684 . . . . 0.0 109.317 179.362 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.528 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 91.0 m -80.09 105.04 11.07 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.003 -1.061 . . . . 0.0 109.984 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 64.2 m -130.45 147.93 52.2 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.187 -0.946 . . . . 0.0 110.375 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . 0.428 ' OXT' ' HG3' ' A' ' 35' ' ' LYS . 64.4 pttt . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.19 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.519 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . 97.3 m-20 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.455 0.645 . . . . 0.0 110.293 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.591 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 69.5 mm-40 -74.18 -40.74 4.79 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.478 -0.764 . . . . 0.0 111.529 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.5 Cg_endo -74.78 -10.83 21.79 Favored 'Trans proline' 0 C--N 1.313 -1.335 0 O-C-N 123.312 1.164 . . . . 0.0 111.516 -178.819 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.559 ' CG2' ' N ' ' A' ' 5' ' ' SER . 1.4 p -151.14 170.97 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 120.845 -1.159 . . . . 0.0 110.802 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.559 ' N ' ' CG2' ' A' ' 4' ' ' VAL . 49.2 m 53.39 37.98 26.8 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.556 -0.715 . . . . 0.0 110.483 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 32.8 t -62.39 -23.12 66.65 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.202 -0.936 . . . . 0.0 110.099 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.546 ' CD1' ' O ' ' A' ' 11' ' ' GLY . 1.0 OUTLIER -69.31 -37.07 75.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.337 -0.852 . . . . 0.0 109.878 179.876 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 23.3 ttp180 -56.98 -32.7 66.35 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.243 -0.911 . . . . 0.0 110.535 -179.611 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -59.77 -30.16 68.69 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.197 -0.939 . . . . 0.0 109.746 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 124.04 14.09 3.85 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 179.433 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.546 ' O ' ' CD1' ' A' ' 7' ' ' ILE . . . -101.77 175.41 25.34 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.714 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.7 mt -119.03 169.54 9.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.27 -1.135 . . . . 0.0 110.026 179.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.497 ' SG ' ' CG1' ' A' ' 7' ' ' ILE . 1.9 m -112.17 153.18 27.43 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.153 -0.967 . . . . 0.0 110.071 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.518 ' O ' ' N ' ' A' ' 32' ' ' LYS . 11.9 tp60 -152.03 154.37 35.85 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.31 -0.869 . . . . 0.0 109.863 179.768 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.555 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 58.6 t80 -56.35 -37.5 70.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.107 -0.996 . . . . 0.0 110.258 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.555 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 35.2 mmt180 -146.14 157.49 43.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.256 -0.902 . . . . 0.0 110.228 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -122.53 154.63 37.63 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.244 -0.91 . . . . 0.0 110.333 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.472 HG13 ' HB2' ' A' ' 20' ' ' LEU . 14.6 pt -106.89 161.64 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.213 -0.929 . . . . 0.0 110.219 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.86 -29.42 54.95 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.534 ' CD1' ' N ' ' A' ' 20' ' ' LEU . 10.0 mp -65.04 -34.67 78.98 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.173 -1.192 . . . . 0.0 110.422 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.1 mtt180 -93.68 137.22 33.16 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.204 -0.935 . . . . 0.0 110.307 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -83.73 134.79 34.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.189 -0.944 . . . . 0.0 110.235 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -98.85 98.57 9.64 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.23 -0.919 . . . . 0.0 110.21 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 89.1 mt -66.78 -33.47 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.286 -0.884 . . . . 0.0 110.314 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.427 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -175.83 -167.14 34.34 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 64.6 p -104.88 104.15 13.87 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.426 -1.044 . . . . 0.0 110.462 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.425 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 49.9 t -56.09 -43.03 77.65 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.266 -0.896 . . . . 0.0 109.83 179.62 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -154.09 -166.57 15.06 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 179.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.596 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.1 m -88.6 -42.32 0.46 Allowed Pre-proline 0 C--N 1.301 -1.525 0 O-C-N 121.077 -1.249 . . . . 0.0 110.232 179.679 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.605 ' HG2' ' CD2' ' A' ' 31' ' ' PHE . 47.8 Cg_endo -81.83 6.59 5.57 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 O-C-N 123.504 1.265 . . . . 0.0 109.949 179.26 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.605 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 83.2 m-85 -151.57 170.78 18.83 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.153 -0.967 . . . . 0.0 110.409 179.728 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.518 ' N ' ' O ' ' A' ' 14' ' ' GLN . 94.4 mttt -132.7 156.89 46.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.336 -0.853 . . . . 0.0 109.653 179.524 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.427 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 9.8 t -84.48 121.6 27.81 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.225 -0.922 . . . . 0.0 110.143 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 71.6 m -133.59 132.75 41.21 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.315 -0.866 . . . . 0.0 110.25 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 84.6 tttt . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.119 179.929 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.526 ' HB2' ' CG2' ' A' ' 4' ' ' VAL . 26.4 m120 . . . . . 0 N--CA 1.492 1.66 0 CA-C-O 121.272 0.558 . . . . 0.0 110.155 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.615 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 75.9 mt-10 -69.92 -35.89 5.8 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.477 -0.764 . . . . 0.0 112.233 -179.57 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.615 ' CD ' ' N ' ' A' ' 2' ' ' GLU . 46.6 Cg_endo -74.49 -9.25 21.37 Favored 'Trans proline' 0 C--N 1.315 -1.213 0 O-C-N 122.943 0.97 . . . . 0.0 111.074 -178.829 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.526 ' CG2' ' HB2' ' A' ' 1' ' ' ASN . 17.4 m -140.64 149.05 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.082 -1.011 . . . . 0.0 110.163 179.693 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.7 p -154.24 160.26 41.72 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.173 -0.954 . . . . 0.0 110.103 -179.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.45 ' O ' ' OD1' ' A' ' 9' ' ' ASN . 80.8 m -61.06 -35.82 77.97 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.272 -0.892 . . . . 0.0 110.385 -179.869 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.457 HG21 ' N ' ' A' ' 8' ' ' ARG . 5.7 tt -58.19 -17.28 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.182 -0.949 . . . . 0.0 110.189 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.457 ' N ' HG21 ' A' ' 7' ' ' ILE . 9.1 tpm_? -66.63 -33.76 76.37 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.223 -0.923 . . . . 0.0 110.247 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.457 ' OD1' ' N ' ' A' ' 11' ' ' GLY . 47.4 p30 -84.98 4.98 31.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.149 -0.969 . . . . 0.0 110.182 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.76 -5.04 53.71 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.457 ' N ' ' OD1' ' A' ' 9' ' ' ASN . . . -72.63 175.78 43.44 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 70.1 mt -130.82 174.41 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -1.114 . . . . 0.0 110.198 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.47 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.6 m -127.16 150.68 49.4 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.213 -0.929 . . . . 0.0 110.174 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 4.4 tp-100 -156.04 151.74 27.22 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.677 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.515 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 73.6 t80 -56.98 -31.64 65.26 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.113 -0.992 . . . . 0.0 110.396 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.515 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 38.0 mmt180 -151.63 150.94 30.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.358 -0.839 . . . . 0.0 110.23 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 96.3 m -121.55 125.91 47.9 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.286 -0.884 . . . . 0.0 110.304 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.43 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 36.8 pt -62.27 166.41 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.239 -0.913 . . . . 0.0 110.126 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.85 -42.4 59.73 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.727 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.43 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 32.8 mt -51.86 -28.58 16.46 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.325 -1.103 . . . . 0.0 110.31 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 61.5 mtt-85 -117.66 118.95 33.49 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.235 -0.915 . . . . 0.0 110.487 -179.742 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -97.99 144.77 27.17 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.883 . . . . 0.0 109.814 179.741 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.473 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -99.78 107.0 18.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.133 -0.979 . . . . 0.0 110.643 -179.718 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 51.3 mm -64.08 -35.63 74.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.253 -0.904 . . . . 0.0 110.19 179.741 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.48 ' C ' ' HB2' ' A' ' 33' ' ' CYS . . . -141.56 -162.77 9.3 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.631 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.513 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 90.0 m -122.44 108.61 13.39 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.476 -1.014 . . . . 0.0 110.286 179.692 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.517 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 10.9 t -58.64 -32.59 69.2 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.224 -0.922 . . . . 0.0 109.587 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.513 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -172.02 -158.35 15.93 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.709 -1.757 . . . . 0.0 108.709 179.621 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.591 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.7 m -88.97 -43.09 0.44 Allowed Pre-proline 0 C--N 1.302 -1.485 0 O-C-N 120.839 -1.389 . . . . 0.0 110.215 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.591 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.2 Cg_endo -83.52 10.22 3.77 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.557 1.293 . . . . 0.0 109.533 179.009 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.548 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 79.0 m-85 -154.21 171.11 19.72 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.342 -0.849 . . . . 0.0 110.737 -179.861 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.47 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 95.5 mttt -134.32 161.28 35.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.588 -0.695 . . . . 0.0 109.196 179.168 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.517 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 58.0 m -80.37 100.06 8.25 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.063 -1.023 . . . . 0.0 110.185 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.455 ' SG ' ' HB3' ' A' ' 23' ' ' LYS . 19.8 m -129.38 158.35 39.38 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.143 -0.973 . . . . 0.0 110.339 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 117.936 -1.03 . . . . 0.0 109.999 179.732 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 28.4 t . . . . . 0 N--CA 1.493 1.679 0 CA-C-O 121.266 0.555 . . . . 0.0 110.482 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.9 tt -57.47 -32.37 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.163 -0.961 . . . . 0.0 110.646 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 59.4 ttt180 -56.08 -31.83 63.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 110.485 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 75.5 m-20 -66.03 -30.38 70.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.263 -0.898 . . . . 0.0 110.239 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.04 5.85 21.26 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -82.59 -178.49 52.39 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 23.8 mm -112.1 166.64 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.146 -1.208 . . . . 0.0 110.273 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.532 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.4 m -120.22 153.79 35.79 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.183 -0.948 . . . . 0.0 109.998 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.511 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 20.0 tp60 -153.7 154.93 35.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.434 -0.791 . . . . 0.0 109.714 179.689 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.564 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 72.5 t80 -59.88 -36.39 76.84 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.164 -0.96 . . . . 0.0 110.252 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.564 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 38.8 mmt180 -148.42 152.44 36.97 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.344 -0.848 . . . . 0.0 109.958 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 69.5 m -123.03 152.25 41.13 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.128 -0.982 . . . . 0.0 110.289 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.7 pt -103.82 165.92 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.326 -0.858 . . . . 0.0 109.899 179.704 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.78 -42.75 37.72 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.834 HD13 ' O ' ' A' ' 20' ' ' LEU . 3.3 tm? -51.01 -35.15 32.49 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.177 -1.19 . . . . 0.0 110.404 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.8 mtp180 -89.87 150.16 22.34 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.186 -0.946 . . . . 0.0 110.485 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 92.4 m-70 -108.3 141.21 40.43 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.313 -0.867 . . . . 0.0 109.818 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.446 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 76.4 tttt -121.83 121.93 38.3 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.179 -0.95 . . . . 0.0 110.74 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 28.8 pt -101.43 -6.3 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.388 -0.82 . . . . 0.0 109.793 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.459 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -178.17 -174.22 44.27 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.697 HG22 ' O ' ' A' ' 28' ' ' GLY . 89.1 m -111.27 111.04 21.82 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.177 -1.19 . . . . 0.0 110.31 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.411 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 38.9 t -53.71 -48.18 69.81 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.225 -0.922 . . . . 0.0 109.958 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.697 ' O ' HG22 ' A' ' 26' ' ' THR . . . -149.84 -163.29 11.01 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.582 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 9.7 m -89.81 -42.94 0.42 Allowed Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 120.998 -1.295 . . . . 0.0 110.221 179.799 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.584 ' O ' ' CD1' ' A' ' 31' ' ' PHE . 50.4 Cg_endo -82.27 7.21 5.24 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.499 1.263 . . . . 0.0 109.555 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.584 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 57.7 m-85 -151.87 169.21 22.84 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.324 -0.86 . . . . 0.0 110.284 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.532 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 93.2 mttt -131.21 157.3 43.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.342 -0.849 . . . . 0.0 109.656 179.285 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.459 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 42.3 t -84.77 119.01 24.81 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.095 -1.003 . . . . 0.0 110.255 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 97.8 m -145.44 157.24 44.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.293 -0.879 . . . . 0.0 110.315 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.209 179.877 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 7.3 t . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.074 0.464 . . . . 0.0 110.525 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.5 pt -60.03 -14.66 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.18 -0.95 . . . . 0.0 110.264 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 78.0 mmt-85 -64.38 -34.91 79.25 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.294 -0.879 . . . . 0.0 110.117 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -65.58 -26.18 67.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.337 -0.852 . . . . 0.0 110.027 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.89 -1.07 13.51 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.79 -176.73 50.97 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.4 pt -128.63 163.77 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.348 -1.089 . . . . 0.0 110.002 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.521 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.2 m -103.38 154.41 19.44 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.092 -1.005 . . . . 0.0 109.951 -179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.533 ' O ' ' N ' ' A' ' 32' ' ' LYS . 4.9 tp60 -149.42 151.26 33.72 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.306 -0.871 . . . . 0.0 109.989 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.457 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 67.6 t80 -55.21 -44.66 75.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 110.131 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.457 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 48.3 mmm-85 -150.23 143.0 24.69 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.363 -0.836 . . . . 0.0 110.233 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 90.4 m -109.49 153.25 24.33 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.25 -0.907 . . . . 0.0 110.127 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.553 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 38.3 pt -103.76 176.45 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.274 -0.891 . . . . 0.0 110.233 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.72 -33.04 81.01 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.622 ' N ' HD22 ' A' ' 20' ' ' LEU . 3.9 mm? -61.2 -34.93 75.88 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -1.162 . . . . 0.0 110.056 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -99.45 149.04 23.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.259 -0.901 . . . . 0.0 110.063 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 72.8 m80 -107.74 134.79 50.2 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.188 -0.945 . . . . 0.0 110.213 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 35.6 tttm -97.22 107.26 19.75 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.325 -0.859 . . . . 0.0 110.239 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.42 HG23 ' N ' ' A' ' 25' ' ' GLY . 18.9 tt -69.74 -32.44 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 110.179 179.762 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.444 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -166.41 -173.17 34.54 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.618 HG22 ' O ' ' A' ' 28' ' ' GLY . 61.8 m -104.25 100.04 9.77 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.244 -1.15 . . . . 0.0 110.309 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.431 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 35.9 t -52.22 -43.88 64.49 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.202 -0.936 . . . . 0.0 109.734 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.618 ' O ' HG22 ' A' ' 26' ' ' THR . . . -154.59 -163.37 11.92 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 179.737 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.584 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 15.8 m -90.46 -41.86 0.4 Allowed Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.035 -1.274 . . . . 0.0 110.34 179.695 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.584 ' CD ' ' N ' ' A' ' 29' ' ' SER . 45.8 Cg_endo -81.92 7.0 5.32 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.466 1.245 . . . . 0.0 109.785 179.084 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.581 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 88.9 m-85 -153.65 170.96 19.58 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.263 -0.898 . . . . 0.0 110.351 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 14' ' ' GLN . 61.5 mttm -133.19 156.55 47.29 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.472 -0.768 . . . . 0.0 109.635 179.512 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 10.8 t -84.74 113.06 21.04 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.243 -0.911 . . . . 0.0 110.282 -179.765 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.7 m -138.84 143.22 38.72 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.345 -0.847 . . . . 0.0 110.064 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.257 -179.858 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 34.4 t . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 121.243 0.544 . . . . 0.0 110.184 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.432 ' HA ' HD12 ' A' ' 7' ' ' ILE . 6.0 tp -52.18 -28.48 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.404 -0.81 . . . . 0.0 110.385 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 48.6 ttp180 -57.16 -31.55 65.51 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.169 -0.957 . . . . 0.0 110.469 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -67.14 -30.6 70.64 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.286 -0.884 . . . . 0.0 110.25 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 116.06 8.28 13.62 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -85.83 -177.19 50.19 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 34.8 pt -116.62 162.35 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.185 -1.185 . . . . 0.0 110.064 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.521 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.1 m -113.19 155.1 25.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.121 -0.987 . . . . 0.0 110.141 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 65.2 tt0 -154.29 155.46 35.21 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.404 -0.81 . . . . 0.0 109.835 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.596 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 60.1 t80 -57.79 -44.69 86.44 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.177 -0.952 . . . . 0.0 110.257 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.596 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 41.0 mmt180 -145.95 150.2 35.62 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.35 -0.844 . . . . 0.0 110.267 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.1 m -120.62 126.06 49.31 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.211 -0.931 . . . . 0.0 110.052 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.5 pt -134.03 165.32 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.227 -0.921 . . . . 0.0 110.205 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.91 -169.73 40.78 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 94.8 mt -51.78 -29.99 21.14 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.34 -1.094 . . . . 0.0 110.273 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 81.0 mtm180 -53.08 148.98 7.23 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.246 -0.909 . . . . 0.0 110.278 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 45.8 p-80 -135.18 164.46 27.62 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.27 -0.894 . . . . 0.0 109.968 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.473 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 68.5 tttt -112.69 99.06 7.64 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.12 -0.987 . . . . 0.0 110.519 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.421 HD12 ' HE3' ' A' ' 35' ' ' LYS . 90.1 mt -60.52 -43.43 94.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.288 -0.883 . . . . 0.0 110.069 179.68 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.459 ' O ' ' HE2' ' A' ' 23' ' ' LYS . . . -144.06 -173.77 15.77 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.569 HG22 ' O ' ' A' ' 28' ' ' GLY . 90.2 m -108.9 105.5 15.08 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.265 -1.138 . . . . 0.0 110.366 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.445 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 48.6 t -55.67 -44.25 77.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -0.929 . . . . 0.0 109.767 179.731 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.569 ' O ' HG22 ' A' ' 26' ' ' THR . . . -152.41 -167.11 14.91 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.805 -1.718 . . . . 0.0 108.805 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.606 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 2.0 m -87.36 -43.18 0.52 Allowed Pre-proline 0 C--N 1.299 -1.602 0 O-C-N 121.227 -1.16 . . . . 0.0 110.003 179.732 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.606 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.3 Cg_endo -83.3 7.63 5.09 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 O-C-N 123.628 1.33 . . . . 0.0 109.564 179.153 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.562 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 88.6 m-85 -152.07 170.63 19.45 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -0.893 . . . . 0.0 110.207 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.521 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 92.2 mttt -134.03 156.4 48.28 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.529 -0.732 . . . . 0.0 109.634 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 42.6 t -84.62 121.51 27.73 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.138 -0.976 . . . . 0.0 110.23 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 65.9 m -142.18 139.5 32.08 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.251 -0.905 . . . . 0.0 110.258 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.421 ' HE3' HD12 ' A' ' 24' ' ' ILE . 94.8 mttt . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.078 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 47.7 t . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 121.077 0.465 . . . . 0.0 110.434 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.539 ' H ' HD12 ' A' ' 7' ' ' ILE . 1.6 mp -63.36 -32.27 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.17 -0.957 . . . . 0.0 109.885 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 17.1 tpt180 -55.97 -36.95 68.42 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.376 -0.828 . . . . 0.0 110.332 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -77.46 -9.78 59.09 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.332 -0.855 . . . . 0.0 110.3 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.92 6.33 65.39 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -74.21 -172.26 26.91 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.494 HG22 ' N ' ' A' ' 13' ' ' CYS . 51.7 mt -122.45 169.35 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -1.161 . . . . 0.0 110.187 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.6 m -134.81 155.22 51.01 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.314 -0.866 . . . . 0.0 110.096 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.45 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 28.1 mt-30 -153.04 156.43 38.75 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.509 -0.744 . . . . 0.0 109.95 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.502 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 81.8 m-85 -52.62 -34.89 53.16 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.142 -0.974 . . . . 0.0 110.032 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.45 ' NH1' ' HE3' ' A' ' 32' ' ' LYS . 26.9 tpt180 -151.95 165.76 33.62 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.395 -0.815 . . . . 0.0 110.097 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 23.4 m -138.28 128.11 25.3 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.22 -0.925 . . . . 0.0 110.129 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 pt -142.44 167.34 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.292 -0.88 . . . . 0.0 110.171 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.44 -150.54 23.59 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.606 ' N ' HD22 ' A' ' 20' ' ' LEU . 4.2 mm? -67.69 -19.66 65.2 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.352 -1.087 . . . . 0.0 109.999 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.0 mtt180 -54.81 142.8 27.75 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.354 -0.841 . . . . 0.0 110.323 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.541 ' CD2' ' O ' ' A' ' 20' ' ' LEU . 96.4 m-70 -128.25 161.06 30.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.401 -0.812 . . . . 0.0 110.015 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.478 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 25.2 ttmt -122.54 126.61 48.14 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.198 -0.939 . . . . 0.0 110.31 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 35.0 pt -99.19 -9.6 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.263 -0.898 . . . . 0.0 110.06 179.877 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.461 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -173.33 -171.74 38.2 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.746 HG23 ' O ' ' A' ' 26' ' ' THR . 15.0 t -109.82 106.93 16.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.253 -1.145 . . . . 0.0 110.218 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 20.7 t -59.31 -37.8 78.66 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.211 -0.931 . . . . 0.0 110.106 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -170.3 -164.9 26.8 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.602 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 61.7 m -88.7 -41.62 0.46 Allowed Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 120.903 -1.351 . . . . 0.0 110.148 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.602 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.1 Cg_endo -82.88 8.62 4.49 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 123.504 1.265 . . . . 0.0 109.425 178.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 69.5 m-85 -155.8 172.42 18.37 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.382 -0.823 . . . . 0.0 110.469 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 65.0 mttm -135.83 158.17 45.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.557 -0.715 . . . . 0.0 109.172 178.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.478 ' O ' ' HG3' ' A' ' 23' ' ' LYS . 38.3 t -77.4 121.07 23.29 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.978 -1.076 . . . . 0.0 109.956 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 56.0 m -147.64 150.95 35.35 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.107 -0.995 . . . . 0.0 110.355 -179.848 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.187 179.99 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 43.0 t . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.263 0.554 . . . . 0.0 110.279 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.492 HG13 ' N ' ' A' ' 8' ' ' ARG . 40.8 pt -56.53 -29.05 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -0.883 . . . . 0.0 110.266 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.492 ' N ' HG13 ' A' ' 7' ' ' ILE . 58.8 ttt-85 -63.43 -41.88 98.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.247 -0.908 . . . . 0.0 110.233 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 -66.0 -26.72 67.67 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.291 -0.881 . . . . 0.0 110.176 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.4 16.34 14.89 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.87 -176.46 36.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 18.9 pt -119.67 151.04 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.262 -1.14 . . . . 0.0 110.011 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.478 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.1 m -101.52 153.13 20.0 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.147 -0.971 . . . . 0.0 109.992 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 43.6 tp60 -154.38 154.29 33.03 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.342 -0.849 . . . . 0.0 109.839 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.477 ' N ' ' HG3' ' A' ' 14' ' ' GLN . 64.2 t80 -54.89 -34.59 63.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.273 -0.892 . . . . 0.0 110.764 -179.649 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 22.1 tpp180 -156.64 164.33 38.29 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.165 -0.959 . . . . 0.0 110.218 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 93.5 m -133.43 127.8 34.15 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.299 -0.876 . . . . 0.0 110.156 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.555 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 42.7 pt -59.28 161.43 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.237 -0.914 . . . . 0.0 110.324 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.82 -35.42 52.95 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.579 ' N ' HD22 ' A' ' 20' ' ' LEU . 4.4 mm? -58.46 -28.72 65.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.285 -1.126 . . . . 0.0 110.436 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.48 ' HG2' ' HB3' ' A' ' 34' ' ' CYS . 20.5 tpp180 -106.5 130.08 54.34 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.137 -0.977 . . . . 0.0 110.479 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 54.5 p-80 -105.82 153.82 21.39 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.401 -0.812 . . . . 0.0 109.636 179.619 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.516 ' CB ' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -118.79 124.85 48.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.085 -1.01 . . . . 0.0 110.572 -179.761 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 61.0 mt -68.08 -34.85 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.931 . . . . 0.0 109.824 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.497 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -151.78 -169.25 17.1 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.865 HG22 ' O ' ' A' ' 28' ' ' GLY . 27.5 m -111.31 101.34 9.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -1.172 . . . . 0.0 110.39 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.417 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 40.5 t -44.54 -51.33 9.01 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.303 -0.873 . . . . 0.0 109.806 179.595 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.865 ' O ' HG22 ' A' ' 26' ' ' THR . . . -145.57 -164.95 11.05 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 108.587 -1.805 . . . . 0.0 108.587 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.581 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.9 m -88.27 -44.38 0.47 Allowed Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 120.821 -1.399 . . . . 0.0 110.08 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.589 ' HG2' ' CE2' ' A' ' 31' ' ' PHE . 45.2 Cg_endo -80.43 7.8 4.55 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 O-C-N 123.554 1.291 . . . . 0.0 110.083 179.203 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.589 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 89.6 m-85 -149.17 170.52 18.25 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.227 -0.921 . . . . 0.0 110.269 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.496 ' N ' ' O ' ' A' ' 14' ' ' GLN . 98.1 mttt -131.37 159.07 39.04 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.463 -0.773 . . . . 0.0 109.505 179.18 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.516 ' O ' ' CB ' ' A' ' 23' ' ' LYS . 47.8 t -84.61 115.79 22.82 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.048 -1.032 . . . . 0.0 110.406 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.48 ' HB3' ' HG2' ' A' ' 21' ' ' ARG . 71.7 m -142.54 130.86 22.2 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.136 -0.977 . . . . 0.0 110.092 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 96.2 mttt . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.26 -179.782 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.415 ' O ' ' HB ' ' A' ' 7' ' ' ILE . 45.9 t . . . . . 0 N--CA 1.492 1.655 0 CA-C-O 121.284 0.564 . . . . 0.0 110.315 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.415 ' HB ' ' O ' ' A' ' 6' ' ' CYS . 7.0 tt -175.06 -28.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.236 -0.915 . . . . 0.0 110.706 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 15.6 mtm180 -57.29 -30.62 64.86 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.943 -1.098 . . . . 0.0 109.492 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -65.99 -29.42 69.8 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.618 -0.676 . . . . 0.0 110.368 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 107.48 9.74 28.52 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.93 171.05 48.36 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.8 pt -111.68 161.8 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -1.124 . . . . 0.0 110.176 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.507 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.2 m -104.36 154.33 19.96 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.162 -0.962 . . . . 0.0 109.921 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.533 ' O ' ' N ' ' A' ' 32' ' ' LYS . 63.2 tt0 -155.13 153.42 30.79 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.41 -0.806 . . . . 0.0 109.565 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.496 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 63.2 t80 -59.14 -39.48 82.52 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.043 -1.036 . . . . 0.0 110.36 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.496 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 17.1 mmm180 -144.59 146.76 32.49 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.268 -0.895 . . . . 0.0 110.348 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.2 t -109.14 156.26 20.05 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.254 -0.903 . . . . 0.0 110.441 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.432 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 31.1 pt -110.46 162.79 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.252 -0.905 . . . . 0.0 110.191 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.06 -36.74 52.58 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.58 ' N ' HD22 ' A' ' 20' ' ' LEU . 4.2 mm? -56.33 -35.31 67.46 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.194 -1.18 . . . . 0.0 110.169 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 -100.77 129.17 46.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.218 -0.926 . . . . 0.0 110.128 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 77.9 t60 -88.07 124.98 34.31 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.352 -0.842 . . . . 0.0 110.295 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.476 ' HD2' ' HB3' ' A' ' 32' ' ' LYS . 27.3 ttpp -97.33 117.18 30.97 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.294 -0.879 . . . . 0.0 110.132 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 35.9 pt -97.62 0.32 10.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.177 -0.952 . . . . 0.0 110.315 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.92 -172.35 43.82 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.705 HG22 ' O ' ' A' ' 28' ' ' GLY . 88.4 m -119.46 111.5 18.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -1.118 . . . . 0.0 110.226 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.436 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 45.8 t -54.04 -53.32 54.61 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.247 -0.908 . . . . 0.0 109.795 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.705 ' O ' HG22 ' A' ' 26' ' ' THR . . . -142.12 -165.36 10.47 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 108.651 -1.779 . . . . 0.0 108.651 179.475 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.608 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 23.5 m -87.27 -41.69 0.52 Allowed Pre-proline 0 C--N 1.304 -1.412 0 O-C-N 121.027 -1.278 . . . . 0.0 110.052 179.618 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.608 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.3 Cg_endo -81.75 7.46 5.02 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 O-C-N 123.506 1.266 . . . . 0.0 109.681 178.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.586 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 86.7 m-85 -151.92 171.09 18.34 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.296 -0.877 . . . . 0.0 110.448 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 14' ' ' GLN . 62.0 mttm -128.6 157.76 40.37 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.429 -0.794 . . . . 0.0 109.264 179.347 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.476 ' O ' ' HG3' ' A' ' 23' ' ' LYS . 48.9 t -91.76 117.56 29.87 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.985 -1.072 . . . . 0.0 110.301 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 96.9 m -135.43 131.42 36.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.211 -0.93 . . . . 0.0 110.595 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.2 ptmm? . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.241 179.925 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.486 ' HB2' ' SG ' ' A' ' 27' ' ' CYS . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.637 0 CA-C-O 121.346 0.593 . . . . 0.0 110.035 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.424 HG23 ' N ' ' A' ' 8' ' ' ARG . 4.8 tp -65.16 -33.43 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.286 -0.884 . . . . 0.0 110.105 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.424 ' N ' HG23 ' A' ' 7' ' ' ILE . 81.0 mtt180 -52.15 -37.94 56.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.3 -0.875 . . . . 0.0 110.336 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -71.08 -6.83 42.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.39 -0.819 . . . . 0.0 110.251 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 81.49 13.96 79.27 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.43 ' C ' HG13 ' A' ' 12' ' ' ILE . . . -96.71 -170.7 34.25 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.483 HG22 ' N ' ' A' ' 13' ' ' CYS . 27.2 mt -132.53 172.53 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.297 -1.119 . . . . 0.0 109.622 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.518 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 6.1 m -137.39 159.59 41.5 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.916 -1.115 . . . . 0.0 111.346 -179.586 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 53.9 tp60 -157.67 153.63 27.02 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.451 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.497 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 44.1 t80 -44.74 -46.4 10.42 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.979 -1.076 . . . . 0.0 110.392 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.497 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 30.3 mmt180 -137.71 146.58 43.9 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.327 -0.858 . . . . 0.0 110.012 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 77.3 m -111.65 131.02 55.57 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.118 -0.988 . . . . 0.0 110.503 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.4 pt -133.47 164.59 34.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.195 -0.941 . . . . 0.0 110.217 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.78 -161.35 23.71 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.489 ' O ' ' CE1' ' A' ' 22' ' ' HIS . 53.2 mt -70.56 -24.52 62.8 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.283 -1.128 . . . . 0.0 110.126 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 100.0 mtt180 -57.36 142.86 42.14 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.326 -0.859 . . . . 0.0 110.313 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.489 ' CE1' ' O ' ' A' ' 20' ' ' LEU . 77.6 m-70 -119.6 160.9 21.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.214 -0.929 . . . . 0.0 110.089 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.523 ' CE ' ' OG1' ' A' ' 26' ' ' THR . 76.9 tttt -99.7 97.94 8.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.166 -0.959 . . . . 0.0 110.381 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 89.9 mt -67.37 -26.96 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.188 -0.945 . . . . 0.0 110.181 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.402 ' H ' ' HB3' ' A' ' 33' ' ' CYS . . . -164.33 -169.05 27.36 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.597 HG22 ' O ' ' A' ' 28' ' ' GLY . 92.3 m -122.98 111.01 16.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.245 -1.15 . . . . 0.0 110.429 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.486 ' SG ' ' HB2' ' A' ' 6' ' ' CYS . 33.4 m -59.43 -43.47 93.07 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.239 -0.913 . . . . 0.0 109.523 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.597 ' O ' HG22 ' A' ' 26' ' ' THR . . . -154.28 -160.96 10.14 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.612 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 5.2 m -86.84 -41.65 0.54 Allowed Pre-proline 0 C--N 1.301 -1.515 0 O-C-N 120.941 -1.329 . . . . 0.0 109.977 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.612 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.8 Cg_endo -81.58 7.79 4.8 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 123.539 1.284 . . . . 0.0 109.987 179.19 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.589 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 52.6 m-85 -149.73 179.36 8.07 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.218 -0.926 . . . . 0.0 110.812 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 26' ' ' THR . 68.7 mttt -148.26 161.85 40.68 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.515 -0.74 . . . . 0.0 109.396 179.625 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.464 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 46.9 t -88.88 110.11 20.79 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.611 -1.306 . . . . 0.0 109.78 179.533 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 89.2 m -137.09 150.51 48.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.184 -0.948 . . . . 0.0 110.334 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 99.9 mttt . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.141 179.814 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.326 0.584 . . . . 0.0 110.133 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.471 HG13 ' N ' ' A' ' 8' ' ' ARG . 32.3 pt -67.86 -26.15 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.356 -0.84 . . . . 0.0 110.098 179.763 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.471 ' N ' HG13 ' A' ' 7' ' ' ILE . 76.7 mtt85 -49.56 -33.07 13.94 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.202 -0.936 . . . . 0.0 110.336 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 55.5 t-20 -68.92 -23.65 64.19 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.357 -0.839 . . . . 0.0 110.723 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 111.36 -2.93 28.04 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.44 -168.94 41.61 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.478 HG22 ' N ' ' A' ' 13' ' ' CYS . 51.3 mt -131.6 170.77 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.355 -1.085 . . . . 0.0 109.949 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.524 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.5 m -135.88 159.39 41.81 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.019 -1.051 . . . . 0.0 110.485 179.682 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.519 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 11.6 pt20 -155.64 169.86 23.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.466 -0.771 . . . . 0.0 109.78 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.487 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 96.3 m-85 -58.04 -36.94 73.47 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.302 -0.874 . . . . 0.0 110.842 -179.653 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.468 ' O ' ' HG3' ' A' ' 14' ' ' GLN . 38.3 mmt180 -146.46 153.63 40.66 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.144 -0.972 . . . . 0.0 110.517 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.4 m -122.31 161.94 22.42 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.249 -0.907 . . . . 0.0 109.839 179.519 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.532 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 34.6 pt -113.98 172.83 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.057 -1.027 . . . . 0.0 110.315 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.99 -33.92 64.79 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.532 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 22.9 mt -59.6 -33.64 71.73 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -1.132 . . . . 0.0 110.264 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -101.8 133.79 45.98 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.344 -0.847 . . . . 0.0 110.056 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 66.6 t-80 -88.28 124.85 34.29 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.261 -0.899 . . . . 0.0 110.216 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.625 ' HE2' HG22 ' A' ' 26' ' ' THR . 74.0 tttt -88.02 90.45 8.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.213 -0.929 . . . . 0.0 110.106 179.827 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.9 tt -64.95 -30.98 51.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.189 -0.944 . . . . 0.0 110.358 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -170.02 -171.21 35.29 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.625 HG22 ' HE2' ' A' ' 23' ' ' LYS . 58.2 p -116.31 103.04 10.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.343 -1.092 . . . . 0.0 110.485 -179.732 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 62.6 m -47.95 -48.6 32.06 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.742 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.16 -160.09 8.53 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.594 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 8.4 m -89.99 -41.61 0.42 Allowed Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.082 -1.246 . . . . 0.0 110.67 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.594 ' CD ' ' N ' ' A' ' 29' ' ' SER . 46.4 Cg_endo -81.16 7.83 4.72 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 123.472 1.248 . . . . 0.0 109.997 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.586 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 83.9 m-85 -150.36 171.79 16.43 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.255 -0.903 . . . . 0.0 110.438 179.575 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.524 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 93.8 mttt -135.58 158.99 43.01 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.408 -0.808 . . . . 0.0 108.995 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.531 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 4.8 t -89.29 118.78 29.21 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.767 -1.208 . . . . 0.0 109.907 179.506 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 95.4 m -144.31 147.43 33.48 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.133 -0.979 . . . . 0.0 110.299 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 91.5 mttt . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.17 179.721 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.469 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 53.1 t . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.232 0.539 . . . . 0.0 110.107 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.517 HG13 ' N ' ' A' ' 8' ' ' ARG . 46.7 pt -57.25 -33.49 43.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.241 -0.912 . . . . 0.0 110.279 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.517 ' N ' HG13 ' A' ' 7' ' ' ILE . 65.9 ttt-85 -59.79 -35.51 74.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.207 -0.933 . . . . 0.0 110.17 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.407 ' O ' ' OD1' ' A' ' 9' ' ' ASN . 45.9 t-20 -75.65 -23.23 56.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 109.983 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 112.32 2.07 26.3 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.96 -178.88 48.94 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.567 HG22 ' N ' ' A' ' 13' ' ' CYS . 57.2 mt -114.63 171.72 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.23 -1.159 . . . . 0.0 110.27 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.567 ' N ' HG22 ' A' ' 12' ' ' ILE . 2.3 m -124.6 150.57 45.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 110.053 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.472 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 56.6 tt0 -152.71 154.18 34.75 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.613 -0.679 . . . . 0.0 109.712 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.53 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 89.2 m-85 -57.89 -40.05 79.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.056 -1.027 . . . . 0.0 110.307 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.42 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 24.9 mmm180 -145.0 156.29 43.86 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.309 -0.869 . . . . 0.0 110.496 -179.754 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.1 m -128.24 160.83 30.89 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.241 -0.912 . . . . 0.0 110.055 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.551 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 48.4 pt -110.71 172.35 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.13 -0.981 . . . . 0.0 110.295 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.45 -33.88 62.79 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.61 ' N ' HD12 ' A' ' 20' ' ' LEU . 9.5 mp -62.01 -34.2 75.75 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.157 -1.202 . . . . 0.0 110.224 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 70.7 mtp85 -102.85 113.82 27.58 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.249 -0.907 . . . . 0.0 109.938 179.754 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 65.7 m170 -68.37 152.26 45.68 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.178 -0.952 . . . . 0.0 110.52 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 71.4 tttt -120.69 96.69 5.22 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.316 -0.865 . . . . 0.0 109.979 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.402 HG23 HD12 ' A' ' 24' ' ' ILE . 49.5 mm -65.53 -26.46 39.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.274 -0.892 . . . . 0.0 110.601 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.423 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -175.99 -167.84 35.42 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 32' ' ' LYS . 49.5 p -106.57 105.87 16.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -1.077 . . . . 0.0 110.52 -179.808 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.471 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 42.4 t -50.67 -35.76 32.46 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -0.914 . . . . 0.0 109.53 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -161.68 -160.77 11.16 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.448 -1.861 . . . . 0.0 108.448 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.589 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 60.6 m -89.64 -41.89 0.43 Allowed Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 120.942 -1.328 . . . . 0.0 109.956 179.495 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.589 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.0 Cg_endo -83.29 8.87 4.36 Favored 'Trans proline' 0 C--N 1.31 -1.496 0 O-C-N 123.422 1.222 . . . . 0.0 109.557 178.853 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.565 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 95.6 m-85 -153.02 172.45 16.82 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.357 -0.839 . . . . 0.0 110.802 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.525 ' HA ' ' HA ' ' A' ' 26' ' ' THR . 93.4 mttt -134.41 160.01 39.29 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 179.092 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 45.7 t -83.8 117.08 23.04 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.983 -1.073 . . . . 0.0 109.911 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 58.9 m -144.12 156.78 44.48 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.233 -0.917 . . . . 0.0 110.506 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 94.8 mttt . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.092 179.829 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.401 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 48.1 t . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 121.225 0.536 . . . . 0.0 110.21 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 37.1 pt -109.93 -11.51 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.293 -0.88 . . . . 0.0 110.235 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 30.0 mmt180 -57.95 -32.4 67.79 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.152 -0.968 . . . . 0.0 110.327 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -67.16 -26.22 66.55 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.385 -0.822 . . . . 0.0 110.436 -179.692 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.4 13.24 33.53 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.78 -169.92 42.92 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.482 HG22 ' N ' ' A' ' 13' ' ' CYS . 47.2 mt -129.09 171.12 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.439 -1.036 . . . . 0.0 109.795 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.547 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 5.8 m -136.47 160.18 39.53 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.936 -1.103 . . . . 0.0 111.214 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.4 ' O ' ' C ' ' A' ' 15' ' ' TYR . 44.2 tt0 -160.06 154.39 23.62 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.725 -0.609 . . . . 0.0 109.501 179.507 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.464 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 40.2 t80 -43.21 -45.81 5.81 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.005 -1.059 . . . . 0.0 110.656 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.464 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 0.6 OUTLIER -139.42 147.04 40.86 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.255 -0.903 . . . . 0.0 110.292 179.819 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 66.5 m -112.72 126.12 55.06 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.304 -0.872 . . . . 0.0 110.324 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 26.9 pt -129.99 163.91 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.936 . . . . 0.0 110.176 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.94 -167.08 26.46 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.689 ' N ' HD12 ' A' ' 20' ' ' LEU . 10.1 mp -68.6 -21.63 64.49 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.264 -1.139 . . . . 0.0 110.347 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 94.7 mtt-85 -54.68 138.69 41.08 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.371 -0.831 . . . . 0.0 110.178 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -109.62 170.41 8.08 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.238 -0.914 . . . . 0.0 109.971 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.522 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 79.9 tttt -115.33 113.25 23.57 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.014 -1.054 . . . . 0.0 110.607 -179.793 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 45.5 mm -70.45 -31.06 45.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.406 -0.809 . . . . 0.0 109.963 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.425 ' O ' ' CE ' ' A' ' 23' ' ' LYS . . . -174.59 -166.49 32.62 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.737 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.48 HG22 ' O ' ' A' ' 28' ' ' GLY . 51.8 m -113.45 109.33 18.49 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.208 -1.172 . . . . 0.0 110.711 -179.669 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.412 ' SG ' ' HA ' ' A' ' 33' ' ' CYS . 60.0 m -58.17 -51.46 69.62 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.173 -0.955 . . . . 0.0 109.897 179.577 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.48 ' O ' HG22 ' A' ' 26' ' ' THR . . . -141.49 -164.22 9.9 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.933 -1.667 . . . . 0.0 108.933 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.622 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 14.9 m -85.96 -41.41 0.6 Allowed Pre-proline 0 C--N 1.301 -1.521 0 O-C-N 120.939 -1.33 . . . . 0.0 109.954 179.358 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.622 ' CD ' ' N ' ' A' ' 29' ' ' SER . 45.4 Cg_endo -81.34 8.16 4.55 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 O-C-N 123.501 1.264 . . . . 0.0 109.84 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.61 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 67.3 m-85 -153.25 169.15 23.76 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.08 -1.012 . . . . 0.0 110.975 -179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.547 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 92.8 mttt -133.8 160.1 38.63 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.1 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.522 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 2.9 t -90.26 120.01 31.05 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.744 -1.222 . . . . 0.0 110.337 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 73.4 m -142.67 142.18 31.99 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.86 . . . . 0.0 110.226 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 86.2 tttt . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.124 179.9 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 81.8 m . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 121.213 0.53 . . . . 0.0 109.955 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.529 HG23 ' N ' ' A' ' 8' ' ' ARG . 12.5 tt -59.46 -39.48 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.322 -0.861 . . . . 0.0 109.957 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.529 ' N ' HG23 ' A' ' 7' ' ' ILE . 17.4 ttm105 -56.77 -38.52 72.59 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.308 -0.87 . . . . 0.0 109.932 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 88.1 m-20 -69.32 -27.72 65.62 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.365 -0.835 . . . . 0.0 109.919 179.761 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.94 8.66 8.68 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -88.98 -177.93 46.21 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.508 ' CG1' ' O ' ' A' ' 34' ' ' CYS . 46.8 pt -132.23 161.24 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.321 -1.105 . . . . 0.0 109.806 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.2 m -113.56 154.21 27.52 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.951 -1.093 . . . . 0.0 110.559 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.497 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 11.5 tp60 -151.17 155.82 39.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.563 -0.71 . . . . 0.0 109.74 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.685 ' CE1' ' CE1' ' A' ' 31' ' ' PHE . 56.4 m-85 -54.94 -42.56 72.45 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.111 -0.993 . . . . 0.0 110.599 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.418 ' HD3' ' O ' ' A' ' 15' ' ' TYR . 89.1 mmt-85 -144.54 154.96 43.43 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.254 -0.903 . . . . 0.0 110.399 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 94.2 m -123.1 138.36 54.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.325 -0.859 . . . . 0.0 109.995 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.0 pt -102.0 170.23 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -0.909 . . . . 0.0 110.326 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -48.21 -43.5 25.95 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 14.2 tp -47.26 -46.7 24.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.207 -1.172 . . . . 0.0 110.311 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -101.39 128.0 47.78 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 110.261 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -88.71 135.32 33.57 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.874 . . . . 0.0 110.198 179.817 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.538 ' CD ' ' HB3' ' A' ' 32' ' ' LYS . 37.9 ttpt -95.95 117.07 29.92 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.282 -0.887 . . . . 0.0 110.064 179.815 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.0 mm -75.4 -27.27 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.339 -0.851 . . . . 0.0 110.136 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.491 ' C ' ' HB2' ' A' ' 33' ' ' CYS . . . -169.9 -156.51 11.09 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 72.9 p -115.74 113.2 23.14 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.354 -1.086 . . . . 0.0 110.14 179.624 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.52 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 42.2 t -68.73 -29.83 68.33 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.396 -0.815 . . . . 0.0 110.019 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -176.81 -163.61 29.34 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.944 -1.663 . . . . 0.0 108.944 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.604 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.5 m -87.39 -42.9 0.52 Allowed Pre-proline 0 C--N 1.303 -1.413 0 O-C-N 121.076 -1.25 . . . . 0.0 110.055 179.647 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.604 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.9 Cg_endo -81.7 6.94 5.33 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 O-C-N 123.666 1.35 . . . . 0.0 109.663 179.13 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.685 ' CE1' ' CE1' ' A' ' 15' ' ' TYR . 73.3 m-85 -156.6 176.19 13.05 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.283 -0.886 . . . . 0.0 110.619 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.538 ' HB3' ' CD ' ' A' ' 23' ' ' LYS . 95.9 mttt -141.22 156.89 45.85 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.451 -0.781 . . . . 0.0 109.391 179.214 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.52 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 66.5 m -76.99 107.58 9.44 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.023 -1.048 . . . . 0.0 109.869 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.508 ' O ' ' CG1' ' A' ' 12' ' ' ILE . 63.5 m -142.52 136.28 29.18 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.168 -0.957 . . . . 0.0 110.318 -179.752 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 61.9 mttp . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.128 179.968 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 74.5 m . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 121.197 0.522 . . . . 0.0 110.292 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.5 tt -58.63 -31.17 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.936 179.74 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -61.13 -37.65 83.58 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.277 -0.89 . . . . 0.0 110.123 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -67.89 -29.22 68.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.383 -0.823 . . . . 0.0 110.326 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 122.78 -2.38 10.06 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.99 -173.36 45.54 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.5 HG22 ' N ' ' A' ' 13' ' ' CYS . 22.4 mm -130.97 170.38 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.284 -1.127 . . . . 0.0 110.159 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.5 ' N ' HG22 ' A' ' 12' ' ' ILE . 2.4 m -119.63 151.49 38.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.185 -0.947 . . . . 0.0 109.862 179.761 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.5 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 51.6 tt0 -152.36 152.52 32.17 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.541 -0.724 . . . . 0.0 109.639 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.503 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 72.6 t80 -57.67 -38.53 75.29 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.183 -0.948 . . . . 0.0 110.473 -179.748 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.503 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 7.0 mmm180 -149.91 142.69 24.68 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.288 -0.883 . . . . 0.0 110.274 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.5 m -111.69 151.8 28.46 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.153 -0.967 . . . . 0.0 110.208 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.692 HG22 ' H ' ' A' ' 19' ' ' GLY . 3.0 mt -97.95 -168.9 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.184 -0.948 . . . . 0.0 109.897 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.692 ' H ' HG22 ' A' ' 18' ' ' ILE . . . -67.38 -43.71 86.84 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 63.9 mt -55.38 -36.78 66.74 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.338 -1.095 . . . . 0.0 109.962 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.7 mmt-85 -100.67 123.24 44.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.354 -0.841 . . . . 0.0 110.244 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -94.39 144.18 25.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 110.107 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.513 ' CE ' ' O ' ' A' ' 25' ' ' GLY . 72.2 tttt -103.53 102.1 11.98 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.216 -0.927 . . . . 0.0 110.371 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 86.1 mt -70.04 -21.37 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.218 -0.926 . . . . 0.0 110.11 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.513 ' O ' ' CE ' ' A' ' 23' ' ' LYS . . . -169.05 -161.5 19.48 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.735 HG23 ' O ' ' A' ' 26' ' ' THR . 14.0 t -119.3 112.03 18.93 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.306 -1.114 . . . . 0.0 110.283 179.595 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.517 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 11.6 t -58.87 -37.42 76.5 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.19 -0.944 . . . . 0.0 109.532 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -164.94 -154.79 8.13 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.432 -1.867 . . . . 0.0 108.432 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.579 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 2.3 m -90.27 -43.99 0.41 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 120.975 -1.309 . . . . 0.0 110.156 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.579 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.5 Cg_endo -82.76 11.72 3.14 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 O-C-N 123.564 1.297 . . . . 0.0 109.859 179.2 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.516 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 83.1 m-85 -155.38 174.16 15.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.209 -0.932 . . . . 0.0 110.57 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 26' ' ' THR . 67.5 mttm -137.11 159.31 42.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.638 -0.664 . . . . 0.0 109.36 179.183 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.517 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 76.7 m -78.07 105.72 9.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.031 -1.043 . . . . 0.0 110.203 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 4.9 m -136.0 138.46 42.26 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.143 -0.973 . . . . 0.0 110.275 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.176 179.93 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 85.3 m . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.178 0.513 . . . . 0.0 110.423 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.415 HG13 ' N ' ' A' ' 8' ' ' ARG . 47.1 pt -75.53 -28.51 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.251 -0.906 . . . . 0.0 110.191 179.858 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.415 ' N ' HG13 ' A' ' 7' ' ' ILE . 25.7 tpt180 -62.3 -32.75 73.53 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.26 -0.9 . . . . 0.0 110.02 179.685 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -78.54 -8.14 58.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 110.16 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 98.72 -2.73 58.74 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.36 172.61 49.14 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.324 -1.511 . . . . 0.0 109.324 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.524 HG22 ' N ' ' A' ' 13' ' ' CYS . 56.6 mt -130.53 170.9 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.287 -1.125 . . . . 0.0 110.275 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.524 ' N ' HG22 ' A' ' 12' ' ' ILE . 3.2 m -103.7 153.75 20.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.162 -0.962 . . . . 0.0 110.087 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 8.5 tp60 -151.67 152.99 33.53 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.514 -0.741 . . . . 0.0 109.748 179.636 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.612 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 57.5 t80 -60.14 -41.96 93.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.175 -0.953 . . . . 0.0 109.955 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.612 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 33.4 mmt180 -147.79 149.35 32.18 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.443 -0.786 . . . . 0.0 110.097 179.779 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 98.5 m -120.86 176.38 5.57 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.211 -0.93 . . . . 0.0 110.1 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.6 pt -122.37 175.45 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.258 -0.901 . . . . 0.0 110.436 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -59.06 -31.46 68.84 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.826 HD13 ' O ' ' A' ' 20' ' ' LEU . 3.1 tm? -59.48 -37.96 79.61 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.282 -1.128 . . . . 0.0 110.272 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -104.81 128.35 52.94 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.274 -0.891 . . . . 0.0 110.289 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -88.07 141.95 28.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.247 -0.908 . . . . 0.0 110.011 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.502 ' CE ' ' HB3' ' A' ' 32' ' ' LYS . 46.4 tttm -94.25 107.12 19.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.859 . . . . 0.0 110.352 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 38.5 mm -68.72 -31.68 51.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.282 -0.887 . . . . 0.0 110.485 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.501 ' O ' ' NZ ' ' A' ' 23' ' ' LYS . . . -165.91 -156.04 9.12 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 -179.544 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.732 HG23 ' O ' ' A' ' 26' ' ' THR . 14.8 t -122.28 106.92 11.54 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.682 -0.893 . . . . 0.0 109.872 179.639 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.516 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 37.9 t -62.75 -35.86 81.16 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.199 -0.938 . . . . 0.0 110.3 -179.452 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -169.08 -163.4 23.05 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.588 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.3 m -88.29 -43.3 0.47 Allowed Pre-proline 0 C--N 1.303 -1.422 0 O-C-N 121.062 -1.258 . . . . 0.0 110.32 179.856 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.588 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.8 Cg_endo -81.18 5.64 6.12 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.525 1.276 . . . . 0.0 109.572 179.307 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 63.7 m-85 -153.0 169.47 22.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.275 -0.891 . . . . 0.0 110.486 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.502 ' HB3' ' CE ' ' A' ' 23' ' ' LYS . 96.0 mttt -136.75 158.45 44.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.437 -0.789 . . . . 0.0 109.69 179.497 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.516 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 59.5 m -80.68 120.14 24.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.126 -0.983 . . . . 0.0 109.471 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.9 m -143.4 134.5 25.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.227 -0.921 . . . . 0.0 110.457 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.914 -1.041 . . . . 0.0 109.952 179.709 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.407 ' O ' ' SG ' ' A' ' 6' ' ' CYS . 45.3 t . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.279 0.561 . . . . 0.0 110.099 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.3 pt -113.73 -9.56 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.267 -0.896 . . . . 0.0 110.218 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 95.0 mtt-85 -65.8 -35.91 82.04 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.09 -1.006 . . . . 0.0 110.106 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.0 m120 -96.41 5.94 49.81 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.252 -0.905 . . . . 0.0 110.2 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 74.15 18.21 79.7 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.91 175.59 51.97 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.501 HG22 ' N ' ' A' ' 13' ' ' CYS . 56.4 mt -120.56 170.27 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -1.137 . . . . 0.0 110.307 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.501 ' N ' HG22 ' A' ' 12' ' ' ILE . 3.0 m -117.72 154.03 32.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.22 -0.925 . . . . 0.0 110.178 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.523 ' O ' ' N ' ' A' ' 32' ' ' LYS . 47.2 tt0 -160.38 151.2 18.75 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.646 -0.658 . . . . 0.0 109.567 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 31' ' ' PHE . 83.8 t80 -55.53 -37.75 68.34 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.028 -1.045 . . . . 0.0 110.606 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.403 ' HG3' ' N ' ' A' ' 17' ' ' CYS . 14.2 tpt180 -146.05 163.1 36.32 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.255 -0.903 . . . . 0.0 110.233 -179.782 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.403 ' N ' ' HG3' ' A' ' 16' ' ' ARG . 20.1 m -139.37 125.63 20.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.468 -0.77 . . . . 0.0 109.789 179.545 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.0 pt -138.13 165.23 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.261 -0.9 . . . . 0.0 110.313 -179.697 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.11 -155.42 26.33 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.567 HD22 ' N ' ' A' ' 20' ' ' LEU . 4.5 mm? -61.78 -28.1 69.21 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.351 -1.087 . . . . 0.0 110.202 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 94.1 mtt180 -53.03 135.52 36.92 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.266 -0.896 . . . . 0.0 110.296 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -113.1 156.11 23.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.332 -0.855 . . . . 0.0 110.073 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 81.6 tttt -101.81 107.62 18.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.188 -0.945 . . . . 0.0 110.177 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 67.7 mt -76.98 -33.71 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.899 . . . . 0.0 110.215 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.485 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -169.71 -169.56 33.1 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 75.2 p -105.95 99.17 8.78 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.394 -1.063 . . . . 0.0 110.474 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.468 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 38.6 t -54.28 -40.05 67.48 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.169 -0.957 . . . . 0.0 109.722 179.655 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -155.99 -165.68 14.85 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 108.598 -1.801 . . . . 0.0 108.598 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.6 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 9.0 m -87.18 -42.97 0.53 Allowed Pre-proline 0 C--N 1.299 -1.625 0 O-C-N 121.128 -1.219 . . . . 0.0 109.825 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.6 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.0 Cg_endo -82.23 7.66 4.97 Favored 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.49 1.258 . . . . 0.0 109.691 178.893 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.579 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 90.5 m-85 -152.36 169.86 21.51 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.299 -0.876 . . . . 0.0 110.64 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 14' ' ' GLN . 96.3 mttt -130.9 159.36 37.65 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.012 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.485 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 47.2 t -85.51 121.18 27.85 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.962 -1.087 . . . . 0.0 109.801 179.759 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 97.3 m -138.21 141.87 39.98 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 110.342 -179.737 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.436 ' OXT' ' HG2' ' A' ' 35' ' ' LYS . 88.0 tttt . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.164 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.527 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 10.1 t . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 121.176 0.512 . . . . 0.0 110.468 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.474 HG13 ' N ' ' A' ' 8' ' ' ARG . 50.0 pt -71.17 -30.52 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.188 -0.945 . . . . 0.0 110.015 -179.795 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.474 ' N ' HG13 ' A' ' 7' ' ' ILE . 51.0 ttt85 -66.21 -54.8 20.84 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.433 -0.792 . . . . 0.0 110.083 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -142.67 9.42 1.78 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.407 -0.808 . . . . 0.0 110.459 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.527 ' HA3' ' HA ' ' A' ' 6' ' ' CYS . . . -83.65 -30.15 30.48 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.764 -1.335 . . . . 0.0 109.764 -179.763 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 129.61 -155.92 21.11 Favored Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.599 -1.286 . . . . 0.0 109.89 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.487 HG22 ' N ' ' A' ' 13' ' ' CYS . 41.2 mt -96.34 171.0 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 O-C-N 121.692 -0.887 . . . . 0.0 109.668 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.1 m -139.7 153.39 47.22 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.069 -1.019 . . . . 0.0 110.414 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -161.09 157.21 25.69 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.726 -0.609 . . . . 0.0 109.908 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.473 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 87.5 m-85 -44.91 -37.31 3.84 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.16 -0.962 . . . . 0.0 110.206 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.431 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 25.7 mmm180 -147.31 147.11 30.03 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.321 -0.862 . . . . 0.0 110.128 179.768 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.1 m -111.56 130.25 55.8 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.24 -0.912 . . . . 0.0 110.065 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 43.3 pt -127.9 172.42 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.159 -0.963 . . . . 0.0 110.321 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.14 -156.04 23.31 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.642 ' N ' HD12 ' A' ' 20' ' ' LEU . 10.4 mp -87.26 -5.12 59.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.181 -1.188 . . . . 0.0 110.214 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 74.4 mtm180 -61.07 148.35 40.66 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.298 -0.876 . . . . 0.0 110.358 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -119.01 143.65 46.95 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.362 -0.836 . . . . 0.0 110.17 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.523 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 36.4 ttpt -93.79 117.79 30.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.174 -0.954 . . . . 0.0 110.318 -179.757 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 22.4 pt -96.93 -8.79 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.16 -0.962 . . . . 0.0 110.176 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.27 -170.57 37.69 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 32' ' ' LYS . 81.7 p -129.82 108.28 10.03 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.278 -1.131 . . . . 0.0 110.347 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.457 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 46.6 m -51.99 -36.03 48.48 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.24 -0.913 . . . . 0.0 109.706 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -159.22 -159.37 9.67 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.589 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 16.9 m -90.12 -41.88 0.41 Allowed Pre-proline 0 C--N 1.302 -1.476 0 O-C-N 121.09 -1.241 . . . . 0.0 110.553 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.589 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.4 Cg_endo -80.24 6.64 5.21 Favored 'Trans proline' 0 C--N 1.311 -1.442 0 O-C-N 123.416 1.219 . . . . 0.0 109.845 179.445 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.527 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 45.4 m-85 -146.06 179.8 7.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.349 -0.845 . . . . 0.0 110.262 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.525 ' HA ' ' HA ' ' A' ' 26' ' ' THR . 91.3 mttt -143.28 170.31 16.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.525 -0.734 . . . . 0.0 109.065 179.228 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.523 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 38.4 t -96.55 115.87 28.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.783 -1.198 . . . . 0.0 109.969 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 84.6 m -141.89 138.04 31.78 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.095 -1.003 . . . . 0.0 110.143 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.178 179.756 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 10.5 t . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.201 0.524 . . . . 0.0 110.157 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.6 tt -60.38 -32.53 51.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.157 -0.964 . . . . 0.0 110.405 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 84.3 mtt180 -60.55 -33.54 72.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.212 -0.93 . . . . 0.0 110.254 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 91.0 m-20 -62.02 -25.34 67.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 110.175 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.62 13.09 23.2 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.28 -172.74 44.66 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.0 pt -129.77 151.51 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.264 -1.139 . . . . 0.0 110.177 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.532 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 1.8 m -91.11 151.96 20.79 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.028 -1.045 . . . . 0.0 109.993 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.549 ' O ' ' N ' ' A' ' 32' ' ' LYS . 55.2 tt0 -146.23 150.68 36.27 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.401 -0.812 . . . . 0.0 109.881 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.576 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 62.0 t80 -59.1 -46.01 89.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.065 -1.022 . . . . 0.0 110.58 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.576 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 19.4 mmt180 -148.92 140.81 23.72 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.289 -0.882 . . . . 0.0 110.325 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 40.5 m -116.63 142.66 46.6 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.435 -0.791 . . . . 0.0 109.847 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.719 HG22 ' H ' ' A' ' 19' ' ' GLY . 3.4 mm -90.85 -168.96 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.155 -0.965 . . . . 0.0 110.149 -179.732 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.719 ' H ' HG22 ' A' ' 18' ' ' ILE . . . -69.99 -30.9 69.7 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.925 -1.67 . . . . 0.0 108.925 179.792 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.589 ' N ' HD12 ' A' ' 20' ' ' LEU . 9.4 mp -63.77 -29.57 70.77 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.427 -1.043 . . . . 0.0 110.19 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 82.5 mtt-85 -105.34 128.27 53.4 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.189 -0.944 . . . . 0.0 110.562 -179.611 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 61.6 m170 -94.53 143.0 26.78 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.269 -0.894 . . . . 0.0 110.44 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.485 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 34.2 ttpt -109.26 117.38 33.94 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.257 -0.902 . . . . 0.0 110.61 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 80.4 mt -73.55 -35.38 44.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.187 -0.946 . . . . 0.0 109.826 179.578 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.483 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -160.72 -170.87 25.91 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.448 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 51.6 m -107.94 103.61 12.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.176 -1.191 . . . . 0.0 110.305 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.426 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 42.0 t -53.11 -48.28 67.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.299 -0.875 . . . . 0.0 109.967 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.448 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -149.59 -165.29 12.3 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 108.906 -1.677 . . . . 0.0 108.906 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.599 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.3 m -89.32 -42.3 0.43 Allowed Pre-proline 0 C--N 1.303 -1.444 0 O-C-N 121.095 -1.238 . . . . 0.0 110.417 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.599 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.2 Cg_endo -81.82 6.68 5.51 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.474 1.249 . . . . 0.0 109.715 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.497 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 97.9 m-85 -152.48 173.71 14.8 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.308 -0.87 . . . . 0.0 110.197 179.632 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.549 ' N ' ' O ' ' A' ' 14' ' ' GLN . 62.0 mttm -136.41 155.96 49.29 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.458 -0.776 . . . . 0.0 109.147 179.452 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.485 ' O ' ' HG3' ' A' ' 23' ' ' LYS . 50.4 t -87.72 115.06 24.9 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.177 -0.952 . . . . 0.0 110.73 -179.67 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 56.3 m -132.39 145.64 51.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.262 -0.899 . . . . 0.0 109.956 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 56.7 tttp . . . . . 0 N--CA 1.492 1.64 0 O-C-N 121.089 -1.007 . . . . 0.0 110.348 -179.815 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.699 ' SG ' HG22 ' A' ' 24' ' ' ILE . 13.1 t . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 121.301 0.572 . . . . 0.0 110.431 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.46 HG13 ' N ' ' A' ' 8' ' ' ARG . 42.5 pt -57.46 -25.49 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.344 -0.847 . . . . 0.0 110.295 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.46 ' N ' HG13 ' A' ' 7' ' ' ILE . 67.8 ttt180 -58.72 -36.17 73.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.221 -0.924 . . . . 0.0 110.473 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 23.8 m120 -67.66 -28.34 67.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.223 -0.923 . . . . 0.0 110.364 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.83 8.0 16.5 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.64 179.62 52.97 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.6 pt -124.05 159.13 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.238 -1.154 . . . . 0.0 110.322 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.514 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 1.7 m -99.49 154.63 18.09 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.274 -0.891 . . . . 0.0 109.835 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.521 ' O ' ' N ' ' A' ' 32' ' ' LYS . 37.6 tp60 -156.74 154.77 30.53 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.223 -0.923 . . . . 0.0 109.887 179.722 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.605 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 50.2 t80 -58.86 -49.28 78.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.124 -0.985 . . . . 0.0 110.231 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.605 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 13.9 mmt85 -145.07 151.34 38.36 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.437 -0.789 . . . . 0.0 110.458 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.527 ' HB2' ' NE ' ' A' ' 21' ' ' ARG . 87.6 m -118.83 178.58 4.43 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.331 -0.856 . . . . 0.0 109.844 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.429 ' O ' ' O ' ' A' ' 19' ' ' GLY . 47.1 pt -101.78 175.3 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.091 -1.006 . . . . 0.0 110.485 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' A' ' 18' ' ' ILE . . . -50.03 178.78 0.03 OUTLIER Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.844 ' N ' HD22 ' A' ' 20' ' ' LEU . 2.7 mm? 46.47 42.3 10.67 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.319 -1.106 . . . . 0.0 109.37 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.527 ' NE ' ' HB2' ' A' ' 17' ' ' CYS . 25.5 ttm180 -79.52 134.85 36.51 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 110.631 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 70.0 m-70 -99.77 37.01 1.68 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 179.328 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.492 ' HE2' ' O ' ' A' ' 25' ' ' GLY . 60.8 tttt -73.36 108.92 6.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.413 -0.804 . . . . 0.0 110.534 -179.514 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.699 HG22 ' SG ' ' A' ' 6' ' ' CYS . 7.6 tp -78.68 -18.04 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.244 -0.91 . . . . 0.0 109.63 179.599 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.492 ' O ' ' HE2' ' A' ' 23' ' ' LYS . . . -165.46 -173.42 33.99 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.737 HG22 ' O ' ' A' ' 28' ' ' GLY . 92.5 m -109.62 107.06 16.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.136 -1.214 . . . . 0.0 110.261 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.435 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 48.8 t -46.12 -63.72 0.92 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.399 -0.813 . . . . 0.0 109.687 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.737 ' O ' HG22 ' A' ' 26' ' ' THR . . . -129.63 -170.47 12.75 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 179.425 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.596 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.9 m -85.88 -42.19 0.61 Allowed Pre-proline 0 C--N 1.303 -1.445 0 O-C-N 121.01 -1.288 . . . . 0.0 109.898 179.484 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.603 ' HG2' ' CD2' ' A' ' 31' ' ' PHE . 52.0 Cg_endo -81.39 6.0 5.9 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 O-C-N 123.557 1.293 . . . . 0.0 109.428 179.189 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.603 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 86.8 m-85 -148.18 170.15 18.48 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.116 -0.99 . . . . 0.0 110.538 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.521 ' N ' ' O ' ' A' ' 14' ' ' GLN . 89.9 mttt -133.37 156.12 48.23 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.6 -0.688 . . . . 0.0 109.285 179.028 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.44 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 50.7 t -89.62 123.59 33.81 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.165 -0.96 . . . . 0.0 109.907 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.401 ' SG ' ' HD3' ' A' ' 21' ' ' ARG . 33.3 m -138.02 130.75 29.68 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 110.085 -179.796 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 86.2 tttt . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 118.041 -0.98 . . . . 0.0 110.171 -179.971 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 86.2 m . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 121.235 0.541 . . . . 0.0 110.334 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.476 HG23 ' N ' ' A' ' 8' ' ' ARG . 16.2 tt -61.43 -36.75 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.232 -0.918 . . . . 0.0 110.389 -179.658 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.476 ' N ' HG23 ' A' ' 7' ' ' ILE . 76.8 ttt-85 -53.12 -39.2 63.27 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.135 -0.978 . . . . 0.0 110.294 -179.849 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -65.59 -23.73 66.9 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.41 -0.806 . . . . 0.0 110.328 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 111.4 5.76 26.05 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.764 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.18 175.67 43.12 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.561 HG22 ' N ' ' A' ' 13' ' ' CYS . 72.9 mt -127.83 171.96 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.273 -1.133 . . . . 0.0 110.021 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.561 ' N ' HG22 ' A' ' 12' ' ' ILE . 1.5 m -102.49 147.84 26.26 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.177 -0.952 . . . . 0.0 109.752 179.565 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.515 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 27.2 tp60 -148.86 152.72 36.96 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.517 -0.739 . . . . 0.0 109.643 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.468 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 97.8 m-85 -60.34 -42.25 95.3 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.229 -0.919 . . . . 0.0 110.698 -179.537 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.432 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 29.2 mmm180 -149.3 142.22 24.76 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.233 -0.917 . . . . 0.0 110.605 -179.68 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 67.5 m -119.94 126.52 51.08 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.304 -0.873 . . . . 0.0 109.955 179.598 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.0 pt -143.35 168.04 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.124 -0.985 . . . . 0.0 110.456 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 66.39 -135.56 33.9 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 35.9 mt -59.38 -34.74 72.78 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.395 -1.062 . . . . 0.0 110.273 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -71.49 132.32 44.57 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.346 -0.846 . . . . 0.0 110.651 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 74.7 t60 -133.86 153.55 51.66 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.334 -0.854 . . . . 0.0 109.879 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.502 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 0.0 OUTLIER -110.61 124.45 51.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.111 -0.993 . . . . 0.0 110.731 -179.746 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 23.7 pt -103.66 -5.87 9.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.317 -0.864 . . . . 0.0 109.853 179.579 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.435 ' N ' ' HB2' ' A' ' 33' ' ' CYS . . . -159.41 -169.89 23.3 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.757 -1.737 . . . . 0.0 108.757 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.761 HG23 ' O ' ' A' ' 26' ' ' THR . 14.8 t -128.47 105.36 8.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.073 -1.251 . . . . 0.0 110.636 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.528 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 53.6 t -60.29 -29.6 68.93 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.283 -0.886 . . . . 0.0 109.43 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -168.7 -163.05 22.04 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.603 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 63.5 m -88.02 -41.58 0.49 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 120.891 -1.358 . . . . 0.0 109.999 179.488 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.603 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.4 Cg_endo -82.76 8.2 4.72 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.43 1.226 . . . . 0.0 109.519 179.003 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.571 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 97.7 m-85 -147.72 173.79 12.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.339 -0.851 . . . . 0.0 110.771 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -136.86 159.62 41.33 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.605 -0.684 . . . . 0.0 109.317 179.362 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.528 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 91.0 m -80.09 105.04 11.07 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.003 -1.061 . . . . 0.0 109.984 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 64.2 m -130.45 147.93 52.2 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.187 -0.946 . . . . 0.0 110.375 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.429 ' OXT' ' HG3' ' A' ' 35' ' ' LYS . 64.4 pttt . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.19 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 32.8 t . . . . . 0 N--CA 1.491 1.603 0 CA-C-O 121.403 0.62 . . . . 0.0 110.099 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.813 HD13 ' O ' ' A' ' 11' ' ' GLY . 1.0 OUTLIER -69.31 -37.07 75.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.337 -0.852 . . . . 0.0 109.878 179.876 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 23.3 ttp180 -56.98 -32.7 66.35 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.243 -0.911 . . . . 0.0 110.535 -179.611 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -59.77 -30.16 68.69 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.197 -0.939 . . . . 0.0 109.746 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 124.04 14.09 3.85 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 179.433 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.813 ' O ' HD13 ' A' ' 7' ' ' ILE . . . -101.77 175.41 25.34 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.714 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.465 ' HA ' HD11 ' A' ' 7' ' ' ILE . 25.7 mt -119.03 169.54 9.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.27 -1.135 . . . . 0.0 110.026 179.743 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.511 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 1.9 m -112.17 153.18 27.43 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.153 -0.967 . . . . 0.0 110.071 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.518 ' O ' ' N ' ' A' ' 32' ' ' LYS . 11.9 tp60 -152.03 154.37 35.85 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.31 -0.869 . . . . 0.0 109.863 179.768 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.575 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 58.6 t80 -56.35 -37.5 70.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.107 -0.996 . . . . 0.0 110.258 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.575 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 35.2 mmt180 -146.14 157.49 43.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.256 -0.902 . . . . 0.0 110.228 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -122.53 154.63 37.63 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.244 -0.91 . . . . 0.0 110.333 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.471 HG13 ' HB2' ' A' ' 20' ' ' LEU . 14.6 pt -106.89 161.64 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.213 -0.929 . . . . 0.0 110.219 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.86 -29.42 54.95 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.579 ' N ' HD12 ' A' ' 20' ' ' LEU . 10.0 mp -65.04 -34.67 78.98 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.173 -1.192 . . . . 0.0 110.422 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.1 mtt180 -93.68 137.22 33.16 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.204 -0.935 . . . . 0.0 110.307 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -83.73 134.79 34.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.189 -0.944 . . . . 0.0 110.235 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.415 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 87.0 tttt -98.85 98.57 9.64 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.23 -0.919 . . . . 0.0 110.21 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 89.1 mt -66.78 -33.47 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.286 -0.884 . . . . 0.0 110.314 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.452 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -175.83 -167.14 34.34 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 64.6 p -104.88 104.15 13.87 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.426 -1.044 . . . . 0.0 110.462 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.434 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 49.9 t -56.09 -43.03 77.65 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.266 -0.896 . . . . 0.0 109.83 179.62 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -154.09 -166.57 15.06 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 179.737 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.596 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.1 m -88.6 -42.32 0.46 Allowed Pre-proline 0 C--N 1.301 -1.525 0 O-C-N 121.077 -1.249 . . . . 0.0 110.232 179.679 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.598 ' HG2' ' CD2' ' A' ' 31' ' ' PHE . 47.8 Cg_endo -81.83 6.59 5.57 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 O-C-N 123.504 1.265 . . . . 0.0 109.949 179.26 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.598 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 83.2 m-85 -151.57 170.78 18.83 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.153 -0.967 . . . . 0.0 110.409 179.728 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.518 ' N ' ' O ' ' A' ' 14' ' ' GLN . 94.4 mttt -132.7 156.89 46.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.336 -0.853 . . . . 0.0 109.653 179.524 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.452 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 9.8 t -84.48 121.6 27.81 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.225 -0.922 . . . . 0.0 110.143 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 71.6 m -133.59 132.75 41.21 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.315 -0.866 . . . . 0.0 110.25 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 84.6 tttt . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.119 179.929 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.45 ' O ' ' OD1' ' A' ' 9' ' ' ASN . 80.8 m . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 121.296 0.57 . . . . 0.0 110.385 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.451 ' HA ' ' O ' ' A' ' 11' ' ' GLY . 5.7 tt -58.19 -17.28 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.182 -0.949 . . . . 0.0 110.189 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 9.1 tpm_? -66.63 -33.76 76.37 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.223 -0.923 . . . . 0.0 110.247 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.454 ' OD1' ' N ' ' A' ' 11' ' ' GLY . 47.4 p30 -84.98 4.98 31.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.149 -0.969 . . . . 0.0 110.182 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.76 -5.04 53.71 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.454 ' N ' ' OD1' ' A' ' 9' ' ' ASN . . . -72.63 175.78 43.44 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.581 HG22 ' N ' ' A' ' 13' ' ' CYS . 70.1 mt -130.82 174.41 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -1.114 . . . . 0.0 110.198 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.581 ' N ' HG22 ' A' ' 12' ' ' ILE . 2.6 m -127.16 150.68 49.4 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.213 -0.929 . . . . 0.0 110.174 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.506 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 4.4 tp-100 -156.04 151.74 27.22 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.677 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.537 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 73.6 t80 -56.98 -31.64 65.26 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.113 -0.992 . . . . 0.0 110.396 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.537 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 38.0 mmt180 -151.63 150.94 30.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.358 -0.839 . . . . 0.0 110.23 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 96.3 m -121.55 125.91 47.9 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.286 -0.884 . . . . 0.0 110.304 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.44 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 36.8 pt -62.27 166.41 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.239 -0.913 . . . . 0.0 110.126 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.85 -42.4 59.73 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.727 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.44 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 32.8 mt -51.86 -28.58 16.46 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.325 -1.103 . . . . 0.0 110.31 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 61.5 mtt-85 -117.66 118.95 33.49 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.235 -0.915 . . . . 0.0 110.487 -179.742 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -97.99 144.77 27.17 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.883 . . . . 0.0 109.814 179.741 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.492 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -99.78 107.0 18.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.133 -0.979 . . . . 0.0 110.643 -179.718 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 51.3 mm -64.08 -35.63 74.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.253 -0.904 . . . . 0.0 110.19 179.741 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.479 ' C ' ' HB2' ' A' ' 33' ' ' CYS . . . -141.56 -162.77 9.3 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.631 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.537 HG22 ' O ' ' A' ' 28' ' ' GLY . 90.0 m -122.44 108.61 13.39 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.476 -1.014 . . . . 0.0 110.286 179.692 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.517 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 10.9 t -58.64 -32.59 69.2 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.224 -0.922 . . . . 0.0 109.587 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.537 ' O ' HG22 ' A' ' 26' ' ' THR . . . -172.02 -158.35 15.93 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.709 -1.757 . . . . 0.0 108.709 179.621 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.591 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.7 m -88.97 -43.09 0.44 Allowed Pre-proline 0 C--N 1.302 -1.485 0 O-C-N 120.839 -1.389 . . . . 0.0 110.215 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.591 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.2 Cg_endo -83.52 10.22 3.77 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.557 1.293 . . . . 0.0 109.533 179.009 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.541 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 79.0 m-85 -154.21 171.11 19.72 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.342 -0.849 . . . . 0.0 110.737 -179.861 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.486 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 95.5 mttt -134.32 161.28 35.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.588 -0.695 . . . . 0.0 109.196 179.168 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.517 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 58.0 m -80.37 100.06 8.25 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.063 -1.023 . . . . 0.0 110.185 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.468 ' SG ' ' HB3' ' A' ' 23' ' ' LYS . 19.8 m -129.38 158.35 39.38 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.143 -0.973 . . . . 0.0 110.339 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 117.936 -1.03 . . . . 0.0 109.999 179.732 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 84.3 m-20 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.243 0.544 . . . . 0.0 110.203 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.586 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 33.4 mp0 -59.8 -41.7 87.09 Favored Pre-proline 0 N--CA 1.492 1.665 0 O-C-N 121.282 -0.886 . . . . 0.0 111.374 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 48.9 Cg_endo -77.22 -6.63 16.65 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 O-C-N 123.369 1.194 . . . . 0.0 110.605 -179.432 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.577 HG12 ' N ' ' A' ' 5' ' ' SER . 60.0 t 56.0 173.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.118 -0.989 . . . . 0.0 110.255 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.826 ' OG ' HG22 ' A' ' 7' ' ' ILE . 74.9 p -67.7 177.15 2.15 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.235 -0.916 . . . . 0.0 110.35 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 28.4 t -61.64 -19.93 62.83 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.329 -0.857 . . . . 0.0 110.482 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.826 HG22 ' OG ' ' A' ' 5' ' ' SER . 9.9 tt -57.47 -32.37 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.163 -0.961 . . . . 0.0 110.646 -179.735 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.467 ' HD2' ' HB ' ' A' ' 4' ' ' VAL . 59.4 ttt180 -56.08 -31.83 63.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 110.485 -179.732 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 75.5 m-20 -66.03 -30.38 70.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.263 -0.898 . . . . 0.0 110.239 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.04 5.85 21.26 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -82.59 -178.49 52.39 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 23.8 mm -112.1 166.64 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.146 -1.208 . . . . 0.0 110.273 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.532 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.4 m -120.22 153.79 35.79 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.183 -0.948 . . . . 0.0 109.998 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.511 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 20.0 tp60 -153.7 154.93 35.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.434 -0.791 . . . . 0.0 109.714 179.689 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.564 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 72.5 t80 -59.88 -36.39 76.84 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.164 -0.96 . . . . 0.0 110.252 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.564 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 38.8 mmt180 -148.42 152.44 36.97 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.344 -0.848 . . . . 0.0 109.958 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 69.5 m -123.03 152.25 41.13 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.128 -0.982 . . . . 0.0 110.289 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.7 pt -103.82 165.92 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.326 -0.858 . . . . 0.0 109.899 179.704 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.78 -42.75 37.72 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.834 HD13 ' O ' ' A' ' 20' ' ' LEU . 3.3 tm? -51.01 -35.15 32.49 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.177 -1.19 . . . . 0.0 110.404 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.8 mtp180 -89.87 150.16 22.34 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.186 -0.946 . . . . 0.0 110.485 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 92.4 m-70 -108.3 141.21 40.43 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.313 -0.867 . . . . 0.0 109.818 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.446 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 76.4 tttt -121.83 121.93 38.3 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.179 -0.95 . . . . 0.0 110.74 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 28.8 pt -101.43 -6.3 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.388 -0.82 . . . . 0.0 109.793 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.459 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -178.17 -174.22 44.27 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.697 HG22 ' O ' ' A' ' 28' ' ' GLY . 89.1 m -111.27 111.04 21.82 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.177 -1.19 . . . . 0.0 110.31 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.411 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 38.9 t -53.71 -48.18 69.81 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.225 -0.922 . . . . 0.0 109.958 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.697 ' O ' HG22 ' A' ' 26' ' ' THR . . . -149.84 -163.29 11.01 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.582 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 9.7 m -89.81 -42.94 0.42 Allowed Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 120.998 -1.295 . . . . 0.0 110.221 179.799 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.584 ' O ' ' CD1' ' A' ' 31' ' ' PHE . 50.4 Cg_endo -82.27 7.21 5.24 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.499 1.263 . . . . 0.0 109.555 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.584 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 57.7 m-85 -151.87 169.21 22.84 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.324 -0.86 . . . . 0.0 110.284 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.532 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 93.2 mttt -131.21 157.3 43.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.342 -0.849 . . . . 0.0 109.656 179.285 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.459 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 42.3 t -84.77 119.01 24.81 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.095 -1.003 . . . . 0.0 110.255 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 97.8 m -145.44 157.24 44.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.293 -0.879 . . . . 0.0 110.315 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.209 179.877 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 24.3 m120 . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 121.329 0.585 . . . . 0.0 110.165 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.6 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 63.6 mm-40 -59.6 -42.99 94.76 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.276 -0.89 . . . . 0.0 110.989 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.6 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.4 Cg_endo -74.98 -11.11 21.5 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.333 1.175 . . . . 0.0 110.467 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.595 HG12 ' N ' ' A' ' 5' ' ' SER . 59.0 t 51.69 173.49 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.278 -0.889 . . . . 0.0 110.374 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.595 ' N ' HG12 ' A' ' 4' ' ' VAL . 68.0 m -105.42 129.39 53.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.3 -0.875 . . . . 0.0 109.987 179.677 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 7.3 t -62.33 -31.61 72.26 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.289 -0.882 . . . . 0.0 110.525 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.5 HG12 ' HB3' ' A' ' 5' ' ' SER . 36.5 pt -60.03 -14.66 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.18 -0.95 . . . . 0.0 110.264 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 78.0 mmt-85 -64.38 -34.91 79.25 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.294 -0.879 . . . . 0.0 110.117 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -65.58 -26.18 67.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.337 -0.852 . . . . 0.0 110.027 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.89 -1.07 13.51 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.79 -176.73 50.97 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.4 pt -128.63 163.77 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.348 -1.089 . . . . 0.0 110.002 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.521 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.2 m -103.38 154.41 19.44 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.092 -1.005 . . . . 0.0 109.951 -179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.533 ' O ' ' N ' ' A' ' 32' ' ' LYS . 4.9 tp60 -149.42 151.26 33.72 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.306 -0.871 . . . . 0.0 109.989 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.457 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 67.6 t80 -55.21 -44.66 75.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 110.131 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.457 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 48.3 mmm-85 -150.23 143.0 24.69 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.363 -0.836 . . . . 0.0 110.233 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 90.4 m -109.49 153.25 24.33 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.25 -0.907 . . . . 0.0 110.127 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.553 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 38.3 pt -103.76 176.45 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.274 -0.891 . . . . 0.0 110.233 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.72 -33.04 81.01 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.622 ' N ' HD22 ' A' ' 20' ' ' LEU . 3.9 mm? -61.2 -34.93 75.88 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -1.162 . . . . 0.0 110.056 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -99.45 149.04 23.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.259 -0.901 . . . . 0.0 110.063 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 72.8 m80 -107.74 134.79 50.2 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.188 -0.945 . . . . 0.0 110.213 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 35.6 tttm -97.22 107.26 19.75 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.325 -0.859 . . . . 0.0 110.239 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.42 HG23 ' N ' ' A' ' 25' ' ' GLY . 18.9 tt -69.74 -32.44 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 110.179 179.762 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.444 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -166.41 -173.17 34.54 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.618 HG22 ' O ' ' A' ' 28' ' ' GLY . 61.8 m -104.25 100.04 9.77 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.244 -1.15 . . . . 0.0 110.309 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.431 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 35.9 t -52.22 -43.88 64.49 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.202 -0.936 . . . . 0.0 109.734 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.618 ' O ' HG22 ' A' ' 26' ' ' THR . . . -154.59 -163.37 11.92 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 179.737 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.584 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 15.8 m -90.46 -41.86 0.4 Allowed Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.035 -1.274 . . . . 0.0 110.34 179.695 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.584 ' CD ' ' N ' ' A' ' 29' ' ' SER . 45.8 Cg_endo -81.92 7.0 5.32 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.466 1.245 . . . . 0.0 109.785 179.084 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.581 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 88.9 m-85 -153.65 170.96 19.58 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.263 -0.898 . . . . 0.0 110.351 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 14' ' ' GLN . 61.5 mttm -133.19 156.55 47.29 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.472 -0.768 . . . . 0.0 109.635 179.512 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 10.8 t -84.74 113.06 21.04 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.243 -0.911 . . . . 0.0 110.282 -179.765 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.7 m -138.84 143.22 38.72 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.345 -0.847 . . . . 0.0 110.064 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.257 -179.858 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ASN . . . . . 0.418 ' O ' ' O ' ' A' ' 4' ' ' VAL . 83.5 m-20 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.437 0.637 . . . . 0.0 110.072 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.607 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 34.7 tt0 -74.75 -39.46 3.57 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.872 . . . . 0.0 111.411 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.607 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.5 Cg_endo -76.23 -14.41 18.57 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.187 1.098 . . . . 0.0 110.789 -179.296 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.418 ' O ' ' O ' ' A' ' 1' ' ' ASN . 15.5 m -135.87 146.8 28.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.154 -0.966 . . . . 0.0 110.351 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 62.8 m -114.99 144.2 43.97 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.223 -0.923 . . . . 0.0 110.159 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 34.4 t -63.22 -28.59 70.14 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.146 -0.972 . . . . 0.0 110.184 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.432 ' HA ' HD12 ' A' ' 7' ' ' ILE . 6.0 tp -52.18 -28.48 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.404 -0.81 . . . . 0.0 110.385 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 48.6 ttp180 -57.16 -31.55 65.51 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.169 -0.957 . . . . 0.0 110.469 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -67.14 -30.6 70.64 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.286 -0.884 . . . . 0.0 110.25 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 116.06 8.28 13.62 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -85.83 -177.19 50.19 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 34.8 pt -116.62 162.35 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.185 -1.185 . . . . 0.0 110.064 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.521 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.1 m -113.19 155.1 25.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.121 -0.987 . . . . 0.0 110.141 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 65.2 tt0 -154.29 155.46 35.21 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.404 -0.81 . . . . 0.0 109.835 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.596 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 60.1 t80 -57.79 -44.69 86.44 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.177 -0.952 . . . . 0.0 110.257 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.596 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 41.0 mmt180 -145.95 150.2 35.62 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.35 -0.844 . . . . 0.0 110.267 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.1 m -120.62 126.06 49.31 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.211 -0.931 . . . . 0.0 110.052 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.5 pt -134.03 165.32 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.227 -0.921 . . . . 0.0 110.205 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.91 -169.73 40.78 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 94.8 mt -51.78 -29.99 21.14 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.34 -1.094 . . . . 0.0 110.273 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 81.0 mtm180 -53.08 148.98 7.23 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.246 -0.909 . . . . 0.0 110.278 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 45.8 p-80 -135.18 164.46 27.62 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.27 -0.894 . . . . 0.0 109.968 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.473 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 68.5 tttt -112.69 99.06 7.64 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.12 -0.987 . . . . 0.0 110.519 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.421 HD12 ' HE3' ' A' ' 35' ' ' LYS . 90.1 mt -60.52 -43.43 94.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.288 -0.883 . . . . 0.0 110.069 179.68 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.459 ' O ' ' HE2' ' A' ' 23' ' ' LYS . . . -144.06 -173.77 15.77 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.569 HG22 ' O ' ' A' ' 28' ' ' GLY . 90.2 m -108.9 105.5 15.08 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.265 -1.138 . . . . 0.0 110.366 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.445 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 48.6 t -55.67 -44.25 77.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -0.929 . . . . 0.0 109.767 179.731 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.569 ' O ' HG22 ' A' ' 26' ' ' THR . . . -152.41 -167.11 14.91 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.805 -1.718 . . . . 0.0 108.805 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.606 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 2.0 m -87.36 -43.18 0.52 Allowed Pre-proline 0 C--N 1.299 -1.602 0 O-C-N 121.227 -1.16 . . . . 0.0 110.003 179.732 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.606 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.3 Cg_endo -83.3 7.63 5.09 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 O-C-N 123.628 1.33 . . . . 0.0 109.564 179.153 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.562 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 88.6 m-85 -152.07 170.63 19.45 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -0.893 . . . . 0.0 110.207 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.521 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 92.2 mttt -134.03 156.4 48.28 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.529 -0.732 . . . . 0.0 109.634 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 42.6 t -84.62 121.51 27.73 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.138 -0.976 . . . . 0.0 110.23 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 65.9 m -142.18 139.5 32.08 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.251 -0.905 . . . . 0.0 110.258 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.421 ' HE3' HD12 ' A' ' 24' ' ' ILE . 94.8 mttt . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.078 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ASN . . . . . 0.487 ' HB2' ' HB ' ' A' ' 4' ' ' VAL . 97.2 m-20 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.37 0.605 . . . . 0.0 110.068 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.613 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 84.0 tt0 -60.81 -41.22 81.1 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.235 -0.916 . . . . 0.0 111.419 -179.751 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.613 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 47.4 Cg_endo -75.45 -1.86 11.84 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.364 1.191 . . . . 0.0 110.762 -179.404 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 5' ' ' SER . 61.0 t -137.49 172.51 14.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.158 -0.964 . . . . 0.0 110.106 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.584 ' N ' HG12 ' A' ' 4' ' ' VAL . 21.4 t -79.15 137.11 37.33 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.247 -0.908 . . . . 0.0 110.022 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 47.7 t -61.47 -40.23 93.75 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.231 -0.918 . . . . 0.0 110.434 -179.696 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.539 ' H ' HD12 ' A' ' 7' ' ' ILE . 1.6 mp -63.36 -32.27 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.17 -0.957 . . . . 0.0 109.885 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 17.1 tpt180 -55.97 -36.95 68.42 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.376 -0.828 . . . . 0.0 110.332 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -77.46 -9.78 59.09 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.332 -0.855 . . . . 0.0 110.3 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.92 6.33 65.39 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -74.21 -172.26 26.91 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.494 HG22 ' N ' ' A' ' 13' ' ' CYS . 51.7 mt -122.45 169.35 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -1.161 . . . . 0.0 110.187 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.6 m -134.81 155.22 51.01 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.314 -0.866 . . . . 0.0 110.096 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.45 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 28.1 mt-30 -153.04 156.43 38.75 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.509 -0.744 . . . . 0.0 109.95 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.502 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 81.8 m-85 -52.62 -34.89 53.16 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.142 -0.974 . . . . 0.0 110.032 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.45 ' NH1' ' HE3' ' A' ' 32' ' ' LYS . 26.9 tpt180 -151.95 165.76 33.62 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.395 -0.815 . . . . 0.0 110.097 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 23.4 m -138.28 128.11 25.3 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.22 -0.925 . . . . 0.0 110.129 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 pt -142.44 167.34 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.292 -0.88 . . . . 0.0 110.171 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.44 -150.54 23.59 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.606 ' N ' HD22 ' A' ' 20' ' ' LEU . 4.2 mm? -67.69 -19.66 65.2 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.352 -1.087 . . . . 0.0 109.999 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.0 mtt180 -54.81 142.8 27.75 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.354 -0.841 . . . . 0.0 110.323 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.541 ' CD2' ' O ' ' A' ' 20' ' ' LEU . 96.4 m-70 -128.25 161.06 30.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.401 -0.812 . . . . 0.0 110.015 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.478 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 25.2 ttmt -122.54 126.61 48.14 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.198 -0.939 . . . . 0.0 110.31 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 35.0 pt -99.19 -9.6 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.263 -0.898 . . . . 0.0 110.06 179.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.461 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -173.33 -171.74 38.2 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.746 HG23 ' O ' ' A' ' 26' ' ' THR . 15.0 t -109.82 106.93 16.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.253 -1.145 . . . . 0.0 110.218 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 20.7 t -59.31 -37.8 78.66 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.211 -0.931 . . . . 0.0 110.106 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -170.3 -164.9 26.8 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.602 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 61.7 m -88.7 -41.62 0.46 Allowed Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 120.903 -1.351 . . . . 0.0 110.148 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.602 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.1 Cg_endo -82.88 8.62 4.49 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 123.504 1.265 . . . . 0.0 109.425 178.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 69.5 m-85 -155.8 172.42 18.37 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.382 -0.823 . . . . 0.0 110.469 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 65.0 mttm -135.83 158.17 45.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.557 -0.715 . . . . 0.0 109.172 178.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.478 ' O ' ' HG3' ' A' ' 23' ' ' LYS . 38.3 t -77.4 121.07 23.29 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.978 -1.076 . . . . 0.0 109.956 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 56.0 m -147.64 150.95 35.35 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.107 -0.995 . . . . 0.0 110.355 -179.848 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.187 179.99 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ASN . . . . . 0.776 ' HB3' HG13 ' A' ' 4' ' ' VAL . 23.8 m120 . . . . . 0 N--CA 1.494 1.747 0 CA-C-O 121.248 0.547 . . . . 0.0 110.108 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.605 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 87.5 tt0 -70.29 -40.45 11.92 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.32 -0.863 . . . . 0.0 111.19 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.605 ' CD ' ' N ' ' A' ' 2' ' ' GLU . 47.2 Cg_endo -76.84 -3.74 14.13 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 O-C-N 123.341 1.18 . . . . 0.0 110.835 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.776 HG13 ' HB3' ' A' ' 1' ' ' ASN . 0.9 OUTLIER -136.13 171.57 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.182 -0.949 . . . . 0.0 110.1 179.504 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.56 ' N ' ' CG2' ' A' ' 4' ' ' VAL . 47.0 m 55.31 54.38 8.74 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.415 -0.803 . . . . 0.0 110.138 -179.823 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 43.0 t -63.7 -39.59 94.69 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.224 -0.922 . . . . 0.0 110.279 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.492 HG13 ' N ' ' A' ' 8' ' ' ARG . 40.8 pt -56.53 -29.05 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -0.883 . . . . 0.0 110.266 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.492 ' N ' HG13 ' A' ' 7' ' ' ILE . 58.8 ttt-85 -63.43 -41.88 98.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.247 -0.908 . . . . 0.0 110.233 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 -66.0 -26.72 67.67 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.291 -0.881 . . . . 0.0 110.176 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.4 16.34 14.89 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.87 -176.46 36.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 18.9 pt -119.67 151.04 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.262 -1.14 . . . . 0.0 110.011 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.478 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.1 m -101.52 153.13 20.0 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.147 -0.971 . . . . 0.0 109.992 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 43.6 tp60 -154.38 154.29 33.03 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.342 -0.849 . . . . 0.0 109.839 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.477 ' N ' ' HG3' ' A' ' 14' ' ' GLN . 64.2 t80 -54.89 -34.59 63.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.273 -0.892 . . . . 0.0 110.764 -179.649 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 22.1 tpp180 -156.64 164.33 38.29 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.165 -0.959 . . . . 0.0 110.218 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 93.5 m -133.43 127.8 34.15 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.299 -0.876 . . . . 0.0 110.156 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.555 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 42.7 pt -59.28 161.43 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.237 -0.914 . . . . 0.0 110.324 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.82 -35.42 52.95 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.579 ' N ' HD22 ' A' ' 20' ' ' LEU . 4.4 mm? -58.46 -28.72 65.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.285 -1.126 . . . . 0.0 110.436 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.48 ' HG2' ' HB3' ' A' ' 34' ' ' CYS . 20.5 tpp180 -106.5 130.08 54.34 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.137 -0.977 . . . . 0.0 110.479 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 54.5 p-80 -105.82 153.82 21.39 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.401 -0.812 . . . . 0.0 109.636 179.619 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.516 ' CB ' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -118.79 124.85 48.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.085 -1.01 . . . . 0.0 110.572 -179.761 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.578 HG22 ' HG2' ' A' ' 2' ' ' GLU . 61.0 mt -68.08 -34.85 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.931 . . . . 0.0 109.824 179.686 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.509 ' HA3' ' HA ' ' A' ' 3' ' ' PRO . . . -151.78 -169.25 17.1 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.865 HG22 ' O ' ' A' ' 28' ' ' GLY . 27.5 m -111.31 101.34 9.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -1.172 . . . . 0.0 110.39 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.417 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 40.5 t -44.54 -51.33 9.01 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.303 -0.873 . . . . 0.0 109.806 179.595 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.865 ' O ' HG22 ' A' ' 26' ' ' THR . . . -145.57 -164.95 11.05 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 108.587 -1.805 . . . . 0.0 108.587 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.581 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.9 m -88.27 -44.38 0.47 Allowed Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 120.821 -1.399 . . . . 0.0 110.08 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.589 ' HG2' ' CE2' ' A' ' 31' ' ' PHE . 45.2 Cg_endo -80.43 7.8 4.55 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 O-C-N 123.554 1.291 . . . . 0.0 110.083 179.203 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.589 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 89.6 m-85 -149.17 170.52 18.25 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.227 -0.921 . . . . 0.0 110.269 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.496 ' N ' ' O ' ' A' ' 14' ' ' GLN . 98.1 mttt -131.37 159.07 39.04 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.463 -0.773 . . . . 0.0 109.505 179.18 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.516 ' O ' ' CB ' ' A' ' 23' ' ' LYS . 47.8 t -84.61 115.79 22.82 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.048 -1.032 . . . . 0.0 110.406 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.48 ' HB3' ' HG2' ' A' ' 21' ' ' ARG . 71.7 m -142.54 130.86 22.2 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.136 -0.977 . . . . 0.0 110.092 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 96.2 mttt . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.26 -179.782 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 66.4 t30 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 121.207 0.527 . . . . 0.0 110.009 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.6 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 93.0 mt-10 -61.37 -42.89 87.42 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.152 -0.968 . . . . 0.0 111.054 -179.821 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.617 ' O ' HG22 ' A' ' 4' ' ' VAL . 48.2 Cg_endo -76.12 -5.2 16.03 Favored 'Trans proline' 0 C--N 1.31 -1.466 0 O-C-N 123.403 1.212 . . . . 0.0 110.643 -179.604 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.617 HG22 ' O ' ' A' ' 3' ' ' PRO . 13.2 m 38.5 -161.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.579 -0.701 . . . . 0.0 110.685 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.487 ' HB3' ' O ' ' A' ' 4' ' ' VAL . 22.9 t 61.01 48.07 6.83 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.547 -0.721 . . . . 0.0 110.375 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.415 ' O ' ' HB ' ' A' ' 7' ' ' ILE . 45.9 t -76.08 119.99 20.77 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.359 -0.838 . . . . 0.0 110.315 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.415 ' HB ' ' O ' ' A' ' 6' ' ' CYS . 7.0 tt -175.06 -28.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.236 -0.915 . . . . 0.0 110.706 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 15.6 mtm180 -57.29 -30.62 64.86 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.943 -1.098 . . . . 0.0 109.492 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -65.99 -29.42 69.8 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.618 -0.676 . . . . 0.0 110.368 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 107.48 9.74 28.52 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.93 171.05 48.36 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.8 pt -111.68 161.8 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -1.124 . . . . 0.0 110.176 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.507 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.2 m -104.36 154.33 19.96 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.162 -0.962 . . . . 0.0 109.921 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.533 ' O ' ' N ' ' A' ' 32' ' ' LYS . 63.2 tt0 -155.13 153.42 30.79 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.41 -0.806 . . . . 0.0 109.565 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.496 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 63.2 t80 -59.14 -39.48 82.52 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.043 -1.036 . . . . 0.0 110.36 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.496 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 17.1 mmm180 -144.59 146.76 32.49 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.268 -0.895 . . . . 0.0 110.348 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.2 t -109.14 156.26 20.05 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.254 -0.903 . . . . 0.0 110.441 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.432 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 31.1 pt -110.46 162.79 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.252 -0.905 . . . . 0.0 110.191 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.06 -36.74 52.58 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.58 ' N ' HD22 ' A' ' 20' ' ' LEU . 4.2 mm? -56.33 -35.31 67.46 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.194 -1.18 . . . . 0.0 110.169 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 -100.77 129.17 46.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.218 -0.926 . . . . 0.0 110.128 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 77.9 t60 -88.07 124.98 34.31 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.352 -0.842 . . . . 0.0 110.295 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.476 ' HD2' ' HB3' ' A' ' 32' ' ' LYS . 27.3 ttpp -97.33 117.18 30.97 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.294 -0.879 . . . . 0.0 110.132 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 35.9 pt -97.62 0.32 10.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.177 -0.952 . . . . 0.0 110.315 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.92 -172.35 43.82 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.705 HG22 ' O ' ' A' ' 28' ' ' GLY . 88.4 m -119.46 111.5 18.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -1.118 . . . . 0.0 110.226 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.436 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 45.8 t -54.04 -53.32 54.61 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.247 -0.908 . . . . 0.0 109.795 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.705 ' O ' HG22 ' A' ' 26' ' ' THR . . . -142.12 -165.36 10.47 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 108.651 -1.779 . . . . 0.0 108.651 179.475 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.608 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 23.5 m -87.27 -41.69 0.52 Allowed Pre-proline 0 C--N 1.304 -1.412 0 O-C-N 121.027 -1.278 . . . . 0.0 110.052 179.618 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.608 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.3 Cg_endo -81.75 7.46 5.02 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 O-C-N 123.506 1.266 . . . . 0.0 109.681 178.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.586 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 86.7 m-85 -151.92 171.09 18.34 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.296 -0.877 . . . . 0.0 110.448 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 14' ' ' GLN . 62.0 mttm -128.6 157.76 40.37 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.429 -0.794 . . . . 0.0 109.264 179.347 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.476 ' O ' ' HG3' ' A' ' 23' ' ' LYS . 48.9 t -91.76 117.56 29.87 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.985 -1.072 . . . . 0.0 110.301 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 96.9 m -135.43 131.42 36.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.211 -0.93 . . . . 0.0 110.595 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.2 ptmm? . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.241 179.925 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 73.8 m-80 . . . . . 0 N--CA 1.496 1.836 0 CA-C-O 121.237 0.541 . . . . 0.0 110.2 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.61 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 79.8 tt0 -61.59 -42.72 85.48 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.142 -0.973 . . . . 0.0 110.726 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.61 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 52.2 Cg_endo -76.24 -155.26 0.05 OUTLIER 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.473 1.249 . . . . 0.0 110.34 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 4.0 t -131.38 167.83 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.115 -0.99 . . . . 0.0 110.178 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 92.7 p -78.35 153.45 31.64 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.201 -0.937 . . . . 0.0 110.289 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.486 ' HB2' ' SG ' ' A' ' 27' ' ' CYS . 0.3 OUTLIER -88.05 9.92 20.85 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.341 -0.849 . . . . 0.0 110.035 179.91 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.424 HG23 ' N ' ' A' ' 8' ' ' ARG . 4.8 tp -65.16 -33.43 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.286 -0.884 . . . . 0.0 110.105 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.424 ' N ' HG23 ' A' ' 7' ' ' ILE . 81.0 mtt180 -52.15 -37.94 56.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.3 -0.875 . . . . 0.0 110.336 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -71.08 -6.83 42.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.39 -0.819 . . . . 0.0 110.251 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 81.49 13.96 79.27 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.43 ' C ' HG13 ' A' ' 12' ' ' ILE . . . -96.71 -170.7 34.25 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.483 HG22 ' N ' ' A' ' 13' ' ' CYS . 27.2 mt -132.53 172.53 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.297 -1.119 . . . . 0.0 109.622 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.518 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 6.1 m -137.39 159.59 41.5 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.916 -1.115 . . . . 0.0 111.346 -179.586 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 53.9 tp60 -157.67 153.63 27.02 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.451 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.497 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 44.1 t80 -44.74 -46.4 10.42 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.979 -1.076 . . . . 0.0 110.392 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.497 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 30.3 mmt180 -137.71 146.58 43.9 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.327 -0.858 . . . . 0.0 110.012 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 77.3 m -111.65 131.02 55.57 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.118 -0.988 . . . . 0.0 110.503 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.4 pt -133.47 164.59 34.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.195 -0.941 . . . . 0.0 110.217 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.78 -161.35 23.71 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.489 ' O ' ' CE1' ' A' ' 22' ' ' HIS . 53.2 mt -70.56 -24.52 62.8 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.283 -1.128 . . . . 0.0 110.126 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 100.0 mtt180 -57.36 142.86 42.14 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.326 -0.859 . . . . 0.0 110.313 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.489 ' CE1' ' O ' ' A' ' 20' ' ' LEU . 77.6 m-70 -119.6 160.9 21.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.214 -0.929 . . . . 0.0 110.089 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.523 ' CE ' ' OG1' ' A' ' 26' ' ' THR . 76.9 tttt -99.7 97.94 8.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.166 -0.959 . . . . 0.0 110.381 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 89.9 mt -67.37 -26.96 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.188 -0.945 . . . . 0.0 110.181 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.402 ' H ' ' HB3' ' A' ' 33' ' ' CYS . . . -164.33 -169.05 27.36 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.597 HG22 ' O ' ' A' ' 28' ' ' GLY . 92.3 m -122.98 111.01 16.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.245 -1.15 . . . . 0.0 110.429 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.486 ' SG ' ' HB2' ' A' ' 6' ' ' CYS . 33.4 m -59.43 -43.47 93.07 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.239 -0.913 . . . . 0.0 109.523 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.597 ' O ' HG22 ' A' ' 26' ' ' THR . . . -154.28 -160.96 10.14 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.612 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 5.2 m -86.84 -41.65 0.54 Allowed Pre-proline 0 C--N 1.301 -1.515 0 O-C-N 120.941 -1.329 . . . . 0.0 109.977 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.612 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.8 Cg_endo -81.58 7.79 4.8 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 123.539 1.284 . . . . 0.0 109.987 179.19 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.589 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 52.6 m-85 -149.73 179.36 8.07 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.218 -0.926 . . . . 0.0 110.812 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 26' ' ' THR . 68.7 mttt -148.26 161.85 40.68 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.515 -0.74 . . . . 0.0 109.396 179.625 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.464 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 46.9 t -88.88 110.11 20.79 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.611 -1.306 . . . . 0.0 109.78 179.533 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 89.2 m -137.09 150.51 48.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.184 -0.948 . . . . 0.0 110.334 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 99.9 mttt . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.141 179.814 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ASN . . . . . 0.511 ' HB3' ' HB ' ' A' ' 4' ' ' VAL . 91.5 m-20 . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.379 0.609 . . . . 0.0 110.271 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.62 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 98.5 mt-10 -62.33 -43.51 85.38 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.385 -0.822 . . . . 0.0 111.277 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.62 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 45.3 Cg_endo -73.47 -6.46 18.81 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.344 1.181 . . . . 0.0 110.739 -179.415 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 5' ' ' SER . 65.5 t -130.15 172.69 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.247 -0.908 . . . . 0.0 109.915 179.635 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.582 ' N ' HG12 ' A' ' 4' ' ' VAL . 94.6 p -146.82 156.51 43.18 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.287 -0.883 . . . . 0.0 110.052 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 1.3 p -95.82 13.7 25.77 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.899 . . . . 0.0 110.133 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.471 HG13 ' N ' ' A' ' 8' ' ' ARG . 32.3 pt -67.86 -26.15 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.356 -0.84 . . . . 0.0 110.098 179.763 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.471 ' N ' HG13 ' A' ' 7' ' ' ILE . 76.7 mtt85 -49.56 -33.07 13.94 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.202 -0.936 . . . . 0.0 110.336 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 55.5 t-20 -68.92 -23.65 64.19 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.357 -0.839 . . . . 0.0 110.723 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 111.36 -2.93 28.04 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.44 -168.94 41.61 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.478 HG22 ' N ' ' A' ' 13' ' ' CYS . 51.3 mt -131.6 170.77 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.355 -1.085 . . . . 0.0 109.949 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.524 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.5 m -135.88 159.39 41.81 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.019 -1.051 . . . . 0.0 110.485 179.682 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.519 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 11.6 pt20 -155.64 169.86 23.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.466 -0.771 . . . . 0.0 109.78 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.487 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 96.3 m-85 -58.04 -36.94 73.47 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.302 -0.874 . . . . 0.0 110.842 -179.653 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.468 ' O ' ' HG3' ' A' ' 14' ' ' GLN . 38.3 mmt180 -146.46 153.63 40.66 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.144 -0.972 . . . . 0.0 110.517 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.4 m -122.31 161.94 22.42 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.249 -0.907 . . . . 0.0 109.839 179.519 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.532 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 34.6 pt -113.98 172.83 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.057 -1.027 . . . . 0.0 110.315 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.99 -33.92 64.79 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.532 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 22.9 mt -59.6 -33.64 71.73 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -1.132 . . . . 0.0 110.264 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -101.8 133.79 45.98 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.344 -0.847 . . . . 0.0 110.056 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 66.6 t-80 -88.28 124.85 34.29 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.261 -0.899 . . . . 0.0 110.216 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.625 ' HE2' HG22 ' A' ' 26' ' ' THR . 74.0 tttt -88.02 90.45 8.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.213 -0.929 . . . . 0.0 110.106 179.827 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.9 tt -64.95 -30.98 51.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.189 -0.944 . . . . 0.0 110.358 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -170.02 -171.21 35.29 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.625 HG22 ' HE2' ' A' ' 23' ' ' LYS . 58.2 p -116.31 103.04 10.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.343 -1.092 . . . . 0.0 110.485 -179.732 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.462 ' O ' ' HB2' ' A' ' 1' ' ' ASN . 62.6 m -47.95 -48.6 32.06 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.742 179.52 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.16 -160.09 8.53 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.594 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 8.4 m -89.99 -41.61 0.42 Allowed Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.082 -1.246 . . . . 0.0 110.67 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.594 ' CD ' ' N ' ' A' ' 29' ' ' SER . 46.4 Cg_endo -81.16 7.83 4.72 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 123.472 1.248 . . . . 0.0 109.997 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.586 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 83.9 m-85 -150.36 171.79 16.43 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.255 -0.903 . . . . 0.0 110.438 179.575 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.524 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 93.8 mttt -135.58 158.99 43.01 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.408 -0.808 . . . . 0.0 108.995 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.531 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 4.8 t -89.29 118.78 29.21 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.767 -1.208 . . . . 0.0 109.907 179.506 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 95.4 m -144.31 147.43 33.48 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.133 -0.979 . . . . 0.0 110.299 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 91.5 mttt . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.17 179.721 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ASN . . . . . 0.547 ' HB2' HG22 ' A' ' 4' ' ' VAL . 82.0 m-20 . . . . . 0 N--CA 1.494 1.768 0 CA-C-O 121.385 0.612 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.621 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 76.3 tt0 -66.99 -41.52 36.4 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.344 -0.847 . . . . 0.0 111.47 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.621 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.0 Cg_endo -74.6 -8.23 20.29 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.241 1.127 . . . . 0.0 110.922 -179.118 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.547 HG22 ' HB2' ' A' ' 1' ' ' ASN . 28.8 m -131.74 150.94 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.016 -1.052 . . . . 0.0 110.2 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.464 ' OG ' HG12 ' A' ' 7' ' ' ILE . 6.1 t -111.99 135.63 52.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.255 -0.903 . . . . 0.0 110.359 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.469 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 53.1 t -63.42 -40.23 96.62 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.222 -0.923 . . . . 0.0 110.107 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.517 HG13 ' N ' ' A' ' 8' ' ' ARG . 46.7 pt -57.25 -33.49 43.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.241 -0.912 . . . . 0.0 110.279 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.517 ' N ' HG13 ' A' ' 7' ' ' ILE . 65.9 ttt-85 -59.79 -35.51 74.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.207 -0.933 . . . . 0.0 110.17 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.407 ' O ' ' OD1' ' A' ' 9' ' ' ASN . 45.9 t-20 -75.65 -23.23 56.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 109.983 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 112.32 2.07 26.3 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.96 -178.88 48.94 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.567 HG22 ' N ' ' A' ' 13' ' ' CYS . 57.2 mt -114.63 171.72 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.23 -1.159 . . . . 0.0 110.27 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.567 ' N ' HG22 ' A' ' 12' ' ' ILE . 2.3 m -124.6 150.57 45.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 110.053 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.472 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 56.6 tt0 -152.71 154.18 34.75 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.613 -0.679 . . . . 0.0 109.712 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.53 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 89.2 m-85 -57.89 -40.05 79.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.056 -1.027 . . . . 0.0 110.307 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.42 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 24.9 mmm180 -145.0 156.29 43.86 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.309 -0.869 . . . . 0.0 110.496 -179.754 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.1 m -128.24 160.83 30.89 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.241 -0.912 . . . . 0.0 110.055 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.551 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 48.4 pt -110.71 172.35 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.13 -0.981 . . . . 0.0 110.295 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.45 -33.88 62.79 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.61 ' N ' HD12 ' A' ' 20' ' ' LEU . 9.5 mp -62.01 -34.2 75.75 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.157 -1.202 . . . . 0.0 110.224 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 70.7 mtp85 -102.85 113.82 27.58 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.249 -0.907 . . . . 0.0 109.938 179.754 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 65.7 m170 -68.37 152.26 45.68 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.178 -0.952 . . . . 0.0 110.52 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 71.4 tttt -120.69 96.69 5.22 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.316 -0.865 . . . . 0.0 109.979 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.402 HG23 HD12 ' A' ' 24' ' ' ILE . 49.5 mm -65.53 -26.46 39.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.274 -0.892 . . . . 0.0 110.601 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.423 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -175.99 -167.84 35.42 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 32' ' ' LYS . 49.5 p -106.57 105.87 16.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -1.077 . . . . 0.0 110.52 -179.808 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.471 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 42.4 t -50.67 -35.76 32.46 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -0.914 . . . . 0.0 109.53 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -161.68 -160.77 11.16 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.448 -1.861 . . . . 0.0 108.448 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.589 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 60.6 m -89.64 -41.89 0.43 Allowed Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 120.942 -1.328 . . . . 0.0 109.956 179.495 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.589 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.0 Cg_endo -83.29 8.87 4.36 Favored 'Trans proline' 0 C--N 1.31 -1.496 0 O-C-N 123.422 1.222 . . . . 0.0 109.557 178.853 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.565 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 95.6 m-85 -153.02 172.45 16.82 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.357 -0.839 . . . . 0.0 110.802 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.525 ' HA ' ' HA ' ' A' ' 26' ' ' THR . 93.4 mttt -134.41 160.01 39.29 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 179.092 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 45.7 t -83.8 117.08 23.04 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.983 -1.073 . . . . 0.0 109.911 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 58.9 m -144.12 156.78 44.48 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.233 -0.917 . . . . 0.0 110.506 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 94.8 mttt . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.092 179.829 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ASN . . . . . 0.537 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . 25.2 m120 . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.278 0.561 . . . . 0.0 110.238 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.629 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 86.6 tt0 -63.99 -42.64 71.11 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.304 -0.872 . . . . 0.0 111.165 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.629 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 49.2 Cg_endo -73.55 -155.18 0.04 OUTLIER 'Trans proline' 0 C--N 1.314 -1.262 0 O-C-N 123.335 1.176 . . . . 0.0 110.269 -179.402 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 26.4 m -109.89 139.29 33.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.064 -1.023 . . . . 0.0 110.519 -179.555 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.404 ' O ' ' HB3' ' A' ' 6' ' ' CYS . 19.8 t -61.45 -26.03 67.62 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.261 -0.9 . . . . 0.0 110.089 179.802 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.404 ' HB3' ' O ' ' A' ' 5' ' ' SER . 48.1 t 55.06 41.33 31.85 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.263 -0.898 . . . . 0.0 110.21 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 37.1 pt -109.93 -11.51 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.293 -0.88 . . . . 0.0 110.235 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 30.0 mmt180 -57.95 -32.4 67.79 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.152 -0.968 . . . . 0.0 110.327 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -67.16 -26.22 66.55 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.385 -0.822 . . . . 0.0 110.436 -179.692 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.4 13.24 33.53 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.78 -169.92 42.92 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.482 HG22 ' N ' ' A' ' 13' ' ' CYS . 47.2 mt -129.09 171.12 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.439 -1.036 . . . . 0.0 109.795 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.547 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 5.8 m -136.47 160.18 39.53 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.936 -1.103 . . . . 0.0 111.214 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.4 ' O ' ' C ' ' A' ' 15' ' ' TYR . 44.2 tt0 -160.06 154.39 23.62 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.725 -0.609 . . . . 0.0 109.501 179.507 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.464 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 40.2 t80 -43.21 -45.81 5.81 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.005 -1.059 . . . . 0.0 110.656 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.464 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 0.6 OUTLIER -139.42 147.04 40.86 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.255 -0.903 . . . . 0.0 110.292 179.819 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 66.5 m -112.72 126.12 55.06 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.304 -0.872 . . . . 0.0 110.324 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 26.9 pt -129.99 163.91 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.936 . . . . 0.0 110.176 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.94 -167.08 26.46 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.689 ' N ' HD12 ' A' ' 20' ' ' LEU . 10.1 mp -68.6 -21.63 64.49 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.264 -1.139 . . . . 0.0 110.347 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 94.7 mtt-85 -54.68 138.69 41.08 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.371 -0.831 . . . . 0.0 110.178 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -109.62 170.41 8.08 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.238 -0.914 . . . . 0.0 109.971 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.522 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 79.9 tttt -115.33 113.25 23.57 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.014 -1.054 . . . . 0.0 110.607 -179.793 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 45.5 mm -70.45 -31.06 45.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.406 -0.809 . . . . 0.0 109.963 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.425 ' O ' ' CE ' ' A' ' 23' ' ' LYS . . . -174.59 -166.49 32.62 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.737 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.48 HG22 ' O ' ' A' ' 28' ' ' GLY . 51.8 m -113.45 109.33 18.49 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.208 -1.172 . . . . 0.0 110.711 -179.669 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.434 ' HA ' ' O ' ' A' ' 4' ' ' VAL . 60.0 m -58.17 -51.46 69.62 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.173 -0.955 . . . . 0.0 109.897 179.577 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.48 ' O ' HG22 ' A' ' 26' ' ' THR . . . -141.49 -164.22 9.9 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.933 -1.667 . . . . 0.0 108.933 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.622 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 14.9 m -85.96 -41.41 0.6 Allowed Pre-proline 0 C--N 1.301 -1.521 0 O-C-N 120.939 -1.33 . . . . 0.0 109.954 179.358 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.622 ' CD ' ' N ' ' A' ' 29' ' ' SER . 45.4 Cg_endo -81.34 8.16 4.55 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 O-C-N 123.501 1.264 . . . . 0.0 109.84 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.61 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 67.3 m-85 -153.25 169.15 23.76 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.08 -1.012 . . . . 0.0 110.975 -179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.547 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 92.8 mttt -133.8 160.1 38.63 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.1 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.522 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 2.9 t -90.26 120.01 31.05 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.744 -1.222 . . . . 0.0 110.337 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 73.4 m -142.67 142.18 31.99 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.86 . . . . 0.0 110.226 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 86.2 tttt . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.124 179.9 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ASN . . . . . 0.772 ' HB2' HG22 ' A' ' 4' ' ' VAL . 79.0 m-20 . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.228 0.537 . . . . 0.0 110.092 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.631 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 90.5 mt-10 -61.99 -44.34 89.51 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.268 -0.895 . . . . 0.0 111.653 -179.618 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.631 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 43.8 Cg_endo -70.54 -8.23 23.12 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 O-C-N 123.353 1.186 . . . . 0.0 111.12 -178.962 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.772 HG22 ' HB2' ' A' ' 1' ' ' ASN . 5.8 m -130.35 128.54 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.055 -1.028 . . . . 0.0 110.029 179.561 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 67.0 m -112.97 150.64 31.59 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.199 -0.938 . . . . 0.0 110.252 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 81.8 m -65.61 -23.9 66.93 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.225 -0.922 . . . . 0.0 109.955 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.529 HG23 ' N ' ' A' ' 8' ' ' ARG . 12.5 tt -59.46 -39.48 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.322 -0.861 . . . . 0.0 109.957 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.529 ' N ' HG23 ' A' ' 7' ' ' ILE . 17.4 ttm105 -56.77 -38.52 72.59 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.308 -0.87 . . . . 0.0 109.932 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 88.1 m-20 -69.32 -27.72 65.62 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.365 -0.835 . . . . 0.0 109.919 179.761 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.94 8.66 8.68 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -88.98 -177.93 46.21 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.508 ' CG1' ' O ' ' A' ' 34' ' ' CYS . 46.8 pt -132.23 161.24 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.321 -1.105 . . . . 0.0 109.806 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.2 m -113.56 154.21 27.52 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.951 -1.093 . . . . 0.0 110.559 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.497 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 11.5 tp60 -151.17 155.82 39.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.563 -0.71 . . . . 0.0 109.74 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.685 ' CE1' ' CE1' ' A' ' 31' ' ' PHE . 56.4 m-85 -54.94 -42.56 72.45 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.111 -0.993 . . . . 0.0 110.599 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.418 ' HD3' ' O ' ' A' ' 15' ' ' TYR . 89.1 mmt-85 -144.54 154.96 43.43 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.254 -0.903 . . . . 0.0 110.399 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 94.2 m -123.1 138.36 54.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.325 -0.859 . . . . 0.0 109.995 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.0 pt -102.0 170.23 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -0.909 . . . . 0.0 110.326 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -48.21 -43.5 25.95 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 14.2 tp -47.26 -46.7 24.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.207 -1.172 . . . . 0.0 110.311 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -101.39 128.0 47.78 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 110.261 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -88.71 135.32 33.57 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.874 . . . . 0.0 110.198 179.817 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.538 ' CD ' ' HB3' ' A' ' 32' ' ' LYS . 37.9 ttpt -95.95 117.07 29.92 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.282 -0.887 . . . . 0.0 110.064 179.815 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.0 mm -75.4 -27.27 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.339 -0.851 . . . . 0.0 110.136 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.491 ' C ' ' HB2' ' A' ' 33' ' ' CYS . . . -169.9 -156.51 11.09 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 72.9 p -115.74 113.2 23.14 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.354 -1.086 . . . . 0.0 110.14 179.624 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.52 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 42.2 t -68.73 -29.83 68.33 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.396 -0.815 . . . . 0.0 110.019 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -176.81 -163.61 29.34 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.944 -1.663 . . . . 0.0 108.944 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.604 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.5 m -87.39 -42.9 0.52 Allowed Pre-proline 0 C--N 1.303 -1.413 0 O-C-N 121.076 -1.25 . . . . 0.0 110.055 179.647 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.604 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.9 Cg_endo -81.7 6.94 5.33 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 O-C-N 123.666 1.35 . . . . 0.0 109.663 179.13 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.685 ' CE1' ' CE1' ' A' ' 15' ' ' TYR . 73.3 m-85 -156.6 176.19 13.05 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.283 -0.886 . . . . 0.0 110.619 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.538 ' HB3' ' CD ' ' A' ' 23' ' ' LYS . 95.9 mttt -141.22 156.89 45.85 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.451 -0.781 . . . . 0.0 109.391 179.214 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.52 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 66.5 m -76.99 107.58 9.44 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.023 -1.048 . . . . 0.0 109.869 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.508 ' O ' ' CG1' ' A' ' 12' ' ' ILE . 63.5 m -142.52 136.28 29.18 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.168 -0.957 . . . . 0.0 110.318 -179.752 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 61.9 mttp . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.128 179.968 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ASN . . . . . 0.475 ' HB2' ' HB ' ' A' ' 4' ' ' VAL . 95.7 m-20 . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 121.358 0.599 . . . . 0.0 110.128 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.609 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 84.9 tt0 -63.79 -41.24 63.03 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.333 -0.854 . . . . 0.0 111.349 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.609 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 48.1 Cg_endo -75.73 -8.36 19.16 Favored 'Trans proline' 0 C--N 1.312 -1.374 0 O-C-N 123.378 1.199 . . . . 0.0 110.624 -179.285 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.522 HG12 ' N ' ' A' ' 5' ' ' SER . 35.5 t -129.3 171.63 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.205 -0.934 . . . . 0.0 110.236 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.728 ' OG ' HG22 ' A' ' 7' ' ' ILE . 43.2 t -137.85 130.39 29.54 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.245 -0.91 . . . . 0.0 110.116 179.873 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 74.5 m -59.85 -26.71 66.05 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.197 -0.939 . . . . 0.0 110.292 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.728 HG22 ' OG ' ' A' ' 5' ' ' SER . 8.5 tt -58.63 -31.17 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.936 179.74 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -61.13 -37.65 83.58 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.277 -0.89 . . . . 0.0 110.123 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -67.89 -29.22 68.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.383 -0.823 . . . . 0.0 110.326 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 122.78 -2.38 10.06 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.99 -173.36 45.54 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.5 HG22 ' N ' ' A' ' 13' ' ' CYS . 22.4 mm -130.97 170.38 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.284 -1.127 . . . . 0.0 110.159 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.5 ' N ' HG22 ' A' ' 12' ' ' ILE . 2.4 m -119.63 151.49 38.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.185 -0.947 . . . . 0.0 109.862 179.761 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.5 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 51.6 tt0 -152.36 152.52 32.17 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.541 -0.724 . . . . 0.0 109.639 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.503 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 72.6 t80 -57.67 -38.53 75.29 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.183 -0.948 . . . . 0.0 110.473 -179.748 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.503 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 7.0 mmm180 -149.91 142.69 24.68 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.288 -0.883 . . . . 0.0 110.274 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.5 m -111.69 151.8 28.46 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.153 -0.967 . . . . 0.0 110.208 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.692 HG22 ' H ' ' A' ' 19' ' ' GLY . 3.0 mt -97.95 -168.9 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.184 -0.948 . . . . 0.0 109.897 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.692 ' H ' HG22 ' A' ' 18' ' ' ILE . . . -67.38 -43.71 86.84 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 63.9 mt -55.38 -36.78 66.74 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.338 -1.095 . . . . 0.0 109.962 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.7 mmt-85 -100.67 123.24 44.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.354 -0.841 . . . . 0.0 110.244 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -94.39 144.18 25.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 110.107 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.513 ' CE ' ' O ' ' A' ' 25' ' ' GLY . 72.2 tttt -103.53 102.1 11.98 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.216 -0.927 . . . . 0.0 110.371 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 86.1 mt -70.04 -21.37 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.218 -0.926 . . . . 0.0 110.11 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.513 ' O ' ' CE ' ' A' ' 23' ' ' LYS . . . -169.05 -161.5 19.48 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.735 HG23 ' O ' ' A' ' 26' ' ' THR . 14.0 t -119.3 112.03 18.93 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.306 -1.114 . . . . 0.0 110.283 179.595 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.517 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 11.6 t -58.87 -37.42 76.5 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.19 -0.944 . . . . 0.0 109.532 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -164.94 -154.79 8.13 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.432 -1.867 . . . . 0.0 108.432 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.579 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 2.3 m -90.27 -43.99 0.41 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 120.975 -1.309 . . . . 0.0 110.156 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.579 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.5 Cg_endo -82.76 11.72 3.14 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 O-C-N 123.564 1.297 . . . . 0.0 109.859 179.2 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.516 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 83.1 m-85 -155.38 174.16 15.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.209 -0.932 . . . . 0.0 110.57 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 26' ' ' THR . 67.5 mttm -137.11 159.31 42.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.638 -0.664 . . . . 0.0 109.36 179.183 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.517 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 76.7 m -78.07 105.72 9.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.031 -1.043 . . . . 0.0 110.203 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 4.9 m -136.0 138.46 42.26 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.143 -0.973 . . . . 0.0 110.275 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.176 179.93 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ASN . . . . . 0.434 ' C ' ' HD2' ' A' ' 3' ' ' PRO . 82.3 m-20 . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.307 0.575 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.623 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 87.0 tt0 -64.15 -38.4 34.49 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.358 -0.839 . . . . 0.0 111.764 179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.623 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 45.6 Cg_endo -73.53 -4.04 14.75 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.05 1.026 . . . . 0.0 110.792 -179.386 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.577 HG12 ' N ' ' A' ' 5' ' ' SER . 57.9 t -118.9 173.08 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.153 -0.967 . . . . 0.0 109.811 179.531 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.577 ' N ' HG12 ' A' ' 4' ' ' VAL . 66.6 m -129.8 143.65 50.91 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.164 -0.96 . . . . 0.0 110.473 -179.765 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 85.3 m -90.62 0.05 57.51 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.327 -0.858 . . . . 0.0 110.423 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.459 HG12 ' HB3' ' A' ' 5' ' ' SER . 47.1 pt -75.53 -28.51 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.251 -0.906 . . . . 0.0 110.191 179.858 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.415 ' N ' HG13 ' A' ' 7' ' ' ILE . 25.7 tpt180 -62.3 -32.75 73.53 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.26 -0.9 . . . . 0.0 110.02 179.685 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -78.54 -8.14 58.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 110.16 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 98.72 -2.73 58.74 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.36 172.61 49.14 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.324 -1.511 . . . . 0.0 109.324 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.524 HG22 ' N ' ' A' ' 13' ' ' CYS . 56.6 mt -130.53 170.9 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.287 -1.125 . . . . 0.0 110.275 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.524 ' N ' HG22 ' A' ' 12' ' ' ILE . 3.2 m -103.7 153.75 20.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.162 -0.962 . . . . 0.0 110.087 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 8.5 tp60 -151.67 152.99 33.53 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.514 -0.741 . . . . 0.0 109.748 179.636 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.612 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 57.5 t80 -60.14 -41.96 93.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.175 -0.953 . . . . 0.0 109.955 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.612 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 33.4 mmt180 -147.79 149.35 32.18 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.443 -0.786 . . . . 0.0 110.097 179.779 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 98.5 m -120.86 176.38 5.57 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.211 -0.93 . . . . 0.0 110.1 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.6 pt -122.37 175.45 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.258 -0.901 . . . . 0.0 110.436 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -59.06 -31.46 68.84 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.826 HD13 ' O ' ' A' ' 20' ' ' LEU . 3.1 tm? -59.48 -37.96 79.61 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.282 -1.128 . . . . 0.0 110.272 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -104.81 128.35 52.94 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.274 -0.891 . . . . 0.0 110.289 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -88.07 141.95 28.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.247 -0.908 . . . . 0.0 110.011 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.502 ' CE ' ' HB3' ' A' ' 32' ' ' LYS . 46.4 tttm -94.25 107.12 19.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.859 . . . . 0.0 110.352 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 38.5 mm -68.72 -31.68 51.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.282 -0.887 . . . . 0.0 110.485 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.501 ' O ' ' NZ ' ' A' ' 23' ' ' LYS . . . -165.91 -156.04 9.12 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 -179.544 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.732 HG23 ' O ' ' A' ' 26' ' ' THR . 14.8 t -122.28 106.92 11.54 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.682 -0.893 . . . . 0.0 109.872 179.639 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.516 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 37.9 t -62.75 -35.86 81.16 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.199 -0.938 . . . . 0.0 110.3 -179.452 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -169.08 -163.4 23.05 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.588 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.3 m -88.29 -43.3 0.47 Allowed Pre-proline 0 C--N 1.303 -1.422 0 O-C-N 121.062 -1.258 . . . . 0.0 110.32 179.856 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.588 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.8 Cg_endo -81.18 5.64 6.12 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.525 1.276 . . . . 0.0 109.572 179.307 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 63.7 m-85 -153.0 169.47 22.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.275 -0.891 . . . . 0.0 110.486 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.502 ' HB3' ' CE ' ' A' ' 23' ' ' LYS . 96.0 mttt -136.75 158.45 44.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.437 -0.789 . . . . 0.0 109.69 179.497 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.516 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 59.5 m -80.68 120.14 24.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.126 -0.983 . . . . 0.0 109.471 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.9 m -143.4 134.5 25.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.227 -0.921 . . . . 0.0 110.457 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.914 -1.041 . . . . 0.0 109.952 179.709 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 . . . . . 0 N--CA 1.491 1.6 0 CA-C-O 121.17 0.51 . . . . 0.0 110.327 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.603 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 51.0 tp10 -66.75 -41.12 36.11 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.239 -0.913 . . . . 0.0 110.752 179.631 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.603 ' CD ' ' N ' ' A' ' 2' ' ' GLU . 54.7 Cg_endo -78.64 -154.71 0.05 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.378 1.199 . . . . 0.0 109.83 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.551 ' CG2' HD13 ' A' ' 7' ' ' ILE . 17.3 m -82.6 136.65 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 120.871 -1.143 . . . . 0.0 110.214 179.832 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.676 ' O ' HG23 ' A' ' 7' ' ' ILE . 58.8 m -129.91 161.02 31.8 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.199 -0.938 . . . . 0.0 110.51 -179.536 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.422 ' HB3' ' O ' ' A' ' 5' ' ' SER . 45.3 t 55.64 31.61 17.64 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.23 -0.919 . . . . 0.0 110.099 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.676 HG23 ' O ' ' A' ' 5' ' ' SER . 7.3 pt -113.73 -9.56 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.267 -0.896 . . . . 0.0 110.218 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 95.0 mtt-85 -65.8 -35.91 82.04 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.09 -1.006 . . . . 0.0 110.106 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.0 m120 -96.41 5.94 49.81 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.252 -0.905 . . . . 0.0 110.2 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 74.15 18.21 79.7 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.91 175.59 51.97 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.501 HG22 ' N ' ' A' ' 13' ' ' CYS . 56.4 mt -120.56 170.27 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -1.137 . . . . 0.0 110.307 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.501 ' N ' HG22 ' A' ' 12' ' ' ILE . 3.0 m -117.72 154.03 32.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.22 -0.925 . . . . 0.0 110.178 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.523 ' O ' ' N ' ' A' ' 32' ' ' LYS . 47.2 tt0 -160.38 151.2 18.75 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.646 -0.658 . . . . 0.0 109.567 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 31' ' ' PHE . 83.8 t80 -55.53 -37.75 68.34 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.028 -1.045 . . . . 0.0 110.606 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.403 ' HG3' ' N ' ' A' ' 17' ' ' CYS . 14.2 tpt180 -146.05 163.1 36.32 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.255 -0.903 . . . . 0.0 110.233 -179.782 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.403 ' N ' ' HG3' ' A' ' 16' ' ' ARG . 20.1 m -139.37 125.63 20.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.468 -0.77 . . . . 0.0 109.789 179.545 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.0 pt -138.13 165.23 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.261 -0.9 . . . . 0.0 110.313 -179.697 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.11 -155.42 26.33 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.567 ' N ' HD22 ' A' ' 20' ' ' LEU . 4.5 mm? -61.78 -28.1 69.21 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.351 -1.087 . . . . 0.0 110.202 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 94.1 mtt180 -53.03 135.52 36.92 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.266 -0.896 . . . . 0.0 110.296 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -113.1 156.11 23.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.332 -0.855 . . . . 0.0 110.073 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 81.6 tttt -101.81 107.62 18.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.188 -0.945 . . . . 0.0 110.177 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 67.7 mt -76.98 -33.71 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.899 . . . . 0.0 110.215 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.485 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -169.71 -169.56 33.1 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 75.2 p -105.95 99.17 8.78 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.394 -1.063 . . . . 0.0 110.474 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.477 ' O ' ' HB2' ' A' ' 5' ' ' SER . 38.6 t -54.28 -40.05 67.48 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.169 -0.957 . . . . 0.0 109.722 179.655 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -155.99 -165.68 14.85 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 108.598 -1.801 . . . . 0.0 108.598 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.6 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 9.0 m -87.18 -42.97 0.53 Allowed Pre-proline 0 C--N 1.299 -1.625 0 O-C-N 121.128 -1.219 . . . . 0.0 109.825 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.6 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.0 Cg_endo -82.23 7.66 4.97 Favored 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.49 1.258 . . . . 0.0 109.691 178.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.579 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 90.5 m-85 -152.36 169.86 21.51 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.299 -0.876 . . . . 0.0 110.64 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 14' ' ' GLN . 96.3 mttt -130.9 159.36 37.65 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.012 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.485 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 47.2 t -85.51 121.18 27.85 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.962 -1.087 . . . . 0.0 109.801 179.759 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 97.3 m -138.21 141.87 39.98 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 110.342 -179.737 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.436 ' HG2' ' OXT' ' A' ' 35' ' ' LYS . 88.0 tttt . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.164 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ASN . . . . . 0.542 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . 88.3 m-20 . . . . . 0 N--CA 1.493 1.675 0 CA-C-O 121.326 0.584 . . . . 0.0 110.201 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.62 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 39.7 tt0 -64.12 -41.12 59.48 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 111.767 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.62 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 47.9 Cg_endo -74.88 0.54 8.71 Favored 'Trans proline' 0 C--N 1.312 -1.381 0 O-C-N 123.318 1.168 . . . . 0.0 110.947 -179.111 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.489 HG22 ' HB2' ' A' ' 1' ' ' ASN . 27.7 m -145.82 128.75 9.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.114 -0.992 . . . . 0.0 110.348 179.806 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 39.0 m -97.88 134.89 40.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.353 -0.842 . . . . 0.0 109.767 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.527 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 10.1 t -72.26 -26.39 61.98 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.183 -0.948 . . . . 0.0 110.468 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.474 HG13 ' N ' ' A' ' 8' ' ' ARG . 50.0 pt -71.17 -30.52 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.188 -0.945 . . . . 0.0 110.015 -179.795 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.474 ' N ' HG13 ' A' ' 7' ' ' ILE . 51.0 ttt85 -66.21 -54.8 20.84 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.433 -0.792 . . . . 0.0 110.083 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -142.67 9.42 1.78 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.407 -0.808 . . . . 0.0 110.459 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.527 ' HA3' ' HA ' ' A' ' 6' ' ' CYS . . . -83.65 -30.15 30.48 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.764 -1.335 . . . . 0.0 109.764 -179.763 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 129.61 -155.92 21.11 Favored Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.599 -1.286 . . . . 0.0 109.89 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.487 HG22 ' N ' ' A' ' 13' ' ' CYS . 41.2 mt -96.34 171.0 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 O-C-N 121.692 -0.887 . . . . 0.0 109.668 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.1 m -139.7 153.39 47.22 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.069 -1.019 . . . . 0.0 110.414 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -161.09 157.21 25.69 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.726 -0.609 . . . . 0.0 109.908 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.473 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 87.5 m-85 -44.91 -37.31 3.84 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.16 -0.962 . . . . 0.0 110.206 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.431 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 25.7 mmm180 -147.31 147.11 30.03 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.321 -0.862 . . . . 0.0 110.128 179.768 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.1 m -111.56 130.25 55.8 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.24 -0.912 . . . . 0.0 110.065 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 43.3 pt -127.9 172.42 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.159 -0.963 . . . . 0.0 110.321 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.14 -156.04 23.31 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.642 ' N ' HD12 ' A' ' 20' ' ' LEU . 10.4 mp -87.26 -5.12 59.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.181 -1.188 . . . . 0.0 110.214 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 74.4 mtm180 -61.07 148.35 40.66 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.298 -0.876 . . . . 0.0 110.358 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -119.01 143.65 46.95 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.362 -0.836 . . . . 0.0 110.17 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.523 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 36.4 ttpt -93.79 117.79 30.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.174 -0.954 . . . . 0.0 110.318 -179.757 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 22.4 pt -96.93 -8.79 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.16 -0.962 . . . . 0.0 110.176 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.27 -170.57 37.69 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 32' ' ' LYS . 81.7 p -129.82 108.28 10.03 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.278 -1.131 . . . . 0.0 110.347 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.457 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 46.6 m -51.99 -36.03 48.48 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.24 -0.913 . . . . 0.0 109.706 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -159.22 -159.37 9.67 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.589 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 16.9 m -90.12 -41.88 0.41 Allowed Pre-proline 0 C--N 1.302 -1.476 0 O-C-N 121.09 -1.241 . . . . 0.0 110.553 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.589 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.4 Cg_endo -80.24 6.64 5.21 Favored 'Trans proline' 0 C--N 1.311 -1.442 0 O-C-N 123.416 1.219 . . . . 0.0 109.845 179.445 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.527 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 45.4 m-85 -146.06 179.8 7.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.349 -0.845 . . . . 0.0 110.262 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.525 ' HA ' ' HA ' ' A' ' 26' ' ' THR . 91.3 mttt -143.28 170.31 16.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.525 -0.734 . . . . 0.0 109.065 179.228 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.523 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 38.4 t -96.55 115.87 28.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.783 -1.198 . . . . 0.0 109.969 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 84.6 m -141.89 138.04 31.78 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.095 -1.003 . . . . 0.0 110.143 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.178 179.756 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ASN . . . . . 0.486 ' N ' ' CG2' ' A' ' 4' ' ' VAL . 58.6 t30 . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 121.357 0.598 . . . . 0.0 110.381 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.619 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 16.0 tp10 -64.05 -42.69 70.93 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.304 -0.872 . . . . 0.0 111.656 -179.575 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.619 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.1 Cg_endo -73.22 -6.28 18.62 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 O-C-N 123.235 1.124 . . . . 0.0 111.04 -179.228 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.523 HG23 ' O ' ' A' ' 4' ' ' VAL . 34.4 m -132.84 125.1 51.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.103 -0.998 . . . . 0.0 109.902 179.708 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.417 ' HB2' HG22 ' A' ' 7' ' ' ILE . 68.3 m -108.02 150.25 27.38 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.286 -0.884 . . . . 0.0 110.397 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 10.5 t -61.71 -23.29 66.03 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.184 -0.948 . . . . 0.0 110.157 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.417 HG22 ' HB2' ' A' ' 5' ' ' SER . 9.6 tt -60.38 -32.53 51.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.157 -0.964 . . . . 0.0 110.405 -179.864 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 84.3 mtt180 -60.55 -33.54 72.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.212 -0.93 . . . . 0.0 110.254 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 91.0 m-20 -62.02 -25.34 67.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 110.175 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.62 13.09 23.2 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.28 -172.74 44.66 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.0 pt -129.77 151.51 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.264 -1.139 . . . . 0.0 110.177 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.532 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 1.8 m -91.11 151.96 20.79 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.028 -1.045 . . . . 0.0 109.993 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.549 ' O ' ' N ' ' A' ' 32' ' ' LYS . 55.2 tt0 -146.23 150.68 36.27 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.401 -0.812 . . . . 0.0 109.881 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.576 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 62.0 t80 -59.1 -46.01 89.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.065 -1.022 . . . . 0.0 110.58 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.576 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 19.4 mmt180 -148.92 140.81 23.72 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.289 -0.882 . . . . 0.0 110.325 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 40.5 m -116.63 142.66 46.6 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.435 -0.791 . . . . 0.0 109.847 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.719 HG22 ' H ' ' A' ' 19' ' ' GLY . 3.4 mm -90.85 -168.96 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.155 -0.965 . . . . 0.0 110.149 -179.732 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.719 ' H ' HG22 ' A' ' 18' ' ' ILE . . . -69.99 -30.9 69.7 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.925 -1.67 . . . . 0.0 108.925 179.792 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.589 ' N ' HD12 ' A' ' 20' ' ' LEU . 9.4 mp -63.77 -29.57 70.77 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.427 -1.043 . . . . 0.0 110.19 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 82.5 mtt-85 -105.34 128.27 53.4 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.189 -0.944 . . . . 0.0 110.562 -179.611 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 61.6 m170 -94.53 143.0 26.78 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.269 -0.894 . . . . 0.0 110.44 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.485 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 34.2 ttpt -109.26 117.38 33.94 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.257 -0.902 . . . . 0.0 110.61 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 80.4 mt -73.55 -35.38 44.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.187 -0.946 . . . . 0.0 109.826 179.578 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.483 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -160.72 -170.87 25.91 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.448 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 51.6 m -107.94 103.61 12.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.176 -1.191 . . . . 0.0 110.305 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.426 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 42.0 t -53.11 -48.28 67.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.299 -0.875 . . . . 0.0 109.967 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.448 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -149.59 -165.29 12.3 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 108.906 -1.677 . . . . 0.0 108.906 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.599 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.3 m -89.32 -42.3 0.43 Allowed Pre-proline 0 C--N 1.303 -1.444 0 O-C-N 121.095 -1.238 . . . . 0.0 110.417 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.599 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.2 Cg_endo -81.82 6.68 5.51 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.474 1.249 . . . . 0.0 109.715 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.497 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 97.9 m-85 -152.48 173.71 14.8 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.308 -0.87 . . . . 0.0 110.197 179.632 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.549 ' N ' ' O ' ' A' ' 14' ' ' GLN . 62.0 mttm -136.41 155.96 49.29 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.458 -0.776 . . . . 0.0 109.147 179.452 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.485 ' O ' ' HG3' ' A' ' 23' ' ' LYS . 50.4 t -87.72 115.06 24.9 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.177 -0.952 . . . . 0.0 110.73 -179.67 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 56.3 m -132.39 145.64 51.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.262 -0.899 . . . . 0.0 109.956 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 56.7 tttp . . . . . 0 N--CA 1.492 1.64 0 O-C-N 121.089 -1.007 . . . . 0.0 110.348 -179.815 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ASN . . . . . 0.46 ' O ' ' OD1' ' A' ' 1' ' ' ASN . 45.2 p-10 . . . . . 0 N--CA 1.493 1.679 0 CA-C-O 121.429 0.633 . . . . 0.0 110.268 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.59 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 26.3 tt0 -58.11 -42.15 93.52 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.234 -0.916 . . . . 0.0 111.293 -179.816 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.59 ' CD ' ' N ' ' A' ' 2' ' ' GLU . 55.4 Cg_endo -78.16 -156.41 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.392 0 O-C-N 123.426 1.224 . . . . 0.0 110.403 -179.522 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.579 HG13 ' O ' ' A' ' 3' ' ' PRO . 20.9 m -157.45 146.93 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.186 -0.946 . . . . 0.0 110.036 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 88.2 p -127.4 144.19 51.09 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.227 -0.921 . . . . 0.0 110.081 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.699 ' SG ' HG22 ' A' ' 24' ' ' ILE . 13.1 t -59.66 -32.48 70.5 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.295 -0.878 . . . . 0.0 110.431 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.46 HG13 ' N ' ' A' ' 8' ' ' ARG . 42.5 pt -57.46 -25.49 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.344 -0.847 . . . . 0.0 110.295 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.46 ' N ' HG13 ' A' ' 7' ' ' ILE . 67.8 ttt180 -58.72 -36.17 73.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.221 -0.924 . . . . 0.0 110.473 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 23.8 m120 -67.66 -28.34 67.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.223 -0.923 . . . . 0.0 110.364 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.83 8.0 16.5 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.64 179.62 52.97 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.6 pt -124.05 159.13 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.238 -1.154 . . . . 0.0 110.322 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.514 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 1.7 m -99.49 154.63 18.09 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.274 -0.891 . . . . 0.0 109.835 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.521 ' O ' ' N ' ' A' ' 32' ' ' LYS . 37.6 tp60 -156.74 154.77 30.53 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.223 -0.923 . . . . 0.0 109.887 179.722 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.605 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 50.2 t80 -58.86 -49.28 78.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.124 -0.985 . . . . 0.0 110.231 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.605 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 13.9 mmt85 -145.07 151.34 38.36 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.437 -0.789 . . . . 0.0 110.458 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.527 ' HB2' ' NE ' ' A' ' 21' ' ' ARG . 87.6 m -118.83 178.58 4.43 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.331 -0.856 . . . . 0.0 109.844 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.429 ' O ' ' O ' ' A' ' 19' ' ' GLY . 47.1 pt -101.78 175.3 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.091 -1.006 . . . . 0.0 110.485 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' A' ' 18' ' ' ILE . . . -50.03 178.78 0.03 OUTLIER Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.844 ' N ' HD22 ' A' ' 20' ' ' LEU . 2.7 mm? 46.47 42.3 10.67 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.319 -1.106 . . . . 0.0 109.37 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.527 ' NE ' ' HB2' ' A' ' 17' ' ' CYS . 25.5 ttm180 -79.52 134.85 36.51 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 110.631 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 70.0 m-70 -99.77 37.01 1.68 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 179.328 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.492 ' HE2' ' O ' ' A' ' 25' ' ' GLY . 60.8 tttt -73.36 108.92 6.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.413 -0.804 . . . . 0.0 110.534 -179.514 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.699 HG22 ' SG ' ' A' ' 6' ' ' CYS . 7.6 tp -78.68 -18.04 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.244 -0.91 . . . . 0.0 109.63 179.599 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.492 ' O ' ' HE2' ' A' ' 23' ' ' LYS . . . -165.46 -173.42 33.99 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.737 HG22 ' O ' ' A' ' 28' ' ' GLY . 92.5 m -109.62 107.06 16.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.136 -1.214 . . . . 0.0 110.261 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.435 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 48.8 t -46.12 -63.72 0.92 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.399 -0.813 . . . . 0.0 109.687 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.737 ' O ' HG22 ' A' ' 26' ' ' THR . . . -129.63 -170.47 12.75 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 179.425 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.596 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.9 m -85.88 -42.19 0.61 Allowed Pre-proline 0 C--N 1.303 -1.445 0 O-C-N 121.01 -1.288 . . . . 0.0 109.898 179.484 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.603 ' HG2' ' CD2' ' A' ' 31' ' ' PHE . 52.0 Cg_endo -81.39 6.0 5.9 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 O-C-N 123.557 1.293 . . . . 0.0 109.428 179.189 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.603 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 86.8 m-85 -148.18 170.15 18.48 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.116 -0.99 . . . . 0.0 110.538 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.521 ' N ' ' O ' ' A' ' 14' ' ' GLN . 89.9 mttt -133.37 156.12 48.23 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.6 -0.688 . . . . 0.0 109.285 179.028 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.44 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 50.7 t -89.62 123.59 33.81 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.165 -0.96 . . . . 0.0 109.907 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.401 ' SG ' ' HD3' ' A' ' 21' ' ' ARG . 33.3 m -138.02 130.75 29.68 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 110.085 -179.796 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 86.2 tttt . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 118.041 -0.98 . . . . 0.0 110.171 -179.971 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ASN . . . . . 0.494 ' HB3' ' O ' ' A' ' 4' ' ' VAL . 85.3 m-20 . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.447 0.641 . . . . 0.0 109.937 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.611 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 67.1 mm-40 -64.8 -40.62 49.62 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.492 -0.755 . . . . 0.0 111.723 -179.656 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.611 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.1 Cg_endo -75.08 -16.59 19.94 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.256 1.135 . . . . 0.0 110.924 -179.04 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.494 ' O ' ' HB3' ' A' ' 1' ' ' ASN . 13.5 m -146.07 135.1 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.099 -1.001 . . . . 0.0 110.231 179.842 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.442 ' OG ' HG22 ' A' ' 7' ' ' ILE . 83.5 p -62.87 148.52 46.96 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.214 -0.928 . . . . 0.0 110.238 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 86.2 m -69.26 -26.59 64.84 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.313 -0.867 . . . . 0.0 110.334 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.476 HG23 ' N ' ' A' ' 8' ' ' ARG . 16.2 tt -61.43 -36.75 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.232 -0.918 . . . . 0.0 110.389 -179.658 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.476 ' N ' HG23 ' A' ' 7' ' ' ILE . 76.8 ttt-85 -53.12 -39.2 63.27 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.135 -0.978 . . . . 0.0 110.294 -179.849 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -65.59 -23.73 66.9 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.41 -0.806 . . . . 0.0 110.328 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 111.4 5.76 26.05 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.764 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.18 175.67 43.12 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.561 HG22 ' N ' ' A' ' 13' ' ' CYS . 72.9 mt -127.83 171.96 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.273 -1.133 . . . . 0.0 110.021 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.561 ' N ' HG22 ' A' ' 12' ' ' ILE . 1.5 m -102.49 147.84 26.26 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.177 -0.952 . . . . 0.0 109.752 179.565 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.515 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 27.2 tp60 -148.86 152.72 36.96 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.517 -0.739 . . . . 0.0 109.643 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.468 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 97.8 m-85 -60.34 -42.25 95.3 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.229 -0.919 . . . . 0.0 110.698 -179.537 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.432 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 29.2 mmm180 -149.3 142.22 24.76 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.233 -0.917 . . . . 0.0 110.605 -179.68 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 67.5 m -119.94 126.52 51.08 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.304 -0.873 . . . . 0.0 109.955 179.598 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.0 pt -143.35 168.04 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.124 -0.985 . . . . 0.0 110.456 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 66.39 -135.56 33.9 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 35.9 mt -59.38 -34.74 72.78 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.395 -1.062 . . . . 0.0 110.273 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -71.49 132.32 44.57 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.346 -0.846 . . . . 0.0 110.651 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 74.7 t60 -133.86 153.55 51.66 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.334 -0.854 . . . . 0.0 109.879 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.502 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 0.0 OUTLIER -110.61 124.45 51.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.111 -0.993 . . . . 0.0 110.731 -179.746 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 23.7 pt -103.66 -5.87 9.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.317 -0.864 . . . . 0.0 109.853 179.579 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.435 ' N ' ' HB2' ' A' ' 33' ' ' CYS . . . -159.41 -169.89 23.3 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.757 -1.737 . . . . 0.0 108.757 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.761 HG23 ' O ' ' A' ' 26' ' ' THR . 14.8 t -128.47 105.36 8.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.073 -1.251 . . . . 0.0 110.636 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.528 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 53.6 t -60.29 -29.6 68.93 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.283 -0.886 . . . . 0.0 109.43 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -168.7 -163.05 22.04 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.603 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 63.5 m -88.02 -41.58 0.49 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 120.891 -1.358 . . . . 0.0 109.999 179.488 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.603 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.4 Cg_endo -82.76 8.2 4.72 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.43 1.226 . . . . 0.0 109.519 179.003 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.571 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 97.7 m-85 -147.72 173.79 12.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.339 -0.851 . . . . 0.0 110.771 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -136.86 159.62 41.33 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.605 -0.684 . . . . 0.0 109.317 179.362 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.528 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 91.0 m -80.09 105.04 11.07 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.003 -1.061 . . . . 0.0 109.984 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 64.2 m -130.45 147.93 52.2 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.187 -0.946 . . . . 0.0 110.375 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.429 ' OXT' ' HG3' ' A' ' 35' ' ' LYS . 64.4 pttt . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.19 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ASN . . . . . 0.534 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . 97.3 m-20 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.455 0.645 . . . . 0.0 110.293 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.611 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 69.5 mm-40 -74.18 -40.74 4.79 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.478 -0.764 . . . . 0.0 111.529 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.611 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.5 Cg_endo -74.78 -10.83 21.79 Favored 'Trans proline' 0 C--N 1.313 -1.335 0 O-C-N 123.312 1.164 . . . . 0.0 111.516 -178.819 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.559 ' CG2' ' N ' ' A' ' 5' ' ' SER . 1.4 p -151.14 170.97 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 120.845 -1.159 . . . . 0.0 110.802 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.559 ' N ' ' CG2' ' A' ' 4' ' ' VAL . 49.2 m 53.39 37.98 26.8 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.556 -0.715 . . . . 0.0 110.483 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 32.8 t -62.39 -23.12 66.65 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.202 -0.936 . . . . 0.0 110.099 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.813 HD13 ' O ' ' A' ' 11' ' ' GLY . 1.0 OUTLIER -69.31 -37.07 75.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.337 -0.852 . . . . 0.0 109.878 179.876 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 23.3 ttp180 -56.98 -32.7 66.35 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.243 -0.911 . . . . 0.0 110.535 -179.611 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -59.77 -30.16 68.69 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.197 -0.939 . . . . 0.0 109.746 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 124.04 14.09 3.85 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 179.433 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.813 ' O ' HD13 ' A' ' 7' ' ' ILE . . . -101.77 175.41 25.34 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.714 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.465 ' HA ' HD11 ' A' ' 7' ' ' ILE . 25.7 mt -119.03 169.54 9.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.27 -1.135 . . . . 0.0 110.026 179.743 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.511 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 1.9 m -112.17 153.18 27.43 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.153 -0.967 . . . . 0.0 110.071 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.518 ' O ' ' N ' ' A' ' 32' ' ' LYS . 11.9 tp60 -152.03 154.37 35.85 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.31 -0.869 . . . . 0.0 109.863 179.768 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.575 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 58.6 t80 -56.35 -37.5 70.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.107 -0.996 . . . . 0.0 110.258 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.575 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 35.2 mmt180 -146.14 157.49 43.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.256 -0.902 . . . . 0.0 110.228 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -122.53 154.63 37.63 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.244 -0.91 . . . . 0.0 110.333 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.471 HG13 ' HB2' ' A' ' 20' ' ' LEU . 14.6 pt -106.89 161.64 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.213 -0.929 . . . . 0.0 110.219 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.86 -29.42 54.95 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.579 ' N ' HD12 ' A' ' 20' ' ' LEU . 10.0 mp -65.04 -34.67 78.98 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.173 -1.192 . . . . 0.0 110.422 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.1 mtt180 -93.68 137.22 33.16 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.204 -0.935 . . . . 0.0 110.307 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -83.73 134.79 34.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.189 -0.944 . . . . 0.0 110.235 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.415 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 87.0 tttt -98.85 98.57 9.64 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.23 -0.919 . . . . 0.0 110.21 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 89.1 mt -66.78 -33.47 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.286 -0.884 . . . . 0.0 110.314 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.452 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -175.83 -167.14 34.34 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 64.6 p -104.88 104.15 13.87 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.426 -1.044 . . . . 0.0 110.462 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.434 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 49.9 t -56.09 -43.03 77.65 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.266 -0.896 . . . . 0.0 109.83 179.62 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -154.09 -166.57 15.06 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 179.737 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.596 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.1 m -88.6 -42.32 0.46 Allowed Pre-proline 0 C--N 1.301 -1.525 0 O-C-N 121.077 -1.249 . . . . 0.0 110.232 179.679 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.598 ' HG2' ' CD2' ' A' ' 31' ' ' PHE . 47.8 Cg_endo -81.83 6.59 5.57 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 O-C-N 123.504 1.265 . . . . 0.0 109.949 179.26 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.598 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 83.2 m-85 -151.57 170.78 18.83 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.153 -0.967 . . . . 0.0 110.409 179.728 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.518 ' N ' ' O ' ' A' ' 14' ' ' GLN . 94.4 mttt -132.7 156.89 46.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.336 -0.853 . . . . 0.0 109.653 179.524 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.452 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 9.8 t -84.48 121.6 27.81 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.225 -0.922 . . . . 0.0 110.143 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 71.6 m -133.59 132.75 41.21 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.315 -0.866 . . . . 0.0 110.25 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 84.6 tttt . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.119 179.929 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ASN . . . . . 0.76 ' HB3' HG22 ' A' ' 4' ' ' VAL . 26.4 m120 . . . . . 0 N--CA 1.492 1.66 0 CA-C-O 121.272 0.558 . . . . 0.0 110.155 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.625 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 75.9 mt-10 -69.92 -35.89 5.8 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.477 -0.764 . . . . 0.0 112.233 -179.57 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.625 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.6 Cg_endo -74.49 -9.25 21.37 Favored 'Trans proline' 0 C--N 1.315 -1.213 0 O-C-N 122.943 0.97 . . . . 0.0 111.074 -178.829 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.76 HG22 ' HB3' ' A' ' 1' ' ' ASN . 17.4 m -140.64 149.05 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.082 -1.011 . . . . 0.0 110.163 179.693 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.648 ' OG ' HG22 ' A' ' 7' ' ' ILE . 86.7 p -154.24 160.26 41.72 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.173 -0.954 . . . . 0.0 110.103 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.45 ' O ' ' OD1' ' A' ' 9' ' ' ASN . 80.8 m -61.06 -35.82 77.97 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.272 -0.892 . . . . 0.0 110.385 -179.869 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.648 HG22 ' OG ' ' A' ' 5' ' ' SER . 5.7 tt -58.19 -17.28 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.182 -0.949 . . . . 0.0 110.189 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 9.1 tpm_? -66.63 -33.76 76.37 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.223 -0.923 . . . . 0.0 110.247 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.454 ' OD1' ' N ' ' A' ' 11' ' ' GLY . 47.4 p30 -84.98 4.98 31.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.149 -0.969 . . . . 0.0 110.182 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.76 -5.04 53.71 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.454 ' N ' ' OD1' ' A' ' 9' ' ' ASN . . . -72.63 175.78 43.44 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.581 HG22 ' N ' ' A' ' 13' ' ' CYS . 70.1 mt -130.82 174.41 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -1.114 . . . . 0.0 110.198 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.581 ' N ' HG22 ' A' ' 12' ' ' ILE . 2.6 m -127.16 150.68 49.4 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.213 -0.929 . . . . 0.0 110.174 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.506 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 4.4 tp-100 -156.04 151.74 27.22 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.677 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.537 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 73.6 t80 -56.98 -31.64 65.26 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.113 -0.992 . . . . 0.0 110.396 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.537 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 38.0 mmt180 -151.63 150.94 30.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.358 -0.839 . . . . 0.0 110.23 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 96.3 m -121.55 125.91 47.9 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.286 -0.884 . . . . 0.0 110.304 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.44 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 36.8 pt -62.27 166.41 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.239 -0.913 . . . . 0.0 110.126 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.85 -42.4 59.73 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.727 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.44 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 32.8 mt -51.86 -28.58 16.46 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.325 -1.103 . . . . 0.0 110.31 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 61.5 mtt-85 -117.66 118.95 33.49 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.235 -0.915 . . . . 0.0 110.487 -179.742 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -97.99 144.77 27.17 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.883 . . . . 0.0 109.814 179.741 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.492 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -99.78 107.0 18.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.133 -0.979 . . . . 0.0 110.643 -179.718 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 51.3 mm -64.08 -35.63 74.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.253 -0.904 . . . . 0.0 110.19 179.741 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.479 ' C ' ' HB2' ' A' ' 33' ' ' CYS . . . -141.56 -162.77 9.3 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.631 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.537 HG22 ' O ' ' A' ' 28' ' ' GLY . 90.0 m -122.44 108.61 13.39 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.476 -1.014 . . . . 0.0 110.286 179.692 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.517 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 10.9 t -58.64 -32.59 69.2 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.224 -0.922 . . . . 0.0 109.587 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.537 ' O ' HG22 ' A' ' 26' ' ' THR . . . -172.02 -158.35 15.93 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.709 -1.757 . . . . 0.0 108.709 179.621 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.591 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.7 m -88.97 -43.09 0.44 Allowed Pre-proline 0 C--N 1.302 -1.485 0 O-C-N 120.839 -1.389 . . . . 0.0 110.215 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.591 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.2 Cg_endo -83.52 10.22 3.77 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.557 1.293 . . . . 0.0 109.533 179.009 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.541 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 79.0 m-85 -154.21 171.11 19.72 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.342 -0.849 . . . . 0.0 110.737 -179.861 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.486 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 95.5 mttt -134.32 161.28 35.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.588 -0.695 . . . . 0.0 109.196 179.168 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.517 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 58.0 m -80.37 100.06 8.25 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.063 -1.023 . . . . 0.0 110.185 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.468 ' SG ' ' HB3' ' A' ' 23' ' ' LYS . 19.8 m -129.38 158.35 39.38 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.143 -0.973 . . . . 0.0 110.339 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 117.936 -1.03 . . . . 0.0 109.999 179.732 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 28.4 t . . . . . 0 N--CA 1.493 1.679 0 CA-C-O 121.266 0.555 . . . . 0.0 110.482 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.9 tt -57.47 -32.37 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.163 -0.961 . . . . 0.0 110.646 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 59.4 ttt180 -56.08 -31.83 63.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 110.485 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -66.03 -30.38 70.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.263 -0.898 . . . . 0.0 110.239 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.04 5.85 21.26 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -82.59 -178.49 52.39 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 23.8 mm -112.1 166.64 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.146 -1.208 . . . . 0.0 110.273 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.532 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.4 m -120.22 153.79 35.79 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.183 -0.948 . . . . 0.0 109.998 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.511 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 20.0 tp60 -153.7 154.93 35.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.434 -0.791 . . . . 0.0 109.714 179.689 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.564 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 72.5 t80 -59.88 -36.39 76.84 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.164 -0.96 . . . . 0.0 110.252 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.564 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 38.8 mmt180 -148.42 152.44 36.97 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.344 -0.848 . . . . 0.0 109.958 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 69.5 m -123.03 152.25 41.13 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.128 -0.982 . . . . 0.0 110.289 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.7 pt -103.82 165.92 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.326 -0.858 . . . . 0.0 109.899 179.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.78 -42.75 37.72 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.834 HD13 ' O ' ' A' ' 20' ' ' LEU . 3.3 tm? -51.01 -35.15 32.49 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.177 -1.19 . . . . 0.0 110.404 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.8 mtp180 -89.87 150.16 22.34 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.186 -0.946 . . . . 0.0 110.485 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 92.4 m-70 -108.3 141.21 40.43 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.313 -0.867 . . . . 0.0 109.818 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.446 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 76.4 tttt -121.83 121.93 38.3 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.179 -0.95 . . . . 0.0 110.74 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 28.8 pt -101.43 -6.3 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.388 -0.82 . . . . 0.0 109.793 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.459 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -178.17 -174.22 44.27 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.697 HG22 ' O ' ' A' ' 28' ' ' GLY . 89.1 m -111.27 111.04 21.82 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.177 -1.19 . . . . 0.0 110.31 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.411 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 38.9 t -53.71 -48.18 69.81 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.225 -0.922 . . . . 0.0 109.958 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.697 ' O ' HG22 ' A' ' 26' ' ' THR . . . -149.84 -163.29 11.01 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.582 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 9.7 m -89.81 -42.94 0.42 Allowed Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 120.998 -1.295 . . . . 0.0 110.221 179.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.584 ' O ' ' CD1' ' A' ' 31' ' ' PHE . 50.4 Cg_endo -82.27 7.21 5.24 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.499 1.263 . . . . 0.0 109.555 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.584 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 57.7 m-85 -151.87 169.21 22.84 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.324 -0.86 . . . . 0.0 110.284 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.532 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 93.2 mttt -131.21 157.3 43.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.342 -0.849 . . . . 0.0 109.656 179.285 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.459 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 42.3 t -84.77 119.01 24.81 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.095 -1.003 . . . . 0.0 110.255 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 97.8 m -145.44 157.24 44.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.293 -0.879 . . . . 0.0 110.315 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.209 179.877 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 7.3 t . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.074 0.464 . . . . 0.0 110.525 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.5 pt -60.03 -14.66 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.18 -0.95 . . . . 0.0 110.264 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 78.0 mmt-85 -64.38 -34.91 79.25 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.294 -0.879 . . . . 0.0 110.117 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -65.58 -26.18 67.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.337 -0.852 . . . . 0.0 110.027 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.89 -1.07 13.51 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.79 -176.73 50.97 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.4 pt -128.63 163.77 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.348 -1.089 . . . . 0.0 110.002 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.521 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.2 m -103.38 154.41 19.44 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.092 -1.005 . . . . 0.0 109.951 -179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.533 ' O ' ' N ' ' A' ' 32' ' ' LYS . 4.9 tp60 -149.42 151.26 33.72 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.306 -0.871 . . . . 0.0 109.989 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.457 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 67.6 t80 -55.21 -44.66 75.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 110.131 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.457 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 48.3 mmm-85 -150.23 143.0 24.69 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.363 -0.836 . . . . 0.0 110.233 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 90.4 m -109.49 153.25 24.33 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.25 -0.907 . . . . 0.0 110.127 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.553 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 38.3 pt -103.76 176.45 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.274 -0.891 . . . . 0.0 110.233 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.72 -33.04 81.01 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.622 ' N ' HD22 ' A' ' 20' ' ' LEU . 3.9 mm? -61.2 -34.93 75.88 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -1.162 . . . . 0.0 110.056 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -99.45 149.04 23.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.259 -0.901 . . . . 0.0 110.063 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 72.8 m80 -107.74 134.79 50.2 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.188 -0.945 . . . . 0.0 110.213 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 35.6 tttm -97.22 107.26 19.75 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.325 -0.859 . . . . 0.0 110.239 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.42 HG23 ' N ' ' A' ' 25' ' ' GLY . 18.9 tt -69.74 -32.44 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 110.179 179.762 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.444 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -166.41 -173.17 34.54 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.618 HG22 ' O ' ' A' ' 28' ' ' GLY . 61.8 m -104.25 100.04 9.77 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.244 -1.15 . . . . 0.0 110.309 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.431 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 35.9 t -52.22 -43.88 64.49 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.202 -0.936 . . . . 0.0 109.734 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.618 ' O ' HG22 ' A' ' 26' ' ' THR . . . -154.59 -163.37 11.92 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 179.737 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.584 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 15.8 m -90.46 -41.86 0.4 Allowed Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.035 -1.274 . . . . 0.0 110.34 179.695 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.584 ' CD ' ' N ' ' A' ' 29' ' ' SER . 45.8 Cg_endo -81.92 7.0 5.32 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.466 1.245 . . . . 0.0 109.785 179.084 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.581 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 88.9 m-85 -153.65 170.96 19.58 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.263 -0.898 . . . . 0.0 110.351 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 14' ' ' GLN . 61.5 mttm -133.19 156.55 47.29 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.472 -0.768 . . . . 0.0 109.635 179.512 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 10.8 t -84.74 113.06 21.04 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.243 -0.911 . . . . 0.0 110.282 -179.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.7 m -138.84 143.22 38.72 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.345 -0.847 . . . . 0.0 110.064 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.257 -179.858 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 34.4 t . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 121.243 0.544 . . . . 0.0 110.184 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.432 ' HA ' HD12 ' A' ' 7' ' ' ILE . 6.0 tp -52.18 -28.48 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.404 -0.81 . . . . 0.0 110.385 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 48.6 ttp180 -57.16 -31.55 65.51 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.169 -0.957 . . . . 0.0 110.469 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -67.14 -30.6 70.64 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.286 -0.884 . . . . 0.0 110.25 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 116.06 8.28 13.62 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -85.83 -177.19 50.19 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 34.8 pt -116.62 162.35 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.185 -1.185 . . . . 0.0 110.064 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.521 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.1 m -113.19 155.1 25.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.121 -0.987 . . . . 0.0 110.141 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 65.2 tt0 -154.29 155.46 35.21 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.404 -0.81 . . . . 0.0 109.835 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.596 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 60.1 t80 -57.79 -44.69 86.44 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.177 -0.952 . . . . 0.0 110.257 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.596 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 41.0 mmt180 -145.95 150.2 35.62 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.35 -0.844 . . . . 0.0 110.267 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.1 m -120.62 126.06 49.31 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.211 -0.931 . . . . 0.0 110.052 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.5 pt -134.03 165.32 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.227 -0.921 . . . . 0.0 110.205 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.91 -169.73 40.78 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 94.8 mt -51.78 -29.99 21.14 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.34 -1.094 . . . . 0.0 110.273 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 81.0 mtm180 -53.08 148.98 7.23 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.246 -0.909 . . . . 0.0 110.278 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 45.8 p-80 -135.18 164.46 27.62 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.27 -0.894 . . . . 0.0 109.968 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.473 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 68.5 tttt -112.69 99.06 7.64 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.12 -0.987 . . . . 0.0 110.519 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.421 HD12 ' HE3' ' A' ' 35' ' ' LYS . 90.1 mt -60.52 -43.43 94.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.288 -0.883 . . . . 0.0 110.069 179.68 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.459 ' O ' ' HE2' ' A' ' 23' ' ' LYS . . . -144.06 -173.77 15.77 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.569 HG22 ' O ' ' A' ' 28' ' ' GLY . 90.2 m -108.9 105.5 15.08 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.265 -1.138 . . . . 0.0 110.366 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.445 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 48.6 t -55.67 -44.25 77.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -0.929 . . . . 0.0 109.767 179.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.569 ' O ' HG22 ' A' ' 26' ' ' THR . . . -152.41 -167.11 14.91 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.805 -1.718 . . . . 0.0 108.805 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.606 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 2.0 m -87.36 -43.18 0.52 Allowed Pre-proline 0 C--N 1.299 -1.602 0 O-C-N 121.227 -1.16 . . . . 0.0 110.003 179.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.606 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.3 Cg_endo -83.3 7.63 5.09 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 O-C-N 123.628 1.33 . . . . 0.0 109.564 179.153 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.562 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 88.6 m-85 -152.07 170.63 19.45 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -0.893 . . . . 0.0 110.207 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.521 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 92.2 mttt -134.03 156.4 48.28 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.529 -0.732 . . . . 0.0 109.634 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 42.6 t -84.62 121.51 27.73 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.138 -0.976 . . . . 0.0 110.23 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 65.9 m -142.18 139.5 32.08 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.251 -0.905 . . . . 0.0 110.258 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.421 ' HE3' HD12 ' A' ' 24' ' ' ILE . 94.8 mttt . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.078 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 47.7 t . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 121.077 0.465 . . . . 0.0 110.434 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.539 ' H ' HD12 ' A' ' 7' ' ' ILE . 1.6 mp -63.36 -32.27 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.17 -0.957 . . . . 0.0 109.885 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 17.1 tpt180 -55.97 -36.95 68.42 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.376 -0.828 . . . . 0.0 110.332 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -77.46 -9.78 59.09 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.332 -0.855 . . . . 0.0 110.3 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.92 6.33 65.39 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -74.21 -172.26 26.91 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.494 HG22 ' N ' ' A' ' 13' ' ' CYS . 51.7 mt -122.45 169.35 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -1.161 . . . . 0.0 110.187 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.6 m -134.81 155.22 51.01 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.314 -0.866 . . . . 0.0 110.096 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.45 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 28.1 mt-30 -153.04 156.43 38.75 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.509 -0.744 . . . . 0.0 109.95 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.502 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 81.8 m-85 -52.62 -34.89 53.16 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.142 -0.974 . . . . 0.0 110.032 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.45 ' NH1' ' HE3' ' A' ' 32' ' ' LYS . 26.9 tpt180 -151.95 165.76 33.62 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.395 -0.815 . . . . 0.0 110.097 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 23.4 m -138.28 128.11 25.3 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.22 -0.925 . . . . 0.0 110.129 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 pt -142.44 167.34 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.292 -0.88 . . . . 0.0 110.171 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.44 -150.54 23.59 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.606 ' N ' HD22 ' A' ' 20' ' ' LEU . 4.2 mm? -67.69 -19.66 65.2 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.352 -1.087 . . . . 0.0 109.999 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.0 mtt180 -54.81 142.8 27.75 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.354 -0.841 . . . . 0.0 110.323 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.541 ' CD2' ' O ' ' A' ' 20' ' ' LEU . 96.4 m-70 -128.25 161.06 30.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.401 -0.812 . . . . 0.0 110.015 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.478 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 25.2 ttmt -122.54 126.61 48.14 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.198 -0.939 . . . . 0.0 110.31 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 35.0 pt -99.19 -9.6 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.263 -0.898 . . . . 0.0 110.06 179.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.461 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -173.33 -171.74 38.2 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.746 HG23 ' O ' ' A' ' 26' ' ' THR . 15.0 t -109.82 106.93 16.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.253 -1.145 . . . . 0.0 110.218 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 20.7 t -59.31 -37.8 78.66 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.211 -0.931 . . . . 0.0 110.106 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -170.3 -164.9 26.8 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.602 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 61.7 m -88.7 -41.62 0.46 Allowed Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 120.903 -1.351 . . . . 0.0 110.148 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.602 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.1 Cg_endo -82.88 8.62 4.49 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 123.504 1.265 . . . . 0.0 109.425 178.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 69.5 m-85 -155.8 172.42 18.37 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.382 -0.823 . . . . 0.0 110.469 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 65.0 mttm -135.83 158.17 45.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.557 -0.715 . . . . 0.0 109.172 178.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.478 ' O ' ' HG3' ' A' ' 23' ' ' LYS . 38.3 t -77.4 121.07 23.29 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.978 -1.076 . . . . 0.0 109.956 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 56.0 m -147.64 150.95 35.35 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.107 -0.995 . . . . 0.0 110.355 -179.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.187 179.99 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 43.0 t . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.263 0.554 . . . . 0.0 110.279 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.492 HG13 ' N ' ' A' ' 8' ' ' ARG . 40.8 pt -56.53 -29.05 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -0.883 . . . . 0.0 110.266 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.492 ' N ' HG13 ' A' ' 7' ' ' ILE . 58.8 ttt-85 -63.43 -41.88 98.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.247 -0.908 . . . . 0.0 110.233 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 -66.0 -26.72 67.67 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.291 -0.881 . . . . 0.0 110.176 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.4 16.34 14.89 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.87 -176.46 36.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 18.9 pt -119.67 151.04 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.262 -1.14 . . . . 0.0 110.011 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.478 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.1 m -101.52 153.13 20.0 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.147 -0.971 . . . . 0.0 109.992 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 43.6 tp60 -154.38 154.29 33.03 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.342 -0.849 . . . . 0.0 109.839 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.477 ' N ' ' HG3' ' A' ' 14' ' ' GLN . 64.2 t80 -54.89 -34.59 63.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.273 -0.892 . . . . 0.0 110.764 -179.649 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 22.1 tpp180 -156.64 164.33 38.29 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.165 -0.959 . . . . 0.0 110.218 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 93.5 m -133.43 127.8 34.15 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.299 -0.876 . . . . 0.0 110.156 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.555 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 42.7 pt -59.28 161.43 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.237 -0.914 . . . . 0.0 110.324 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.82 -35.42 52.95 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.579 ' N ' HD22 ' A' ' 20' ' ' LEU . 4.4 mm? -58.46 -28.72 65.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.285 -1.126 . . . . 0.0 110.436 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.48 ' HG2' ' HB3' ' A' ' 34' ' ' CYS . 20.5 tpp180 -106.5 130.08 54.34 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.137 -0.977 . . . . 0.0 110.479 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.424 ' H ' ' CD2' ' A' ' 22' ' ' HIS . 12.8 p80 -105.82 153.82 21.39 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.401 -0.812 . . . . 0.0 109.636 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.516 ' CB ' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -118.79 124.85 48.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.085 -1.01 . . . . 0.0 110.572 -179.761 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 61.0 mt -68.08 -34.85 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.931 . . . . 0.0 109.824 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.497 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -151.78 -169.25 17.1 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.865 HG22 ' O ' ' A' ' 28' ' ' GLY . 27.5 m -111.31 101.34 9.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -1.172 . . . . 0.0 110.39 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.417 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 40.5 t -44.54 -51.33 9.01 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.303 -0.873 . . . . 0.0 109.806 179.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.865 ' O ' HG22 ' A' ' 26' ' ' THR . . . -145.57 -164.95 11.05 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 108.587 -1.805 . . . . 0.0 108.587 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.581 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.9 m -88.27 -44.38 0.47 Allowed Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 120.821 -1.399 . . . . 0.0 110.08 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.589 ' HG2' ' CE2' ' A' ' 31' ' ' PHE . 45.2 Cg_endo -80.43 7.8 4.55 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 O-C-N 123.554 1.291 . . . . 0.0 110.083 179.203 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.589 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 89.6 m-85 -149.17 170.52 18.25 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.227 -0.921 . . . . 0.0 110.269 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.496 ' N ' ' O ' ' A' ' 14' ' ' GLN . 98.1 mttt -131.37 159.07 39.04 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.463 -0.773 . . . . 0.0 109.505 179.18 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.516 ' O ' ' CB ' ' A' ' 23' ' ' LYS . 47.8 t -84.61 115.79 22.82 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.048 -1.032 . . . . 0.0 110.406 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.48 ' HB3' ' HG2' ' A' ' 21' ' ' ARG . 71.7 m -142.54 130.86 22.2 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.136 -0.977 . . . . 0.0 110.092 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 96.2 mttt . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.26 -179.782 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.415 ' O ' ' HB ' ' A' ' 7' ' ' ILE . 45.9 t . . . . . 0 N--CA 1.492 1.655 0 CA-C-O 121.284 0.564 . . . . 0.0 110.315 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.415 ' HB ' ' O ' ' A' ' 6' ' ' CYS . 7.0 tt -175.06 -28.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.236 -0.915 . . . . 0.0 110.706 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 15.6 mtm180 -57.29 -30.62 64.86 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.943 -1.098 . . . . 0.0 109.492 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -65.99 -29.42 69.8 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.618 -0.676 . . . . 0.0 110.368 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 107.48 9.74 28.52 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.93 171.05 48.36 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.8 pt -111.68 161.8 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -1.124 . . . . 0.0 110.176 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.507 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.2 m -104.36 154.33 19.96 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.162 -0.962 . . . . 0.0 109.921 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.533 ' O ' ' N ' ' A' ' 32' ' ' LYS . 63.2 tt0 -155.13 153.42 30.79 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.41 -0.806 . . . . 0.0 109.565 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.496 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 63.2 t80 -59.14 -39.48 82.52 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.043 -1.036 . . . . 0.0 110.36 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.496 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 17.1 mmm180 -144.59 146.76 32.49 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.268 -0.895 . . . . 0.0 110.348 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.2 t -109.14 156.26 20.05 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.254 -0.903 . . . . 0.0 110.441 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.432 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 31.1 pt -110.46 162.79 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.252 -0.905 . . . . 0.0 110.191 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.06 -36.74 52.58 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.58 ' N ' HD22 ' A' ' 20' ' ' LEU . 4.2 mm? -56.33 -35.31 67.46 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.194 -1.18 . . . . 0.0 110.169 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 -100.77 129.17 46.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.218 -0.926 . . . . 0.0 110.128 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 77.9 t60 -88.07 124.98 34.31 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.352 -0.842 . . . . 0.0 110.295 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.476 ' HD2' ' HB3' ' A' ' 32' ' ' LYS . 27.3 ttpp -97.33 117.18 30.97 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.294 -0.879 . . . . 0.0 110.132 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 35.9 pt -97.62 0.32 10.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.177 -0.952 . . . . 0.0 110.315 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.92 -172.35 43.82 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.705 HG22 ' O ' ' A' ' 28' ' ' GLY . 88.4 m -119.46 111.5 18.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -1.118 . . . . 0.0 110.226 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.436 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 45.8 t -54.04 -53.32 54.61 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.247 -0.908 . . . . 0.0 109.795 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.705 ' O ' HG22 ' A' ' 26' ' ' THR . . . -142.12 -165.36 10.47 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 108.651 -1.779 . . . . 0.0 108.651 179.475 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.608 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 23.5 m -87.27 -41.69 0.52 Allowed Pre-proline 0 C--N 1.304 -1.412 0 O-C-N 121.027 -1.278 . . . . 0.0 110.052 179.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.608 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.3 Cg_endo -81.75 7.46 5.02 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 O-C-N 123.506 1.266 . . . . 0.0 109.681 178.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.586 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 86.7 m-85 -151.92 171.09 18.34 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.296 -0.877 . . . . 0.0 110.448 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 14' ' ' GLN . 62.0 mttm -128.6 157.76 40.37 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.429 -0.794 . . . . 0.0 109.264 179.347 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.476 ' O ' ' HG3' ' A' ' 23' ' ' LYS . 48.9 t -91.76 117.56 29.87 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.985 -1.072 . . . . 0.0 110.301 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 96.9 m -135.43 131.42 36.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.211 -0.93 . . . . 0.0 110.595 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.2 ptmm? . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.241 179.925 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.486 ' HB2' ' SG ' ' A' ' 27' ' ' CYS . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.637 0 CA-C-O 121.346 0.593 . . . . 0.0 110.035 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.424 HG23 ' N ' ' A' ' 8' ' ' ARG . 4.8 tp -65.16 -33.43 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.286 -0.884 . . . . 0.0 110.105 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.424 ' N ' HG23 ' A' ' 7' ' ' ILE . 81.0 mtt180 -52.15 -37.94 56.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.3 -0.875 . . . . 0.0 110.336 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -71.08 -6.83 42.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.39 -0.819 . . . . 0.0 110.251 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 81.49 13.96 79.27 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.43 ' C ' HG13 ' A' ' 12' ' ' ILE . . . -96.71 -170.7 34.25 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.483 HG22 ' N ' ' A' ' 13' ' ' CYS . 27.2 mt -132.53 172.53 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.297 -1.119 . . . . 0.0 109.622 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.518 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 6.1 m -137.39 159.59 41.5 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.916 -1.115 . . . . 0.0 111.346 -179.586 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 53.9 tp60 -157.67 153.63 27.02 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.497 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 44.1 t80 -44.74 -46.4 10.42 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.979 -1.076 . . . . 0.0 110.392 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.497 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 30.3 mmt180 -137.71 146.58 43.9 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.327 -0.858 . . . . 0.0 110.012 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 77.3 m -111.65 131.02 55.57 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.118 -0.988 . . . . 0.0 110.503 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.4 pt -133.47 164.59 34.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.195 -0.941 . . . . 0.0 110.217 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.78 -161.35 23.71 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.489 ' O ' ' CE1' ' A' ' 22' ' ' HIS . 53.2 mt -70.56 -24.52 62.8 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.283 -1.128 . . . . 0.0 110.126 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 100.0 mtt180 -57.36 142.86 42.14 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.326 -0.859 . . . . 0.0 110.313 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.489 ' CE1' ' O ' ' A' ' 20' ' ' LEU . 77.6 m-70 -119.6 160.9 21.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.214 -0.929 . . . . 0.0 110.089 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.523 ' CE ' ' OG1' ' A' ' 26' ' ' THR . 76.9 tttt -99.7 97.94 8.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.166 -0.959 . . . . 0.0 110.381 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 89.9 mt -67.37 -26.96 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.188 -0.945 . . . . 0.0 110.181 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.402 ' H ' ' HB3' ' A' ' 33' ' ' CYS . . . -164.33 -169.05 27.36 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.597 HG22 ' O ' ' A' ' 28' ' ' GLY . 92.3 m -122.98 111.01 16.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.245 -1.15 . . . . 0.0 110.429 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.486 ' SG ' ' HB2' ' A' ' 6' ' ' CYS . 33.4 m -59.43 -43.47 93.07 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.239 -0.913 . . . . 0.0 109.523 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.597 ' O ' HG22 ' A' ' 26' ' ' THR . . . -154.28 -160.96 10.14 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.612 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 5.2 m -86.84 -41.65 0.54 Allowed Pre-proline 0 C--N 1.301 -1.515 0 O-C-N 120.941 -1.329 . . . . 0.0 109.977 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.612 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.8 Cg_endo -81.58 7.79 4.8 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 123.539 1.284 . . . . 0.0 109.987 179.19 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.589 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 52.6 m-85 -149.73 179.36 8.07 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.218 -0.926 . . . . 0.0 110.812 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 26' ' ' THR . 68.7 mttt -148.26 161.85 40.68 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.515 -0.74 . . . . 0.0 109.396 179.625 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.464 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 46.9 t -88.88 110.11 20.79 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.611 -1.306 . . . . 0.0 109.78 179.533 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 89.2 m -137.09 150.51 48.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.184 -0.948 . . . . 0.0 110.334 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 99.9 mttt . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.141 179.814 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.326 0.584 . . . . 0.0 110.133 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.471 HG13 ' N ' ' A' ' 8' ' ' ARG . 32.3 pt -67.86 -26.15 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.356 -0.84 . . . . 0.0 110.098 179.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.471 ' N ' HG13 ' A' ' 7' ' ' ILE . 76.7 mtt85 -49.56 -33.07 13.94 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.202 -0.936 . . . . 0.0 110.336 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 55.5 t-20 -68.92 -23.65 64.19 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.357 -0.839 . . . . 0.0 110.723 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 111.36 -2.93 28.04 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.44 -168.94 41.61 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.478 HG22 ' N ' ' A' ' 13' ' ' CYS . 51.3 mt -131.6 170.77 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.355 -1.085 . . . . 0.0 109.949 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.524 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.5 m -135.88 159.39 41.81 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.019 -1.051 . . . . 0.0 110.485 179.682 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.519 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 11.6 pt20 -155.64 169.86 23.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.466 -0.771 . . . . 0.0 109.78 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.487 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 96.3 m-85 -58.04 -36.94 73.47 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.302 -0.874 . . . . 0.0 110.842 -179.653 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.468 ' O ' ' HG3' ' A' ' 14' ' ' GLN . 38.3 mmt180 -146.46 153.63 40.66 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.144 -0.972 . . . . 0.0 110.517 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.4 m -122.31 161.94 22.42 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.249 -0.907 . . . . 0.0 109.839 179.519 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.532 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 34.6 pt -113.98 172.83 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.057 -1.027 . . . . 0.0 110.315 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.99 -33.92 64.79 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.532 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 22.9 mt -59.6 -33.64 71.73 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -1.132 . . . . 0.0 110.264 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -101.8 133.79 45.98 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.344 -0.847 . . . . 0.0 110.056 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 66.6 t-80 -88.28 124.85 34.29 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.261 -0.899 . . . . 0.0 110.216 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.625 ' HE2' HG22 ' A' ' 26' ' ' THR . 74.0 tttt -88.02 90.45 8.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.213 -0.929 . . . . 0.0 110.106 179.827 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.9 tt -64.95 -30.98 51.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.189 -0.944 . . . . 0.0 110.358 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -170.02 -171.21 35.29 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.625 HG22 ' HE2' ' A' ' 23' ' ' LYS . 58.2 p -116.31 103.04 10.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.343 -1.092 . . . . 0.0 110.485 -179.732 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 62.6 m -47.95 -48.6 32.06 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.742 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.16 -160.09 8.53 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.594 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 8.4 m -89.99 -41.61 0.42 Allowed Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.082 -1.246 . . . . 0.0 110.67 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.594 ' CD ' ' N ' ' A' ' 29' ' ' SER . 46.4 Cg_endo -81.16 7.83 4.72 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 123.472 1.248 . . . . 0.0 109.997 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.586 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 83.9 m-85 -150.36 171.79 16.43 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.255 -0.903 . . . . 0.0 110.438 179.575 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.524 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 93.8 mttt -135.58 158.99 43.01 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.408 -0.808 . . . . 0.0 108.995 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.531 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 4.8 t -89.29 118.78 29.21 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.767 -1.208 . . . . 0.0 109.907 179.506 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 95.4 m -144.31 147.43 33.48 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.133 -0.979 . . . . 0.0 110.299 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 91.5 mttt . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.17 179.721 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.469 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 53.1 t . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.232 0.539 . . . . 0.0 110.107 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.517 HG13 ' N ' ' A' ' 8' ' ' ARG . 46.7 pt -57.25 -33.49 43.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.241 -0.912 . . . . 0.0 110.279 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.517 ' N ' HG13 ' A' ' 7' ' ' ILE . 65.9 ttt-85 -59.79 -35.51 74.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.207 -0.933 . . . . 0.0 110.17 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.407 ' O ' ' OD1' ' A' ' 9' ' ' ASN . 45.9 t-20 -75.65 -23.23 56.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 109.983 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 112.32 2.07 26.3 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.96 -178.88 48.94 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.567 HG22 ' N ' ' A' ' 13' ' ' CYS . 57.2 mt -114.63 171.72 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.23 -1.159 . . . . 0.0 110.27 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.567 ' N ' HG22 ' A' ' 12' ' ' ILE . 2.3 m -124.6 150.57 45.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 110.053 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.472 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 56.6 tt0 -152.71 154.18 34.75 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.613 -0.679 . . . . 0.0 109.712 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.53 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 89.2 m-85 -57.89 -40.05 79.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.056 -1.027 . . . . 0.0 110.307 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.42 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 24.9 mmm180 -145.0 156.29 43.86 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.309 -0.869 . . . . 0.0 110.496 -179.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.1 m -128.24 160.83 30.89 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.241 -0.912 . . . . 0.0 110.055 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.551 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 48.4 pt -110.71 172.35 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.13 -0.981 . . . . 0.0 110.295 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.45 -33.88 62.79 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.61 ' N ' HD12 ' A' ' 20' ' ' LEU . 9.5 mp -62.01 -34.2 75.75 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.157 -1.202 . . . . 0.0 110.224 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 70.7 mtp85 -102.85 113.82 27.58 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.249 -0.907 . . . . 0.0 109.938 179.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 65.7 m170 -68.37 152.26 45.68 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.178 -0.952 . . . . 0.0 110.52 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 71.4 tttt -120.69 96.69 5.22 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.316 -0.865 . . . . 0.0 109.979 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.402 HG23 HD12 ' A' ' 24' ' ' ILE . 49.5 mm -65.53 -26.46 39.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.274 -0.892 . . . . 0.0 110.601 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.423 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -175.99 -167.84 35.42 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 32' ' ' LYS . 49.5 p -106.57 105.87 16.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -1.077 . . . . 0.0 110.52 -179.808 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.471 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 42.4 t -50.67 -35.76 32.46 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -0.914 . . . . 0.0 109.53 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -161.68 -160.77 11.16 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.448 -1.861 . . . . 0.0 108.448 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.589 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 60.6 m -89.64 -41.89 0.43 Allowed Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 120.942 -1.328 . . . . 0.0 109.956 179.495 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.589 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.0 Cg_endo -83.29 8.87 4.36 Favored 'Trans proline' 0 C--N 1.31 -1.496 0 O-C-N 123.422 1.222 . . . . 0.0 109.557 178.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.565 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 95.6 m-85 -153.02 172.45 16.82 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.357 -0.839 . . . . 0.0 110.802 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.525 ' HA ' ' HA ' ' A' ' 26' ' ' THR . 93.4 mttt -134.41 160.01 39.29 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 179.092 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 45.7 t -83.8 117.08 23.04 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.983 -1.073 . . . . 0.0 109.911 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 58.9 m -144.12 156.78 44.48 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.233 -0.917 . . . . 0.0 110.506 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 94.8 mttt . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.092 179.829 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.401 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 48.1 t . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 121.225 0.536 . . . . 0.0 110.21 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 37.1 pt -109.93 -11.51 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.293 -0.88 . . . . 0.0 110.235 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 30.0 mmt180 -57.95 -32.4 67.79 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.152 -0.968 . . . . 0.0 110.327 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -67.16 -26.22 66.55 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.385 -0.822 . . . . 0.0 110.436 -179.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.4 13.24 33.53 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.78 -169.92 42.92 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.482 HG22 ' N ' ' A' ' 13' ' ' CYS . 47.2 mt -129.09 171.12 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.439 -1.036 . . . . 0.0 109.795 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.547 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 5.8 m -136.47 160.18 39.53 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.936 -1.103 . . . . 0.0 111.214 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.4 ' O ' ' C ' ' A' ' 15' ' ' TYR . 44.2 tt0 -160.06 154.39 23.62 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.725 -0.609 . . . . 0.0 109.501 179.507 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.464 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 40.2 t80 -43.21 -45.81 5.81 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.005 -1.059 . . . . 0.0 110.656 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.464 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 0.6 OUTLIER -139.42 147.04 40.86 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.255 -0.903 . . . . 0.0 110.292 179.819 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 66.5 m -112.72 126.12 55.06 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.304 -0.872 . . . . 0.0 110.324 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 26.9 pt -129.99 163.91 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.936 . . . . 0.0 110.176 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.94 -167.08 26.46 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.689 ' N ' HD12 ' A' ' 20' ' ' LEU . 10.1 mp -68.6 -21.63 64.49 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.264 -1.139 . . . . 0.0 110.347 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 94.7 mtt-85 -54.68 138.69 41.08 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.371 -0.831 . . . . 0.0 110.178 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -109.62 170.41 8.08 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.238 -0.914 . . . . 0.0 109.971 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.522 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 79.9 tttt -115.33 113.25 23.57 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.014 -1.054 . . . . 0.0 110.607 -179.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 45.5 mm -70.45 -31.06 45.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.406 -0.809 . . . . 0.0 109.963 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.425 ' O ' ' CE ' ' A' ' 23' ' ' LYS . . . -174.59 -166.49 32.62 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.48 HG22 ' O ' ' A' ' 28' ' ' GLY . 51.8 m -113.45 109.33 18.49 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.208 -1.172 . . . . 0.0 110.711 -179.669 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.412 ' SG ' ' HA ' ' A' ' 33' ' ' CYS . 60.0 m -58.17 -51.46 69.62 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.173 -0.955 . . . . 0.0 109.897 179.577 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.48 ' O ' HG22 ' A' ' 26' ' ' THR . . . -141.49 -164.22 9.9 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.933 -1.667 . . . . 0.0 108.933 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.622 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 14.9 m -85.96 -41.41 0.6 Allowed Pre-proline 0 C--N 1.301 -1.521 0 O-C-N 120.939 -1.33 . . . . 0.0 109.954 179.358 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.622 ' CD ' ' N ' ' A' ' 29' ' ' SER . 45.4 Cg_endo -81.34 8.16 4.55 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 O-C-N 123.501 1.264 . . . . 0.0 109.84 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.61 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 67.3 m-85 -153.25 169.15 23.76 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.08 -1.012 . . . . 0.0 110.975 -179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.547 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 92.8 mttt -133.8 160.1 38.63 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.1 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.522 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 2.9 t -90.26 120.01 31.05 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.744 -1.222 . . . . 0.0 110.337 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 73.4 m -142.67 142.18 31.99 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.86 . . . . 0.0 110.226 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 86.2 tttt . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.124 179.9 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 81.8 m . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 121.213 0.53 . . . . 0.0 109.955 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.529 HG23 ' N ' ' A' ' 8' ' ' ARG . 12.5 tt -59.46 -39.48 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.322 -0.861 . . . . 0.0 109.957 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.529 ' N ' HG23 ' A' ' 7' ' ' ILE . 17.4 ttm105 -56.77 -38.52 72.59 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.308 -0.87 . . . . 0.0 109.932 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 88.1 m-20 -69.32 -27.72 65.62 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.365 -0.835 . . . . 0.0 109.919 179.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.94 8.66 8.68 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -88.98 -177.93 46.21 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.508 ' CG1' ' O ' ' A' ' 34' ' ' CYS . 46.8 pt -132.23 161.24 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.321 -1.105 . . . . 0.0 109.806 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.2 m -113.56 154.21 27.52 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.951 -1.093 . . . . 0.0 110.559 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.497 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 11.5 tp60 -151.17 155.82 39.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.563 -0.71 . . . . 0.0 109.74 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.685 ' CE1' ' CE1' ' A' ' 31' ' ' PHE . 56.4 m-85 -54.94 -42.56 72.45 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.111 -0.993 . . . . 0.0 110.599 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.418 ' HD3' ' O ' ' A' ' 15' ' ' TYR . 89.1 mmt-85 -144.54 154.96 43.43 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.254 -0.903 . . . . 0.0 110.399 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 94.2 m -123.1 138.36 54.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.325 -0.859 . . . . 0.0 109.995 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.0 pt -102.0 170.23 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -0.909 . . . . 0.0 110.326 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -48.21 -43.5 25.95 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 14.2 tp -47.26 -46.7 24.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.207 -1.172 . . . . 0.0 110.311 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -101.39 128.0 47.78 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 110.261 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -88.71 135.32 33.57 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.874 . . . . 0.0 110.198 179.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.538 ' CD ' ' HB3' ' A' ' 32' ' ' LYS . 37.9 ttpt -95.95 117.07 29.92 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.282 -0.887 . . . . 0.0 110.064 179.815 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.0 mm -75.4 -27.27 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.339 -0.851 . . . . 0.0 110.136 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.491 ' C ' ' HB2' ' A' ' 33' ' ' CYS . . . -169.9 -156.51 11.09 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 72.9 p -115.74 113.2 23.14 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.354 -1.086 . . . . 0.0 110.14 179.624 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.52 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 42.2 t -68.73 -29.83 68.33 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.396 -0.815 . . . . 0.0 110.019 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -176.81 -163.61 29.34 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.944 -1.663 . . . . 0.0 108.944 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.604 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.5 m -87.39 -42.9 0.52 Allowed Pre-proline 0 C--N 1.303 -1.413 0 O-C-N 121.076 -1.25 . . . . 0.0 110.055 179.647 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.604 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.9 Cg_endo -81.7 6.94 5.33 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 O-C-N 123.666 1.35 . . . . 0.0 109.663 179.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.685 ' CE1' ' CE1' ' A' ' 15' ' ' TYR . 73.3 m-85 -156.6 176.19 13.05 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.283 -0.886 . . . . 0.0 110.619 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.538 ' HB3' ' CD ' ' A' ' 23' ' ' LYS . 95.9 mttt -141.22 156.89 45.85 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.451 -0.781 . . . . 0.0 109.391 179.214 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.52 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 66.5 m -76.99 107.58 9.44 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.023 -1.048 . . . . 0.0 109.869 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.508 ' O ' ' CG1' ' A' ' 12' ' ' ILE . 63.5 m -142.52 136.28 29.18 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.168 -0.957 . . . . 0.0 110.318 -179.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 61.9 mttp . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.128 179.968 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 74.5 m . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 121.197 0.522 . . . . 0.0 110.292 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.5 tt -58.63 -31.17 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.936 179.74 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -61.13 -37.65 83.58 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.277 -0.89 . . . . 0.0 110.123 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -67.89 -29.22 68.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.383 -0.823 . . . . 0.0 110.326 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 122.78 -2.38 10.06 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.99 -173.36 45.54 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.5 HG22 ' N ' ' A' ' 13' ' ' CYS . 22.4 mm -130.97 170.38 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.284 -1.127 . . . . 0.0 110.159 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.5 ' N ' HG22 ' A' ' 12' ' ' ILE . 2.4 m -119.63 151.49 38.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.185 -0.947 . . . . 0.0 109.862 179.761 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.5 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 51.6 tt0 -152.36 152.52 32.17 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.541 -0.724 . . . . 0.0 109.639 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.503 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 72.6 t80 -57.67 -38.53 75.29 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.183 -0.948 . . . . 0.0 110.473 -179.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.503 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 7.0 mmm180 -149.91 142.69 24.68 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.288 -0.883 . . . . 0.0 110.274 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.5 m -111.69 151.8 28.46 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.153 -0.967 . . . . 0.0 110.208 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.692 HG22 ' H ' ' A' ' 19' ' ' GLY . 3.0 mt -97.95 -168.9 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.184 -0.948 . . . . 0.0 109.897 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.692 ' H ' HG22 ' A' ' 18' ' ' ILE . . . -67.38 -43.71 86.84 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 63.9 mt -55.38 -36.78 66.74 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.338 -1.095 . . . . 0.0 109.962 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.7 mmt-85 -100.67 123.24 44.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.354 -0.841 . . . . 0.0 110.244 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -94.39 144.18 25.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 110.107 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.513 ' CE ' ' O ' ' A' ' 25' ' ' GLY . 72.2 tttt -103.53 102.1 11.98 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.216 -0.927 . . . . 0.0 110.371 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 86.1 mt -70.04 -21.37 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.218 -0.926 . . . . 0.0 110.11 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.513 ' O ' ' CE ' ' A' ' 23' ' ' LYS . . . -169.05 -161.5 19.48 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.735 HG23 ' O ' ' A' ' 26' ' ' THR . 14.0 t -119.3 112.03 18.93 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.306 -1.114 . . . . 0.0 110.283 179.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.517 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 11.6 t -58.87 -37.42 76.5 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.19 -0.944 . . . . 0.0 109.532 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -164.94 -154.79 8.13 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.432 -1.867 . . . . 0.0 108.432 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.579 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 2.3 m -90.27 -43.99 0.41 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 120.975 -1.309 . . . . 0.0 110.156 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.579 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.5 Cg_endo -82.76 11.72 3.14 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 O-C-N 123.564 1.297 . . . . 0.0 109.859 179.2 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.516 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 83.1 m-85 -155.38 174.16 15.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.209 -0.932 . . . . 0.0 110.57 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 26' ' ' THR . 67.5 mttm -137.11 159.31 42.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.638 -0.664 . . . . 0.0 109.36 179.183 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.517 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 76.7 m -78.07 105.72 9.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.031 -1.043 . . . . 0.0 110.203 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 4.9 m -136.0 138.46 42.26 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.143 -0.973 . . . . 0.0 110.275 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.176 179.93 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 85.3 m . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.178 0.513 . . . . 0.0 110.423 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.415 HG13 ' N ' ' A' ' 8' ' ' ARG . 47.1 pt -75.53 -28.51 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.251 -0.906 . . . . 0.0 110.191 179.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.415 ' N ' HG13 ' A' ' 7' ' ' ILE . 25.7 tpt180 -62.3 -32.75 73.53 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.26 -0.9 . . . . 0.0 110.02 179.685 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -78.54 -8.14 58.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 110.16 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 98.72 -2.73 58.74 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.36 172.61 49.14 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.324 -1.511 . . . . 0.0 109.324 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.524 HG22 ' N ' ' A' ' 13' ' ' CYS . 56.6 mt -130.53 170.9 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.287 -1.125 . . . . 0.0 110.275 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.524 ' N ' HG22 ' A' ' 12' ' ' ILE . 3.2 m -103.7 153.75 20.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.162 -0.962 . . . . 0.0 110.087 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 8.5 tp60 -151.67 152.99 33.53 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.514 -0.741 . . . . 0.0 109.748 179.636 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.612 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 57.5 t80 -60.14 -41.96 93.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.175 -0.953 . . . . 0.0 109.955 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.612 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 33.4 mmt180 -147.79 149.35 32.18 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.443 -0.786 . . . . 0.0 110.097 179.779 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 98.5 m -120.86 176.38 5.57 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.211 -0.93 . . . . 0.0 110.1 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.6 pt -122.37 175.45 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.258 -0.901 . . . . 0.0 110.436 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -59.06 -31.46 68.84 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.826 HD13 ' O ' ' A' ' 20' ' ' LEU . 3.1 tm? -59.48 -37.96 79.61 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.282 -1.128 . . . . 0.0 110.272 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -104.81 128.35 52.94 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.274 -0.891 . . . . 0.0 110.289 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -88.07 141.95 28.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.247 -0.908 . . . . 0.0 110.011 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.502 ' CE ' ' HB3' ' A' ' 32' ' ' LYS . 46.4 tttm -94.25 107.12 19.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.859 . . . . 0.0 110.352 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 38.5 mm -68.72 -31.68 51.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.282 -0.887 . . . . 0.0 110.485 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.501 ' O ' ' NZ ' ' A' ' 23' ' ' LYS . . . -165.91 -156.04 9.12 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 -179.544 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.732 HG23 ' O ' ' A' ' 26' ' ' THR . 14.8 t -122.28 106.92 11.54 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.682 -0.893 . . . . 0.0 109.872 179.639 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.516 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 37.9 t -62.75 -35.86 81.16 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.199 -0.938 . . . . 0.0 110.3 -179.452 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -169.08 -163.4 23.05 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.588 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.3 m -88.29 -43.3 0.47 Allowed Pre-proline 0 C--N 1.303 -1.422 0 O-C-N 121.062 -1.258 . . . . 0.0 110.32 179.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.588 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.8 Cg_endo -81.18 5.64 6.12 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.525 1.276 . . . . 0.0 109.572 179.307 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 63.7 m-85 -153.0 169.47 22.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.275 -0.891 . . . . 0.0 110.486 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.502 ' HB3' ' CE ' ' A' ' 23' ' ' LYS . 96.0 mttt -136.75 158.45 44.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.437 -0.789 . . . . 0.0 109.69 179.497 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.516 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 59.5 m -80.68 120.14 24.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.126 -0.983 . . . . 0.0 109.471 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.9 m -143.4 134.5 25.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.227 -0.921 . . . . 0.0 110.457 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.914 -1.041 . . . . 0.0 109.952 179.709 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.407 ' O ' ' SG ' ' A' ' 6' ' ' CYS . 45.3 t . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.279 0.561 . . . . 0.0 110.099 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.3 pt -113.73 -9.56 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.267 -0.896 . . . . 0.0 110.218 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 95.0 mtt-85 -65.8 -35.91 82.04 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.09 -1.006 . . . . 0.0 110.106 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.0 m120 -96.41 5.94 49.81 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.252 -0.905 . . . . 0.0 110.2 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 74.15 18.21 79.7 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.91 175.59 51.97 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.501 HG22 ' N ' ' A' ' 13' ' ' CYS . 56.4 mt -120.56 170.27 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -1.137 . . . . 0.0 110.307 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.501 ' N ' HG22 ' A' ' 12' ' ' ILE . 3.0 m -117.72 154.03 32.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.22 -0.925 . . . . 0.0 110.178 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.523 ' O ' ' N ' ' A' ' 32' ' ' LYS . 8.0 tt0 -160.38 151.2 18.75 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.646 -0.658 . . . . 0.0 109.567 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 31' ' ' PHE . 83.8 t80 -55.53 -37.75 68.34 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.028 -1.045 . . . . 0.0 110.606 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.403 ' HG3' ' N ' ' A' ' 17' ' ' CYS . 14.2 tpt180 -146.05 163.1 36.32 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.255 -0.903 . . . . 0.0 110.233 -179.782 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.403 ' N ' ' HG3' ' A' ' 16' ' ' ARG . 20.1 m -139.37 125.63 20.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.468 -0.77 . . . . 0.0 109.789 179.545 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.0 pt -138.13 165.23 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.261 -0.9 . . . . 0.0 110.313 -179.697 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.11 -155.42 26.33 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.567 HD22 ' N ' ' A' ' 20' ' ' LEU . 4.5 mm? -61.78 -28.1 69.21 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.351 -1.087 . . . . 0.0 110.202 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 94.1 mtt180 -53.03 135.52 36.92 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.266 -0.896 . . . . 0.0 110.296 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -113.1 156.11 23.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.332 -0.855 . . . . 0.0 110.073 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 81.6 tttt -101.81 107.62 18.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.188 -0.945 . . . . 0.0 110.177 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 67.7 mt -76.98 -33.71 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.899 . . . . 0.0 110.215 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.485 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -169.71 -169.56 33.1 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 75.2 p -105.95 99.17 8.78 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.394 -1.063 . . . . 0.0 110.474 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.468 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 38.6 t -54.28 -40.05 67.48 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.169 -0.957 . . . . 0.0 109.722 179.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -155.99 -165.68 14.85 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 108.598 -1.801 . . . . 0.0 108.598 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.6 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 9.0 m -87.18 -42.97 0.53 Allowed Pre-proline 0 C--N 1.299 -1.625 0 O-C-N 121.128 -1.219 . . . . 0.0 109.825 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.6 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.0 Cg_endo -82.23 7.66 4.97 Favored 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.49 1.258 . . . . 0.0 109.691 178.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.579 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 90.5 m-85 -152.36 169.86 21.51 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.299 -0.876 . . . . 0.0 110.64 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 14' ' ' GLN . 96.3 mttt -130.9 159.36 37.65 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.012 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.485 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 47.2 t -85.51 121.18 27.85 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.962 -1.087 . . . . 0.0 109.801 179.759 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 97.3 m -138.21 141.87 39.98 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 110.342 -179.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.436 ' OXT' ' HG2' ' A' ' 35' ' ' LYS . 88.0 tttt . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.164 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.527 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 10.1 t . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 121.176 0.512 . . . . 0.0 110.468 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.474 HG13 ' N ' ' A' ' 8' ' ' ARG . 50.0 pt -71.17 -30.52 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.188 -0.945 . . . . 0.0 110.015 -179.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.474 ' N ' HG13 ' A' ' 7' ' ' ILE . 51.0 ttt85 -66.21 -54.8 20.84 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.433 -0.792 . . . . 0.0 110.083 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -142.67 9.42 1.78 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.407 -0.808 . . . . 0.0 110.459 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.527 ' HA3' ' HA ' ' A' ' 6' ' ' CYS . . . -83.65 -30.15 30.48 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.764 -1.335 . . . . 0.0 109.764 -179.763 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 129.61 -155.92 21.11 Favored Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.599 -1.286 . . . . 0.0 109.89 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.487 HG22 ' N ' ' A' ' 13' ' ' CYS . 41.2 mt -96.34 171.0 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 O-C-N 121.692 -0.887 . . . . 0.0 109.668 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.1 m -139.7 153.39 47.22 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.069 -1.019 . . . . 0.0 110.414 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -161.09 157.21 25.69 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.726 -0.609 . . . . 0.0 109.908 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.473 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 87.5 m-85 -44.91 -37.31 3.84 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.16 -0.962 . . . . 0.0 110.206 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.431 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 25.7 mmm180 -147.31 147.11 30.03 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.321 -0.862 . . . . 0.0 110.128 179.768 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.1 m -111.56 130.25 55.8 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.24 -0.912 . . . . 0.0 110.065 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 43.3 pt -127.9 172.42 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.159 -0.963 . . . . 0.0 110.321 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.14 -156.04 23.31 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.642 ' N ' HD12 ' A' ' 20' ' ' LEU . 10.4 mp -87.26 -5.12 59.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.181 -1.188 . . . . 0.0 110.214 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 74.4 mtm180 -61.07 148.35 40.66 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.298 -0.876 . . . . 0.0 110.358 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.516 ' CE1' ' O ' ' A' ' 20' ' ' LEU . 63.4 m80 -119.01 143.65 46.95 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.362 -0.836 . . . . 0.0 110.17 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.523 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 36.4 ttpt -93.79 117.79 30.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.174 -0.954 . . . . 0.0 110.318 -179.757 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 22.4 pt -96.93 -8.79 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.16 -0.962 . . . . 0.0 110.176 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.27 -170.57 37.69 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 32' ' ' LYS . 81.7 p -129.82 108.28 10.03 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.278 -1.131 . . . . 0.0 110.347 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.457 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 46.6 m -51.99 -36.03 48.48 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.24 -0.913 . . . . 0.0 109.706 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -159.22 -159.37 9.67 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.589 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 16.9 m -90.12 -41.88 0.41 Allowed Pre-proline 0 C--N 1.302 -1.476 0 O-C-N 121.09 -1.241 . . . . 0.0 110.553 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.589 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.4 Cg_endo -80.24 6.64 5.21 Favored 'Trans proline' 0 C--N 1.311 -1.442 0 O-C-N 123.416 1.219 . . . . 0.0 109.845 179.445 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.527 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 45.4 m-85 -146.06 179.8 7.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.349 -0.845 . . . . 0.0 110.262 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.525 ' HA ' ' HA ' ' A' ' 26' ' ' THR . 91.3 mttt -143.28 170.31 16.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.525 -0.734 . . . . 0.0 109.065 179.228 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.523 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 38.4 t -96.55 115.87 28.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.783 -1.198 . . . . 0.0 109.969 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 84.6 m -141.89 138.04 31.78 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.095 -1.003 . . . . 0.0 110.143 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.178 179.756 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 10.5 t . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.201 0.524 . . . . 0.0 110.157 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.6 tt -60.38 -32.53 51.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.157 -0.964 . . . . 0.0 110.405 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 84.3 mtt180 -60.55 -33.54 72.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.212 -0.93 . . . . 0.0 110.254 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 91.0 m-20 -62.02 -25.34 67.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 110.175 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.62 13.09 23.2 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.28 -172.74 44.66 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.0 pt -129.77 151.51 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.264 -1.139 . . . . 0.0 110.177 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.532 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 1.8 m -91.11 151.96 20.79 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.028 -1.045 . . . . 0.0 109.993 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.549 ' O ' ' N ' ' A' ' 32' ' ' LYS . 55.2 tt0 -146.23 150.68 36.27 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.401 -0.812 . . . . 0.0 109.881 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.576 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 62.0 t80 -59.1 -46.01 89.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.065 -1.022 . . . . 0.0 110.58 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.576 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 19.4 mmt180 -148.92 140.81 23.72 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.289 -0.882 . . . . 0.0 110.325 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 40.5 m -116.63 142.66 46.6 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.435 -0.791 . . . . 0.0 109.847 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.719 HG22 ' H ' ' A' ' 19' ' ' GLY . 3.4 mm -90.85 -168.96 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.155 -0.965 . . . . 0.0 110.149 -179.732 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.719 ' H ' HG22 ' A' ' 18' ' ' ILE . . . -69.99 -30.9 69.7 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.925 -1.67 . . . . 0.0 108.925 179.792 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.589 ' N ' HD12 ' A' ' 20' ' ' LEU . 9.4 mp -63.77 -29.57 70.77 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.427 -1.043 . . . . 0.0 110.19 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 82.5 mtt-85 -105.34 128.27 53.4 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.189 -0.944 . . . . 0.0 110.562 -179.611 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 61.6 m170 -94.53 143.0 26.78 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.269 -0.894 . . . . 0.0 110.44 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.485 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 34.2 ttpt -109.26 117.38 33.94 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.257 -0.902 . . . . 0.0 110.61 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 80.4 mt -73.55 -35.38 44.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.187 -0.946 . . . . 0.0 109.826 179.578 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.483 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -160.72 -170.87 25.91 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.448 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 51.6 m -107.94 103.61 12.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.176 -1.191 . . . . 0.0 110.305 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.426 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 42.0 t -53.11 -48.28 67.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.299 -0.875 . . . . 0.0 109.967 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.448 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -149.59 -165.29 12.3 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 108.906 -1.677 . . . . 0.0 108.906 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.599 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.3 m -89.32 -42.3 0.43 Allowed Pre-proline 0 C--N 1.303 -1.444 0 O-C-N 121.095 -1.238 . . . . 0.0 110.417 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.599 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.2 Cg_endo -81.82 6.68 5.51 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.474 1.249 . . . . 0.0 109.715 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.497 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 97.9 m-85 -152.48 173.71 14.8 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.308 -0.87 . . . . 0.0 110.197 179.632 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.549 ' N ' ' O ' ' A' ' 14' ' ' GLN . 62.0 mttm -136.41 155.96 49.29 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.458 -0.776 . . . . 0.0 109.147 179.452 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.485 ' O ' ' HG3' ' A' ' 23' ' ' LYS . 50.4 t -87.72 115.06 24.9 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.177 -0.952 . . . . 0.0 110.73 -179.67 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 56.3 m -132.39 145.64 51.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.262 -0.899 . . . . 0.0 109.956 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 56.7 tttp . . . . . 0 N--CA 1.492 1.64 0 O-C-N 121.089 -1.007 . . . . 0.0 110.348 -179.815 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.699 ' SG ' HG22 ' A' ' 24' ' ' ILE . 13.1 t . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 121.301 0.572 . . . . 0.0 110.431 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.46 HG13 ' N ' ' A' ' 8' ' ' ARG . 42.5 pt -57.46 -25.49 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.344 -0.847 . . . . 0.0 110.295 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.46 ' N ' HG13 ' A' ' 7' ' ' ILE . 67.8 ttt180 -58.72 -36.17 73.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.221 -0.924 . . . . 0.0 110.473 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 23.8 m120 -67.66 -28.34 67.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.223 -0.923 . . . . 0.0 110.364 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.83 8.0 16.5 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.64 179.62 52.97 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.6 pt -124.05 159.13 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.238 -1.154 . . . . 0.0 110.322 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.514 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 1.7 m -99.49 154.63 18.09 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.274 -0.891 . . . . 0.0 109.835 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.521 ' O ' ' N ' ' A' ' 32' ' ' LYS . 37.6 tp60 -156.74 154.77 30.53 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.223 -0.923 . . . . 0.0 109.887 179.722 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.605 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 50.2 t80 -58.86 -49.28 78.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.124 -0.985 . . . . 0.0 110.231 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.605 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 13.9 mmt85 -145.07 151.34 38.36 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.437 -0.789 . . . . 0.0 110.458 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.527 ' HB2' ' NE ' ' A' ' 21' ' ' ARG . 87.6 m -118.83 178.58 4.43 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.331 -0.856 . . . . 0.0 109.844 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.429 ' O ' ' O ' ' A' ' 19' ' ' GLY . 47.1 pt -101.78 175.3 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.091 -1.006 . . . . 0.0 110.485 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' A' ' 18' ' ' ILE . . . -50.03 178.78 0.03 OUTLIER Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.844 ' N ' HD22 ' A' ' 20' ' ' LEU . 2.7 mm? 46.47 42.3 10.67 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.319 -1.106 . . . . 0.0 109.37 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.527 ' NE ' ' HB2' ' A' ' 17' ' ' CYS . 25.5 ttm180 -79.52 134.85 36.51 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 110.631 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 70.0 m-70 -99.77 37.01 1.68 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 179.328 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.492 ' HE2' ' O ' ' A' ' 25' ' ' GLY . 60.8 tttt -73.36 108.92 6.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.413 -0.804 . . . . 0.0 110.534 -179.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.699 HG22 ' SG ' ' A' ' 6' ' ' CYS . 7.6 tp -78.68 -18.04 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.244 -0.91 . . . . 0.0 109.63 179.599 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.492 ' O ' ' HE2' ' A' ' 23' ' ' LYS . . . -165.46 -173.42 33.99 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.737 HG22 ' O ' ' A' ' 28' ' ' GLY . 92.5 m -109.62 107.06 16.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.136 -1.214 . . . . 0.0 110.261 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.435 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 48.8 t -46.12 -63.72 0.92 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.399 -0.813 . . . . 0.0 109.687 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.737 ' O ' HG22 ' A' ' 26' ' ' THR . . . -129.63 -170.47 12.75 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 179.425 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.596 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.9 m -85.88 -42.19 0.61 Allowed Pre-proline 0 C--N 1.303 -1.445 0 O-C-N 121.01 -1.288 . . . . 0.0 109.898 179.484 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.603 ' HG2' ' CD2' ' A' ' 31' ' ' PHE . 52.0 Cg_endo -81.39 6.0 5.9 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 O-C-N 123.557 1.293 . . . . 0.0 109.428 179.189 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.603 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 86.8 m-85 -148.18 170.15 18.48 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.116 -0.99 . . . . 0.0 110.538 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.521 ' N ' ' O ' ' A' ' 14' ' ' GLN . 89.9 mttt -133.37 156.12 48.23 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.6 -0.688 . . . . 0.0 109.285 179.028 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.44 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 50.7 t -89.62 123.59 33.81 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.165 -0.96 . . . . 0.0 109.907 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.401 ' SG ' ' HD3' ' A' ' 21' ' ' ARG . 33.3 m -138.02 130.75 29.68 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 110.085 -179.796 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 86.2 tttt . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 118.041 -0.98 . . . . 0.0 110.171 -179.971 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 86.2 m . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 121.235 0.541 . . . . 0.0 110.334 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.476 HG23 ' N ' ' A' ' 8' ' ' ARG . 16.2 tt -61.43 -36.75 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.232 -0.918 . . . . 0.0 110.389 -179.658 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.476 ' N ' HG23 ' A' ' 7' ' ' ILE . 76.8 ttt-85 -53.12 -39.2 63.27 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.135 -0.978 . . . . 0.0 110.294 -179.849 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -65.59 -23.73 66.9 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.41 -0.806 . . . . 0.0 110.328 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 111.4 5.76 26.05 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.18 175.67 43.12 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.561 HG22 ' N ' ' A' ' 13' ' ' CYS . 72.9 mt -127.83 171.96 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.273 -1.133 . . . . 0.0 110.021 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.561 ' N ' HG22 ' A' ' 12' ' ' ILE . 1.5 m -102.49 147.84 26.26 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.177 -0.952 . . . . 0.0 109.752 179.565 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.515 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 27.2 tp60 -148.86 152.72 36.96 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.517 -0.739 . . . . 0.0 109.643 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.468 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 97.8 m-85 -60.34 -42.25 95.3 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.229 -0.919 . . . . 0.0 110.698 -179.537 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.432 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 29.2 mmm180 -149.3 142.22 24.76 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.233 -0.917 . . . . 0.0 110.605 -179.68 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 67.5 m -119.94 126.52 51.08 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.304 -0.873 . . . . 0.0 109.955 179.598 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.0 pt -143.35 168.04 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.124 -0.985 . . . . 0.0 110.456 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 66.39 -135.56 33.9 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 35.9 mt -59.38 -34.74 72.78 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.395 -1.062 . . . . 0.0 110.273 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -71.49 132.32 44.57 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.346 -0.846 . . . . 0.0 110.651 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 74.7 t60 -133.86 153.55 51.66 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.334 -0.854 . . . . 0.0 109.879 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.502 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 0.0 OUTLIER -110.61 124.45 51.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.111 -0.993 . . . . 0.0 110.731 -179.746 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 23.7 pt -103.66 -5.87 9.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.317 -0.864 . . . . 0.0 109.853 179.579 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.435 ' N ' ' HB2' ' A' ' 33' ' ' CYS . . . -159.41 -169.89 23.3 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.757 -1.737 . . . . 0.0 108.757 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.761 HG23 ' O ' ' A' ' 26' ' ' THR . 14.8 t -128.47 105.36 8.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.073 -1.251 . . . . 0.0 110.636 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.528 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 53.6 t -60.29 -29.6 68.93 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.283 -0.886 . . . . 0.0 109.43 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -168.7 -163.05 22.04 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.603 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 63.5 m -88.02 -41.58 0.49 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 120.891 -1.358 . . . . 0.0 109.999 179.488 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.603 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.4 Cg_endo -82.76 8.2 4.72 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.43 1.226 . . . . 0.0 109.519 179.003 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.571 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 97.7 m-85 -147.72 173.79 12.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.339 -0.851 . . . . 0.0 110.771 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -136.86 159.62 41.33 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.605 -0.684 . . . . 0.0 109.317 179.362 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.528 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 91.0 m -80.09 105.04 11.07 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.003 -1.061 . . . . 0.0 109.984 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 64.2 m -130.45 147.93 52.2 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.187 -0.946 . . . . 0.0 110.375 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.429 ' OXT' ' HG3' ' A' ' 35' ' ' LYS . 64.4 pttt . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.19 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 32.8 t . . . . . 0 N--CA 1.491 1.603 0 CA-C-O 121.403 0.62 . . . . 0.0 110.099 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.813 HD13 ' O ' ' A' ' 11' ' ' GLY . 1.0 OUTLIER -69.31 -37.07 75.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.337 -0.852 . . . . 0.0 109.878 179.876 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 23.3 ttp180 -56.98 -32.7 66.35 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.243 -0.911 . . . . 0.0 110.535 -179.611 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -59.77 -30.16 68.69 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.197 -0.939 . . . . 0.0 109.746 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 124.04 14.09 3.85 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 179.433 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.813 ' O ' HD13 ' A' ' 7' ' ' ILE . . . -101.77 175.41 25.34 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.714 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.465 ' HA ' HD11 ' A' ' 7' ' ' ILE . 25.7 mt -119.03 169.54 9.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.27 -1.135 . . . . 0.0 110.026 179.743 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.511 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 1.9 m -112.17 153.18 27.43 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.153 -0.967 . . . . 0.0 110.071 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.518 ' O ' ' N ' ' A' ' 32' ' ' LYS . 11.9 tp60 -152.03 154.37 35.85 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.31 -0.869 . . . . 0.0 109.863 179.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.575 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 58.6 t80 -56.35 -37.5 70.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.107 -0.996 . . . . 0.0 110.258 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.575 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 35.2 mmt180 -146.14 157.49 43.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.256 -0.902 . . . . 0.0 110.228 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -122.53 154.63 37.63 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.244 -0.91 . . . . 0.0 110.333 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.471 HG13 ' HB2' ' A' ' 20' ' ' LEU . 14.6 pt -106.89 161.64 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.213 -0.929 . . . . 0.0 110.219 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.86 -29.42 54.95 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.579 ' N ' HD12 ' A' ' 20' ' ' LEU . 10.0 mp -65.04 -34.67 78.98 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.173 -1.192 . . . . 0.0 110.422 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.1 mtt180 -93.68 137.22 33.16 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.204 -0.935 . . . . 0.0 110.307 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -83.73 134.79 34.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.189 -0.944 . . . . 0.0 110.235 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.415 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 87.0 tttt -98.85 98.57 9.64 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.23 -0.919 . . . . 0.0 110.21 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 89.1 mt -66.78 -33.47 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.286 -0.884 . . . . 0.0 110.314 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.452 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -175.83 -167.14 34.34 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 64.6 p -104.88 104.15 13.87 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.426 -1.044 . . . . 0.0 110.462 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.434 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 49.9 t -56.09 -43.03 77.65 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.266 -0.896 . . . . 0.0 109.83 179.62 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -154.09 -166.57 15.06 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 179.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.596 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.1 m -88.6 -42.32 0.46 Allowed Pre-proline 0 C--N 1.301 -1.525 0 O-C-N 121.077 -1.249 . . . . 0.0 110.232 179.679 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.598 ' HG2' ' CD2' ' A' ' 31' ' ' PHE . 47.8 Cg_endo -81.83 6.59 5.57 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 O-C-N 123.504 1.265 . . . . 0.0 109.949 179.26 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.598 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 83.2 m-85 -151.57 170.78 18.83 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.153 -0.967 . . . . 0.0 110.409 179.728 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.518 ' N ' ' O ' ' A' ' 14' ' ' GLN . 94.4 mttt -132.7 156.89 46.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.336 -0.853 . . . . 0.0 109.653 179.524 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.452 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 9.8 t -84.48 121.6 27.81 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.225 -0.922 . . . . 0.0 110.143 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 71.6 m -133.59 132.75 41.21 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.315 -0.866 . . . . 0.0 110.25 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 84.6 tttt . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.119 179.929 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.45 ' O ' ' OD1' ' A' ' 9' ' ' ASN . 80.8 m . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 121.296 0.57 . . . . 0.0 110.385 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.451 ' HA ' ' O ' ' A' ' 11' ' ' GLY . 5.7 tt -58.19 -17.28 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.182 -0.949 . . . . 0.0 110.189 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 9.1 tpm_? -66.63 -33.76 76.37 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.223 -0.923 . . . . 0.0 110.247 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.454 ' OD1' ' N ' ' A' ' 11' ' ' GLY . 47.4 p30 -84.98 4.98 31.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.149 -0.969 . . . . 0.0 110.182 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.76 -5.04 53.71 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.454 ' N ' ' OD1' ' A' ' 9' ' ' ASN . . . -72.63 175.78 43.44 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.581 HG22 ' N ' ' A' ' 13' ' ' CYS . 70.1 mt -130.82 174.41 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -1.114 . . . . 0.0 110.198 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.581 ' N ' HG22 ' A' ' 12' ' ' ILE . 2.6 m -127.16 150.68 49.4 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.213 -0.929 . . . . 0.0 110.174 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.506 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 4.4 tp-100 -156.04 151.74 27.22 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.677 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.537 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 73.6 t80 -56.98 -31.64 65.26 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.113 -0.992 . . . . 0.0 110.396 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.537 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 38.0 mmt180 -151.63 150.94 30.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.358 -0.839 . . . . 0.0 110.23 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 96.3 m -121.55 125.91 47.9 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.286 -0.884 . . . . 0.0 110.304 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.44 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 36.8 pt -62.27 166.41 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.239 -0.913 . . . . 0.0 110.126 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.85 -42.4 59.73 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.727 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.44 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 32.8 mt -51.86 -28.58 16.46 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.325 -1.103 . . . . 0.0 110.31 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 61.5 mtt-85 -117.66 118.95 33.49 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.235 -0.915 . . . . 0.0 110.487 -179.742 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -97.99 144.77 27.17 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.883 . . . . 0.0 109.814 179.741 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.492 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -99.78 107.0 18.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.133 -0.979 . . . . 0.0 110.643 -179.718 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 51.3 mm -64.08 -35.63 74.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.253 -0.904 . . . . 0.0 110.19 179.741 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.479 ' C ' ' HB2' ' A' ' 33' ' ' CYS . . . -141.56 -162.77 9.3 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.631 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.537 HG22 ' O ' ' A' ' 28' ' ' GLY . 90.0 m -122.44 108.61 13.39 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.476 -1.014 . . . . 0.0 110.286 179.692 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.517 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 10.9 t -58.64 -32.59 69.2 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.224 -0.922 . . . . 0.0 109.587 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.537 ' O ' HG22 ' A' ' 26' ' ' THR . . . -172.02 -158.35 15.93 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.709 -1.757 . . . . 0.0 108.709 179.621 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.591 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.7 m -88.97 -43.09 0.44 Allowed Pre-proline 0 C--N 1.302 -1.485 0 O-C-N 120.839 -1.389 . . . . 0.0 110.215 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.591 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.2 Cg_endo -83.52 10.22 3.77 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.557 1.293 . . . . 0.0 109.533 179.009 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.541 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 79.0 m-85 -154.21 171.11 19.72 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.342 -0.849 . . . . 0.0 110.737 -179.861 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.486 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 95.5 mttt -134.32 161.28 35.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.588 -0.695 . . . . 0.0 109.196 179.168 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.517 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 58.0 m -80.37 100.06 8.25 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.063 -1.023 . . . . 0.0 110.185 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.468 ' SG ' ' HB3' ' A' ' 23' ' ' LYS . 19.8 m -129.38 158.35 39.38 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.143 -0.973 . . . . 0.0 110.339 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 117.936 -1.03 . . . . 0.0 109.999 179.732 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 84.3 m-20 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.243 0.544 . . . . 0.0 110.203 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.586 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 33.4 mp0 -59.8 -41.7 87.09 Favored Pre-proline 0 N--CA 1.492 1.665 0 O-C-N 121.282 -0.886 . . . . 0.0 111.374 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 48.9 Cg_endo -77.22 -6.63 16.65 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 O-C-N 123.369 1.194 . . . . 0.0 110.605 -179.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.577 HG12 ' N ' ' A' ' 5' ' ' SER . 60.0 t 56.0 173.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.118 -0.989 . . . . 0.0 110.255 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.826 ' OG ' HG22 ' A' ' 7' ' ' ILE . 74.9 p -67.7 177.15 2.15 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.235 -0.916 . . . . 0.0 110.35 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 28.4 t -61.64 -19.93 62.83 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.329 -0.857 . . . . 0.0 110.482 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.826 HG22 ' OG ' ' A' ' 5' ' ' SER . 9.9 tt -57.47 -32.37 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.163 -0.961 . . . . 0.0 110.646 -179.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.467 ' HD2' ' HB ' ' A' ' 4' ' ' VAL . 59.4 ttt180 -56.08 -31.83 63.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 110.485 -179.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -66.03 -30.38 70.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.263 -0.898 . . . . 0.0 110.239 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.04 5.85 21.26 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -82.59 -178.49 52.39 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 23.8 mm -112.1 166.64 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.146 -1.208 . . . . 0.0 110.273 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.532 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.4 m -120.22 153.79 35.79 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.183 -0.948 . . . . 0.0 109.998 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.511 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 20.0 tp60 -153.7 154.93 35.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.434 -0.791 . . . . 0.0 109.714 179.689 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.564 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 72.5 t80 -59.88 -36.39 76.84 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.164 -0.96 . . . . 0.0 110.252 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.564 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 38.8 mmt180 -148.42 152.44 36.97 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.344 -0.848 . . . . 0.0 109.958 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 69.5 m -123.03 152.25 41.13 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.128 -0.982 . . . . 0.0 110.289 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.7 pt -103.82 165.92 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.326 -0.858 . . . . 0.0 109.899 179.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.78 -42.75 37.72 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.834 HD13 ' O ' ' A' ' 20' ' ' LEU . 3.3 tm? -51.01 -35.15 32.49 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.177 -1.19 . . . . 0.0 110.404 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.8 mtp180 -89.87 150.16 22.34 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.186 -0.946 . . . . 0.0 110.485 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 92.4 m-70 -108.3 141.21 40.43 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.313 -0.867 . . . . 0.0 109.818 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.446 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 76.4 tttt -121.83 121.93 38.3 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.179 -0.95 . . . . 0.0 110.74 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 28.8 pt -101.43 -6.3 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.388 -0.82 . . . . 0.0 109.793 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.459 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -178.17 -174.22 44.27 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.697 HG22 ' O ' ' A' ' 28' ' ' GLY . 89.1 m -111.27 111.04 21.82 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.177 -1.19 . . . . 0.0 110.31 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.411 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 38.9 t -53.71 -48.18 69.81 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.225 -0.922 . . . . 0.0 109.958 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.697 ' O ' HG22 ' A' ' 26' ' ' THR . . . -149.84 -163.29 11.01 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.582 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 9.7 m -89.81 -42.94 0.42 Allowed Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 120.998 -1.295 . . . . 0.0 110.221 179.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.584 ' O ' ' CD1' ' A' ' 31' ' ' PHE . 50.4 Cg_endo -82.27 7.21 5.24 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.499 1.263 . . . . 0.0 109.555 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.584 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 57.7 m-85 -151.87 169.21 22.84 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.324 -0.86 . . . . 0.0 110.284 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.532 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 93.2 mttt -131.21 157.3 43.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.342 -0.849 . . . . 0.0 109.656 179.285 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.459 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 42.3 t -84.77 119.01 24.81 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.095 -1.003 . . . . 0.0 110.255 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 97.8 m -145.44 157.24 44.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.293 -0.879 . . . . 0.0 110.315 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.209 179.877 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 24.3 m120 . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 121.329 0.585 . . . . 0.0 110.165 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.6 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 63.6 mm-40 -59.6 -42.99 94.76 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.276 -0.89 . . . . 0.0 110.989 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.6 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.4 Cg_endo -74.98 -11.11 21.5 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.333 1.175 . . . . 0.0 110.467 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.595 HG12 ' N ' ' A' ' 5' ' ' SER . 59.0 t 51.69 173.49 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.278 -0.889 . . . . 0.0 110.374 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.595 ' N ' HG12 ' A' ' 4' ' ' VAL . 68.0 m -105.42 129.39 53.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.3 -0.875 . . . . 0.0 109.987 179.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 7.3 t -62.33 -31.61 72.26 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.289 -0.882 . . . . 0.0 110.525 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.5 HG12 ' HB3' ' A' ' 5' ' ' SER . 36.5 pt -60.03 -14.66 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.18 -0.95 . . . . 0.0 110.264 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 78.0 mmt-85 -64.38 -34.91 79.25 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.294 -0.879 . . . . 0.0 110.117 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -65.58 -26.18 67.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.337 -0.852 . . . . 0.0 110.027 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.89 -1.07 13.51 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.79 -176.73 50.97 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.4 pt -128.63 163.77 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.348 -1.089 . . . . 0.0 110.002 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.521 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.2 m -103.38 154.41 19.44 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.092 -1.005 . . . . 0.0 109.951 -179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.533 ' O ' ' N ' ' A' ' 32' ' ' LYS . 4.9 tp60 -149.42 151.26 33.72 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.306 -0.871 . . . . 0.0 109.989 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.457 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 67.6 t80 -55.21 -44.66 75.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 110.131 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.457 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 48.3 mmm-85 -150.23 143.0 24.69 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.363 -0.836 . . . . 0.0 110.233 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 90.4 m -109.49 153.25 24.33 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.25 -0.907 . . . . 0.0 110.127 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.553 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 38.3 pt -103.76 176.45 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.274 -0.891 . . . . 0.0 110.233 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.72 -33.04 81.01 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.622 ' N ' HD22 ' A' ' 20' ' ' LEU . 3.9 mm? -61.2 -34.93 75.88 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -1.162 . . . . 0.0 110.056 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -99.45 149.04 23.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.259 -0.901 . . . . 0.0 110.063 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 72.8 m80 -107.74 134.79 50.2 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.188 -0.945 . . . . 0.0 110.213 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 35.6 tttm -97.22 107.26 19.75 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.325 -0.859 . . . . 0.0 110.239 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.42 HG23 ' N ' ' A' ' 25' ' ' GLY . 18.9 tt -69.74 -32.44 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 110.179 179.762 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.444 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -166.41 -173.17 34.54 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.618 HG22 ' O ' ' A' ' 28' ' ' GLY . 61.8 m -104.25 100.04 9.77 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.244 -1.15 . . . . 0.0 110.309 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.431 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 35.9 t -52.22 -43.88 64.49 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.202 -0.936 . . . . 0.0 109.734 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.618 ' O ' HG22 ' A' ' 26' ' ' THR . . . -154.59 -163.37 11.92 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 179.737 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.584 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 15.8 m -90.46 -41.86 0.4 Allowed Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.035 -1.274 . . . . 0.0 110.34 179.695 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.584 ' CD ' ' N ' ' A' ' 29' ' ' SER . 45.8 Cg_endo -81.92 7.0 5.32 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.466 1.245 . . . . 0.0 109.785 179.084 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.581 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 88.9 m-85 -153.65 170.96 19.58 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.263 -0.898 . . . . 0.0 110.351 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 14' ' ' GLN . 61.5 mttm -133.19 156.55 47.29 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.472 -0.768 . . . . 0.0 109.635 179.512 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 10.8 t -84.74 113.06 21.04 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.243 -0.911 . . . . 0.0 110.282 -179.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.7 m -138.84 143.22 38.72 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.345 -0.847 . . . . 0.0 110.064 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.257 -179.858 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . 0.418 ' O ' ' O ' ' A' ' 4' ' ' VAL . 83.5 m-20 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.437 0.637 . . . . 0.0 110.072 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.607 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 34.7 tt0 -74.75 -39.46 3.57 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.872 . . . . 0.0 111.411 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.607 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.5 Cg_endo -76.23 -14.41 18.57 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.187 1.098 . . . . 0.0 110.789 -179.296 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.418 ' O ' ' O ' ' A' ' 1' ' ' ASN . 15.5 m -135.87 146.8 28.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.154 -0.966 . . . . 0.0 110.351 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 62.8 m -114.99 144.2 43.97 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.223 -0.923 . . . . 0.0 110.159 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 34.4 t -63.22 -28.59 70.14 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.146 -0.972 . . . . 0.0 110.184 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.432 ' HA ' HD12 ' A' ' 7' ' ' ILE . 6.0 tp -52.18 -28.48 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.404 -0.81 . . . . 0.0 110.385 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 48.6 ttp180 -57.16 -31.55 65.51 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.169 -0.957 . . . . 0.0 110.469 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -67.14 -30.6 70.64 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.286 -0.884 . . . . 0.0 110.25 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 116.06 8.28 13.62 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -85.83 -177.19 50.19 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 34.8 pt -116.62 162.35 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.185 -1.185 . . . . 0.0 110.064 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.521 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.1 m -113.19 155.1 25.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.121 -0.987 . . . . 0.0 110.141 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 65.2 tt0 -154.29 155.46 35.21 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.404 -0.81 . . . . 0.0 109.835 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.596 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 60.1 t80 -57.79 -44.69 86.44 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.177 -0.952 . . . . 0.0 110.257 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.596 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 41.0 mmt180 -145.95 150.2 35.62 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.35 -0.844 . . . . 0.0 110.267 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.1 m -120.62 126.06 49.31 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.211 -0.931 . . . . 0.0 110.052 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.5 pt -134.03 165.32 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.227 -0.921 . . . . 0.0 110.205 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.91 -169.73 40.78 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 94.8 mt -51.78 -29.99 21.14 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.34 -1.094 . . . . 0.0 110.273 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 81.0 mtm180 -53.08 148.98 7.23 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.246 -0.909 . . . . 0.0 110.278 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 45.8 p-80 -135.18 164.46 27.62 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.27 -0.894 . . . . 0.0 109.968 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.473 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 68.5 tttt -112.69 99.06 7.64 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.12 -0.987 . . . . 0.0 110.519 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.421 HD12 ' HE3' ' A' ' 35' ' ' LYS . 90.1 mt -60.52 -43.43 94.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.288 -0.883 . . . . 0.0 110.069 179.68 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.459 ' O ' ' HE2' ' A' ' 23' ' ' LYS . . . -144.06 -173.77 15.77 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.569 HG22 ' O ' ' A' ' 28' ' ' GLY . 90.2 m -108.9 105.5 15.08 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.265 -1.138 . . . . 0.0 110.366 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.445 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 48.6 t -55.67 -44.25 77.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -0.929 . . . . 0.0 109.767 179.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.569 ' O ' HG22 ' A' ' 26' ' ' THR . . . -152.41 -167.11 14.91 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.805 -1.718 . . . . 0.0 108.805 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.606 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 2.0 m -87.36 -43.18 0.52 Allowed Pre-proline 0 C--N 1.299 -1.602 0 O-C-N 121.227 -1.16 . . . . 0.0 110.003 179.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.606 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.3 Cg_endo -83.3 7.63 5.09 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 O-C-N 123.628 1.33 . . . . 0.0 109.564 179.153 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.562 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 88.6 m-85 -152.07 170.63 19.45 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -0.893 . . . . 0.0 110.207 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.521 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 92.2 mttt -134.03 156.4 48.28 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.529 -0.732 . . . . 0.0 109.634 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 42.6 t -84.62 121.51 27.73 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.138 -0.976 . . . . 0.0 110.23 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 65.9 m -142.18 139.5 32.08 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.251 -0.905 . . . . 0.0 110.258 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.421 ' HE3' HD12 ' A' ' 24' ' ' ILE . 94.8 mttt . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.078 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . 0.487 ' HB2' ' HB ' ' A' ' 4' ' ' VAL . 97.2 m-20 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.37 0.605 . . . . 0.0 110.068 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.613 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 84.0 tt0 -60.81 -41.22 81.1 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.235 -0.916 . . . . 0.0 111.419 -179.751 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.613 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 47.4 Cg_endo -75.45 -1.86 11.84 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.364 1.191 . . . . 0.0 110.762 -179.404 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 5' ' ' SER . 61.0 t -137.49 172.51 14.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.158 -0.964 . . . . 0.0 110.106 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.584 ' N ' HG12 ' A' ' 4' ' ' VAL . 21.4 t -79.15 137.11 37.33 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.247 -0.908 . . . . 0.0 110.022 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 47.7 t -61.47 -40.23 93.75 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.231 -0.918 . . . . 0.0 110.434 -179.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.539 ' H ' HD12 ' A' ' 7' ' ' ILE . 1.6 mp -63.36 -32.27 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.17 -0.957 . . . . 0.0 109.885 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 17.1 tpt180 -55.97 -36.95 68.42 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.376 -0.828 . . . . 0.0 110.332 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -77.46 -9.78 59.09 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.332 -0.855 . . . . 0.0 110.3 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.92 6.33 65.39 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -74.21 -172.26 26.91 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.494 HG22 ' N ' ' A' ' 13' ' ' CYS . 51.7 mt -122.45 169.35 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -1.161 . . . . 0.0 110.187 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.6 m -134.81 155.22 51.01 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.314 -0.866 . . . . 0.0 110.096 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.45 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 28.1 mt-30 -153.04 156.43 38.75 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.509 -0.744 . . . . 0.0 109.95 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.502 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 81.8 m-85 -52.62 -34.89 53.16 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.142 -0.974 . . . . 0.0 110.032 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.45 ' NH1' ' HE3' ' A' ' 32' ' ' LYS . 26.9 tpt180 -151.95 165.76 33.62 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.395 -0.815 . . . . 0.0 110.097 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 23.4 m -138.28 128.11 25.3 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.22 -0.925 . . . . 0.0 110.129 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 pt -142.44 167.34 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.292 -0.88 . . . . 0.0 110.171 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.44 -150.54 23.59 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.606 ' N ' HD22 ' A' ' 20' ' ' LEU . 4.2 mm? -67.69 -19.66 65.2 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.352 -1.087 . . . . 0.0 109.999 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.0 mtt180 -54.81 142.8 27.75 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.354 -0.841 . . . . 0.0 110.323 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.541 ' CD2' ' O ' ' A' ' 20' ' ' LEU . 96.4 m-70 -128.25 161.06 30.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.401 -0.812 . . . . 0.0 110.015 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.478 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 25.2 ttmt -122.54 126.61 48.14 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.198 -0.939 . . . . 0.0 110.31 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 35.0 pt -99.19 -9.6 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.263 -0.898 . . . . 0.0 110.06 179.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.461 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -173.33 -171.74 38.2 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.746 HG23 ' O ' ' A' ' 26' ' ' THR . 15.0 t -109.82 106.93 16.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.253 -1.145 . . . . 0.0 110.218 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 20.7 t -59.31 -37.8 78.66 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.211 -0.931 . . . . 0.0 110.106 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -170.3 -164.9 26.8 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.602 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 61.7 m -88.7 -41.62 0.46 Allowed Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 120.903 -1.351 . . . . 0.0 110.148 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.602 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.1 Cg_endo -82.88 8.62 4.49 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 123.504 1.265 . . . . 0.0 109.425 178.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 69.5 m-85 -155.8 172.42 18.37 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.382 -0.823 . . . . 0.0 110.469 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 65.0 mttm -135.83 158.17 45.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.557 -0.715 . . . . 0.0 109.172 178.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.478 ' O ' ' HG3' ' A' ' 23' ' ' LYS . 38.3 t -77.4 121.07 23.29 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.978 -1.076 . . . . 0.0 109.956 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 56.0 m -147.64 150.95 35.35 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.107 -0.995 . . . . 0.0 110.355 -179.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.187 179.99 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . 0.776 ' HB3' HG13 ' A' ' 4' ' ' VAL . 23.8 m120 . . . . . 0 N--CA 1.494 1.747 0 CA-C-O 121.248 0.547 . . . . 0.0 110.108 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.605 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 87.5 tt0 -70.29 -40.45 11.92 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.32 -0.863 . . . . 0.0 111.19 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.605 ' CD ' ' N ' ' A' ' 2' ' ' GLU . 47.2 Cg_endo -76.84 -3.74 14.13 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 O-C-N 123.341 1.18 . . . . 0.0 110.835 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.776 HG13 ' HB3' ' A' ' 1' ' ' ASN . 0.9 OUTLIER -136.13 171.57 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.182 -0.949 . . . . 0.0 110.1 179.504 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.56 ' N ' ' CG2' ' A' ' 4' ' ' VAL . 47.0 m 55.31 54.38 8.74 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.415 -0.803 . . . . 0.0 110.138 -179.823 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 43.0 t -63.7 -39.59 94.69 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.224 -0.922 . . . . 0.0 110.279 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.492 HG13 ' N ' ' A' ' 8' ' ' ARG . 40.8 pt -56.53 -29.05 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -0.883 . . . . 0.0 110.266 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.492 ' N ' HG13 ' A' ' 7' ' ' ILE . 58.8 ttt-85 -63.43 -41.88 98.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.247 -0.908 . . . . 0.0 110.233 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 -66.0 -26.72 67.67 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.291 -0.881 . . . . 0.0 110.176 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.4 16.34 14.89 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.87 -176.46 36.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 18.9 pt -119.67 151.04 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.262 -1.14 . . . . 0.0 110.011 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.478 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.1 m -101.52 153.13 20.0 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.147 -0.971 . . . . 0.0 109.992 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 43.6 tp60 -154.38 154.29 33.03 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.342 -0.849 . . . . 0.0 109.839 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.477 ' N ' ' HG3' ' A' ' 14' ' ' GLN . 64.2 t80 -54.89 -34.59 63.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.273 -0.892 . . . . 0.0 110.764 -179.649 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 22.1 tpp180 -156.64 164.33 38.29 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.165 -0.959 . . . . 0.0 110.218 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 93.5 m -133.43 127.8 34.15 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.299 -0.876 . . . . 0.0 110.156 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.555 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 42.7 pt -59.28 161.43 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.237 -0.914 . . . . 0.0 110.324 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.82 -35.42 52.95 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.579 ' N ' HD22 ' A' ' 20' ' ' LEU . 4.4 mm? -58.46 -28.72 65.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.285 -1.126 . . . . 0.0 110.436 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.48 ' HG2' ' HB3' ' A' ' 34' ' ' CYS . 20.5 tpp180 -106.5 130.08 54.34 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.137 -0.977 . . . . 0.0 110.479 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.424 ' H ' ' CD2' ' A' ' 22' ' ' HIS . 12.8 p80 -105.82 153.82 21.39 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.401 -0.812 . . . . 0.0 109.636 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.516 ' CB ' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -118.79 124.85 48.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.085 -1.01 . . . . 0.0 110.572 -179.761 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.578 HG22 ' HG2' ' A' ' 2' ' ' GLU . 61.0 mt -68.08 -34.85 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.931 . . . . 0.0 109.824 179.686 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.509 ' HA3' ' HA ' ' A' ' 3' ' ' PRO . . . -151.78 -169.25 17.1 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.865 HG22 ' O ' ' A' ' 28' ' ' GLY . 27.5 m -111.31 101.34 9.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -1.172 . . . . 0.0 110.39 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.417 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 40.5 t -44.54 -51.33 9.01 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.303 -0.873 . . . . 0.0 109.806 179.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.865 ' O ' HG22 ' A' ' 26' ' ' THR . . . -145.57 -164.95 11.05 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 108.587 -1.805 . . . . 0.0 108.587 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.581 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.9 m -88.27 -44.38 0.47 Allowed Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 120.821 -1.399 . . . . 0.0 110.08 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.589 ' HG2' ' CE2' ' A' ' 31' ' ' PHE . 45.2 Cg_endo -80.43 7.8 4.55 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 O-C-N 123.554 1.291 . . . . 0.0 110.083 179.203 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.589 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 89.6 m-85 -149.17 170.52 18.25 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.227 -0.921 . . . . 0.0 110.269 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.496 ' N ' ' O ' ' A' ' 14' ' ' GLN . 98.1 mttt -131.37 159.07 39.04 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.463 -0.773 . . . . 0.0 109.505 179.18 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.516 ' O ' ' CB ' ' A' ' 23' ' ' LYS . 47.8 t -84.61 115.79 22.82 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.048 -1.032 . . . . 0.0 110.406 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.48 ' HB3' ' HG2' ' A' ' 21' ' ' ARG . 71.7 m -142.54 130.86 22.2 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.136 -0.977 . . . . 0.0 110.092 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 96.2 mttt . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.26 -179.782 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 66.4 t30 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 121.207 0.527 . . . . 0.0 110.009 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.6 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 93.0 mt-10 -61.37 -42.89 87.42 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.152 -0.968 . . . . 0.0 111.054 -179.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.617 ' O ' HG22 ' A' ' 4' ' ' VAL . 48.2 Cg_endo -76.12 -5.2 16.03 Favored 'Trans proline' 0 C--N 1.31 -1.466 0 O-C-N 123.403 1.212 . . . . 0.0 110.643 -179.604 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.617 HG22 ' O ' ' A' ' 3' ' ' PRO . 13.2 m 38.5 -161.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.579 -0.701 . . . . 0.0 110.685 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.487 ' HB3' ' O ' ' A' ' 4' ' ' VAL . 22.9 t 61.01 48.07 6.83 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.547 -0.721 . . . . 0.0 110.375 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.415 ' O ' ' HB ' ' A' ' 7' ' ' ILE . 45.9 t -76.08 119.99 20.77 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.359 -0.838 . . . . 0.0 110.315 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.415 ' HB ' ' O ' ' A' ' 6' ' ' CYS . 7.0 tt -175.06 -28.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.236 -0.915 . . . . 0.0 110.706 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 15.6 mtm180 -57.29 -30.62 64.86 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.943 -1.098 . . . . 0.0 109.492 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -65.99 -29.42 69.8 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.618 -0.676 . . . . 0.0 110.368 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 107.48 9.74 28.52 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.93 171.05 48.36 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.8 pt -111.68 161.8 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -1.124 . . . . 0.0 110.176 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.507 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 2.2 m -104.36 154.33 19.96 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.162 -0.962 . . . . 0.0 109.921 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.533 ' O ' ' N ' ' A' ' 32' ' ' LYS . 63.2 tt0 -155.13 153.42 30.79 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.41 -0.806 . . . . 0.0 109.565 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.496 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 63.2 t80 -59.14 -39.48 82.52 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.043 -1.036 . . . . 0.0 110.36 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.496 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 17.1 mmm180 -144.59 146.76 32.49 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.268 -0.895 . . . . 0.0 110.348 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.2 t -109.14 156.26 20.05 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.254 -0.903 . . . . 0.0 110.441 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.432 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 31.1 pt -110.46 162.79 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.252 -0.905 . . . . 0.0 110.191 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.06 -36.74 52.58 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.58 ' N ' HD22 ' A' ' 20' ' ' LEU . 4.2 mm? -56.33 -35.31 67.46 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.194 -1.18 . . . . 0.0 110.169 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 -100.77 129.17 46.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.218 -0.926 . . . . 0.0 110.128 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 77.9 t60 -88.07 124.98 34.31 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.352 -0.842 . . . . 0.0 110.295 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.476 ' HD2' ' HB3' ' A' ' 32' ' ' LYS . 27.3 ttpp -97.33 117.18 30.97 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.294 -0.879 . . . . 0.0 110.132 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 35.9 pt -97.62 0.32 10.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.177 -0.952 . . . . 0.0 110.315 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.92 -172.35 43.82 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.705 HG22 ' O ' ' A' ' 28' ' ' GLY . 88.4 m -119.46 111.5 18.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -1.118 . . . . 0.0 110.226 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.436 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 45.8 t -54.04 -53.32 54.61 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.247 -0.908 . . . . 0.0 109.795 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.705 ' O ' HG22 ' A' ' 26' ' ' THR . . . -142.12 -165.36 10.47 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 108.651 -1.779 . . . . 0.0 108.651 179.475 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.608 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 23.5 m -87.27 -41.69 0.52 Allowed Pre-proline 0 C--N 1.304 -1.412 0 O-C-N 121.027 -1.278 . . . . 0.0 110.052 179.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.608 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.3 Cg_endo -81.75 7.46 5.02 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 O-C-N 123.506 1.266 . . . . 0.0 109.681 178.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.586 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 86.7 m-85 -151.92 171.09 18.34 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.296 -0.877 . . . . 0.0 110.448 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 14' ' ' GLN . 62.0 mttm -128.6 157.76 40.37 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.429 -0.794 . . . . 0.0 109.264 179.347 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.476 ' O ' ' HG3' ' A' ' 23' ' ' LYS . 48.9 t -91.76 117.56 29.87 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.985 -1.072 . . . . 0.0 110.301 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 96.9 m -135.43 131.42 36.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.211 -0.93 . . . . 0.0 110.595 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.2 ptmm? . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.241 179.925 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 73.8 m-80 . . . . . 0 N--CA 1.496 1.836 0 CA-C-O 121.237 0.541 . . . . 0.0 110.2 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.61 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 79.8 tt0 -61.59 -42.72 85.48 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.142 -0.973 . . . . 0.0 110.726 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.61 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 52.2 Cg_endo -76.24 -155.26 0.05 OUTLIER 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.473 1.249 . . . . 0.0 110.34 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 4.0 t -131.38 167.83 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.115 -0.99 . . . . 0.0 110.178 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 92.7 p -78.35 153.45 31.64 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.201 -0.937 . . . . 0.0 110.289 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.486 ' HB2' ' SG ' ' A' ' 27' ' ' CYS . 0.3 OUTLIER -88.05 9.92 20.85 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.341 -0.849 . . . . 0.0 110.035 179.91 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.424 HG23 ' N ' ' A' ' 8' ' ' ARG . 4.8 tp -65.16 -33.43 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.286 -0.884 . . . . 0.0 110.105 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.424 ' N ' HG23 ' A' ' 7' ' ' ILE . 81.0 mtt180 -52.15 -37.94 56.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.3 -0.875 . . . . 0.0 110.336 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -71.08 -6.83 42.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.39 -0.819 . . . . 0.0 110.251 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 81.49 13.96 79.27 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.43 ' C ' HG13 ' A' ' 12' ' ' ILE . . . -96.71 -170.7 34.25 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.483 HG22 ' N ' ' A' ' 13' ' ' CYS . 27.2 mt -132.53 172.53 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.297 -1.119 . . . . 0.0 109.622 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.518 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 6.1 m -137.39 159.59 41.5 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.916 -1.115 . . . . 0.0 111.346 -179.586 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 53.9 tp60 -157.67 153.63 27.02 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.497 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 44.1 t80 -44.74 -46.4 10.42 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.979 -1.076 . . . . 0.0 110.392 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.497 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 30.3 mmt180 -137.71 146.58 43.9 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.327 -0.858 . . . . 0.0 110.012 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 77.3 m -111.65 131.02 55.57 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.118 -0.988 . . . . 0.0 110.503 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.4 pt -133.47 164.59 34.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.195 -0.941 . . . . 0.0 110.217 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.78 -161.35 23.71 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.489 ' O ' ' CE1' ' A' ' 22' ' ' HIS . 53.2 mt -70.56 -24.52 62.8 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.283 -1.128 . . . . 0.0 110.126 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 100.0 mtt180 -57.36 142.86 42.14 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.326 -0.859 . . . . 0.0 110.313 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.489 ' CE1' ' O ' ' A' ' 20' ' ' LEU . 77.6 m-70 -119.6 160.9 21.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.214 -0.929 . . . . 0.0 110.089 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.523 ' CE ' ' OG1' ' A' ' 26' ' ' THR . 76.9 tttt -99.7 97.94 8.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.166 -0.959 . . . . 0.0 110.381 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 89.9 mt -67.37 -26.96 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.188 -0.945 . . . . 0.0 110.181 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.402 ' H ' ' HB3' ' A' ' 33' ' ' CYS . . . -164.33 -169.05 27.36 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.597 HG22 ' O ' ' A' ' 28' ' ' GLY . 92.3 m -122.98 111.01 16.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.245 -1.15 . . . . 0.0 110.429 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.486 ' SG ' ' HB2' ' A' ' 6' ' ' CYS . 33.4 m -59.43 -43.47 93.07 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.239 -0.913 . . . . 0.0 109.523 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.597 ' O ' HG22 ' A' ' 26' ' ' THR . . . -154.28 -160.96 10.14 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.612 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 5.2 m -86.84 -41.65 0.54 Allowed Pre-proline 0 C--N 1.301 -1.515 0 O-C-N 120.941 -1.329 . . . . 0.0 109.977 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.612 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.8 Cg_endo -81.58 7.79 4.8 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 123.539 1.284 . . . . 0.0 109.987 179.19 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.589 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 52.6 m-85 -149.73 179.36 8.07 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.218 -0.926 . . . . 0.0 110.812 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 26' ' ' THR . 68.7 mttt -148.26 161.85 40.68 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.515 -0.74 . . . . 0.0 109.396 179.625 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.464 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 46.9 t -88.88 110.11 20.79 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.611 -1.306 . . . . 0.0 109.78 179.533 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 89.2 m -137.09 150.51 48.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.184 -0.948 . . . . 0.0 110.334 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 99.9 mttt . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.141 179.814 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . 0.511 ' HB3' ' HB ' ' A' ' 4' ' ' VAL . 91.5 m-20 . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.379 0.609 . . . . 0.0 110.271 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.62 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 98.5 mt-10 -62.33 -43.51 85.38 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.385 -0.822 . . . . 0.0 111.277 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.62 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 45.3 Cg_endo -73.47 -6.46 18.81 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.344 1.181 . . . . 0.0 110.739 -179.415 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 5' ' ' SER . 65.5 t -130.15 172.69 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.247 -0.908 . . . . 0.0 109.915 179.635 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.582 ' N ' HG12 ' A' ' 4' ' ' VAL . 94.6 p -146.82 156.51 43.18 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.287 -0.883 . . . . 0.0 110.052 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 1.3 p -95.82 13.7 25.77 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.899 . . . . 0.0 110.133 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.471 HG13 ' N ' ' A' ' 8' ' ' ARG . 32.3 pt -67.86 -26.15 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.356 -0.84 . . . . 0.0 110.098 179.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.471 ' N ' HG13 ' A' ' 7' ' ' ILE . 76.7 mtt85 -49.56 -33.07 13.94 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.202 -0.936 . . . . 0.0 110.336 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 55.5 t-20 -68.92 -23.65 64.19 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.357 -0.839 . . . . 0.0 110.723 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 111.36 -2.93 28.04 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.44 -168.94 41.61 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.478 HG22 ' N ' ' A' ' 13' ' ' CYS . 51.3 mt -131.6 170.77 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.355 -1.085 . . . . 0.0 109.949 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.524 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.5 m -135.88 159.39 41.81 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.019 -1.051 . . . . 0.0 110.485 179.682 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.519 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 11.6 pt20 -155.64 169.86 23.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.466 -0.771 . . . . 0.0 109.78 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.487 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 96.3 m-85 -58.04 -36.94 73.47 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.302 -0.874 . . . . 0.0 110.842 -179.653 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.468 ' O ' ' HG3' ' A' ' 14' ' ' GLN . 38.3 mmt180 -146.46 153.63 40.66 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.144 -0.972 . . . . 0.0 110.517 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.4 m -122.31 161.94 22.42 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.249 -0.907 . . . . 0.0 109.839 179.519 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.532 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 34.6 pt -113.98 172.83 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.057 -1.027 . . . . 0.0 110.315 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.99 -33.92 64.79 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.532 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 22.9 mt -59.6 -33.64 71.73 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -1.132 . . . . 0.0 110.264 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -101.8 133.79 45.98 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.344 -0.847 . . . . 0.0 110.056 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 66.6 t-80 -88.28 124.85 34.29 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.261 -0.899 . . . . 0.0 110.216 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.625 ' HE2' HG22 ' A' ' 26' ' ' THR . 74.0 tttt -88.02 90.45 8.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.213 -0.929 . . . . 0.0 110.106 179.827 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.9 tt -64.95 -30.98 51.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.189 -0.944 . . . . 0.0 110.358 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -170.02 -171.21 35.29 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.625 HG22 ' HE2' ' A' ' 23' ' ' LYS . 58.2 p -116.31 103.04 10.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.343 -1.092 . . . . 0.0 110.485 -179.732 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.462 ' O ' ' HB2' ' A' ' 1' ' ' ASN . 62.6 m -47.95 -48.6 32.06 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.742 179.52 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.16 -160.09 8.53 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.594 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 8.4 m -89.99 -41.61 0.42 Allowed Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.082 -1.246 . . . . 0.0 110.67 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.594 ' CD ' ' N ' ' A' ' 29' ' ' SER . 46.4 Cg_endo -81.16 7.83 4.72 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 123.472 1.248 . . . . 0.0 109.997 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.586 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 83.9 m-85 -150.36 171.79 16.43 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.255 -0.903 . . . . 0.0 110.438 179.575 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.524 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 93.8 mttt -135.58 158.99 43.01 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.408 -0.808 . . . . 0.0 108.995 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.531 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 4.8 t -89.29 118.78 29.21 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.767 -1.208 . . . . 0.0 109.907 179.506 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 95.4 m -144.31 147.43 33.48 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.133 -0.979 . . . . 0.0 110.299 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 91.5 mttt . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.17 179.721 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . 0.547 ' HB2' HG22 ' A' ' 4' ' ' VAL . 82.0 m-20 . . . . . 0 N--CA 1.494 1.768 0 CA-C-O 121.385 0.612 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.621 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 76.3 tt0 -66.99 -41.52 36.4 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.344 -0.847 . . . . 0.0 111.47 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.621 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.0 Cg_endo -74.6 -8.23 20.29 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.241 1.127 . . . . 0.0 110.922 -179.118 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.547 HG22 ' HB2' ' A' ' 1' ' ' ASN . 28.8 m -131.74 150.94 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.016 -1.052 . . . . 0.0 110.2 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.464 ' OG ' HG12 ' A' ' 7' ' ' ILE . 6.1 t -111.99 135.63 52.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.255 -0.903 . . . . 0.0 110.359 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.469 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 53.1 t -63.42 -40.23 96.62 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.222 -0.923 . . . . 0.0 110.107 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.517 HG13 ' N ' ' A' ' 8' ' ' ARG . 46.7 pt -57.25 -33.49 43.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.241 -0.912 . . . . 0.0 110.279 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.517 ' N ' HG13 ' A' ' 7' ' ' ILE . 65.9 ttt-85 -59.79 -35.51 74.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.207 -0.933 . . . . 0.0 110.17 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.407 ' O ' ' OD1' ' A' ' 9' ' ' ASN . 45.9 t-20 -75.65 -23.23 56.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 109.983 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 112.32 2.07 26.3 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.96 -178.88 48.94 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.567 HG22 ' N ' ' A' ' 13' ' ' CYS . 57.2 mt -114.63 171.72 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.23 -1.159 . . . . 0.0 110.27 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.567 ' N ' HG22 ' A' ' 12' ' ' ILE . 2.3 m -124.6 150.57 45.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 110.053 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.472 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 56.6 tt0 -152.71 154.18 34.75 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.613 -0.679 . . . . 0.0 109.712 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.53 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 89.2 m-85 -57.89 -40.05 79.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.056 -1.027 . . . . 0.0 110.307 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.42 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 24.9 mmm180 -145.0 156.29 43.86 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.309 -0.869 . . . . 0.0 110.496 -179.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.1 m -128.24 160.83 30.89 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.241 -0.912 . . . . 0.0 110.055 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.551 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 48.4 pt -110.71 172.35 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.13 -0.981 . . . . 0.0 110.295 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.45 -33.88 62.79 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.61 ' N ' HD12 ' A' ' 20' ' ' LEU . 9.5 mp -62.01 -34.2 75.75 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.157 -1.202 . . . . 0.0 110.224 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 70.7 mtp85 -102.85 113.82 27.58 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.249 -0.907 . . . . 0.0 109.938 179.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 65.7 m170 -68.37 152.26 45.68 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.178 -0.952 . . . . 0.0 110.52 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 71.4 tttt -120.69 96.69 5.22 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.316 -0.865 . . . . 0.0 109.979 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.402 HG23 HD12 ' A' ' 24' ' ' ILE . 49.5 mm -65.53 -26.46 39.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.274 -0.892 . . . . 0.0 110.601 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.423 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -175.99 -167.84 35.42 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 32' ' ' LYS . 49.5 p -106.57 105.87 16.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -1.077 . . . . 0.0 110.52 -179.808 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.471 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 42.4 t -50.67 -35.76 32.46 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -0.914 . . . . 0.0 109.53 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -161.68 -160.77 11.16 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.448 -1.861 . . . . 0.0 108.448 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.589 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 60.6 m -89.64 -41.89 0.43 Allowed Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 120.942 -1.328 . . . . 0.0 109.956 179.495 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.589 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.0 Cg_endo -83.29 8.87 4.36 Favored 'Trans proline' 0 C--N 1.31 -1.496 0 O-C-N 123.422 1.222 . . . . 0.0 109.557 178.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.565 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 95.6 m-85 -153.02 172.45 16.82 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.357 -0.839 . . . . 0.0 110.802 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.525 ' HA ' ' HA ' ' A' ' 26' ' ' THR . 93.4 mttt -134.41 160.01 39.29 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 179.092 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 45.7 t -83.8 117.08 23.04 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.983 -1.073 . . . . 0.0 109.911 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 58.9 m -144.12 156.78 44.48 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.233 -0.917 . . . . 0.0 110.506 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 94.8 mttt . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.092 179.829 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . 0.537 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . 25.2 m120 . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.278 0.561 . . . . 0.0 110.238 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.629 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 86.6 tt0 -63.99 -42.64 71.11 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.304 -0.872 . . . . 0.0 111.165 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.629 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 49.2 Cg_endo -73.55 -155.18 0.04 OUTLIER 'Trans proline' 0 C--N 1.314 -1.262 0 O-C-N 123.335 1.176 . . . . 0.0 110.269 -179.402 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 26.4 m -109.89 139.29 33.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.064 -1.023 . . . . 0.0 110.519 -179.555 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.404 ' O ' ' HB3' ' A' ' 6' ' ' CYS . 19.8 t -61.45 -26.03 67.62 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.261 -0.9 . . . . 0.0 110.089 179.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.404 ' HB3' ' O ' ' A' ' 5' ' ' SER . 48.1 t 55.06 41.33 31.85 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.263 -0.898 . . . . 0.0 110.21 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 37.1 pt -109.93 -11.51 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.293 -0.88 . . . . 0.0 110.235 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 30.0 mmt180 -57.95 -32.4 67.79 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.152 -0.968 . . . . 0.0 110.327 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -67.16 -26.22 66.55 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.385 -0.822 . . . . 0.0 110.436 -179.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.4 13.24 33.53 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.78 -169.92 42.92 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.482 HG22 ' N ' ' A' ' 13' ' ' CYS . 47.2 mt -129.09 171.12 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.439 -1.036 . . . . 0.0 109.795 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.547 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 5.8 m -136.47 160.18 39.53 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.936 -1.103 . . . . 0.0 111.214 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.4 ' O ' ' C ' ' A' ' 15' ' ' TYR . 44.2 tt0 -160.06 154.39 23.62 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.725 -0.609 . . . . 0.0 109.501 179.507 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.464 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 40.2 t80 -43.21 -45.81 5.81 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.005 -1.059 . . . . 0.0 110.656 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.464 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 0.6 OUTLIER -139.42 147.04 40.86 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.255 -0.903 . . . . 0.0 110.292 179.819 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 66.5 m -112.72 126.12 55.06 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.304 -0.872 . . . . 0.0 110.324 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 26.9 pt -129.99 163.91 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.936 . . . . 0.0 110.176 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.94 -167.08 26.46 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.689 ' N ' HD12 ' A' ' 20' ' ' LEU . 10.1 mp -68.6 -21.63 64.49 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.264 -1.139 . . . . 0.0 110.347 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 94.7 mtt-85 -54.68 138.69 41.08 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.371 -0.831 . . . . 0.0 110.178 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -109.62 170.41 8.08 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.238 -0.914 . . . . 0.0 109.971 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.522 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 79.9 tttt -115.33 113.25 23.57 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.014 -1.054 . . . . 0.0 110.607 -179.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 45.5 mm -70.45 -31.06 45.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.406 -0.809 . . . . 0.0 109.963 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.425 ' O ' ' CE ' ' A' ' 23' ' ' LYS . . . -174.59 -166.49 32.62 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.48 HG22 ' O ' ' A' ' 28' ' ' GLY . 51.8 m -113.45 109.33 18.49 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.208 -1.172 . . . . 0.0 110.711 -179.669 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.434 ' HA ' ' O ' ' A' ' 4' ' ' VAL . 60.0 m -58.17 -51.46 69.62 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.173 -0.955 . . . . 0.0 109.897 179.577 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.48 ' O ' HG22 ' A' ' 26' ' ' THR . . . -141.49 -164.22 9.9 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.933 -1.667 . . . . 0.0 108.933 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.622 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 14.9 m -85.96 -41.41 0.6 Allowed Pre-proline 0 C--N 1.301 -1.521 0 O-C-N 120.939 -1.33 . . . . 0.0 109.954 179.358 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.622 ' CD ' ' N ' ' A' ' 29' ' ' SER . 45.4 Cg_endo -81.34 8.16 4.55 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 O-C-N 123.501 1.264 . . . . 0.0 109.84 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.61 ' CE2' ' HG2' ' A' ' 30' ' ' PRO . 67.3 m-85 -153.25 169.15 23.76 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.08 -1.012 . . . . 0.0 110.975 -179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.547 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 92.8 mttt -133.8 160.1 38.63 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.1 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.522 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 2.9 t -90.26 120.01 31.05 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.744 -1.222 . . . . 0.0 110.337 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 73.4 m -142.67 142.18 31.99 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.86 . . . . 0.0 110.226 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 86.2 tttt . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.124 179.9 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . 0.772 ' HB2' HG22 ' A' ' 4' ' ' VAL . 79.0 m-20 . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.228 0.537 . . . . 0.0 110.092 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.631 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 90.5 mt-10 -61.99 -44.34 89.51 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.268 -0.895 . . . . 0.0 111.653 -179.618 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.631 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 43.8 Cg_endo -70.54 -8.23 23.12 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 O-C-N 123.353 1.186 . . . . 0.0 111.12 -178.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.772 HG22 ' HB2' ' A' ' 1' ' ' ASN . 5.8 m -130.35 128.54 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.055 -1.028 . . . . 0.0 110.029 179.561 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 67.0 m -112.97 150.64 31.59 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.199 -0.938 . . . . 0.0 110.252 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 81.8 m -65.61 -23.9 66.93 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.225 -0.922 . . . . 0.0 109.955 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.529 HG23 ' N ' ' A' ' 8' ' ' ARG . 12.5 tt -59.46 -39.48 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.322 -0.861 . . . . 0.0 109.957 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.529 ' N ' HG23 ' A' ' 7' ' ' ILE . 17.4 ttm105 -56.77 -38.52 72.59 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.308 -0.87 . . . . 0.0 109.932 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 88.1 m-20 -69.32 -27.72 65.62 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.365 -0.835 . . . . 0.0 109.919 179.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.94 8.66 8.68 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -88.98 -177.93 46.21 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.508 ' CG1' ' O ' ' A' ' 34' ' ' CYS . 46.8 pt -132.23 161.24 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.321 -1.105 . . . . 0.0 109.806 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.2 m -113.56 154.21 27.52 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.951 -1.093 . . . . 0.0 110.559 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.497 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 11.5 tp60 -151.17 155.82 39.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.563 -0.71 . . . . 0.0 109.74 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.685 ' CE1' ' CE1' ' A' ' 31' ' ' PHE . 56.4 m-85 -54.94 -42.56 72.45 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.111 -0.993 . . . . 0.0 110.599 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.418 ' HD3' ' O ' ' A' ' 15' ' ' TYR . 89.1 mmt-85 -144.54 154.96 43.43 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.254 -0.903 . . . . 0.0 110.399 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 94.2 m -123.1 138.36 54.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.325 -0.859 . . . . 0.0 109.995 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.0 pt -102.0 170.23 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -0.909 . . . . 0.0 110.326 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -48.21 -43.5 25.95 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 14.2 tp -47.26 -46.7 24.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.207 -1.172 . . . . 0.0 110.311 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -101.39 128.0 47.78 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 110.261 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -88.71 135.32 33.57 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.874 . . . . 0.0 110.198 179.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.538 ' CD ' ' HB3' ' A' ' 32' ' ' LYS . 37.9 ttpt -95.95 117.07 29.92 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.282 -0.887 . . . . 0.0 110.064 179.815 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.0 mm -75.4 -27.27 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.339 -0.851 . . . . 0.0 110.136 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.491 ' C ' ' HB2' ' A' ' 33' ' ' CYS . . . -169.9 -156.51 11.09 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 72.9 p -115.74 113.2 23.14 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.354 -1.086 . . . . 0.0 110.14 179.624 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.52 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 42.2 t -68.73 -29.83 68.33 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.396 -0.815 . . . . 0.0 110.019 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -176.81 -163.61 29.34 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.944 -1.663 . . . . 0.0 108.944 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.604 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.5 m -87.39 -42.9 0.52 Allowed Pre-proline 0 C--N 1.303 -1.413 0 O-C-N 121.076 -1.25 . . . . 0.0 110.055 179.647 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.604 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.9 Cg_endo -81.7 6.94 5.33 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 O-C-N 123.666 1.35 . . . . 0.0 109.663 179.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.685 ' CE1' ' CE1' ' A' ' 15' ' ' TYR . 73.3 m-85 -156.6 176.19 13.05 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.283 -0.886 . . . . 0.0 110.619 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.538 ' HB3' ' CD ' ' A' ' 23' ' ' LYS . 95.9 mttt -141.22 156.89 45.85 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.451 -0.781 . . . . 0.0 109.391 179.214 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.52 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 66.5 m -76.99 107.58 9.44 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.023 -1.048 . . . . 0.0 109.869 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.508 ' O ' ' CG1' ' A' ' 12' ' ' ILE . 63.5 m -142.52 136.28 29.18 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.168 -0.957 . . . . 0.0 110.318 -179.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 61.9 mttp . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.128 179.968 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . 0.475 ' HB2' ' HB ' ' A' ' 4' ' ' VAL . 95.7 m-20 . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 121.358 0.599 . . . . 0.0 110.128 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.609 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 84.9 tt0 -63.79 -41.24 63.03 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.333 -0.854 . . . . 0.0 111.349 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.609 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 48.1 Cg_endo -75.73 -8.36 19.16 Favored 'Trans proline' 0 C--N 1.312 -1.374 0 O-C-N 123.378 1.199 . . . . 0.0 110.624 -179.285 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.522 HG12 ' N ' ' A' ' 5' ' ' SER . 35.5 t -129.3 171.63 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.205 -0.934 . . . . 0.0 110.236 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.728 ' OG ' HG22 ' A' ' 7' ' ' ILE . 43.2 t -137.85 130.39 29.54 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.245 -0.91 . . . . 0.0 110.116 179.873 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 74.5 m -59.85 -26.71 66.05 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.197 -0.939 . . . . 0.0 110.292 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.728 HG22 ' OG ' ' A' ' 5' ' ' SER . 8.5 tt -58.63 -31.17 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.936 179.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -61.13 -37.65 83.58 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.277 -0.89 . . . . 0.0 110.123 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -67.89 -29.22 68.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.383 -0.823 . . . . 0.0 110.326 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 122.78 -2.38 10.06 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.99 -173.36 45.54 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.5 HG22 ' N ' ' A' ' 13' ' ' CYS . 22.4 mm -130.97 170.38 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.284 -1.127 . . . . 0.0 110.159 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.5 ' N ' HG22 ' A' ' 12' ' ' ILE . 2.4 m -119.63 151.49 38.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.185 -0.947 . . . . 0.0 109.862 179.761 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.5 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 51.6 tt0 -152.36 152.52 32.17 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.541 -0.724 . . . . 0.0 109.639 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.503 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 72.6 t80 -57.67 -38.53 75.29 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.183 -0.948 . . . . 0.0 110.473 -179.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.503 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 7.0 mmm180 -149.91 142.69 24.68 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.288 -0.883 . . . . 0.0 110.274 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.5 m -111.69 151.8 28.46 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.153 -0.967 . . . . 0.0 110.208 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.692 HG22 ' H ' ' A' ' 19' ' ' GLY . 3.0 mt -97.95 -168.9 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.184 -0.948 . . . . 0.0 109.897 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.692 ' H ' HG22 ' A' ' 18' ' ' ILE . . . -67.38 -43.71 86.84 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 63.9 mt -55.38 -36.78 66.74 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.338 -1.095 . . . . 0.0 109.962 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.7 mmt-85 -100.67 123.24 44.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.354 -0.841 . . . . 0.0 110.244 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -94.39 144.18 25.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 110.107 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.513 ' CE ' ' O ' ' A' ' 25' ' ' GLY . 72.2 tttt -103.53 102.1 11.98 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.216 -0.927 . . . . 0.0 110.371 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 86.1 mt -70.04 -21.37 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.218 -0.926 . . . . 0.0 110.11 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.513 ' O ' ' CE ' ' A' ' 23' ' ' LYS . . . -169.05 -161.5 19.48 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.735 HG23 ' O ' ' A' ' 26' ' ' THR . 14.0 t -119.3 112.03 18.93 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.306 -1.114 . . . . 0.0 110.283 179.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.517 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 11.6 t -58.87 -37.42 76.5 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.19 -0.944 . . . . 0.0 109.532 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -164.94 -154.79 8.13 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.432 -1.867 . . . . 0.0 108.432 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.579 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 2.3 m -90.27 -43.99 0.41 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 120.975 -1.309 . . . . 0.0 110.156 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.579 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.5 Cg_endo -82.76 11.72 3.14 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 O-C-N 123.564 1.297 . . . . 0.0 109.859 179.2 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.516 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 83.1 m-85 -155.38 174.16 15.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.209 -0.932 . . . . 0.0 110.57 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 26' ' ' THR . 67.5 mttm -137.11 159.31 42.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.638 -0.664 . . . . 0.0 109.36 179.183 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.517 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 76.7 m -78.07 105.72 9.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.031 -1.043 . . . . 0.0 110.203 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 4.9 m -136.0 138.46 42.26 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.143 -0.973 . . . . 0.0 110.275 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.176 179.93 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . 0.434 ' C ' ' HD2' ' A' ' 3' ' ' PRO . 82.3 m-20 . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.307 0.575 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.623 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 87.0 tt0 -64.15 -38.4 34.49 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.358 -0.839 . . . . 0.0 111.764 179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.623 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 45.6 Cg_endo -73.53 -4.04 14.75 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.05 1.026 . . . . 0.0 110.792 -179.386 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.577 HG12 ' N ' ' A' ' 5' ' ' SER . 57.9 t -118.9 173.08 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.153 -0.967 . . . . 0.0 109.811 179.531 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.577 ' N ' HG12 ' A' ' 4' ' ' VAL . 66.6 m -129.8 143.65 50.91 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.164 -0.96 . . . . 0.0 110.473 -179.765 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 85.3 m -90.62 0.05 57.51 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.327 -0.858 . . . . 0.0 110.423 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.459 HG12 ' HB3' ' A' ' 5' ' ' SER . 47.1 pt -75.53 -28.51 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.251 -0.906 . . . . 0.0 110.191 179.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.415 ' N ' HG13 ' A' ' 7' ' ' ILE . 25.7 tpt180 -62.3 -32.75 73.53 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.26 -0.9 . . . . 0.0 110.02 179.685 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -78.54 -8.14 58.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 110.16 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 98.72 -2.73 58.74 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.36 172.61 49.14 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.324 -1.511 . . . . 0.0 109.324 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.524 HG22 ' N ' ' A' ' 13' ' ' CYS . 56.6 mt -130.53 170.9 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.287 -1.125 . . . . 0.0 110.275 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.524 ' N ' HG22 ' A' ' 12' ' ' ILE . 3.2 m -103.7 153.75 20.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.162 -0.962 . . . . 0.0 110.087 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 8.5 tp60 -151.67 152.99 33.53 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.514 -0.741 . . . . 0.0 109.748 179.636 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.612 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 57.5 t80 -60.14 -41.96 93.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.175 -0.953 . . . . 0.0 109.955 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.612 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 33.4 mmt180 -147.79 149.35 32.18 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.443 -0.786 . . . . 0.0 110.097 179.779 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 98.5 m -120.86 176.38 5.57 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.211 -0.93 . . . . 0.0 110.1 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.6 pt -122.37 175.45 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.258 -0.901 . . . . 0.0 110.436 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -59.06 -31.46 68.84 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.826 HD13 ' O ' ' A' ' 20' ' ' LEU . 3.1 tm? -59.48 -37.96 79.61 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.282 -1.128 . . . . 0.0 110.272 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -104.81 128.35 52.94 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.274 -0.891 . . . . 0.0 110.289 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -88.07 141.95 28.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.247 -0.908 . . . . 0.0 110.011 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.502 ' CE ' ' HB3' ' A' ' 32' ' ' LYS . 46.4 tttm -94.25 107.12 19.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.859 . . . . 0.0 110.352 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 38.5 mm -68.72 -31.68 51.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.282 -0.887 . . . . 0.0 110.485 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.501 ' O ' ' NZ ' ' A' ' 23' ' ' LYS . . . -165.91 -156.04 9.12 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 -179.544 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.732 HG23 ' O ' ' A' ' 26' ' ' THR . 14.8 t -122.28 106.92 11.54 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.682 -0.893 . . . . 0.0 109.872 179.639 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.516 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 37.9 t -62.75 -35.86 81.16 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.199 -0.938 . . . . 0.0 110.3 -179.452 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -169.08 -163.4 23.05 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.588 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.3 m -88.29 -43.3 0.47 Allowed Pre-proline 0 C--N 1.303 -1.422 0 O-C-N 121.062 -1.258 . . . . 0.0 110.32 179.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.588 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.8 Cg_endo -81.18 5.64 6.12 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.525 1.276 . . . . 0.0 109.572 179.307 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 63.7 m-85 -153.0 169.47 22.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.275 -0.891 . . . . 0.0 110.486 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.502 ' HB3' ' CE ' ' A' ' 23' ' ' LYS . 96.0 mttt -136.75 158.45 44.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.437 -0.789 . . . . 0.0 109.69 179.497 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.516 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 59.5 m -80.68 120.14 24.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.126 -0.983 . . . . 0.0 109.471 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.9 m -143.4 134.5 25.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.227 -0.921 . . . . 0.0 110.457 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.914 -1.041 . . . . 0.0 109.952 179.709 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 . . . . . 0 N--CA 1.491 1.6 0 CA-C-O 121.17 0.51 . . . . 0.0 110.327 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.603 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 51.0 tp10 -66.75 -41.12 36.11 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.239 -0.913 . . . . 0.0 110.752 179.631 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.603 ' CD ' ' N ' ' A' ' 2' ' ' GLU . 54.7 Cg_endo -78.64 -154.71 0.05 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.378 1.199 . . . . 0.0 109.83 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.551 ' CG2' HD13 ' A' ' 7' ' ' ILE . 17.3 m -82.6 136.65 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 120.871 -1.143 . . . . 0.0 110.214 179.832 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.676 ' O ' HG23 ' A' ' 7' ' ' ILE . 58.8 m -129.91 161.02 31.8 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.199 -0.938 . . . . 0.0 110.51 -179.536 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.422 ' HB3' ' O ' ' A' ' 5' ' ' SER . 45.3 t 55.64 31.61 17.64 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.23 -0.919 . . . . 0.0 110.099 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.676 HG23 ' O ' ' A' ' 5' ' ' SER . 7.3 pt -113.73 -9.56 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.267 -0.896 . . . . 0.0 110.218 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 95.0 mtt-85 -65.8 -35.91 82.04 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.09 -1.006 . . . . 0.0 110.106 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.0 m120 -96.41 5.94 49.81 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.252 -0.905 . . . . 0.0 110.2 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 74.15 18.21 79.7 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.91 175.59 51.97 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.501 HG22 ' N ' ' A' ' 13' ' ' CYS . 56.4 mt -120.56 170.27 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -1.137 . . . . 0.0 110.307 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.501 ' N ' HG22 ' A' ' 12' ' ' ILE . 3.0 m -117.72 154.03 32.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.22 -0.925 . . . . 0.0 110.178 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.523 ' O ' ' N ' ' A' ' 32' ' ' LYS . 8.0 tt0 -160.38 151.2 18.75 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.646 -0.658 . . . . 0.0 109.567 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 31' ' ' PHE . 83.8 t80 -55.53 -37.75 68.34 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.028 -1.045 . . . . 0.0 110.606 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.403 ' HG3' ' N ' ' A' ' 17' ' ' CYS . 14.2 tpt180 -146.05 163.1 36.32 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.255 -0.903 . . . . 0.0 110.233 -179.782 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.403 ' N ' ' HG3' ' A' ' 16' ' ' ARG . 20.1 m -139.37 125.63 20.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.468 -0.77 . . . . 0.0 109.789 179.545 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.0 pt -138.13 165.23 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.261 -0.9 . . . . 0.0 110.313 -179.697 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.11 -155.42 26.33 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.567 ' N ' HD22 ' A' ' 20' ' ' LEU . 4.5 mm? -61.78 -28.1 69.21 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.351 -1.087 . . . . 0.0 110.202 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 94.1 mtt180 -53.03 135.52 36.92 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.266 -0.896 . . . . 0.0 110.296 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -113.1 156.11 23.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.332 -0.855 . . . . 0.0 110.073 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 81.6 tttt -101.81 107.62 18.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.188 -0.945 . . . . 0.0 110.177 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 67.7 mt -76.98 -33.71 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.899 . . . . 0.0 110.215 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.485 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -169.71 -169.56 33.1 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 75.2 p -105.95 99.17 8.78 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.394 -1.063 . . . . 0.0 110.474 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.477 ' O ' ' HB2' ' A' ' 5' ' ' SER . 38.6 t -54.28 -40.05 67.48 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.169 -0.957 . . . . 0.0 109.722 179.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -155.99 -165.68 14.85 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 108.598 -1.801 . . . . 0.0 108.598 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.6 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 9.0 m -87.18 -42.97 0.53 Allowed Pre-proline 0 C--N 1.299 -1.625 0 O-C-N 121.128 -1.219 . . . . 0.0 109.825 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.6 ' CD ' ' N ' ' A' ' 29' ' ' SER . 49.0 Cg_endo -82.23 7.66 4.97 Favored 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.49 1.258 . . . . 0.0 109.691 178.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.579 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 90.5 m-85 -152.36 169.86 21.51 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.299 -0.876 . . . . 0.0 110.64 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 14' ' ' GLN . 96.3 mttt -130.9 159.36 37.65 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.012 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.485 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 47.2 t -85.51 121.18 27.85 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.962 -1.087 . . . . 0.0 109.801 179.759 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 97.3 m -138.21 141.87 39.98 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 110.342 -179.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.436 ' HG2' ' OXT' ' A' ' 35' ' ' LYS . 88.0 tttt . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.164 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . 0.542 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . 88.3 m-20 . . . . . 0 N--CA 1.493 1.675 0 CA-C-O 121.326 0.584 . . . . 0.0 110.201 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.62 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 39.7 tt0 -64.12 -41.12 59.48 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 111.767 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.62 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 47.9 Cg_endo -74.88 0.54 8.71 Favored 'Trans proline' 0 C--N 1.312 -1.381 0 O-C-N 123.318 1.168 . . . . 0.0 110.947 -179.111 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.489 HG22 ' HB2' ' A' ' 1' ' ' ASN . 27.7 m -145.82 128.75 9.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.114 -0.992 . . . . 0.0 110.348 179.806 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 39.0 m -97.88 134.89 40.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.353 -0.842 . . . . 0.0 109.767 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.527 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 10.1 t -72.26 -26.39 61.98 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.183 -0.948 . . . . 0.0 110.468 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.474 HG13 ' N ' ' A' ' 8' ' ' ARG . 50.0 pt -71.17 -30.52 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.188 -0.945 . . . . 0.0 110.015 -179.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.474 ' N ' HG13 ' A' ' 7' ' ' ILE . 51.0 ttt85 -66.21 -54.8 20.84 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.433 -0.792 . . . . 0.0 110.083 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -142.67 9.42 1.78 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.407 -0.808 . . . . 0.0 110.459 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.527 ' HA3' ' HA ' ' A' ' 6' ' ' CYS . . . -83.65 -30.15 30.48 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.764 -1.335 . . . . 0.0 109.764 -179.763 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 129.61 -155.92 21.11 Favored Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.599 -1.286 . . . . 0.0 109.89 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.487 HG22 ' N ' ' A' ' 13' ' ' CYS . 41.2 mt -96.34 171.0 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 O-C-N 121.692 -0.887 . . . . 0.0 109.668 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 3.1 m -139.7 153.39 47.22 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.069 -1.019 . . . . 0.0 110.414 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -161.09 157.21 25.69 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.726 -0.609 . . . . 0.0 109.908 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.473 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 87.5 m-85 -44.91 -37.31 3.84 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.16 -0.962 . . . . 0.0 110.206 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.431 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 25.7 mmm180 -147.31 147.11 30.03 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.321 -0.862 . . . . 0.0 110.128 179.768 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.1 m -111.56 130.25 55.8 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.24 -0.912 . . . . 0.0 110.065 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 43.3 pt -127.9 172.42 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.159 -0.963 . . . . 0.0 110.321 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.14 -156.04 23.31 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.642 ' N ' HD12 ' A' ' 20' ' ' LEU . 10.4 mp -87.26 -5.12 59.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.181 -1.188 . . . . 0.0 110.214 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 74.4 mtm180 -61.07 148.35 40.66 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.298 -0.876 . . . . 0.0 110.358 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.516 ' CE1' ' O ' ' A' ' 20' ' ' LEU . 63.4 m80 -119.01 143.65 46.95 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.362 -0.836 . . . . 0.0 110.17 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.523 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 36.4 ttpt -93.79 117.79 30.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.174 -0.954 . . . . 0.0 110.318 -179.757 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 22.4 pt -96.93 -8.79 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.16 -0.962 . . . . 0.0 110.176 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.27 -170.57 37.69 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 32' ' ' LYS . 81.7 p -129.82 108.28 10.03 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.278 -1.131 . . . . 0.0 110.347 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.457 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 46.6 m -51.99 -36.03 48.48 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.24 -0.913 . . . . 0.0 109.706 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -159.22 -159.37 9.67 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.589 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 16.9 m -90.12 -41.88 0.41 Allowed Pre-proline 0 C--N 1.302 -1.476 0 O-C-N 121.09 -1.241 . . . . 0.0 110.553 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.589 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.4 Cg_endo -80.24 6.64 5.21 Favored 'Trans proline' 0 C--N 1.311 -1.442 0 O-C-N 123.416 1.219 . . . . 0.0 109.845 179.445 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.527 ' CD1' ' O ' ' A' ' 30' ' ' PRO . 45.4 m-85 -146.06 179.8 7.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.349 -0.845 . . . . 0.0 110.262 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.525 ' HA ' ' HA ' ' A' ' 26' ' ' THR . 91.3 mttt -143.28 170.31 16.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.525 -0.734 . . . . 0.0 109.065 179.228 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.523 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 38.4 t -96.55 115.87 28.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.783 -1.198 . . . . 0.0 109.969 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 84.6 m -141.89 138.04 31.78 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.095 -1.003 . . . . 0.0 110.143 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.178 179.756 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . 0.486 ' N ' ' CG2' ' A' ' 4' ' ' VAL . 58.6 t30 . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 121.357 0.598 . . . . 0.0 110.381 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.619 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 16.0 tp10 -64.05 -42.69 70.93 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.304 -0.872 . . . . 0.0 111.656 -179.575 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.619 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.1 Cg_endo -73.22 -6.28 18.62 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 O-C-N 123.235 1.124 . . . . 0.0 111.04 -179.228 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.523 HG23 ' O ' ' A' ' 4' ' ' VAL . 34.4 m -132.84 125.1 51.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.103 -0.998 . . . . 0.0 109.902 179.708 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.417 ' HB2' HG22 ' A' ' 7' ' ' ILE . 68.3 m -108.02 150.25 27.38 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.286 -0.884 . . . . 0.0 110.397 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 10.5 t -61.71 -23.29 66.03 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.184 -0.948 . . . . 0.0 110.157 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.417 HG22 ' HB2' ' A' ' 5' ' ' SER . 9.6 tt -60.38 -32.53 51.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.157 -0.964 . . . . 0.0 110.405 -179.864 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 84.3 mtt180 -60.55 -33.54 72.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.212 -0.93 . . . . 0.0 110.254 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 91.0 m-20 -62.02 -25.34 67.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 110.175 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.62 13.09 23.2 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.28 -172.74 44.66 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.0 pt -129.77 151.51 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.264 -1.139 . . . . 0.0 110.177 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.532 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 1.8 m -91.11 151.96 20.79 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.028 -1.045 . . . . 0.0 109.993 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.549 ' O ' ' N ' ' A' ' 32' ' ' LYS . 55.2 tt0 -146.23 150.68 36.27 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.401 -0.812 . . . . 0.0 109.881 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.576 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 62.0 t80 -59.1 -46.01 89.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.065 -1.022 . . . . 0.0 110.58 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.576 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 19.4 mmt180 -148.92 140.81 23.72 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.289 -0.882 . . . . 0.0 110.325 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 40.5 m -116.63 142.66 46.6 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.435 -0.791 . . . . 0.0 109.847 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.719 HG22 ' H ' ' A' ' 19' ' ' GLY . 3.4 mm -90.85 -168.96 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.155 -0.965 . . . . 0.0 110.149 -179.732 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.719 ' H ' HG22 ' A' ' 18' ' ' ILE . . . -69.99 -30.9 69.7 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.925 -1.67 . . . . 0.0 108.925 179.792 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.589 ' N ' HD12 ' A' ' 20' ' ' LEU . 9.4 mp -63.77 -29.57 70.77 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.427 -1.043 . . . . 0.0 110.19 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 82.5 mtt-85 -105.34 128.27 53.4 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.189 -0.944 . . . . 0.0 110.562 -179.611 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 61.6 m170 -94.53 143.0 26.78 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.269 -0.894 . . . . 0.0 110.44 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.485 ' HG3' ' O ' ' A' ' 33' ' ' CYS . 34.2 ttpt -109.26 117.38 33.94 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.257 -0.902 . . . . 0.0 110.61 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 80.4 mt -73.55 -35.38 44.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.187 -0.946 . . . . 0.0 109.826 179.578 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.483 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -160.72 -170.87 25.91 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.448 ' CG2' ' O ' ' A' ' 28' ' ' GLY . 51.6 m -107.94 103.61 12.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.176 -1.191 . . . . 0.0 110.305 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.426 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 42.0 t -53.11 -48.28 67.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.299 -0.875 . . . . 0.0 109.967 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.448 ' O ' ' CG2' ' A' ' 26' ' ' THR . . . -149.59 -165.29 12.3 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 108.906 -1.677 . . . . 0.0 108.906 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.599 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.3 m -89.32 -42.3 0.43 Allowed Pre-proline 0 C--N 1.303 -1.444 0 O-C-N 121.095 -1.238 . . . . 0.0 110.417 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.599 ' CD ' ' N ' ' A' ' 29' ' ' SER . 48.2 Cg_endo -81.82 6.68 5.51 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.474 1.249 . . . . 0.0 109.715 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.497 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 97.9 m-85 -152.48 173.71 14.8 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.308 -0.87 . . . . 0.0 110.197 179.632 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.549 ' N ' ' O ' ' A' ' 14' ' ' GLN . 62.0 mttm -136.41 155.96 49.29 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.458 -0.776 . . . . 0.0 109.147 179.452 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.485 ' O ' ' HG3' ' A' ' 23' ' ' LYS . 50.4 t -87.72 115.06 24.9 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.177 -0.952 . . . . 0.0 110.73 -179.67 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 56.3 m -132.39 145.64 51.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.262 -0.899 . . . . 0.0 109.956 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 56.7 tttp . . . . . 0 N--CA 1.492 1.64 0 O-C-N 121.089 -1.007 . . . . 0.0 110.348 -179.815 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . 0.46 ' O ' ' OD1' ' A' ' 1' ' ' ASN . 45.2 p-10 . . . . . 0 N--CA 1.493 1.679 0 CA-C-O 121.429 0.633 . . . . 0.0 110.268 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.59 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 26.3 tt0 -58.11 -42.15 93.52 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.234 -0.916 . . . . 0.0 111.293 -179.816 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.59 ' CD ' ' N ' ' A' ' 2' ' ' GLU . 55.4 Cg_endo -78.16 -156.41 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.392 0 O-C-N 123.426 1.224 . . . . 0.0 110.403 -179.522 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.579 HG13 ' O ' ' A' ' 3' ' ' PRO . 20.9 m -157.45 146.93 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.186 -0.946 . . . . 0.0 110.036 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 88.2 p -127.4 144.19 51.09 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.227 -0.921 . . . . 0.0 110.081 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.699 ' SG ' HG22 ' A' ' 24' ' ' ILE . 13.1 t -59.66 -32.48 70.5 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.295 -0.878 . . . . 0.0 110.431 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.46 HG13 ' N ' ' A' ' 8' ' ' ARG . 42.5 pt -57.46 -25.49 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.344 -0.847 . . . . 0.0 110.295 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.46 ' N ' HG13 ' A' ' 7' ' ' ILE . 67.8 ttt180 -58.72 -36.17 73.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.221 -0.924 . . . . 0.0 110.473 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 23.8 m120 -67.66 -28.34 67.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.223 -0.923 . . . . 0.0 110.364 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.83 8.0 16.5 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.64 179.62 52.97 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.6 pt -124.05 159.13 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.238 -1.154 . . . . 0.0 110.322 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.514 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 1.7 m -99.49 154.63 18.09 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.274 -0.891 . . . . 0.0 109.835 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.521 ' O ' ' N ' ' A' ' 32' ' ' LYS . 37.6 tp60 -156.74 154.77 30.53 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.223 -0.923 . . . . 0.0 109.887 179.722 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.605 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 50.2 t80 -58.86 -49.28 78.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.124 -0.985 . . . . 0.0 110.231 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.605 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 13.9 mmt85 -145.07 151.34 38.36 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.437 -0.789 . . . . 0.0 110.458 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.527 ' HB2' ' NE ' ' A' ' 21' ' ' ARG . 87.6 m -118.83 178.58 4.43 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.331 -0.856 . . . . 0.0 109.844 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.429 ' O ' ' O ' ' A' ' 19' ' ' GLY . 47.1 pt -101.78 175.3 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.091 -1.006 . . . . 0.0 110.485 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' A' ' 18' ' ' ILE . . . -50.03 178.78 0.03 OUTLIER Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.844 ' N ' HD22 ' A' ' 20' ' ' LEU . 2.7 mm? 46.47 42.3 10.67 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.319 -1.106 . . . . 0.0 109.37 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.527 ' NE ' ' HB2' ' A' ' 17' ' ' CYS . 25.5 ttm180 -79.52 134.85 36.51 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 110.631 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 70.0 m-70 -99.77 37.01 1.68 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 179.328 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.492 ' HE2' ' O ' ' A' ' 25' ' ' GLY . 60.8 tttt -73.36 108.92 6.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.413 -0.804 . . . . 0.0 110.534 -179.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.699 HG22 ' SG ' ' A' ' 6' ' ' CYS . 7.6 tp -78.68 -18.04 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.244 -0.91 . . . . 0.0 109.63 179.599 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.492 ' O ' ' HE2' ' A' ' 23' ' ' LYS . . . -165.46 -173.42 33.99 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.737 HG22 ' O ' ' A' ' 28' ' ' GLY . 92.5 m -109.62 107.06 16.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.136 -1.214 . . . . 0.0 110.261 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.435 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 48.8 t -46.12 -63.72 0.92 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.399 -0.813 . . . . 0.0 109.687 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.737 ' O ' HG22 ' A' ' 26' ' ' THR . . . -129.63 -170.47 12.75 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 179.425 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.596 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.9 m -85.88 -42.19 0.61 Allowed Pre-proline 0 C--N 1.303 -1.445 0 O-C-N 121.01 -1.288 . . . . 0.0 109.898 179.484 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.603 ' HG2' ' CD2' ' A' ' 31' ' ' PHE . 52.0 Cg_endo -81.39 6.0 5.9 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 O-C-N 123.557 1.293 . . . . 0.0 109.428 179.189 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.603 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 86.8 m-85 -148.18 170.15 18.48 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.116 -0.99 . . . . 0.0 110.538 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.521 ' N ' ' O ' ' A' ' 14' ' ' GLN . 89.9 mttt -133.37 156.12 48.23 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.6 -0.688 . . . . 0.0 109.285 179.028 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.44 ' O ' ' HA ' ' A' ' 23' ' ' LYS . 50.7 t -89.62 123.59 33.81 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.165 -0.96 . . . . 0.0 109.907 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.401 ' SG ' ' HD3' ' A' ' 21' ' ' ARG . 33.3 m -138.02 130.75 29.68 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 110.085 -179.796 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 86.2 tttt . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 118.041 -0.98 . . . . 0.0 110.171 -179.971 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . 0.494 ' HB3' ' O ' ' A' ' 4' ' ' VAL . 85.3 m-20 . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.447 0.641 . . . . 0.0 109.937 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.611 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 67.1 mm-40 -64.8 -40.62 49.62 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.492 -0.755 . . . . 0.0 111.723 -179.656 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.611 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.1 Cg_endo -75.08 -16.59 19.94 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.256 1.135 . . . . 0.0 110.924 -179.04 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.494 ' O ' ' HB3' ' A' ' 1' ' ' ASN . 13.5 m -146.07 135.1 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.099 -1.001 . . . . 0.0 110.231 179.842 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.442 ' OG ' HG22 ' A' ' 7' ' ' ILE . 83.5 p -62.87 148.52 46.96 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.214 -0.928 . . . . 0.0 110.238 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 86.2 m -69.26 -26.59 64.84 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.313 -0.867 . . . . 0.0 110.334 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.476 HG23 ' N ' ' A' ' 8' ' ' ARG . 16.2 tt -61.43 -36.75 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.232 -0.918 . . . . 0.0 110.389 -179.658 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.476 ' N ' HG23 ' A' ' 7' ' ' ILE . 76.8 ttt-85 -53.12 -39.2 63.27 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.135 -0.978 . . . . 0.0 110.294 -179.849 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -65.59 -23.73 66.9 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.41 -0.806 . . . . 0.0 110.328 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 111.4 5.76 26.05 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.18 175.67 43.12 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.561 HG22 ' N ' ' A' ' 13' ' ' CYS . 72.9 mt -127.83 171.96 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.273 -1.133 . . . . 0.0 110.021 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.561 ' N ' HG22 ' A' ' 12' ' ' ILE . 1.5 m -102.49 147.84 26.26 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.177 -0.952 . . . . 0.0 109.752 179.565 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.515 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 27.2 tp60 -148.86 152.72 36.96 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.517 -0.739 . . . . 0.0 109.643 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.468 ' CZ ' ' CE1' ' A' ' 31' ' ' PHE . 97.8 m-85 -60.34 -42.25 95.3 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.229 -0.919 . . . . 0.0 110.698 -179.537 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.432 ' HG2' ' C ' ' A' ' 15' ' ' TYR . 29.2 mmm180 -149.3 142.22 24.76 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.233 -0.917 . . . . 0.0 110.605 -179.68 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 67.5 m -119.94 126.52 51.08 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.304 -0.873 . . . . 0.0 109.955 179.598 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.0 pt -143.35 168.04 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.124 -0.985 . . . . 0.0 110.456 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 66.39 -135.56 33.9 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 35.9 mt -59.38 -34.74 72.78 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.395 -1.062 . . . . 0.0 110.273 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -71.49 132.32 44.57 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.346 -0.846 . . . . 0.0 110.651 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 74.7 t60 -133.86 153.55 51.66 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.334 -0.854 . . . . 0.0 109.879 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.502 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 0.0 OUTLIER -110.61 124.45 51.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.111 -0.993 . . . . 0.0 110.731 -179.746 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 23.7 pt -103.66 -5.87 9.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.317 -0.864 . . . . 0.0 109.853 179.579 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.435 ' N ' ' HB2' ' A' ' 33' ' ' CYS . . . -159.41 -169.89 23.3 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.757 -1.737 . . . . 0.0 108.757 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.761 HG23 ' O ' ' A' ' 26' ' ' THR . 14.8 t -128.47 105.36 8.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.073 -1.251 . . . . 0.0 110.636 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.528 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 53.6 t -60.29 -29.6 68.93 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.283 -0.886 . . . . 0.0 109.43 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -168.7 -163.05 22.04 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.603 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 63.5 m -88.02 -41.58 0.49 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 120.891 -1.358 . . . . 0.0 109.999 179.488 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.603 ' CD ' ' N ' ' A' ' 29' ' ' SER . 50.4 Cg_endo -82.76 8.2 4.72 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.43 1.226 . . . . 0.0 109.519 179.003 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.571 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 97.7 m-85 -147.72 173.79 12.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.339 -0.851 . . . . 0.0 110.771 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -136.86 159.62 41.33 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.605 -0.684 . . . . 0.0 109.317 179.362 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.528 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 91.0 m -80.09 105.04 11.07 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.003 -1.061 . . . . 0.0 109.984 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 64.2 m -130.45 147.93 52.2 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.187 -0.946 . . . . 0.0 110.375 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.429 ' OXT' ' HG3' ' A' ' 35' ' ' LYS . 64.4 pttt . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.19 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . 0.534 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . 97.3 m-20 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.455 0.645 . . . . 0.0 110.293 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.611 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 69.5 mm-40 -74.18 -40.74 4.79 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.478 -0.764 . . . . 0.0 111.529 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.611 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.5 Cg_endo -74.78 -10.83 21.79 Favored 'Trans proline' 0 C--N 1.313 -1.335 0 O-C-N 123.312 1.164 . . . . 0.0 111.516 -178.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.559 ' CG2' ' N ' ' A' ' 5' ' ' SER . 1.4 p -151.14 170.97 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 120.845 -1.159 . . . . 0.0 110.802 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.559 ' N ' ' CG2' ' A' ' 4' ' ' VAL . 49.2 m 53.39 37.98 26.8 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.556 -0.715 . . . . 0.0 110.483 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 32.8 t -62.39 -23.12 66.65 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.202 -0.936 . . . . 0.0 110.099 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.813 HD13 ' O ' ' A' ' 11' ' ' GLY . 1.0 OUTLIER -69.31 -37.07 75.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.337 -0.852 . . . . 0.0 109.878 179.876 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 23.3 ttp180 -56.98 -32.7 66.35 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.243 -0.911 . . . . 0.0 110.535 -179.611 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -59.77 -30.16 68.69 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.197 -0.939 . . . . 0.0 109.746 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 124.04 14.09 3.85 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 179.433 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.813 ' O ' HD13 ' A' ' 7' ' ' ILE . . . -101.77 175.41 25.34 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.714 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.465 ' HA ' HD11 ' A' ' 7' ' ' ILE . 25.7 mt -119.03 169.54 9.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.27 -1.135 . . . . 0.0 110.026 179.743 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.511 ' HA ' ' O ' ' A' ' 32' ' ' LYS . 1.9 m -112.17 153.18 27.43 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.153 -0.967 . . . . 0.0 110.071 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.518 ' O ' ' N ' ' A' ' 32' ' ' LYS . 11.9 tp60 -152.03 154.37 35.85 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.31 -0.869 . . . . 0.0 109.863 179.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.575 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 58.6 t80 -56.35 -37.5 70.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.107 -0.996 . . . . 0.0 110.258 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.575 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 35.2 mmt180 -146.14 157.49 43.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.256 -0.902 . . . . 0.0 110.228 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -122.53 154.63 37.63 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.244 -0.91 . . . . 0.0 110.333 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.471 HG13 ' HB2' ' A' ' 20' ' ' LEU . 14.6 pt -106.89 161.64 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.213 -0.929 . . . . 0.0 110.219 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.86 -29.42 54.95 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.579 ' N ' HD12 ' A' ' 20' ' ' LEU . 10.0 mp -65.04 -34.67 78.98 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.173 -1.192 . . . . 0.0 110.422 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.1 mtt180 -93.68 137.22 33.16 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.204 -0.935 . . . . 0.0 110.307 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -83.73 134.79 34.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.189 -0.944 . . . . 0.0 110.235 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.415 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 87.0 tttt -98.85 98.57 9.64 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.23 -0.919 . . . . 0.0 110.21 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 89.1 mt -66.78 -33.47 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.286 -0.884 . . . . 0.0 110.314 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.452 ' O ' ' HB3' ' A' ' 33' ' ' CYS . . . -175.83 -167.14 34.34 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 64.6 p -104.88 104.15 13.87 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.426 -1.044 . . . . 0.0 110.462 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.434 ' HB3' ' HB3' ' A' ' 13' ' ' CYS . 49.9 t -56.09 -43.03 77.65 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.266 -0.896 . . . . 0.0 109.83 179.62 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -154.09 -166.57 15.06 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 179.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.596 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 4.1 m -88.6 -42.32 0.46 Allowed Pre-proline 0 C--N 1.301 -1.525 0 O-C-N 121.077 -1.249 . . . . 0.0 110.232 179.679 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.598 ' HG2' ' CD2' ' A' ' 31' ' ' PHE . 47.8 Cg_endo -81.83 6.59 5.57 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 O-C-N 123.504 1.265 . . . . 0.0 109.949 179.26 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.598 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 83.2 m-85 -151.57 170.78 18.83 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.153 -0.967 . . . . 0.0 110.409 179.728 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.518 ' N ' ' O ' ' A' ' 14' ' ' GLN . 94.4 mttt -132.7 156.89 46.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.336 -0.853 . . . . 0.0 109.653 179.524 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.452 ' HB3' ' O ' ' A' ' 25' ' ' GLY . 9.8 t -84.48 121.6 27.81 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.225 -0.922 . . . . 0.0 110.143 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 71.6 m -133.59 132.75 41.21 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.315 -0.866 . . . . 0.0 110.25 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 84.6 tttt . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.119 179.929 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . 0.76 ' HB3' HG22 ' A' ' 4' ' ' VAL . 26.4 m120 . . . . . 0 N--CA 1.492 1.66 0 CA-C-O 121.272 0.558 . . . . 0.0 110.155 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.625 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 75.9 mt-10 -69.92 -35.89 5.8 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.477 -0.764 . . . . 0.0 112.233 -179.57 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.625 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 46.6 Cg_endo -74.49 -9.25 21.37 Favored 'Trans proline' 0 C--N 1.315 -1.213 0 O-C-N 122.943 0.97 . . . . 0.0 111.074 -178.829 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.76 HG22 ' HB3' ' A' ' 1' ' ' ASN . 17.4 m -140.64 149.05 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.082 -1.011 . . . . 0.0 110.163 179.693 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.648 ' OG ' HG22 ' A' ' 7' ' ' ILE . 86.7 p -154.24 160.26 41.72 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.173 -0.954 . . . . 0.0 110.103 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.45 ' O ' ' OD1' ' A' ' 9' ' ' ASN . 80.8 m -61.06 -35.82 77.97 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.272 -0.892 . . . . 0.0 110.385 -179.869 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.648 HG22 ' OG ' ' A' ' 5' ' ' SER . 5.7 tt -58.19 -17.28 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.182 -0.949 . . . . 0.0 110.189 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 9.1 tpm_? -66.63 -33.76 76.37 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.223 -0.923 . . . . 0.0 110.247 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.454 ' OD1' ' N ' ' A' ' 11' ' ' GLY . 47.4 p30 -84.98 4.98 31.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.149 -0.969 . . . . 0.0 110.182 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.76 -5.04 53.71 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.454 ' N ' ' OD1' ' A' ' 9' ' ' ASN . . . -72.63 175.78 43.44 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.581 HG22 ' N ' ' A' ' 13' ' ' CYS . 70.1 mt -130.82 174.41 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -1.114 . . . . 0.0 110.198 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.581 ' N ' HG22 ' A' ' 12' ' ' ILE . 2.6 m -127.16 150.68 49.4 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.213 -0.929 . . . . 0.0 110.174 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.506 ' O ' ' HA ' ' A' ' 31' ' ' PHE . 4.4 tp-100 -156.04 151.74 27.22 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.677 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.537 ' CD2' ' HG2' ' A' ' 16' ' ' ARG . 73.6 t80 -56.98 -31.64 65.26 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.113 -0.992 . . . . 0.0 110.396 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.537 ' HG2' ' CD2' ' A' ' 15' ' ' TYR . 38.0 mmt180 -151.63 150.94 30.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.358 -0.839 . . . . 0.0 110.23 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 96.3 m -121.55 125.91 47.9 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.286 -0.884 . . . . 0.0 110.304 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.44 ' CD1' ' HB2' ' A' ' 20' ' ' LEU . 36.8 pt -62.27 166.41 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.239 -0.913 . . . . 0.0 110.126 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.85 -42.4 59.73 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.727 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.44 ' HB2' ' CD1' ' A' ' 18' ' ' ILE . 32.8 mt -51.86 -28.58 16.46 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.325 -1.103 . . . . 0.0 110.31 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 61.5 mtt-85 -117.66 118.95 33.49 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.235 -0.915 . . . . 0.0 110.487 -179.742 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -97.99 144.77 27.17 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.883 . . . . 0.0 109.814 179.741 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.492 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -99.78 107.0 18.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.133 -0.979 . . . . 0.0 110.643 -179.718 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 51.3 mm -64.08 -35.63 74.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.253 -0.904 . . . . 0.0 110.19 179.741 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.479 ' C ' ' HB2' ' A' ' 33' ' ' CYS . . . -141.56 -162.77 9.3 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.631 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.537 HG22 ' O ' ' A' ' 28' ' ' GLY . 90.0 m -122.44 108.61 13.39 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.476 -1.014 . . . . 0.0 110.286 179.692 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.517 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 10.9 t -58.64 -32.59 69.2 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.224 -0.922 . . . . 0.0 109.587 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.537 ' O ' HG22 ' A' ' 26' ' ' THR . . . -172.02 -158.35 15.93 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.709 -1.757 . . . . 0.0 108.709 179.621 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.591 ' N ' ' CD ' ' A' ' 30' ' ' PRO . 3.7 m -88.97 -43.09 0.44 Allowed Pre-proline 0 C--N 1.302 -1.485 0 O-C-N 120.839 -1.389 . . . . 0.0 110.215 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.591 ' CD ' ' N ' ' A' ' 29' ' ' SER . 51.2 Cg_endo -83.52 10.22 3.77 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.557 1.293 . . . . 0.0 109.533 179.009 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.541 ' CD2' ' HG2' ' A' ' 30' ' ' PRO . 79.0 m-85 -154.21 171.11 19.72 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.342 -0.849 . . . . 0.0 110.737 -179.861 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.486 ' O ' ' HA ' ' A' ' 13' ' ' CYS . 95.5 mttt -134.32 161.28 35.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.588 -0.695 . . . . 0.0 109.196 179.168 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.517 ' SG ' ' N ' ' A' ' 27' ' ' CYS . 58.0 m -80.37 100.06 8.25 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.063 -1.023 . . . . 0.0 110.185 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.468 ' SG ' ' HB3' ' A' ' 23' ' ' LYS . 19.8 m -129.38 158.35 39.38 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.143 -0.973 . . . . 0.0 110.339 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 117.936 -1.03 . . . . 0.0 109.999 179.732 . . . . . . . . 0 0 . 1 stop_ save_